0001493152-24-011730.txt : 20240328 0001493152-24-011730.hdr.sgml : 20240328 20240328160112 ACCESSION NUMBER: 0001493152-24-011730 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 89 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240328 DATE AS OF CHANGE: 20240328 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVD EQUIPMENT CORP CENTRAL INDEX KEY: 0000766792 STANDARD INDUSTRIAL CLASSIFICATION: SPECIAL INDUSTRY MACHINERY, NEC [3559] ORGANIZATION NAME: 06 Technology IRS NUMBER: 112621692 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16525 FILM NUMBER: 24798673 BUSINESS ADDRESS: STREET 1: 355 S. TECHNOLOGY DRIVE CITY: CENTRAL ISLIP STATE: NY ZIP: 11722 BUSINESS PHONE: 6319817081 MAIL ADDRESS: STREET 1: 355 S. TECHNOLOGY DRIVE CITY: CENTRAL ISLIP STATE: NY ZIP: 11722 10-K 1 form10-k.htm
false FY 0000766792 P7Y P10Y P1Y 0000766792 2023-01-01 2023-12-31 0000766792 2023-06-30 0000766792 2024-03-25 0000766792 2023-12-31 0000766792 2022-12-31 0000766792 2022-01-01 2022-12-31 0000766792 us-gaap:CommonStockMember 2021-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000766792 us-gaap:RetainedEarningsMember 2021-12-31 0000766792 2021-12-31 0000766792 us-gaap:CommonStockMember 2022-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000766792 us-gaap:RetainedEarningsMember 2022-12-31 0000766792 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000766792 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000766792 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000766792 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000766792 us-gaap:CommonStockMember 2023-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000766792 us-gaap:RetainedEarningsMember 2023-12-31 0000766792 us-gaap:BuildingAndBuildingImprovementsMember srt:MinimumMember 2023-12-31 0000766792 us-gaap:BuildingAndBuildingImprovementsMember srt:MaximumMember 2023-12-31 0000766792 us-gaap:MachineryAndEquipmentMember srt:MinimumMember 2023-12-31 0000766792 us-gaap:MachineryAndEquipmentMember srt:MaximumMember 2023-12-31 0000766792 srt:MinimumMember 2023-12-31 0000766792 srt:MaximumMember 2023-12-31 0000766792 country:DK 2022-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerMember 2023-01-01 2023-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerOneMember 2023-01-01 2023-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerTwoMember 2023-01-01 2023-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerThreeMember 2023-01-01 2023-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerOneMember 2022-01-01 2022-12-31 0000766792 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerTwoMember 2022-01-01 2022-12-31 0000766792 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerMember 2023-01-01 2023-12-31 0000766792 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerAMember 2023-01-01 2023-12-31 0000766792 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerBMember 2023-01-01 2023-12-31 0000766792 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerCMember 2023-01-01 2023-12-31 0000766792 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember CVV:CustomerAMember 2022-01-01 2022-12-31 0000766792 CVV:ExportSalesMember us-gaap:CustomerConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2023-01-01 2023-12-31 0000766792 CVV:ExportSalesMember us-gaap:CustomerConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2022-01-01 2022-12-31 0000766792 us-gaap:CargoAndFreightMember 2023-01-01 2023-12-31 0000766792 us-gaap:CargoAndFreightMember 2022-01-01 2022-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:EnergyMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:EnergyMember 2023-01-01 2023-12-31 0000766792 CVV:EnergyMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:AerospaceMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:AerospaceMember 2023-01-01 2023-12-31 0000766792 CVV:AerospaceMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:IndustrialMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:IndustrialMember 2023-01-01 2023-12-31 0000766792 CVV:IndustrialMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:ResearchOneMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:ResearchOneMember 2023-01-01 2023-12-31 0000766792 CVV:ResearchOneMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:EnergyMember 2022-01-01 2022-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:EnergyMember 2022-01-01 2022-12-31 0000766792 CVV:EnergyMember 2022-01-01 2022-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:AerospaceMember 2022-01-01 2022-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:AerospaceMember 2022-01-01 2022-12-31 0000766792 CVV:AerospaceMember 2022-01-01 2022-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:IndustrialMember 2022-01-01 2022-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:IndustrialMember 2022-01-01 2022-12-31 0000766792 CVV:IndustrialMember 2022-01-01 2022-12-31 0000766792 us-gaap:TransferredOverTimeMember CVV:ResearchOneMember 2022-01-01 2022-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember CVV:ResearchOneMember 2022-01-01 2022-12-31 0000766792 CVV:ResearchOneMember 2022-01-01 2022-12-31 0000766792 us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-12-31 0000766792 us-gaap:LandMember 2023-12-31 0000766792 us-gaap:LandMember 2022-12-31 0000766792 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0000766792 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0000766792 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000766792 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000766792 us-gaap:ConstructionInProgressMember 2023-12-31 0000766792 us-gaap:ConstructionInProgressMember 2022-12-31 0000766792 us-gaap:PatentsMember 2023-12-31 0000766792 us-gaap:PatentsMember 2022-12-31 0000766792 2022-09-30 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2023-12-31 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2023-01-01 2023-12-31 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2023-12-31 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2023-01-01 2023-12-31 0000766792 CVV:TwoThousandSevenShareIncentivePlanMember 2007-12-12 0000766792 CVV:TwoThousandSevenShareIncentivePlanMember 2023-12-31 0000766792 CVV:TwoThousandSixteenShareIncentivePlanMember 2016-12-09 0000766792 CVV:TwoThousandSixteenShareIncentivePlanMember 2023-12-31 0000766792 CVV:TwoThousandTwentyTwoShareIncentivePlanMember 2022-07-14 0000766792 CVV:TwoThousandTwentyTwoShareIncentivePlanMember 2023-12-31 0000766792 CVV:TwoThousandTwentyTwoShareIncentivePlanMember srt:MinimumMember 2022-07-14 2022-07-14 0000766792 CVV:TwoThousandTwentyTwoShareIncentivePlanMember srt:MaximumMember 2022-07-14 2022-07-14 0000766792 us-gaap:RestrictedStockMember srt:DirectorMember 2023-01-01 2023-12-31 0000766792 us-gaap:RestrictedStockMember srt:DirectorMember 2022-01-01 2022-12-31 0000766792 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000766792 us-gaap:EmployeeStockOptionMember 2023-12-31 0000766792 CVV:FiveDirectorsMember 2021-10-11 0000766792 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0000766792 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000766792 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000766792 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0000766792 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000766792 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0000766792 CVV:CostOfRevenueMember 2023-01-01 2023-12-31 0000766792 CVV:CostOfRevenueMember 2022-01-01 2022-12-31 0000766792 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0000766792 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000766792 CVV:SellingExpenseMember 2023-01-01 2023-12-31 0000766792 CVV:SellingExpenseMember 2022-01-01 2022-12-31 0000766792 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0000766792 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0000766792 CVV:ExercisePriceRangeOneMember 2023-01-01 2023-12-31 0000766792 CVV:ExercisePriceRangeOneMember 2023-12-31 0000766792 CVV:ExercisePriceRangeTwoMember 2023-01-01 2023-12-31 0000766792 CVV:ExercisePriceRangeTwoMember 2023-12-31 0000766792 CVV:ExercisePriceRangeThreeMember 2023-01-01 2023-12-31 0000766792 CVV:ExercisePriceRangeThreeMember 2023-12-31 0000766792 CVV:ExercisePriceRangeFourMember 2023-01-01 2023-12-31 0000766792 CVV:ExercisePriceRangeFourMember 2023-12-31 0000766792 us-gaap:RestrictedStockMember 2021-12-31 0000766792 us-gaap:RestrictedStockMember 2022-12-31 0000766792 us-gaap:RestrictedStockMember 2023-12-31 0000766792 2022-07-01 2022-07-01 0000766792 us-gaap:IntersegmentEliminationMember CVV:SDCMember 2023-01-01 2023-12-31 0000766792 us-gaap:IntersegmentEliminationMember CVV:SDCMember 2022-01-01 2022-12-31 0000766792 us-gaap:IntersegmentEliminationMember CVV:CVDEquipmentMember 2023-01-01 2023-12-31 0000766792 us-gaap:IntersegmentEliminationMember CVV:CVDEquipmentMember 2022-01-01 2022-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDEquipmentMember 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMaterialsMember 2023-12-31 0000766792 us-gaap:CorporateNonSegmentMember 2023-12-31 0000766792 us-gaap:IntersegmentEliminationMember 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDEquipmentMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMaterialsMember 2023-01-01 2023-12-31 0000766792 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-12-31 0000766792 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDEquipmentMember 2022-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2022-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMaterialsMember 2022-12-31 0000766792 us-gaap:CorporateNonSegmentMember 2022-12-31 0000766792 us-gaap:IntersegmentEliminationMember 2022-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDEquipmentMember 2022-01-01 2022-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2022-01-01 2022-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMaterialsMember 2022-01-01 2022-12-31 0000766792 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0000766792 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-12-31 0000766792 CVV:CVDMaterialsMember CVV:TantalineASOfNordborgMember 2023-01-01 2023-12-31 0000766792 CVV:CVDMaterialsMember CVV:MesoScribeTechnologiesIncMember 2023-01-01 2023-12-31 0000766792 CVV:CVDEquipmentMember 2022-01-01 2022-12-31 0000766792 CVV:SDCMember 2022-01-01 2022-12-31 0000766792 CVV:CVDMaterialsMember 2022-01-01 2022-12-31 0000766792 CVV:TantalineASOfNordborgMember 2023-05-26 2023-05-26 0000766792 CVV:TantalineASOfNordborgMember 2023-01-01 2023-12-31 0000766792 CVV:TantalineASOfNordborgMember 2022-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2023-08-08 0000766792 CVV:MesoScribeTechnologiesIncMember 2023-01-01 2023-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2023-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2022-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares CVV:Segment xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 10-K

(Mark One)  
     
  ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the fiscal year ended December 31, 2023

 

  ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the transition period from ___ to _____

 

Commission file number: 1-16525

 

CVD EQUIPMENT CORPORATION

(Exact name of registrant as specified in its charter)

 

New York   11-2621692

(State or Other Jurisdiction of

Incorporation or Organization)

  

(I.R.S. Employer

Identification No.)

 

355 South Technology Drive Central Islip, New York 11722

(Address including zip code of registrant’s Principal Executive Offices)

 

(631) 981-7081

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, Par value $0.01   CVV   NASDAQ Capital Market

 

Securities registered pursuant to Section 12(g) of the Act:

None

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data file required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and emerging growth company in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter: $48,002,094 at June 30, 2023.

 

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date: 6,824,511 shares of Common Stock, $0.01 par value at March 25, 2024.

 

DOCUMENTS INCORPORATED BY REFERENCE: None.

 

 

 

 
 

 

INFORMATION CONCERNING FORWARD-LOOKING STATEMENTS

 

Except for historical information contained herein, this Annual Report on Form 10-K contains forward–looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. These statements involve known and unknown risks and uncertainties that may cause our actual results or outcomes to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These forward-looking statements are based on various factors and are derived utilizing numerous important assumptions and other important factors that could cause actual results to differ materially from those in the forward-looking statements. Important assumptions and other factors that could cause actual results to differ materially from those in the forward-looking statements, include, but are not limited to:

 

  ● competition in our existing and potential future product lines of business, including our PVT150 / PVT 200 systems;
     
  ● our ability to attract and retain key personnel and employees;
     
  ● our ability to obtain financing on acceptable terms if and when needed;
     
  ● uncertainty as to our ability to develop new products for the high power electronics market including our plan to commercialize and market a PVT200 to grow silicon carbide crystals for 200 mm wafers;
     
  ● uncertainty as to our future growth and profitability; and
     
  ● uncertainty as to our ability to adequately obtain raw materials and on commercially reasonable terms.

 

Other factors and assumptions not identified above were also involved in the derivation of these forward-looking statements and the failure of such assumptions to be realized as well as other factors may also cause actual results to differ materially from those projected. We assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting such forward-looking statements. Past performance is no guaranty of future results.

 

You should not place undue reliance on any forward-looking statements, which speak only as of the dates they are made. When used with this Report, the words “believes”, “anticipates”, “expects”, “estimates”, “plans”, “intends”, “will” and similar expressions are intended to identify forward-looking statements.

 

2
 

 

Item 1. Description of Business.

 

Definitions

 

The use of the words “CVD,” “we,” “us,” or “our,” refers to CVD Equipment Corporation, a New York corporation incorporated on October 13, 1982, and its wholly owned subsidiaries, CVD Materials Corporation (including its wholly owned subsidiaries, and CVD MesoScribe Technologies Corporation and Tantaline CVD Holding ApS, collectively “CVD Materials”), and FAE Holdings 411519R LLC except where the context otherwise requires.

 

Overview

 

CVD has served the advanced materials markets with chemical vapor deposition, physical vapor transport and thermal process equipment for over 40 years. We are headquartered in Central Islip, New York with one other location in Saugerties, New York.

 

We design, develop, and manufacture a broad range of equipment used to develop and manufacture materials and coatings for the compound semiconductor, semiconductor, aerospace, battery energy storage markets as well as advanced industrial applications, and research.

 

We conduct our business through three reportable operating segments: i) CVD Equipment that supplies chemical vapor deposition, physical vapor transport and thermal process equipment; ii) SDC that designs and manufactures ultra-high purity gas and chemical delivery control systems; and iii) CVD Materials that provide products related to advanced materials and coatings.

 

Developments

 

On May 26, 2023, we sold our Tantaline subsidiary located in Nordborg, Denmark in exchange for a nominal amount at closing and an earn-out provision based on any net income that Tantaline may earn during the five-year period ending December 31, 2027. The decision to sell Tantaline was based on our ongoing strategy to focus on the equipment business consisting of the CVD Equipment and SDC segments and reduce its focus on the non-core CVD Materials business.

 

On August 8, 2023, we entered into an agreement with a third party to sell certain assets and license certain propriety information of MesoScribe. We will continue to fulfill remaining orders for MesoScribe products through the end of 2024 at which time we plan to cease the remaining operations of MesoScribe and dispose of any remaining equipment.

 

The decisions to sell our Tantaline subsidiary and wind down the operations of MesoScribe were based on our ongoing strategy to focus on the equipment business consisting of the CVD Equipment and SDC segments.

 

3
 

 

Key Company Strengths

 

Based on more than 40 years of equipment experience, we use our capabilities in process development, engineering, and vertical manufacturing to transform emerging applications into mainstream manufacturing solutions.

 

We have built a library of design expertise, know-how and innovative solutions to assist our customers in developing these intricate processes and to accelerate their production and commercialization. This library of equipment design solutions, along with our manufacturing and systems integration facilities, allows us to provide application-specific design, process, and manufacturing solutions to our customers.

 

Our core competencies in equipment and software design, manufacturing and process development are used to engineer our finished products and to accelerate the commercialization path of our customer base. Our proprietary real-time software allows for rapid configuration, and provides our customers with enabling tools to understand, optimize and repeatedly control their processes. These factors reduce cost, improve quality, and reduce the time it takes between customers’ orders and the shipment of our products. Our Application Laboratory allows customers the option to bring their process tools to our laboratory and to work collaboratively with our scientists and engineers to optimize process performance.

 

To expand our presence into our major target markets, we are developing a line of proprietary standard use products to complement our customized legacy systems. Historically, we manufactured products for research and development on an application-specific basis to meet an individual customer’s specific research and production requirements. Our proprietary systems leverage the technological expertise that we have developed through designing these custom systems into a broader standardized product line. The standard product line can be configured from a wide range of available options to meet diverse product and budgetary requirements. Manufacturing these standardized systems in higher volumes may provide us the flexibility to reduce both the cost and delivery time of our systems. These systems, which we market and sell under the CVD, FirstNano and EasyTube® product names, are sold to commercial companies, universities and research laboratories in the United States and throughout the world.

 

Sales of our proprietary standard systems, custom systems and process solutions have been driven by our installed customer base, which includes Fortune 500 companies. The performance and success of our products has historically driven repeat orders from existing customers as well as generated business from new customers. Furthermore, with our proprietary solutions and expanded focus on “enabling tomorrow’s technologies”TM we have been developing a new customer base in addition to growing with our existing customers.

 

Key Growth Strategies

 

Our core strategy is to focus on growth market applications in end markets related to the “electrification of everything,” aerospace and industrial applications. The phrase “electrification of everything” refers to the shift from fossil fuels to the use of electricity to power devices, buildings, electric vehicles (“EVs”), and many other applications. With respect to aerospace, our systems are being used by our customers to produce ceramic matrix composite materials (“CMCs”) that will be used in next generation gas turbine jet engines with the objective of reducing jet fuel consumption and contributing to the decarbonization of that industry.

 

4
 

 

Our current strategy yielded multisystem orders of PVT150 equipment that was delivered to one company that manufactures silicon carbide wafers.

 

In February 2024, we received an order from an additional customer for our new PVT200 system used to grow silicon carbide crystals for the manufacture of 200 mm wafers. This represents our second customer for our PVT equipment. This customer plans to evaluate our equipment for potential additional purchases of PVT equipment. We have also received orders from OneD Battery Materials in 2023, a company that is engaged in providing battery nanomaterials.

 

Both technologies are essential for the support of the EV market. These systems should provide us with standard product offering to continue to support the EV focused market as well as energy storage, power conversion and power transmission. We plan to expand our product offerings in the power electronics market to build off the introduction of the PVT150 and PVT200 systems. We are also evaluating our ability to provide other equipment used in the manufacturing process of silicon carbide wafers.

 

During 2022, we also received an order from an aerospace company for a production chemical vapor infiltration (CVI) system that will be used to manufacture CMCs for gas turbine jet engines. In 2023, we received an order from the same aerospace company for an additional three CVI systems.

 

In February 2024, we received a multisystem order from an industrial customer for approximately $10 million that will be used for depositing a silicon carbide protective coating on OEM components.

 

We have generally gained new customers through our industry reputation, as well as limited print advertising and trade show attendance. We have increased the number of trade shows and industry conferences in 2023. In addition, we added to our sales and marketing team in 2022 and expanded our sales team in early 2023.

 

Major Target Markets

 

Our major target markets are high power electronics, EV battery materials / energy storage and aerospace, defense and industrial applications – all of which have the objective of improving energy efficiency.

 

High Power Electronics

 

Demand for silicon carbide wafers to support high power electronics for energy storage and transmission/charging resulted in a multi-system order from a US-based, silicon carbide wafer manufacturer. Through December 31, 2023, we have received and delivered orders for 30 of our PVT150 physical vapor transport systems from one customer, which uses our systems to grow silicon carbide crystals that are made into 150 mm silicon carbide wafers for use in power electronics. In late 2023, we launched our PVT200 system designed to manufacture silicon carbide crystals for 200 mm wafer and received our first order from a second customer. We plan to expand our marketing and future product development for the PVT product line as well as expand our product offerings to manufacturers of silicon carbide wafers.

 

5
 

 

EV Battery Materials / Energy Storage

 

We have experienced increased interest and demand for nanotechnology materials including carbon nanotubes (CNTs), graphene and silicon nanowires (Si-NWs) to support the development and manufacturing for battery materials used in electric vehicles. We received two system orders in 2021 to deposit coatings onto powders used in silicon-graphite anodes, including a production system and a second for research and material development. We received additional system orders from this customer in 2023 that were completed during 2023.

 

Aerospace & Defense

 

CVD is a leading manufacturer of CVI and tow-coating systems to manufacture CMCs for aerospace gas turbine jet engine applications. Our customers include two of the leaders in aerospace gas turbine engines.

 

We continue to engage customers in the aerospace market regarding CMCs. During 2022, we received an order for a production CVI system valued at approximately $3.7 million. We received an additional order for three CVI systems during 2023 from the same customer. These systems will be used to manufacture CMCs for aerospace gas turbine jet engines.

 

We believe our future growth will be derived from production applications in our major target markets. Our legacy product line continues to provide advanced equipment and subsystems to enable development of emerging technology and research applications.

 

Our major targeted markets are further described as follows (the term “legacy product” refers to products and systems within our product offerings that we have produced in our history):

 

Major Target Markets:   Description and Growth Drivers:   CVD Equipment Products and Services:

High Power Electronics

 

 

   The shift to electrification has the objectives of reducing emissions and reducing dependency on fossil fuels. This has driven the demand for electric vehicle and associated high power electronics used in charging and motor power conversion.  

Production Applications:

 

- PVT150 SiC crystal growth system launched in 2022.

 

- PVT200 SiC crystal growth system launched in 2023.

 

- HVPE400: polycrystalline GaN (legacy product).
         

EV Battery Materials / Energy Storage

 

   The shift to electrification also requires improvements in energy storage, specifically with the use of novel anode materials.  

Production Applications:

 

- PowderCoat-1100 production system launched in 2021 grows Si nanowires on carbon nanoparticles.

 

- Carbon-150: Single substrate system for CNT growth. Versatile substrate format, on wafer or foil.

 

- Carbon-300: Multiple substrate batch tube system for CNT growth. Versatile substrate format, on wafer or foil.

 

R&D Applications:

 

- ET-3000: Versatile CNT growth system for research and development.
         
Aerospace, Defense and Industrial  

Next generation gas turbine jet engines are incorporating CMC material for the hot section or exhaust of the engine to improve fuel efficiency.

 

Silicon carbide coating is use as a protective barrier in many OEM components used in LED and other applications.

  

Production and R&D Applications:

 

- Fiber tow coat system. Mass production system for multi-layer coating for CMCs.

 

- Silicon bond coat environmental barrier depositing system. Deposits Si on machined gas turbine jet engine CMC components and other OEM components.

 

- Chemical Vapor Deposition/ Chemical Vapor Infiltration production coating system for multi-layer CMC coatings on SiC fiber preforms.

 

6
 

 

Other Markets   CVD Equipment Products:
   

- Universal liquid and gas storage cabinets, management, and delivery systems (SDC segment).

 

- Production MOCVD Super Conducting Tape system.

 

- ET-3000: MOCVD for compound semiconductor R&D.

 

- ET-3000 for graphene.

 

- ET-6000: Multi-Tube Chemical Vapor Deposition Tube furnace (metals, oxides and nitrides).

 

- PowderCoat-300 for powder material R&D (including battery anode).

 

- TMD: cluster tool for advanced material development.

 

Our wholly owned subsidiary, CVD Materials Corporation, includes our MesoScribe product lines. Our MesoScribe product line supports the aerospace and defense markets with novel robust direct write instrumentation. We plan to wind down the operations of MesoScribe in 2024 after satisfaction of customer purchase orders.

 

Bookings

 

During 2023, bookings of new orders from customers was approximately $25.8 million, representing a decrease of approximately 22.1% compared to 2022 bookings of $33.1 million. The decline in bookings was related to $8.8 million of orders of PVT150 systems that were received in 2022 as compared to no such orders in 2023.

 

Segments

 

CVD Equipment - supplies state-of-the-art chemical vapor deposition and thermal process equipment targeting growth production markets as well as systems for use in research and development. This includes systems marketed under the FirstNano product brand. Utilizing our over 40 years of expertise in the design and manufacture of chemical vapor deposition and thermal process equipment, we provide material processing capability and control at a competitive cost of ownership.

 

The targeted growth production markets include high power electronics (both silicon carbide (SiC) and gallium nitride (GaN)), aerospace advanced materials primarily for gas turbine jet engines, and nanomaterials used in batteries. The product group also consists of legacy products serving the production and R&D applications such as semiconductors, LEDs, carbon nanotubes, nanowires, solar cells and a number of other industrial & research applications.

 

7
 

 

Our developments and opportunities for the carbon composite business come from achievements in our Applications Laboratory. The Applications Laboratory, along with the sales and marketing team continue to explore carbon-based products and applications that can be made from our CNT, infiltrated carbon/CVI and carbon nano fiber technology (CNF). Some applications include CNT and infiltrated carbon/CVI based battery material and CNF capacitors for 5G technology.

 

To support new emerging applications, we provide equipment to and collaborate with laboratory scientists to bring state-of-the-art processes from the research laboratory into production. CVD Equipment group provides process development value through our Application Laboratory where our personnel interact directly with the scientists and engineers of our customer base to develop solutions to tomorrow’s challenges today. CVD Equipment segment operates from our 135,000 sq. ft. facility in Central Islip, New York.

 

SDC - designs and manufactures ultra-high purity gas and chemical delivery control systems for state-of-the-art semiconductor fabrication processes, aerospace, solar cells, LEDs, carbon nanotubes, nanowires, and a number of industrial applications. Our SDC products are sold on a stand-alone basis and are also integrated into certain CVD equipment. This internal supply of chemical and gas delivery systems and components provide a competitive advantage for our CVD Equipment group over its competition. SDC operates from a 22,000 square foot facility fitted with a clean room manufacturing space located in Saugerties, New York.

 

CVD Materials - consist of MesoScribe’s direct write printed electronics business. MesoScribe provides MesoPlasma™ printing services and products (heaters, antennas, and sensors) to aerospace, satellite, power generation, defense, and other markets requiring high performance. MesoScribe operations are located at our main facility in Central Islip, New York.

 

On August 8, 2023, we entered into an agreement with a third party to sell certain assets and license certain proprietary information of MesoScribe. We will continue to fulfill remaining orders for MesoScribe products through the end of 2024 at which time we plan to cease the remaining operations of MesoScribe and dispose of any remaining equipment.

 

Intellectual Property

 

Our success is dependent, in part upon the development and protection of our proprietary technology and other proprietary rights. We have historically and continue to protect our proprietary information and intellectual property such as design specifications, blueprints, technical processes, and employee know-how through the use of patents and non-disclosure agreements. In the area of patents, we believe there is value in having protected intellectual property and will continue to file for patent protection of our proprietary technology that we believe has the potential to be incorporated into our products and sold to multiple customers. We also maintain certain trademarks relating to certain of our products and product lines and claim copyright protection for certain proprietary software and documentation.

 

8
 

 

While patent, copyright and trademark protections for our intellectual property are important to different degrees for our various products and solutions, we believe our future success in highly dynamic markets is most dependent upon the technical competence and creative skills of our personnel and our ability to accelerate the commercialization of next generation intellectual properties. We attempt to protect our trade secrets and other proprietary information through non-disclosure agreements with our customers, suppliers, employees and consultants and other security measures.

 

Research and Development

 

We develop new products based on market analysis or by customer request. The technology included in our product development includes mechanical hardware, software and controls systems and overall configuration. We have conducted research and development over the last 40 years and have a wealth of technology from which systems and solutions can be derived from and productized. Together with a number of leading universities and startup companies with whom we partner from time to time, we conduct research on SiC growth, the growth and infiltration of carbon nanotubes, graphene and nanowires as well as on selected aerospace manufacturing processes. Our intention is that together with customers and universities, we will leverage our collective expertise in this field, which we believe will allow us to capitalize on commercial opportunities in the future.

 

Products and Technology

 

Chemical Vapor Deposition/Infiltration – Chemical vapor deposition is a method of coating or growing material through a chemical recombination at elevated temperatures onto or within pores of a substrate material. A single or collection of gases or vapor introduced on to the surface or into pores of a substrate material that is heated to such a degree that the gases decompose and deposits a desired layer onto and or into a substrate material. Chemical vapor infiltration (CVI) is a variant of a chemical vapor deposition process that is performed at low pressures to allow for coating the internal surfaces of a porous material. Using heat and low pressure, precursor vapors penetrate the pores/fiber of the material and deposit to form a conformal coating on the internal surfaces. Both processes are accomplished by combining appropriate gases in a reaction chamber, of the kind we manufacture, at elevated temperatures (typically 500° to 2,500° Celsius). Our chemical vapor deposition and CVI systems are complete and include all necessary heating techniques, precise control instrumentation, gas delivery and abatement subsystems and components and include state-of-the-art proprietary process control software. We provide both standard and emerging applications specified products. Some of the standard systems we offer are for SiC, GaN, Aluminum Nitride (AlN), CMCs, silicon (Si), CNT, graphene, silicon nanowires. The systems are sold under the CVD and FirstNano product brands.

 

Physical Vapor Transport (PVT) – While the PVT150 was officially launched for production in 2022, we have sold PVT systems in prior years and have pioneered both resistive heating and more effectively inductively heated PVT systems. The PVT150 system was specifically designed to address the SiC crystal growth market for 150 mm substrates or wafers. Designed to provide enhanced process parameter control it allows existing and future customers the ability to tightly control and monitor the crystal growth process for 150mm substrates. A 200 mm version called the PVT200 was developed during 2023 and the first order was received in February 2024. The crystal growth technique utilized a high temperature furnace to vaporize from seed granular material of SiC and further deposit out in an ordered crystal structure onto substrate wafer. The process takes days to over a week to complete and yield a SiC crystal ready for further processing into wafers.

 

9
 

 

Rapid Thermal Processing (RTP) – Used to heat semiconductor materials to elevated temperatures of up to 1,200° Celsius at rapid rates of up to 200° Celsius per second. Our RTP systems are offered for implant activation, oxidation, silicide formation and many other processes. We offer systems that can operate both at atmospheric and reduced pressures.

 

Annealing, Diffusion and Low-Pressure Chemical Vapor Deposition (LPCVD) Furnaces – These furnaces are used for dislocation removal in crystals, dopant diffusion, oxidation, for SiC, Si, SiOx and other applications. The systems are normally operated at atmospheric and/or reduced pressure with gaseous atmospheres related to the process. An optional feature of the system allows for the heating element to be moved away from the process chamber allowing the wafers to rapidly cool or be heated in a controlled environment. Our temperature control system enables more precise control of the wafers. The systems are equipped with an automatic process controller, permitting automatic process sequencing and monitoring with safety alarm provisions.

 

Ultra-High Purity Gas and Liquid Control Systems – Our standard and custom designed gas and liquid control systems, which encompass gas cylinder storage cabinets, custom gas and chemical delivery systems, gas and liquid valve manifold boxes and gas isolation boxes, provide safe storage and handling of pressurized gases and chemicals. Our system design allows for automatic or manual control from both a local and remote location. These subsystems and components are provided to the general market as well as support the CVD Equipment segment.

 

Quartzware – The majority of our process equipment solutions, utilize quartz components which we partially manufacturer internally. In addition, the equipment typically requires routine maintenance, consumable and spare parts. One such spare part and consumable which is core to our technology offering is quartz hardware. We provide standard and custom fabricated quartzware used in our equipment and to a lesser extent for other customer tools.

 

MesoPlasma™ Direct Write Printing – A materials deposition process that provides robust direct write high-definition instrumentation, fine feature patterns, and coatings onto conformal components. The technique involves powder material that is injected into a thermal plasma where it is rapidly heated and deposited onto the substrate or component. The versatility of the process enables a wide range of materials to be deposited including ceramic dielectrics, nickel-based sensor alloys, metallic conductors, precious metals, and protective coatings. Products include temperature sensors, heaters, antennas and patterns per customer specifications.

 

Markets and Marketing

 

We serve multiple emerging and mature global markets including compound semiconductor high power electronics, aerospace, defense, battery energy storage, silicon and other microelectronic and micromechanical devices, semiconductor, universities, and research centers. Due to the highly technical nature of our products, we believe it is essential to engage with customers directly through our sales personnel, our network of domestic and international independent sales representatives, and distributors specializing in the type of equipment, products, and services that we sell. Our primary marketing activities include direct sales engagement, participation in trade associations and trade shows and our internet websites. We expanded our marketing activities in 2023 through attendance at key tradeshows and online marketing.

 

10
 

 

Customers

 

Our systems and products are used in both production applications and advanced materials research. We market and sell primarily to companies that are the engaged in producing compound semiconductor wafers, aerospace gas turbine jet engine component material, defense, battery energy storage, silicon and other microelectronic and micromechanical devices, semiconductor, universities and research centers. We have both a domestic and international customer base.

 

Given the complexity and magnitude of the systems we sell, revenue from a single customer in any one year can exceed 10% of our total sales. During the year ended December 31, 2023, three customers represented 14.3%, 13.5% and 10.9% of our revenues, while in 2022 one customer represented 29.2% of our revenues. While we believe that our relationships with these customers are generally positive, the loss of a large customer would have to be replaced by others, and our inability to do so could have a material adverse effect on our business and financial condition.

 

For the year ended December 31, 2023, approximately $4.1 million or 17% of our revenues were generated by sales to customers outside the U.S., compared to approximately $4.4 million or 17% for the year ended December 31, 2022.

 

Competition

 

We can experience intense direct competition from both domestic and international competitors in all our product segments. Our CVD Equipment product lines including FirstNano, target multiple markets and both production and research customers. Competition is substantial in both the production applications and research. In production application, competition comes from larger companies offering enhanced services. In research applications, the competition comes from small companies that compete with us mostly on price. We are aware of other competitors that offer a substantial number of products and services comparable to ours. Many of our competitors (including customers who may elect to manufacture systems for internal use) have financial, marketing and other resources greater than our own. To date, we believe that each of our product and service segments has been able to compete favorably in markets that include these competitors, primarily based on know-how, technical performance, quality, delivery, price and aftermarket support. We continue to focus on products, which serve markets that are growing and where we have a technical and commercially competitive advantage.

 

CVD Equipment competes with companies located in Asia, Europe, and the US in both the production and research market. In the production and research markets, some of our potential customers built their own equipment. Additionally, there are large established companies who compete with us and pose a competitive risk in the market. Due to budgetary and funding constraints, many customers are price sensitive. We believe that our systems are among the most advanced available for the targeted market and coupled with our vertical integration in engineering and manufacturing, we believe that we can compete effectively.

 

11
 

 

SDC’s gas management and chemical delivery control systems are among the most advanced available. We further believe that SDC is differentiated from our competitors through our deep understanding of how the systems in which our products are incorporated are used in field applications. We have gained this understanding as a result of having designed and built complex process gas systems for our CVD Equipment group as well as for a number of the world’s leading semiconductor, aerospace, medical, solar manufacturers, research laboratories and universities.

 

CVD Materials consists of our MesoScribe subsidiary. There is no viable direct competitor for the MesoScribe services. There are technology competitors in the direct write applications and other additive manufacturing technologies competing for the same contracts and business opportunity.

 

Sources of Supply

 

Many of the components used in producing our products are purchased from unrelated suppliers. We have OEM status with our suppliers, but we are not obligated to purchase a pre-determined quantity. We are not dependent on a principal or major supplier and alternate suppliers are available. Historically, subject to lead times, the components and raw materials we used in manufacturing our products were readily obtainable.

 

We maintain a fully equipped machine shop that we use to fabricate a significant portion of our metal components in-house, including the most intricately designed parts of our equipment. We expanded our machine shop in 2022 to allow us to expand our ability to fabricate parts. Our quartz fabrication capability is currently sufficient to meet our quartzware needs. We believe our vertical manufacturing integration is a competitive advantage.

 

Materials procured from suppliers and/or manufactured internally undergo a rigorous quality control process to ensure that the parts meet or exceed our requirements and those of our customers. Upon final assembly, all equipment undergoes a final series of complete testing to ensure maximum product performance.

 

Backlog

 

As of December 31, 2023, our backlog was approximately $18.4 million, compared to $17.8 million as of December 31, 2022, an increase of $0.6 million. Our backlog at December 31, 2023 consists of approximately $16.3 million remaining performance obligations for contracts in progress and the balance of approximately $2.1 million represents orders received from customers. We continue to work at diversifying our customer base away from any one customer as we focus on new opportunities with new and existing customers within our existing marketplaces and in new applications. The timing for completion of backlog varies depending on the product mix and can be as long as two years or as short as 30-60 days.

 

12
 

 

There can be no assurance that our backlog will result in actual revenue in any particular period, or at all, or that any contract included in backlog will be profitable. The actual amount and timing of any revenue is subject to various contingencies, many of which are beyond our control, such as cancellations and delays. As a result of these contingencies, we may adjust our backlog if we determine that such orders are no longer firm. In addition to adjustments from these types of contingencies, variations in backlog from time to time are attributable, in part, to changes in sales mix, the timing of contract proposals, the timing of contract awards, delivery schedules on specific contracts. As a result, we believe our backlog and orders, at any point in time, are not necessarily indicative of the total sales anticipated for any future period.

 

Government Regulations

 

We are subject to a variety of federal, state and local government regulations, such as environmental, labor and export control regulations. We believe that we have obtained all necessary permits to operate our business and that we are in material compliance with all laws and regulations applicable to us. These regulations are subject to change and the effect of these changes could materially impact our business in certain technology areas and regions.

 

Utilizing our in-house safety team, engineering expertise and consultants as required, we continue to monitor and comply with applicable Environmental Health and Safety regulations at our facilities as well as the installation of equipment at our customer facilities.

 

With respect to our sales to customers located in China or elsewhere outside the United States, products which (i) are manufactured in the United States, (ii) incorporate controlled U.S. origin parts, technology, or software, or (iii) are based on U.S. technology, are subject to the U.S. Export Administration Regulations (“EAR”). We continue to monitor, review, and maintain ongoing compliance with the EAR with respect to our export sales.

 

Product Liability

 

Our products are used in our customers’ manufacturing processes, which in some cases contain explosive, flammable, corrosive, and toxic gases. There are potential exposures to personal injury as well as property damage, particularly if operated without regard to the design limits of the systems and components. Additionally, the end products of some of our customers are used in areas such as aerospace and high-tech devices where safety is of great concern. Management reviews its insurance coverage on an annual basis or more frequently, if appropriate, and we believe we have the types and amounts of insurance coverage that are sufficient for our business.

 

Human Capital

 

We consider our employees a vital asset to our business and strive to ensure we foster a work environment of respect, communication, objective orientation, and personal life balance. We believe this results in a higher level of employee satisfaction and hence improved performance and employment longevity. On December 31, 2023, we had 128 employees. We had 70 employees in manufacturing, 30 in engineering (including research and development and efforts related to product improvement), 5 in field service, 9 in sales and marketing and 14 in general management, maintenance and administration, compared to 136 employees as of December 31, 2022. None of our employees were subject to a collective bargaining agreement.

 

13
 

 

The implementation of our business strategy depends on our ability to hire, train, and retain qualified and diverse professionals, and we must emphasize employee development and training in order to do so. We are committed to identifying and developing the talents of our next generation of managers and intend to establish a strong succession-planning program for our critical positions, including internships for technical and engineering resources from local universities. Moreover, a key strategic focus of our management team is to foster and maintain a strong and healthy culture, where collaboration to achieve results and focus on the success of our customers and shareholders is paramount.

 

Employee Safety

 

The health and safety of our employees and partners is our highest priority, and this is consistent with our operating philosophy. We maintain strong environmental, health and safety protocols that focus on implementing policies and training programs, as well as performing self-audits to ensure our colleagues and partners leave the workplace safely on a daily basis.

 

Employee Compensation

 

Management continues to review our employee compensation programs to better align the compensation of our employees with our objectives, performance, and personal performance, and to provide the proper short-term and long-term incentives to attract, retain and motivate them to achieve superior results. We believe we must offer wages that are competitive and consistent with employee positions, skill levels, experience, and knowledge, and in order to do so we may work with a nationally recognized outside compensation and benefits consulting firm to independently evaluate the effectiveness of our executive and non-executive compensation and benefit programs and to provide benchmarking against our peers within our industry.

 

Equal Opportunity

 

We are committed to building and sustaining a culture of equal opportunity that encourages all of our employees to reach their full potential. Our CVD team, like the technologies we enable, is a rich combination of diverse individuals coming together to make a material difference for our people, our customers, and the world. As a company that enables tomorrow’s technologies, we recognize that a diverse employee population makes CVD a stronger, more innovative, and a more engaging place to work. We are always striving to attract talented individuals from a diverse candidate pool.

 

Available Information

 

Our website address is www.cvdequipment.com and the contents of our website, including our investor relations website, is not incorporated by reference into this filing or any other report we file with or furnish to the SEC. We have no duty to update or revise any forward-looking statements in this Annual Report on Form 10-K or in other reports filed with the SEC, whether as a result of new information, future events or otherwise, unless we are required to do so by law. The SEC maintains a website (www.sec.gov) that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.

 

14
 

 

Item 1A.Risk Factors

 

In addition to the other information set forth in this Annual Report on Form 10-K, our shareholders should carefully consider the risk factors described below. The risks set forth below may not be the only risk factors relating to the Company. Any of these factors, many of which are beyond our control, could materially adversely affect our business, financial condition, operating results, cash flow and stock price.

 

Risk categories:

 

  ● Risks related to sales and product development
  ● Risks related to manufacturing and supply chain
  ● Risks related to cybersecurity, intellectual property and regulatory compliance
  ● Risks related to financial and accounting matters
  ● Risks related to product liability
  ● Risks related to our stock
  ● General risk factors

 

Risks related to sales and product development

 

Historically, we have maintained a highly concentrated customer base so that changes in ordering patterns, delays or order cancellations could have a material adverse effect on our business and results of operations.

 

During 2023, three customers represented 14.3%, 13.5% and 10.9% of our total revenues. The loss of a major customer would have to be replaced by others, and our inability to do so may have a material adverse effect on our business and financial condition. We expect that contracts or orders from a relatively limited number of customers will, at times, continue to account for a substantial portion of our business. The mix and type of customers, and sales to any single customer, may vary significantly from quarter to quarter and from year to year. If any major customer did not place orders, or if they substantially reduced, delayed, or cancelled orders, we may not be able to replace the business in a timely manner or at all, which can and has had a material adverse effect on our results of operations and financial condition.

 

Our lengthy and variable sales cycle makes it difficult to predict our financial results.

 

The marketing, sale and manufacture of our products, often requires a lengthy sales cycle ranging from several months to over one year before we can complete production and delivery. The lengthy sales cycle makes forecasting the volume and timing of sales difficult and raises additional risks that customers may cancel or decide not to enter into contracts. The length of the sales cycle depends on the size and complexity of the project, the customer’s in-depth evaluation of our products, and, in some cases, the protracted nature of a bidding process.

 

15
 

 

Because a significant portion of our operating expenses are fixed, we have and may continue to incur substantial expense before we earn associated revenue. If customer cancellations occur, they could result in the loss of anticipated sales without allowing us sufficient time to reduce our operating expenses.

 

If any of our customers cancel or fail to accept a large system order, our financial position and results of operations could be materially and adversely affected.

 

Our backlog includes orders for customized systems including our chemical vapor deposition equipment and furnaces which are built to client specifications. These customized systems can have prices up to several million dollars, depending on the configuration, specific options included and any specific requirements of the customer. Because our orders are subject to cancellation or delay by the customer, our backlog at any point in time is not necessarily representative of actual sales for succeeding periods, nor does our backlog provide any assurance of achievement of revenues or that we will realize a profit from completing these orders. Our financial position and results of operations could be materially and adversely affected should any large system order be cancelled prior to shipment, or not be accepted by the customer due to alleged non-conformity with product specifications or otherwise. Likewise, a significant change in the liquidity or financial position of any of our customers that purchase large systems, could have a material impact on the collectability of our accounts receivable and our future operating results. Our backlog does not provide any assurance that we will realize a profit from those orders or indicate in which period revenue will be recognized.

 

If demand declines for chemical vapor deposition/infiltration, physical vapor transport, gas control and related equipment, or for carbon nanotube and nanowire deposition systems, our financial position and results of operations could be materially adversely affected.

 

Our products are utilized to develop and manufacture materials and coatings for industrial and research applications that are used in numerous markets including but not limited to power electronics, battery materials, aerospace, nano and advanced electronic components. A significant part of our growth strategy involves continued expansion of the sales of our products for industrial as well as research and development purposes by companies, universities, and government-funded research laboratories. The availability of funds for these purposes may be subject to budgetary and political restrictions, as well as cost-cutting measures by manufacturers in the markets in which we operate.

 

If the availability of funds or the demand for capital equipment in the markets in which we operate declines, the demand for our products would also decline and our financial position and results of operations could be harmed.

 

16
 

 

The demand for our products and the profitability of our products can change significantly from period to period because of numerous factors.

 

The industries in which we operate are characterized by ongoing factors, including:

 

  ● global and regional economic developments and conditions including in Europe and Asia;
  ● governmental budgetary and political constraints;
  ● changes in the capacity utilization and production volume for research and industrial applications in the markets in which we operate;
  ● the profitability and capital resources of manufacturers in the markets in which we operate;
  ● changes in technology;
  ● the availability of funds for research and development; and
  ● the effects of supply chain disruptions.

 

For these and other reasons, our results of operations for past periods may not necessarily be indicative of future operating results.

 

Our business might be adversely affected by our dependence on foreign business.

 

Because a material portion of our revenues are traditionally derived from international customers, our operating results could be negatively affected by a decline in the economies of any of the countries or regions in which we do business. Each region can exhibit unique characteristics, which can cause capital equipment investment patterns to vary significantly from period to period. Periodic local or international economic downturns, trade balance issues and political instability, as well as fluctuations in interest and currency exchange rates, could negatively affect our business and results of operations.

 

The majority of our sales to date have been primarily priced in U.S. dollars. While our business has not been materially affected in the past by currency fluctuations, there is a risk that it may be materially adversely affected in the future. Such risks include possible losses due to both currency exchange rate fluctuations and from possible social and political instability.

 

Our reputation and operating performance may be negatively affected if our products are not timely delivered.

 

We provide complex products that often require substantial lead-time for design, ordering parts and materials, and for assembly and installation. The time required to design, order parts and materials and to manufacture, assemble and install our products, may in turn lead to delays or shortages in the availability of some products. If a product is delayed or is the subject of shortage because of problems with our ability to design, manufacture or assemble the product on a timely basis, obtain necessary materials and components, or if a product or software otherwise fails to meet performance criteria, we may lose revenue opportunities entirely, or experience delays in revenue recognition associated with a product or service. In addition, we may incur higher operating expenses during the period required to correct the problem.

 

17
 

 

We may not be able to keep pace with the rapid change in the technology we use in our products.

 

We believe that our continued success in the markets in which we operate depends, in part, on our ability to continually improve existing technologies and to develop and manufacture new products and product enhancements on a timely and cost-effective basis. We must be able to introduce these products and product enhancements into the market in a timely manner, in response to customer’s demands for higher-performance research and assembly equipment, customized to address rapid technological advances in capital equipment designs.

 

Technological innovations are inherently complex and require long development cycles and appropriate professional staffing. Our future business success depends on our ability to develop and introduce new products, or new uses for existing products, that successfully address changing customer needs. Our success also depends on our ability to achieve market acceptance of our new products. To maintain our success in the marketplace, we may have to substantially increase our expenditures on research and development. If we do not develop and introduce new products, technologies or uses for existing products in a timely manner and continually find ways to reduce the cost of developing and producing them in response to changing market conditions or customer requirements, our business could be seriously harmed.

 

We face significant competition, and we are relatively small in size and have fewer resources in comparison with many of our competitors.

 

We face significant competition throughout the world, which may increase as certain markets in which we operate continue to evolve. Our future performance depends, in part, upon our ability to continue to compete successfully worldwide. Some of our competitors are diversified companies that have substantially greater financial resources and more extensive research, engineering, manufacturing, marketing and customer service and support capabilities than we can provide. We face competition from companies whose strategy is to provide a broad array of products, some of which compete with the products and services that we offer, as well as companies, universities and research laboratories that have the capacity to design and build their own equipment internally. These competitors may bundle their products and services in a manner that may discourage customers from purchasing our products. In addition, we face competition from smaller emerging processing equipment companies, whose strategy is to provide a portion of the products and services that we offer at often lower prices than ours, using innovative technology to sell products into specialized markets. Loss of competitive position could impair our prices, customer orders, revenue, gross margin, and market share, any of which would negatively affect our financial position and results of operations. Our failure to compete successfully with these other companies would seriously harm our business. There is a risk that larger, better financed competitors will develop and market more advanced products than those we currently offer, or that competitors with greater financial resources may decrease prices, thereby putting us under financial pressure.

 

18
 

 

Risks related to manufacturing and our supply chain

 

Manufacturing interruptions or delays could affect our ability to meet customer demand and lead to higher costs, while the failure to estimate customer demand accurately could result in excess or obsolete inventory.

 

Our business depends on timely supply of equipment, services and related products that meet the rapidly changing technical and volume requirements of our customers. Some key parts to our products are subject to long lead-times and/or obtainable only from a single supplier or limited group of suppliers. Cyclical industry conditions and the volatility of demand for manufacturing equipment increase capital, technical, operational and other risks for us and for companies throughout our supply chain. Further, these conditions may cause some suppliers to scale back operations, exit businesses, merge with other companies, or file for bankruptcy protection and possibly cease operations. We have also experienced and continue to experience significant disruptions in our supply chain, resulting in delays and higher costs to procure certain components and materials that we utilize in our business.

 

We may also experience significant interruptions of our manufacturing operations, delays in our ability to deliver products or services, increased costs or customer order cancellations as a result of:

 

  ● The failure or inability of suppliers to timely deliver sufficient quantities of quality parts on a cost-effective basis;
  ● Volatility in the availability and cost of materials, including rare earth elements;
  ● Difficulties or delays in obtaining required import or export approvals;
  ● Information technology or infrastructure failures; and
  ● Natural disasters or other events beyond our control (such as earthquakes, floods or storms, regional economic downturns, pandemics, social unrest, political instability, terrorism, or acts of war).

 

If a supplier fails to meet our requirements concerning quality, cost, or other performance factors, we may transfer our business to alternative sources, which could entail manufacturing delays, additional costs, or other difficulties. In addition, if we need to rapidly increase our business and manufacturing capacity to meet increases in demand or expedited shipment schedules, this may exacerbate any interruptions in our manufacturing operations and supply chain and the associated effect on our working capital.

 

We are presently experiencing supply chain delays and cost increases that may adversely affect our business.

 

Geopolitical developments across Europe and Asia have and may continue to restrict our ability to procure raw materials and components such as nickel and integrated circuits. Since 2021, we have experienced increased costs on certain components as well as delays in supply chain delivery, which may also impact our ability to recognize revenue and reduce our gross profit margins, as well as extend our manufacturing lead times and reduce our manufacturing efficiencies. We have begun placing orders with more lead time to help mitigate the manufacturing delays, as well as assessing other suppliers or components to attempt to mitigate the potential cost impacts. In addition, we are utilizing our in-house flexible manufacturing to attempt to further mitigate both potential schedule delivery delays and material cost increase, as well as increasing sales prices. While we have taken actions to mitigate the potential negative impacts to our revenue and profitability, there can be no assurance of the ultimate impact and the length of time that the supply chain factors may impact our revenues and profitability.

 

19
 

 

Inflation has and may continue to adversely affect our business, financial condition, and results of operations.

 

Recent global inflation has adversely affected our costs, including the cost of materials, production, and labor. As such, we have had to implement measures to mitigate the negative impacts of inflation on our costs. As the selling prices in our customer contracts are fixed, any increase in the cost of materials, labor and other costs as we manufacture any system would negatively impact our gross margins and results of operations. Longstanding or increased periods of inflation could perpetuate these material adverse effects on our business, financial condition and results of operations.

 

If our critical suppliers fail to deliver enough quality materials and components in a timely and cost-effective manner, it could negatively affect our business.

 

We use numerous unrelated suppliers of materials and components. Due to geopolitical developments across Europe and Asia, we are experiencing reduced availability of raw materials and components. In turn, any reduction in the availability of these materials and components may reduce our ability to obtain sufficient amounts in a cost-effective manner. We generally do not have guaranteed supply arrangements with our suppliers. Because of the variability and uniqueness of our customer’s orders, we try to avoid maintaining an extensive inventory of materials and components for manufacturing. While we are not dependent on any principal or major supplier for most of our material and component needs, switching to an alternative supplier may take significant amounts of time and added expense, which could result in a disruption of our operations and adversely affect our business. It is not always practical or even possible to ensure that component parts are available from multiple suppliers; accordingly, we procure some key parts from a single supplier or a limited group of suppliers. At certain times, increases in demand for capital equipment can result in longer lead-times for many important system components, which may cause delays in meeting shipments to our customers. The delay in the shipment of even a few systems could cause significant variations in our quarterly revenue, operating results and the market value of our common stock.

 

Our manufacturing facilities are in Central Islip, New York and Saugerties, New York could be affected due to multiple weather risks, including risks to our Central Islip facility from hurricanes and similar phenomena.

 

Our manufacturing facilities are located in Central Islip, New York and Saugerties, New York could be affected by multiple weather risks, most notably hurricanes for our Central Islip facility which is located on Long Island, New York. Although we carry property and casualty insurance and business interruption insurance, future possible disruptions of operations or damage to property, plant and equipment due to hurricanes or other weather risks could result in impaired production and affect our ability to meet our commitments to our customers and impair important business relationships, the loss of which could adversely affect our operations and profitability. We do, however, maintain a backup power source at our Central Islip facility, are working to establish deeper redundancies between our New York facilities to help mitigate this risk.

 

20
 

 

Risks related to cybersecurity, intellectual property and regulatory compliance

 

If we are subject to cyberattacks, we could incur substantial costs and, if such attacks are successful, we could incur significant liabilities, reputational harm, and disruption to our operations.

 

We manage, store, and transmit proprietary information and sensitive data relating to our operations. We may be subject to breaches of the information technology systems we use for these purposes. Experienced computer programmers and hackers may be able to penetrate our network security and misappropriate and/or compromise our confidential information (and or third-party confidential information), create system disruptions, or cause shutdowns. Computer programmers and hackers also may be able to develop and deploy viruses, worms, and other malicious software programs that attack our systems or our products, or that otherwise exploit any security vulnerabilities.

 

While we have an active security training program for all employees during the year, utilize intrusion prevention and detection systems, as well as hardware firewall and virus security, the costs to address the foregoing security problems and security vulnerabilities before or after a cyber-incident could be significant. Our remediation efforts may not be successful and could result in interruptions, delays, or cessation of service, and loss of existing or potential customers, impeding our sales, manufacturing, distribution, or other critical functions. In addition, breaches of our security measures and the unapproved dissemination of proprietary information or sensitive data about us, our customer, or other third parties, could expose us, our customers, or other third parties to a risk of loss or misuse of this information, result in litigation and potential liability for us, damage our reputation, or otherwise harm our business.

 

Our financial position and results of operations may be materially harmed if we are unable to recoup our investment in research and development.

 

The rapid change in technology in our industry requires that we continue to make substantial investments in research and development and selective acquisitions of technologies and products, to enhance the performance and functionality of our product line, to keep pace with competitive products and to satisfy customer demands for improved performance, features and functionality. There can be no assurance that revenue from future products or enhancements will be sufficient to recover the development costs associated with such products, enhancements, or acquisitions, or that we will be able to secure the financial resources necessary to fund future research and development or acquisitions. Research and development costs are typically incurred before we confirm the technical feasibility and commercial viability of a product, and not all development activities result in commercially viable products. In addition, we cannot ensure that products or enhancements will receive market acceptance, or that we will be able to sell these products at prices that are favorable to us. Our business could be seriously harmed if we are unable to sell our products at favorable prices, or if our products are not accepted by the markets in which we operate.

 

21
 

 

We have made investments in our proprietary technologies. If third parties violate our proprietary rights, or accuse us of infringing upon their proprietary rights, such events could result in a loss of value of some of our intellectual property or costly litigation.

 

We attempt to protect certain of our intellectual property rights by obtaining patent and trademark protection where we believe it is appropriate to do so. While patent, copyright and trademark protection for our intellectual property may be important, we believe our future success in highly dynamic markets is most dependent upon the technical competence and creative skills of our personnel. We may also attempt to protect our trade secrets and other proprietary information through confidentiality agreements with our customers, suppliers, employees, and consultants, and through other internal security measures. However, these employees, consultants and third parties may breach these agreements, and we may not have adequate remedies for wrongdoing. In addition, the laws of certain territories in which we sell our products may not protect our intellectual property rights to the same extent as do the laws of the United States.

 

Occasionally, we may receive communications from other parties asserting the existence of patent rights or other intellectual property rights that they believe cover certain of our products, processes, technologies, or information. In addition, it is possible we could have a dispute with a customer concerning the use of intellectual property utilized in their equipment. If such cases arise, we will evaluate our position and consider the available alternatives, which may include seeking licenses to use the technology in question on commercially reasonable terms, developing new alternative technology or defending our position. Nevertheless, we cannot ensure that we will be able to obtain licenses, or, if we are able to obtain licenses, which related terms will be acceptable, or that litigation or other administrative proceedings will not occur. Defending our intellectual property rights through litigation could be very costly. If we are not able to negotiate the necessary licenses on commercially reasonable terms or successfully defend our position, our ability to utilize such intellectual property could substantially inhibit our access to certain markets and our ability to compete in these markets which could have a material adverse effect on our financial position and results of operations.

 

We may be unable to obtain required export licenses for the sale of our products.

 

Whether with respect to sales to customers located in China or otherwise, products which (i) are manufactured in the United States, (ii) incorporate controlled U.S. origin parts, technology, or software, or (iii) are based on U.S. technology, are subject to the U.S. Export Administration Regulations (“EAR”) when exported to and re-exported from international jurisdictions, in addition to the local jurisdiction’s export regulations applicable to individual shipments. Licenses or proper license exceptions may be required for the shipment of our products to certain customers or countries. Obtaining an export license or determining whether an export license exception exists often requires considerable effort by us and cooperation from the customer, which can add time to the order fulfillment process. We may be unable to obtain required export licenses or qualify for export license exceptions and, as a result, we may be unable to export products to our customers and/or meet their servicing needs. Non-compliance with the EAR or other applicable export regulations could result in a wide range of penalties including the denial of export privileges, fines, criminal penalties, and the seizure of commodities. If an export regulatory body determines that any of our shipments violate applicable export regulations, we could be fined significant sums and our export capabilities could be restricted, which could have a material adverse impact on our business.

 

22
 

 

Failure to comply with the United States Foreign Corrupt Practices Act could subject us to penalties and other adverse consequences.

 

We are subject to the United States Foreign Corrupt Practices Act, which generally prohibits United States companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or retaining business. We have agreements with third parties and make sales in countries known to experience corruption, extortion, bribery, pay-offs, theft, and other fraudulent practices. We can make no assurance, however, that our employees or other agents will not engage in such conduct for which we might be held responsible. If our employees or other agents are found to have engaged in such practices, we could suffer severe penalties and other consequences that may have a material adverse effect on our business, financial condition, and results of operations.

 

We are subject to environmental regulations, and our inability or failure to comply with these regulations could adversely affect our business.

 

We are subject to environmental regulations in connection with our business operations, including regulations related to the development and manufacture of our products and our customers’ use of our products. Our failure or inability to comply with existing or future environmental regulations could result in significant remediation liabilities, the imposition of fines or the suspension or termination of development, manufacturing, or use of certain of our products, or affect the operation of our facilities, use or value of our real property, each of which could damage our financial position and results of operations.

 

Regulations related to conflict minerals will force us to incur additional expenses, may make our supply chains more complex, and may result in damage to our relationships with customers.

 

Under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, or the Dodd-Frank Act, the SEC adopted requirements for companies that manufacture products that contain certain minerals and metals known as “conflict minerals”. These rules require public companies to perform diligence and to report annually to the SEC whether such minerals originate from the Democratic Republic of Congo and adjoining countries. The implementation of these requirements could adversely affect the sourcing, availability, and pricing of minerals we use in the manufacture of our products. In addition, we have incurred and will continue to incur additional costs to comply with the disclosure requirements, including costs related to determining the source of any of the relevant minerals used in our products. Given the complexity of our supply chain, we may not be able to ascertain the origins of these minerals used in our products through the due diligence procedures that we implement, which may harm our reputation. We may also face difficulties in satisfying customers who may require that our products be certified as conflict mineral free, which could harm our relationships with these customers and lead to a loss of revenue. These requirements could limit the pool of suppliers that can provide conflict-free minerals, and we may be unable to obtain conflict-free minerals at competitive prices, which could increase our costs and adversely affect our manufacturing operations and our profitability.

 

23
 

 

Risks related to financial and accounting matters

 

Cyclical demand for our products may make it difficult for us to accurately budget our expense levels, which are based in part on our projections of future revenues.

 

Historically, demand for our equipment and related consumable products have been volatile because of changes in supply and demand, and other factors in the manufacturing process. Our orders tend to be more volatile than our revenue, as any change in demand is reflected immediately in orders booked, which are net of cancellations, while revenue, tends to be recognized over multiple quarters because of procurement and production lead times, and the deferral of certain revenue under our revenue recognition policies. The fiscal period in which we can recognize revenue is also at times subject to the length of time that our customers require to evaluate the performance of our equipment. This could cause our quarterly operating results to fluctuate.

 

When cyclical fluctuations result in lower-than-expected revenue levels, operating results have been and may continue to be materially adversely affected and cost reduction measures have been and may continue to be necessary for us to remain competitive and financially sound. During a down cycle, we must be able to make timely adjustments to our cost and expense structure to correspond to the prevailing market conditions. In addition, during periods of rapid growth, we must be able to increase manufacturing capacity and the number of our personnel to meet customer demand, which may require additional liquidity. We can provide no assurance, that these objectives can be met in a timely manner in response to changes within the industry cycles in which we operate. If we fail to respond to these cyclical changes, our business could be seriously harmed.

 

We do not have long-term volume production contracts with our customers, and we do not control the timing or volume of orders placed by our customers. Whether and to what extent our customers place orders for any specific products, and the mix and quantities of products included in those orders are factors beyond our control. Insufficient orders would result in under-utilization of our manufacturing facilities and infrastructure and will negatively affect our financial position and results of operations.

 

We might require additional financing.

 

Our continuing operating losses may make it difficult for us to obtain financing on commercially reasonable terms, if at all. If adequate financing is not available when required on commercially reasonable terms, if at all, our business and operations may be materially and adversely affected. In addition, we could issue additional common stock, to fund our growth initiatives and operations which could materially dilute the ownership interests of the then existing shareholders.

 

We may, in the future, identify deficiencies in controls over financial reporting.

 

While we have concluded that, as of December 31, 2023, our disclosure and reporting controls were effective as included in Part II, Item 9A, there can be no assurance that material weaknesses will not be identified in the future. If we do identify material weaknesses in our internal controls over financial reporting in the future, our ability to analyze, record and report financial information free of material misstatements, and to prepare our financial statements within the time periods specified by the rules and forms of the SEC, may likely be adversely affected.

 

24
 

 

We have and may continue to be required to take impairment charges on assets.

 

We are required to assess our long-lived assets, including acquired intangible assets and property, plant and equipment, for recoverability and impairment whenever there are indicators or impairment, such as an adverse change in business climate.

 

As part of our long-term strategy, we have pursued acquisitions of other companies or assets, and may pursue future acquisitions of other companies or assets which could potentially increase our assets. Adverse changes in business conditions could materially impact our estimates of future operations and result in impairment charges to these assets. If our assets were impaired, our financial condition and results of operations could be materially and adversely affected.

 

Acquisitions can result in an increase in our operating costs, divert management’s attention away from other operational matters and expose us to other associated risks.

 

We evaluate potential acquisitions of businesses and technologies, and we consider targeted acquisitions that expand our core competencies to be an important part of our future growth strategy. In the past, we have made acquisitions of other businesses with synergistic products, services and technologies, and plan to continue to do so in the future.

 

Acquisitions involve numerous risks, which include but are not limited to:

 

  ● difficulties and increased costs in connection with the integration of the personnel, operations, technologies, services and products of the acquired companies into our existing facilities and operations;
  ● diversion of management’s attention from other operational matters;
  ● failure to commercialize the acquired technology;
  ● the potential loss of key employees of the acquired companies;
  ● lack of synergy, or inability to realize expected synergies, resulting from the acquisitions;
  ● the risk that the issuance of our common stock, if any, in an acquisition or merger could be dilutive to our shareholders;
  ● the inability to obtain and protect intellectual property rights in key technologies; and
  ● the acquired assets becoming impaired as a result of technological advancements or worse-than-expected performance of the acquired assets.

 

Risks related to product liability

 

We face the risk of product liability claims.

 

The manufacture and sale of our products, which in operation sometimes involve the use of toxic materials and extreme temperatures and could result in product liability claims. For example, our rapid thermal processing systems used to heat semiconductor materials to temperatures more than 1000º Celsius have certain inherent risks. A failure of our products at a customer site could also result in losses due to interruption of the business operations of our customer. While we regularly evaluate the nature and limits of our insurance coverages, there can be no assurance that our existing policies of insurance will be adequate to protect us from all liabilities that we might incur in connection with the manufacture and sale of our products in the event of a successful product liability claim or series of successful claims against us.

 

25
 

 

The health and environmental effects of nanotechnology are unknown, and this uncertainty could adversely affect the expansion of our business.

 

The health and environmental effects of nanotechnology are unknown. There is no scientific agreement on the health effects of nanomaterials in general and carbon nanotubes but some scientists believe that in some cases, nanomaterials may be hazardous to an individual’s health or to the environment.

 

The science of nanotechnology is based on arranging atoms in such a way as to modify or build materials not made in nature; therefore, the effects are unknown. Future research into the effects of nanomaterials in general, and carbon nanotubes, on health and environmental issues, may have an adverse effect on products incorporating nanotechnology. Since part of our growth strategy is based on sales of research equipment to produce carbon nanotubes and the sale of such materials, the determination that these materials are harmful could adversely affect the expansion of our business.

 

Risk related to our stock

 

The price of our common shares is volatile and could decline significantly.

 

The stock market in general and the market for technology stocks has experienced volatility. If those industry-based market fluctuations continue, the trading price of our common shares could decline significantly independent of the overall market, and shareholders could lose all or a substantial part of their investment. The market price of our common shares could fluctuate significantly in response to several factors, including, among others:

 

  ● difficult macroeconomic conditions, unfavorable geopolitical events, and general stock market uncertainties, such as those occasioned by a global liquidity crisis and a failure of large financial institutions;
  ● an offering of our common shares to raise capital;
  ● receipt of large orders or cancellations of orders for our products;
  ● issues associated with the performance and reliability of our products;
  ● actual or anticipated variations in our results of operations;
  ● announcements of financial developments or technological innovations;
  ● changes in recommendations and/or financial estimates by investment research analysis;
  ● strategic transactions, such as acquisitions, divestitures, or spin-offs;
  ● offerings of our securities;
  ● the occurrence of major catastrophic events; and
  ● volatile trading volumes.

 

26
 

 

Significant price and value fluctuations have occurred with respect to our publicly traded securities and those of technology companies generally. The price of our common shares is likely to be volatile in the future. In the past, securities class action litigation often has been brought against a company following periods of volatility in the market price of its securities. If similar litigation were pursued against us, it could result in substantial costs and a diversion of management’s attention and resources, which could materially and adversely affect our financial condition, results of operations, and liquidity.

 

General risks

 

Our success is highly dependent on the technical, sales, marketing and managerial contributions of key individuals, including our Chief Executive Officer and President, and we may be unable to retain these individuals or recruit others.

 

We depend on our senior executives including our Chief Executive Officer and President, and certain key managers as well as, engineering, research and development, sales, marketing and manufacturing personnel, who are critical to our business. Except for our Chief Executive Officer and President, we do not have employment agreements with our key employees. Furthermore, the current labor market remains very competitive and challenging for the acquisition and retention of key employees. Larger competitors may be able to offer more generous compensation packages to our executives and key employees, and therefore we risk losing key personnel to those competitors. If we were to lose the services of any of our key personnel, our engineering, product development, manufacturing and sales efforts could be slowed. We may also incur increased operating expenses and be required to divert the attention of our senior executives to search for their replacements. The integration of any new personnel could disrupt our ongoing operations.

 

We may not be able to hire or retain the number of qualified personnel, particularly engineering personnel, required for our business, which would harm the development and sales of our products and limit our ability to grow.

 

Competition in our industry for senior management, technical, sales, marketing and other key personnel is intense and has been made even more challenging in the current labor market. If we are unable to retain our existing personnel, or attract and train additional qualified personnel, our growth may be limited due to a lack of capacity to develop and market our products.

 

We have, from time to time, had trouble in hiring and retaining skilled engineers with appropriate qualifications to support our growth strategy. Our success depends on our ability to identify, hire, train and retain qualified engineering personnel with experience in equipment design. Specifically, we need to continue to attract and retain mechanical, electrical, software and field service engineers to work with our direct sales force to technically qualify and perform on new sales opportunities and orders, and to demonstrate our products.

 

27
 

 

Item 1B.Unresolved Staff Comments

 

None.

 

Item 1C.Cybersecurity

 

We have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems. We use recognized commercially reasonable measures, tools, and methodologies to manage cybersecurity risk, which are tested regularly. We also monitor and evaluate our cybersecurity posture on an ongoing basis through regular malware scans, penetration tests, and third-party reviews. Specific controls that are used to some extent include endpoint threat detection, identity and access management (IAM), privileged access management (PAM), logging and monitoring, multi-factor authentication (MFA), firewalls and intrusion detection and prevention, and vulnerability and patch management.

 

To manage our material risks from cybersecurity threats and to protect against, detect, and prepare to respond to cybersecurity incidents, we undertake the below listed activities:

 

  ● Monitor emerging data protection laws and implement changes to our compliance processes;
  ● Conduct annual cybersecurity assessments for employees who use our system to evaluate training needs;
  ● Conduct onboarding and cyber security training for all employees on an ongoing basis;
  ● Conduct regular phishing email simulations for all employees; and
  ● Carry cybersecurity risk insurance that protects against the potential losses from a cybersecurity incident.

 

Our incident response plan coordinates the activities that we and our third-party cybersecurity provider take to prepare to respond to and recover from cybersecurity incidents. These include processes to triage, assess severity, investigate, escalate, contain, and remediate an incident, as well as to comply with potentially applicable legal obligations and mitigate brand and reputational damage. We have an IT continuity plan that we continuously review and update in line with our evolving applications architecture.

 

Our Board of Directors and Audit Committee oversee our cybersecurity efforts to ensure effective governance in managing risks associated with cybersecurity threats. Our Director of Information Technology provides periodic updates to the Board of Directors and Audit Committee regarding our cybersecurity program, including status updates on various projects to enhance our overall cybersecurity posture.

 

We describe whether and how risks from cybersecurity threats have or are reasonably likely to affect our financial position, results of operations, and cash flows under the heading “Risk related to cybersecurity, intellectual property and regulatory compliance,” which is included as part of Item 1A. Risk Factors of this Annual Report on Form 10-K, which disclosures are incorporated by reference herein.

 

Item 2. Properties

 

Our corporate headquarters, research and development, manufacturing and process coating facilities as of December 31, 2023 are as follows:

 

Owned Locations   Size (sf)   Segment   Mortgage/Loan   Principal use
Central Islip, NY   128,000   CVD Equipment / CVD Materials   No   Corporate headquarters; R&D; Manufacturing
                 
Saugerties, NY   22,000   SDC   No   Manufacturing; Administration

 

Item 3. Legal Proceedings.

 

Not applicable.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

28
 

 

PART II

 

Item 5.Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

As of March 25, 2024, there were approximately 55 holders of record and approximately 3,544 beneficial owners of our common stock, and the closing sales price of our common stock as reported on the NASDAQ Capital Market was $4.93.

 

Dividend Policy

 

We have never paid dividends on our common stock and we do not anticipate paying dividends on common stock at the present time. We currently intend to retain earnings, if any, for use in our business. There can be no assurance that we will ever pay dividends on our common stock. Our dividend policy with respect to our common stock is within the discretion of the Board of Directors and its policy with respect to dividends in the future will depend on numerous factors, including earnings, financial requirements, and general business conditions.

 

Recent Sales of Unregistered Securities

 

None.

 

Issuer Purchases of Equity Securities

 

None.

 

Item 6. Reserved.

 

29
 

 

Item 7.Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

You should read the following discussion and analysis in conjunction with our consolidated financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.

 

Executive Summary

 

We have served the advanced materials markets with chemical vapor and thermal process equipment for over 40 years. CVD designs, develops, and manufactures a broad range of chemical vapor deposition, gas control, and other state-of-the-art equipment and process solutions used to develop and manufacture materials and coatings for industrial applications and research. To learn more about CVD’s systems and offerings, visit www.cvdequipement.com.

 

During 2023:

 

  ● Revenue declined by $1.7 million or 6.6% as the prior year benefited from a large number of PVT150 orders.
     
  ● Gross margin declined by $1.6 million or 23.5% due to cost overruns experienced on one large contract.
     
  ● Total bookings for 2023 were approximately $25.8 million, a decrease of $7.3 million or 22.1% as compared to 2022. Bookings for 2022 included orders for PVT equipment as compared to none in 2023.
     
  ● Received $8.7 million in orders from a major aerospace company for the production of CVI systems. The systems will be used by our customer to manufacture CMCs for their gas turbine jet engines.
     
  ● Increased our backlog from $17.8 million to $18.4 million.
     
  ● Cash balance at December 31, 2023 was $14.0 million.

 

30
 

 

Business Update

 

Our core strategy is to focus on growth market applications in end-user markets related to the “electrification of everything,” aerospace and industrial applications. The phrase “electrification of everything” refers to the shift from fossil fuels to the use of electricity to power devices, buildings, electric vehicles or EVs, and many other applications. With respect to aerospace, our systems are being used by our customers to produce ceramic matrix composite materials or CMCs that will be used in next generation jet engines with the objective of reducing jet fuel consumption and contributing to the decarbonization of that industry.

 

During 2021, we received the first six (6) orders for our PVT150 system that is used by our customer to grow silicon carbide crystals and received an additional 24 orders from the same customer in 2022. The crystals would be further processed into 150 mm silicon carbide wafers and later processed into integrated circuits and other devices. Devices based on silicon carbide have been shown to reduce energy consumption in EVs and reduce the need for additional cooling elements. While we did not receive any additional orders from this customer, we remain in continuing discussions regarding potential additional orders.

 

We launched our marketing campaign for the PVT150 in the latter part of 2022 as we seek orders from other potential customers. We also developed and launched our new PVT200 system used to grow silicon carbide crystals for the manufacture of 200 mm wafers in 2023.

 

In February 2024, we received our first order for a PVT200. This is our second customer for PVT equipment. This customer plans to evaluate our equipment with the objective to select a vendor for potential additional purchases of PVT equipment.

 

During 2022, we completed the production of a system for a customer that deposits coatings onto powders used in silicon-graphite anodes that has the objective of increasing EV battery performance while lowering cost. We received two additional orders from this customer in 2023 that were completed during the year.

 

During 2023, we also received a total $10.6 million of aerospace orders from multiple customers, reflecting continuing strong interest in the application of CMCs in gas turbine jet engines.

 

In February 2024, we received a multisystem order for approximately $10 million that will be used for depositing a silicon carbide protective coating on OEM components.

 

31
 

 

Results of Operations

 

Years Ended December 31, 2023 and 2022

 

The following table presents revenue and expense line items reported in our Consolidated Statements of Operations for the years ended December 31, 2023 and 2022 and the period-over-period dollar and percentage changes for those line items (in thousands, except percentages).

 

   December 31, 2023   December 31, 2022  

 

Change

  

 

Percent

 
                 
Revenue  $24,109   $25,813   $(1,704)   (7%)
                     
Cost of revenue   19,038    19,186    (148)   (1%)
                     
Gross profit   5,071    6,627    (1,556)   (24%)
                     
Operating expenses                    
Research and development   2,596    1,906    690    36%
Selling   1,632    1,216    416    34%
General and administrative   5,451    5,328    123    2%
Loss on disposition of Tantaline   162    -    162    * 
Impairment charge   111    -    111    * 
                     
Total operating expenses   9,952    8,450    1,502    18%
                     
Operating loss   (4,881)   (1,823)   (3,058)   (168%)
                     
Other income (expense):                    
Interest income   577    162    415    256%
Interest expense   (23)   (8)   (15)   188%
Employee retention credits   -    1,529    (1,529)   (100%)
Foreign exchange loss   42    (95)   137    * 
Other income   91    15    76    * 
Total other income, net   687    1,603    (916)   (57%)
                     
Loss before income tax   (4,194)   (220)   (3,974)   * 
                     
Income tax (benefit) expense   (14)   4    (18)   *  
                     
Net loss  $(4,180)  $(224)  $(3,956)    * 

 

* Not meaningful

 

32
 

 

Revenue

 

   December 31, 2023   December 31, 2022   Change   Percent 
CVD Equipment  $16,334   $16,674   $(340)   (2%)
SDC   7,139    6,541    598    9%
CVD Materials   1,184    3,171    (1,987)   (63%)
Intersegment sales elimination   (548)   (573)   25     * 
Total  $24,109   $25,813   $(1,704)   (7%)

 

* Not meaningful

 

Our revenue for the year ended December 31, 2023 was $24.1 million compared to $25.8 million for the year ended December 31, 2022, a decrease of $1.7 million or 7%.

 

The decrease in revenue versus the prior year period was primarily attributable to decreased revenue of $0.3 million from the CVD Equipment segment related to lower equipment sales and spare parts, $2.0 million decrease from our CVD Materials segment due to the disposition of Tantaline and wind down of MesoScribe’s operations, offset by a $0.6 million increase in revenue from our SDC segment due to higher demand.

 

Revenue from one aerospace customer in 2023 represented 13.5% of our total revenues and 20.1% of CVD Equipment segment revenues. Sales of PVT150 systems made to one customer in 2023 and 2022 represented 14.3% and 29.2%, respectively, of our total revenues and 21.2% and 45.2%, respectively, of CVD Equipment segment revenues.

 

The revenue contributed by the CVD Equipment segment for the year ended December 31, 2023 represented 67% of overall revenue as compared to 65% of overall revenue for the year ended December 31, 2022. The decrease in revenues of $0.3 million or 2% resulted from lower PVT150 revenues offset by an increase in aerospace revenue.

 

The revenue contributed by the SDC segment for the year ended December 31, 2023 represented 28% of overall revenue as compared to 25% of overall revenue for the year ended December 31, 2022. Revenue for our SDC segment increased $0.6 million or 9% due to increased orders and demand for the SDC’s products during 2023 as compared to the prior year.

 

The revenue contributed by the CVD Materials segment for the year ended December 31, 2023 represented 5% of our overall revenue as compared to 12% of overall revenue for the year ended December 31, 2022 The decrease of $2.0 million was principally due to the disposition of Tantaline in May 2023 and the wind down of MesoScribe’s operations.

 

Our order backlog at December 31, 2023 was approximately $18.4 million as compared to December 31, 2022 of $17.8 million. Our order backlog at December 31, 2023 consists of approximately $16.3 million related to remaining performance obligations of contracts in progress and the balance of approximately $2.1 million represents other orders received from customers. One aerospace customer represented 49.2% of our backlog as of December 31, 2023. Historically, our revenues and orders have fluctuated based on changes in order rate as well as other factors in our manufacturing process that impacts the timing of revenue recognition. Accordingly, orders received from customers and revenue recognized may fluctuate from quarter to quarter.

 

33
 

 

Gross Profit

 

Gross profit for the year ended December 31, 2023 amounted to $5.1 million, with a gross profit margin of 21%, compared to a gross profit of $6.6 million and a gross profit margin of 26% for the year ended December 31, 2022. The decrease in gross profit of $1.6 million was primarily due to significant cost overruns on one contract and lower PVT150 and CVD Materials revenues as compared to 2022.

 

Research and Development

 

For the year ended December 31, 2023, research and development expenses were $2.6 million, or 10.8% of revenue as compared to $1.9 million, or 7.4% for the year ended December 31, 2022. The increase in 2023 was the result of increased personnel and employee-related costs to develop new products for key growth markets.

 

General engineering support and expenses related to the development of more standard products and value-added development of existing products are reflected as part of research and development expense. General engineering support and expenses are charged to costs of goods sold when work is performed directly on a customer order.

 

Selling

 

Selling expenses were $1.6 million or 6.8% of the revenue for the year ended December 31, 2023 as compared to $1.2 million or 4.7% for the year ended December 31, 2022. The increase in 2023 was primarily the result of increased personnel and employee-related costs during to support increased marketing efforts.

 

General and Administrative

 

General and administrative expenses for the year ended December 31, 2023 were $5.5 million or 22.6% of revenue compared to $5.3 million or 20.6% of revenue for the year ended December 31, 2022, an increase of $0.1 million. The increase in expenses was principally due to increases in stock-based compensation of $0.2 million, higher professional fees of $0.3 million, and increase in 401(k) match of $0.2 million, offset by lower bonus expense of $0.4 million and lower expenses for CVD Materials of $0.1 million due to the disposition of Tantaline.

 

Loss on Disposition of Tantaline

 

This expense represents the net loss on the sale of our Tantaline subsidiary including professional fees.

 

34
 

 

Impairment Charge

 

This expense represents the loss on the impairment of certain assets of MesoScribe based on the decision to wind down its operations.

 

Other Income, Net

 

Other income, net was $0.7 million for the year ended December 31, 2023 as compared to other income, net of $1.6 million for the year ended December 31, 2022.

 

The increase in interest income of $0.4 million was due to higher interest rates and increased amounts invested in U.S. treasury bills. During 2022, we conducted an analysis to determine if we were entitled to an employee retention credit (“ERC”) under the Coronavirus Aid, Relief, and Economic Security Act as amended by the Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Plan Act of 2021. Based on our analysis, we determined that we were entitled to an ERC of approximately $1.5 million related to payroll paid in the first and third quarters of 2021 under the applicable Internal Revenue Service regulations and . we recognized other income of this amount during the year ended December 31, 2022. This amount was collected in July 2023.

 

Income Taxes

 

Income tax (benefit) expense for the years ended December 31, 2023 and 2022, was ($14,000) and $4,000, respectively. We continue to evaluate for potential utilization of our deferred tax asset, which has been fully reserved for, on a quarterly basis, by reviewing our economic models, including projections of future operating results.

 

Inflation and Supply Chain Matters

 

We experienced increased costs on certain materials and components as well as delays in supply chain delivery, which may also impact our ability to recognize revenue and reduce our gross profit margins, as well as extend our manufacturing lead times and reduce our manufacturing efficiencies. We have commenced placing orders with more lead time to help mitigate the manufacturing delays, as well as assessing other suppliers or components to attempt to mitigate the potential cost impacts. In addition, we are utilizing our in-house flexible manufacturing to attempt to further mitigate both potential schedule delivery delays and material cost increase. While we have initiated actions to mitigate the potential negative impacts to our revenue and profitability, there can be no assurance of the ultimate impact and the length of time that the supply chain factors may impact our revenues and profitability.

 

Inflation has also had an impact on salaries and compensation. To remain competitive in the acquisition and retention of our employees, we have reviewed and adjusted salaries and implemented bonus incentives to mitigate the potential negative impacts of inflation on our employees.

 

35
 

 

Liquidity and Capital Resources

 

As of December 31, 2023, we had aggregate working capital of $14.3 million compared to aggregate working capital of $15.5 million at December 31, 2022. Our cash and cash equivalents at December 31, 2023 and 2022 were $14.0 million and $14.4 million, respectively.

 

Net cash used in operating activities during 2023 was $0.2 million and was principally due to the net loss of $4.2 million, decrease in contract assets of $0.6 million, increase in inventories of $1.9 million, decrease in accrued expenses of $0.7 million (primarily due to payment of 2022 bonus) offset by a decrease in accounts receivable of $1.8 million, collection of employee retention credit receivable of $1.5 million, an increase in contract liabilities of $0.9 million and non-cash items of $2.0 million. The increase in inventory was related to the production of PVT150 systems in anticipation of potential future orders and increases related to new system orders.

 

Net cash used in investing activities during 2023 was $0.1 million. Capital expenditures of $0.4 million related to purchases of manufacturing equipment and building improvements. The disposition of Tantaline resulted in a cash outflow of $0.3 million based on the terms of the agreement. We received $0.6 million of deposits from the purchaser of certain MesoScribe equipment as described below.


Cash flows from financing activities during 2023 was not significant and included $0.1 million of proceeds from the exercise of employee stock options and $0.1 million of repayment of an equipment loan.

 

On August 4, 2023, we entered into a Purchase and License Agreement with a third-party. Pursuant to the Purchase and License Agreement, we will sell certain proprietary assets relating to its plasma spray technology and material deposition system and grant a non-exclusive license to use certain of our related intellectual property as more fully described in the Purchase and License Agreement, for an aggregate purchase price of $0.9 million. The purchase price is payable in several installments and contingent upon certain performance metrics and other milestones.

 

During the year ended December 31, 2023, we received payments under the Purchase and License Agreement in the amount of $0.6 million which is reflected as deposits from purchaser in the accompanying consolidated balance sheet as of December 31, 2023. We expect the transaction to be completed during 2024.

 

We expect to continue to fulfill remaining customer orders for MesoScribe products through the end of 2024 at which time it plans to cease the remaining operations of MesoScribe and dispose of any remaining equipment.

 

We believe that our cash and cash equivalent positions and our projected cash flow from operations will be sufficient to meet our working capital and capital expenditure requirements for the next twelve months from the filing of this Form 10-K. We will continue to assess our operations and take actions anticipated to maintain our operating cash to support the working capital needs.

 

36
 

 

Critical Accounting Policies and Estimates

 

Use of Estimates

 

This discussion and analysis of the Company’s financial condition and results of operations is based on the Company’s consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported periods. In accordance with U.S. GAAP, the Company bases its estimates on historical experience and on various other assumptions the Company believes are reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.

 

We consider an accounting estimate to be critical if: (1) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (2) changes in the estimate that are reasonably likely to occur from period to period, or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations.

 

We believe that of our significant accounting policies, which are described in the notes to the consolidated financial statements, the following accounting policies involve a greater degree of judgments, estimates and assumptions. Accordingly, these are the policies that we believe are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations. For information on the Company’s significant accounting policies and estimates refer to Note 2 “Summary of Significant Accounting Policies” including the “Use of Estimates” section, in the consolidated financial statements.

 

Revenue Recognition

 

We design, manufacture, and sell custom chemical vapor deposition equipment through contractual agreements. These system sales require us to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. We recognize revenue over time by using an input method based on costs incurred as it depicts our progress toward satisfaction of the performance obligation. Under this method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations.

 

Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as indirect labor, supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process as required by the project’s engineering design. Cost based input methods of revenue recognition require us to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to evaluate assumptions related to the costs to complete the projects, including materials, labor, and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, we recognize the entire estimated loss in the period the loss becomes known and can be reasonably estimated.

 

37
 

 

We have been engaged in the production and delivery of goods on a continual basis under contractual arrangements for many years. Historically, we have demonstrated an ability to accurately estimate total revenues and total expenses relating to our long-term contracts. However, there exist many inherent risks and uncertainties in estimating revenues, expenses and progress toward completion, particularly on larger or longer-term contracts. If we do not estimate the total sales, related costs, and progress toward completion on such contracts, the estimated gross margins may be significantly impacted, or losses may need to be recognized in future periods. Any such resulting changes in margins or contract losses could be material to our results of operations and financial condition.

 

Long-Lived Assets

 

Long-lived assets consist primarily of property, plant and equipment. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable. When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists pursuant to the requirements of ASC 360-10-35, “Impairment or Disposal of Long-Lived Assets.” If the asset is determined to be impaired, the impairment loss is measured on the excess of it carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value. It is not possible for us to predict the likelihood of any possible future impairments or, if such an impairment were to occur, the magnitude of any impairment.

 

Item 7A.Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 8. Financial Statements and Supplementary Data.

 

The consolidated financial statements and supplementary data required by this item are included in this Annual Report on Form 10-K beginning on page F-1.

 

Item 9.Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

 

None.

 

Item 9A.Controls and Procedures.

 

Disclosure Controls and Procedures. We maintain a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 13d-15(e) under the Exchange Act of 1934, as amended, (the “Exchange Act”)). As required by Rule 13a-15(b) under the Exchange Act, management of the Company, under the direction of our Chief Executive Officer and Chief Financial Officer, reviewed and performed an evaluation of the effectiveness of design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act) as of December 31, 2023.

 

38
 

 

Based on that review and evaluation, our Chief Executive Officer and Chief Financial Officer, along with others in our management, have determined that as of the end of the period covered by this Report on Form 10-K, the disclosure controls and procedures were effective to provide reasonable assurance that such information is accumulated and communicated to our management, including our principal executive and financial officers, as appropriate to allow timely decisions regarding disclosures.

 

Changes in Internal Controls

 

There were no changes in our internal controls over financial reporting as defined in Rule 13a-15(f) or Rule 15d-15(f) under the Exchange Act that occurred during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the internal controls over financial reporting.

 

Limitations on the Effectiveness of Controls

 

We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control systems are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

 

Management’s Annual Report on Internal Control Over Financial Reporting. Our management is responsible for establishing and maintaining effective internal control over financial reporting (as defined in Rule 13a – 15(f) of the Exchange Act). There are inherent limitations to the effectiveness of any internal control, including the possibility of human error and the circumvention or overriding of controls. Accordingly, even effective internal controls can provide only reasonable assurance with respect to financial statement preparation. Further, because of changes in conditions, the effectiveness of internal control may vary over time. We have assessed the effectiveness of our internal controls over financial reporting (as defined in Rule 13a -15(f) of the Exchange Act) as of December 31, 2023. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in “Internal Control – Integrated Framework (2013)”. Management concluded that, as of December 31, 2023, our internal control over financial reporting was effective based on the criteria established by the COSO Internal Control Framework.

 

This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to the rules of the Securities and Exchange Commission that permit us to provide only management’s report in this Annual Report on Form 10-K.

 

Item 9B.Other Information.

 

Not applicable.

 

Item 9C.Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.

 

Not applicable.

 

39
 

 

PART III

 

Item 10.Directors, Executive Officers, and Corporate Governance.

 

Background and Experience of Directors

 

When considering whether directors and nominees have the experience, qualifications, attributes or skills, taken as a whole, to enable the Board of Directors to satisfy its oversight responsibilities effectively in light of our business and structure, the Nominating, Governance and Compliance Committee focused primarily on each person’s background and experience as reflected in the information discussed in each of the directors’ individual biographies set forth immediately below. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business. As more specifically described in such person’s individual biographies set forth below, our directors possess relevant and industry-specific experience and knowledge in the engineering financial and business fields, as the case may be, which we believe enhances the Board’s ability to oversee, evaluate and direct our overall corporate strategy. The Nominating, Governance and Compliance Committee annually reviews and makes recommendations to the Board regarding the composition and size of the Board so that the Board consists of members with the proper expertise, skills, attributes, and personal and professional backgrounds needed by the Board, consistent with applicable regulatory requirements.

 

The Nominating, Governance and Compliance Committee believes that all directors, including nominees, should possess the highest personal and professional ethics, integrity, and values, and be committed to representing the long-term interests of our shareholders. The Nominating, Governance and Compliance Committee will consider criteria including the nominee’s current or recent experience as a senior executive officer, whether the nominee is independent, as that term is defined in existing independence requirements of the NASDAQ Capital Market and the Securities and Exchange Commission, the business, scientific or engineering experience currently desired on the Board, geography, the nominee’s industry experience, and the nominee’s general ability to enhance the overall composition of the Board.

 

The Nominating, Governance and Compliance Committee does not have a formal policy on diversity; however, in recommending directors, the Board and the Committee consider the specific background and experience of the Board members and other personal attributes in an effort to provide a diverse mix of capabilities, contributions and viewpoints which the Board believes enables it to function effectively as the Board of Directors of a company with our size and the nature of our business.

 

40
 

 

Legal Proceedings Involving Directors

 

None.

 

Board Leadership

 

Our Corporate Governance practices contain several features which we believe will ensure that the Board maintains effective and independent oversight of management, including the following:

 

  ● Executive sessions without management and non-independent directors present are a standing Board agenda item. Executive sessions of the independent directors are held at any time requested by an independent director and, in any event, are held in connection with at least 100% of regularly scheduled Board meetings.
  ● The Board regularly meets in executive session with the CEO without other members of management present.
  ● All Board committee members are independent directors. The committee chairs have authority to hold executive sessions with management and non-independent directors present.

 

While our Board has no formal policy with respect to separation of the positions of Chairman and CEO or with respect to whether the Chairman should be a member of management or an independent director, we believe that the appointment of Mr. Waldman as Chairman properly facilitates better communication between the Independent Directors on the one hand and the non-Independent Director and members of management on the other hand and leads to improved oversight and discussions by the Board as a whole. The Chief Executive Officer of the Company, Emmanuel Lakios, is tasked with the responsibility of implementing our corporate strategy, we believe he is best suited for leading discussions with input from the Chairman, at the Board level, regarding performance relative to our corporate strategy and this discussion accounts for a significant portion of the time devoted at the Board meetings.

 

Our Certificate of Incorporation and Bylaws provide for our Company to be managed by or under the direction of the Board of Directors. Under our Certificate of Incorporation and Bylaws, the number of directors is fixed from time to time by the Board of Directors. The Board of Directors currently consists of six members. Directors are elected for a period of one year and thereafter serve, subject to the Bylaws, until the next annual meeting at which their successors are duly elected by the shareholders.

 

The following table sets forth the names, ages and positions with the Company of each of our directors and executive officers, as of March 25, 2024.

 

Name   Age   Position(s) with the Company
Emmanuel Lakios   62   Chief Executive Officer, President, Director
Lawrence J. Waldman   77   Chairman of the Board of Directors, Chairman-Audit Committee
Raymond A. Nielsen   73   Director, Chairman - Nominating, Governance and Compliance Committee
Robert M. Brill   77   Director, Chairman - Strategic Planning Committee
Debra Wasser   59   Director
Ashraf Lotfi   63   Director
Richard A. Catalano   64   Chief Financial Officer, Vice President, Secretary and Treasurer
Kevin R. Collins   58   Vice President and General Manager of SDC
Jeffrey A. Brogan   54   Vice President of Sales and Marketing
Maxim S. Shatalov   53   Vice President of Engineering and Technology
Warren D. Cheesman   51   Vice President of Manufacturing Operations

 

41
 

 

Emmanuel Lakios

 

Emmanuel Lakios was appointed to serve as President and Chief Executive Officer of the Company on January 22, 2021, and on July 15, 2021 was elected by the shareholders as a member of the Board of Directors. Mr. Lakios joined the Company as Vice President Sales and Marketing in February 2017. Mr. Lakios has over 30 years of experience serving the aerospace, semiconductor, data storage and optical device industries and is the holder of several patents in the field of process equipment and device structure. From January 2015 through February 2017, Mr. Lakios was the President and Chief Executive Officer at Sensor Electronic Technology, Inc., overseeing that company’s transition from R&D to a leading global commercial UV LED supplier. From 2003 to 2011 he was the Executive Vice President of Field Operations and President and Chief Operating Officer at Imago Scientific, bringing it from pre-revenue to a commercial leadership position in the 3D atomic scale tomography field. Mr. Lakios was previously employed at Veeco Instruments Inc. from 1984 until 2003, where he held several positions, including President of the Process Equipment Group and Executive Vice President of Field Operations. He has been involved in several acquisitions and numerous product line launches. He received his BE in Mechanical Engineering with focus in Material Science from SUNY Stony Brook in 1984.

 

Lawrence J. Waldman

 

Lawrence J. Waldman was appointed a member of the Board of Directors on October 5, 2016 and currently serves as Chairman of the Board and Chairman of the Audit Committee. Mr. Waldman has over 40 years of experience in public accounting.

 

Mr. Waldman is a member of the board of directors of Comtech Telecommunications Corporation since August 2015 and Lead Independent Director since December 2021. He serves as the chairperson of Comtech’s Audit Committee. Mr. Waldman is a member of the board of directors and Lead Independent Director and Audit Committee Chairperson at APYX Medical Corporation, a Nasdaq-listed advanced energy medical technology company. Mr. Waldman serves as a Senior Advisor at First Long Island Investors, LLC since 2016 and was previously an Advisor to the accounting firm of EisnerAmper LLP following his role as Partner-in-Charge of Commercial Audit Practice Development for Long Island. Mr. Waldman served as the Managing Partner of the Long Island office of KPMG LLP from 1994 through 2006, the accounting firm where he began his career in 1972. During his tenure at KPMG, Mr. Waldman served as audit partner to a number of public and privately held technology companies.

 

42
 

 

Mr. Waldman is currently Chairman of the Board of Directors of the Long Island Association and a member of the boards of directors of the Long Island Angel Network and the Advanced Energy Research Center at Stony Brook University. Through October 21, 2018, Mr. Waldman was a member of the board of directors of Northstar/RXR Metro Income, Inc., an SEC registered non-traded real estate investment trust.

 

Mr. Waldman is the current Chairman of the Supervisory Committee of Bethpage Federal Credit Union and previously served as the Chairman of the Audit Committee of the State University of New York’s (“SUNY”) Board of Trustees, the largest state university system in the United States. Mr. Waldman previously served as Chairman of the Audit and Finance Committee Board of Trustees of the Long Island Power Authority (“LIPA”), the second largest government utility in the United States, and as the Chairman of the Board. Mr. Waldman also served as an adjunct professor at Hofstra University, teaching graduate courses in advanced accounting theory and advanced auditing. Mr. Waldman is a certified public accountant in New York State. He is a member of the American Institute of Certified Public Accountants and the New York State Society of CPAs. Mr. Waldman holds a Bachelor of Science and a Master of Business Administration from Hofstra University in Hempstead, New York.

 

Mr. Waldman qualifies to serve as a director, Audit Committee Chairman and Lead Independent Director because of his significant experience leading public company boards, his extensive relevant industry and financial and accounting expertise.

 

Ashraf Lotfi

 

Dr. Ashraf Lotfi is currently a venture partner with Deep Sciences Ventures and serves on the board of Lotus Microsystems, ApS, Xonia Ltd., HyperCIM Ltd. Dr. Lotfi previously served as Vice President and a Fellow at Intel Corporation. Prior to Intel, he was Power Chief Technology Officer for Altera Corporation serving its Enpirion Power Business as well as the broader Field Programmable Gate Array community. Altera was acquired by Intel in 2015. Prior to Altera, he served as President and Chief Executive Officer of Enpirion, Inc., which he founded in 2002.

 

From Enpirion’s inception, Dr. Lotfi led its strategic direction with a unique industry-first vision to create the ultimate power converter-on-chip creating ubiquitous DC-DC conversion at the silicon level. In 2013, he led Enpirion’s merger into Altera to realize his vision of highly integrated power management closely coupled to leading-edge digital silicon loads. Prior to founding Enpirion, he was Director of Advanced Power Research at Bell Laboratories.

 

Dr. Lotfi has a B.S. in Electrical Engineering from Cairo University and an M.S. and PhD. in Electrical Engineering from Virginia Tech.

 

Dr. Lotfi currently serves on the boards of Lotus Microsystems ApS, Xonai Ltd., HyperCIM Ltd. and his extensive experience in high power electronics provide a valuable resource to the Board of Directors and Executive Management.

 

43
 

 

Debra Wasser

 

Ms. Wasser currently serves as Vice President of Investor Relations and ESG Engagement for Etsy, Inc. (Nasdaq: ETSY), the global marketplace for unique and creative goods. She is responsible for Etsy’s external shareholder relationships, with a focus on corporate and financial reporting, driving increased analyst coverage and investor connectivity, effective corporate messaging, strategic investor targeting, and elevating the company’s ESG messaging with the financial community. Ms. Wasser has led investor and broad internal and external communications strategies on multiple financial transactions and offerings, and a host of product and technology launches and marketing initiatives.

 

Prior to joining Etsy in April 2018, Ms. Wasser led Edelman’s Investor Relations practice in the U.S., and advised boards of directors and senior managements of public companies on strategic communications including investor relations, financial and corporate public relations, transaction communications, crisis communications and leadership positioning.

 

Prior to joining Edelman in 2015, Ms. Wasser was Senior Vice President, Investor Relations & Corporate Communications for Veeco Instruments, Inc. (Nasdaq: VECO) for over 15 years. While at Veeco, Ms. Wasser created and implemented a global investor relations program to raise visibility and deepen ownership to reflect business trends. She led effective communications strategy through positive periods of growth, over a dozen merger and acquisition transactions, a highly successful secondary equity offering, and new market opportunities.

 

Prior to joining Veeco, Ms. Wasser was Vice President of Dewe Rogerson Inc. where she ran the firm’s U.S. investor relations client base, focused on healthcare/biotech, high-tech, consumer products, financial services, publishing, and general industry. During her tenure at the firm, Ms. Wasser serviced clients across the globe and helped grow the firm from four to 80 employees. Debra has a B.S. in Communications and Business from The State University of New York at Albany.

 

Ms. Wasser has provided business and communications advice to Boards of Directors of publicly traded and privately held companies for over three decades. She has served on the Board of Directors of NIRI, the Association of Investor Relations Professionals, including the maximum service of four years on the National Chapter Board, as well as earlier as a Board member of the organizations New York Chapter.

 

Raymond A. Nielsen

 

Raymond A. Nielsen was appointed a member of the Board of Directors on October 5, 2016. Mr. Nielsen was the Director of Finance for The Beechwood Organization until January 2019 and had been responsible for Project and Corporate Finance including Strategic Planning Initiatives since 2014. He has been a member of the Board of Directors of Dime Community Bank since its merger on February 1, 2021 with Bridge Bancorp Inc. In addition, he is Chairman of the Credit Risk Committee and a member of the Audit and Compliance Committees. Prior to the merger, he was a member of the Board of Directors of Bridgehampton National Bank and Bridge Bancorp Inc., its Parent holding company since 2013, and served on the Audit Committee, Compensation Committee, Corporate Governance & Nominating Committee, as well as on the ALCO and Loan Committees and the Compliance BSA & CRA Committee. Mr. Nielsen also served as a Director of North Fork Bancorporation and its subsidiary North Fork Bank from 2000 to 2006 where he chaired both the Compensation Committee and Audit Committee as well as having served as Lead Independent Director. Mr. Nielsen is the former CEO of Reliance Federal Savings Bank and Herald National Bank, and a 45-year veteran of the banking industry. Mr. Nielsen’s extensive public company, banking and real estate development experience provides a valuable resource to the Board of Directors and Executive Management.

 

44
 

 

Dr. Robert M. Brill

 

Dr. Brill was appointed a Director of the Company on March 5, 2021. Dr. Brill was co-founder and managing partner of Newlight Management from 1997 to 2019, which managed venture capital funds that focused on early-stage technology companies. Prior to co-founding Newlight, Dr. Brill was a general partner of Poly Ventures, a Long Island based venture capital fund. Dr. Brill is a member of the Board of Directors of the Long Island Angel Network and one private company. Dr. Brill has also previously served on the Board of Directors of multiple public and private companies. Dr. Brill has been the CEO of both public and private companies. Dr. Brill served as General Manager of Harris Corporation’s CMOS Semiconductor Division. He also held various technical and management positions at IBM’s semiconductor operation. Dr. Brill holds a Ph.D. in nuclear physics from Brown University and a B.A. and a B.S. in Engineering Physics from Lehigh University. Dr. Brill had previously served on the Company’s Board from April 2018 until October 2019.

 

Richard A. Catalano

 

Richard Catalano was appointed as the Company’s Vice President and Chief Financial Officer effective as of August 30, 2022. Mr. Catalano began his career at KPMG LLP and became an audit partner in 1993. Throughout his over 35 years as an audit professional at KPMG LLP, Mr. Catalano advised a diverse array of clients through private equity financed transactions, merger-related accounting, and filings with the U.S. Securities and Exchange Commission. Towards the later part of his tenure, Mr. Catalano served as the leader of KPMG LLP’s Metro New York Healthcare and Life Sciences Practice and then co-led KPMG’s Global Audit Methodology Group. Mr. Catalano is a Certified Public Accountant in New York State and received a Bachelor of Business Administration in accounting from Hofstra University.

 

Kevin R. Collins

 

Prior to his appointment as Vice President and General Manager of SDC, Mr. Collins served as the General Manager of SDC since 1999. From 1990 to 1999 he was employed by Stainless Design Corp. as Manager of Field Operations and Product Development Advisor. Mr. Collins attended Columbia University School of Engineering and Applied Science.

 

45
 

 

Jeffrey A. Brogan

 

Dr. Jeffrey Brogan was appointed as Vice President Sales and Marketing for the Company on March 23, 2021. Previously he was Director of Sales and Marketing for CVD Materials Corporation since November 2017 with General Management responsibilities of CVD MesoScribe Technologies Corporation. Dr. Brogan served as the President and CEO of MesoScribe Technologies, Inc., spearheading its sale to CVD in 2017. He has over 20 years of experience in strategic sales and marketing, technology management, and advanced research & development. Dr. Brogan has led the development of innovative sensor products, transitioning high performance products to manufacturing using the Company’s Direct Write MesoPlasma™ printing technology. He received his PhD in Materials Science and Engineering from Stony Brook University in 1996.

 

Maxim S. Shatalov

 

Dr. Shatalov was appointed Vice President of Engineering and Technology in April 2018. Prior to CVD, Mr. Shatalov was employed by Sensor Electronic Technology Inc. (SETi) a LED company where he held multiple technical and management positions from 2006 thru 2018. In 2017, Dr. Shatalov became Vice President of Technology responsible for UV LED technology and LED application development at SETi. Dr. Shatalov has over twenty years of experience in semiconductor research and devices and holds more than 12 U.S. patents.

 

Warren D. Cheesman

 

Warren Cheesman was appointed Vice President of Manufacturing Operations in October 2022. He has over 25 years of management experience in the semiconductor, medical device and defense equipment sectors. Mr. Cheesman has held roles of increasing responsibility in engineering, operations, quality and strategic sourcing, at equipment manufacturers including Veeco Instruments, Air Techniques, and Kongsberg Defense & Aerospace. Mr. Cheesman provides strategic leadership across all divisions related to manufacturing, quality, and continuous improvement initiatives, with emphasis on process improvement, lean manufacturing, risk management, and collaboration. He holds two master of science degrees from Stony Brook University in Technology Management and Materials Science & Engineering, and a Bachelor of Science degree in Mechanical Engineering from Virginia Tech. His academic and professional experience is also complemented by a Six Sigma Black Belt certification.

 

Code of Ethics

 

We have adopted a Corporate Code of Conduct and Ethics that applies to our employees, senior management and Board of Directors, including the Chief Executive Officer and Chief Financial Officer. The Corporate Code of Conduct and Ethics is available on our website, www.cvdequipment.com, by clicking on “About Us” and then clicking on “Governance.”

 

46
 

 

Audit Committee

 

Our Board of Directors has an Audit Committee that currently consists of Lawrence J. Waldman, Chairman, Raymond A. Nielsen, Robert M. Brill, Debra Wasser (effective July 13, 2023), Ashraf Lotfi (effective August 18, 2023) and Conrad J. Gunther (until July 13, 2023). During the fiscal year ended December 31, 2023, the Audit Committee held four meetings. Pursuant to the Audit Committee Charter, the Audit Committee is directly responsible for the appointment, compensation, retention and oversight of the work of any independent registered public accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for us, and each such independent auditor shall report directly to the Committee. The Audit Committee also reviews with management and the independent auditors, our annual audited financial statements (including the disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”), the scope and results of annual audits and the audit and non-audit fees of the independent registered public accounting firm. Messrs. Waldman, Gunther, Nielsen and Brill and Ms. Wasser are “independent” under the requirements of the NASDAQ Stock Market.

 

The Board of Directors has determined that Mr. Waldman is an “audit committee financial expert” as that term is defined in the rules and regulations of the Securities and Exchange Commission.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

The rules of the Securities and Exchange Commission require us to disclose late filings of reports of stock ownership and changes in stock ownership by our directors, officers and ten percent shareholders. To our knowledge, based solely on our review of (a) the copies of such reports and amendments thereto furnished to us and (b) written representations that no other reports were required, during our fiscal year ended December 31, 2023, all of the filings for our officers, directors and ten percent shareholders were made on a timely basis, with the exception of: (i) a delinquent Form 4 disclosing a single transaction for each of Mr. Lakios, Mr. Catalano, Dr. Brogan, Dr. Shatalov, Mr. Collins, and Mr. Cheesman; and (ii) a delinquent Form 4 disclosing one transaction for Mr. Africk.

 

Item 11.Executive Compensation.

 

Summary Compensation Table

 

The following table sets forth the compensation of our chief executive officer and chief financial officer, and our “named executive officers,” for the years ended December 31, 2023 and 2022.

 

Name and principal position 

Year

  

Salary ($)

  

 

Bonus ($) (1)

   Option Awards ($) (2)   Stock Awards ($) (2)   All Other Compensation ($) (3)  

 

Total ($)

 
Emmanuel Lakios                                   
President and Chief Executive   2023    388,600    -    699,990    -    19,522    1,108,112 
Officer   2022    316,800    191,600    236,704    -    13,830    758,934 
                                    
Richard Catalano (4)                                   
Secretary, Chief Financial   2023    274,700    -    233,330    -    27,201    533,231 
Officer and Executive Vice President   2022    80,769    31,250    68,151    -    288    180,458 
                                    
Thomas McNeill (5)                                   
Secretary, Chief Financial Officer   2023    -    -    -    -    -      
and Executive Vice President   2022    187,425    29,988    -    -    137,689    355,102 
                                    
Jeffrey A. Brogan Vice   2023    203,300    -    139,998    -    7,863    351,161 
President Sales & Marketing   2022    196,000    58,800    47,341    -    3,053    305,194 

  

47
 

 

(1)Reflects cash bonuses under the Company’s Management Bonus Plan. Bonuses listed for a particular year represents amounts earned with respect to such year even though all or part of such amounts have been paid during the following year.

 

(2)These columns represent the grant date fair value of the stock awards as calculated in accordance with FASB ASC 718 (Stock Compensation). The stock options granted in 2022 and 2023 vest 25% per year over four years and have a ten-year life.

 

(3)All other compensation consists of 1) 401(k) match in 2023 and 2022 of $9,900 and $8,895 for Emmanuel Lakios, $9,179 and $288 for Richard Catalano, $0 and $4,094 for Thomas McNeill and $7,863 and $3,053 for Jeffrey Brogan, respectively; 2) severance in 2022 of $104,125 and accrued and used vacation time in 2022 of $29,470 for Thomas McNeill; and 3) health insurance premiums in 2023 and 2022 of 9,622 and $8,895 for Emmanuel Lakios and $18,022 and $0 for Richard Catalano.

 

(4)Effective August 30, 2022, Richard Catalano was appointed Vice President and Chief Financial Officer.

 

(5)Effective August 30, 2022, Thomas McNeill resigned as Executive Vice President and Chief Financial Officer.

 

Employment Agreements and Potential Payments Upon Termination or Change in Control

 

Emmanuel Lakios Employment Agreement

 

On June 1, 2021, the Company entered into an Employment Agreement with Emmanuel Lakios, the Company’s President and Chief Executive Officer (the “Lakios Agreement”). The term of Mr. Lakios’s employment under the Lakios Agreement commenced as of the effective date thereof and shall continue until terminated in accordance with the terms of the Lakios Agreement. Under the Lakios Agreement, Mr. Lakios will receive an initial annual base salary of $288,000, which shall be reviewed from time to time and may be increased, but not decreased, by the Compensation Committee of the Board of Directors (the “Committee”) in its sole and exclusive discretion. Mr. Lakios shall be entitled to participate in any bonus or incentive plan available to the Company’s senior executives generally, on such terms as the Committee may determine in its discretion.

 

In the event of the termination of the Lakios Agreement and Mr. Lakios’s employment thereunder, Mr. Lakios or his estate (in the event of his death) shall be entitled to (A) receive any unpaid base salary earned and accrued under the Lakios Agreement prior to the date of termination (and reimbursement for expenses incurred prior to the date of termination), (B) indemnification in accordance with any applicable indemnification plan, program, corporate governance document or other arrangement, and any vested rights pursuant to any insurance plan, benefit plan or retirement plan, and, except in the event of Mr. Lakios’s termination by the Company for Cause (as defined in the Lakios Agreement, (C) treatment of his stock option grants in accordance with the terms of the applicable plan and award agreement.

 

48
 

 

In the event Mr. Lakios’s employment is terminated as a result of death or disability, Mr. Lakios shall also be entitled to receive a pro rata bonus payment under the Company’s bonus Plan for the year of termination, if applicable.

 

In the event Mr. Lakios’s employment is terminated by the Company for Cause, Mr. Lakios’s stock option grants, whether vested or unvested, shall immediately terminate and be null and void.

 

In the event Mr. Lakios’s employment is terminated by the Company without Cause, or by Mr. Lakios for Good Reason (as defined in the Lakios Agreement), Mr. Lakios shall also be entitled to (A) a pro rata bonus for the year of termination, and (B) continued payment of his base salary and the Company’s portion of Mr. Lakios’s then existing medical benefits for the nine (9) month period following the date of termination.

 

The Lakios Agreement contains customary non-competition, non-solicitation, and confidentiality provisions in favor of the Company.

 

Other then as set forth above, there are no arrangements for compensation of directors or Named Executive Officers and there are no employment contracts between the Company and its directors or any change in control arrangements.

 

Outstanding Equity Awards at December 31, 2023

 

The following table sets forth the outstanding equity awards held by our named executive officers as of December 31, 2023.

 

   OPTION AWARDS   STOCK AWARDS 
Name  Number of Securities Underlying Options Exercisable   Number of Securities Options Unexercisable   Exercise Price   Option Expiration Date  Number of shares or units of stock that have not vested   Market value of shares or units of stock that have not vested   Equity Incentive Plan Awards: Number of unearned shares or units that not vested   Equity Incentive Plan Awards: Market or payout value of unearned shares or units that have not vested 
Emmanuel Lakios   -    100,000   $14.11    3/23/2033   -    -    -   $- 
    18,750    56,250   $5.02   8/17/2032                    
    50,000    50,000   $4.26   6/1/2023                    
    100,000    -   $10.30    2/6/2027   -    -           
Richard Catalano   -    25,000   $14.11    3/23/2033   -    -    -   $- 
    5,000    15,000   $5.42   8/30/2032                    
                                       
Jeffrey A. Brogan   -    15,000   $14.11   3/23/2033   -    -    -   $- 
    3,750    11,250   $5.02   8/17/2032                    
    10,000    10,000   $4.01   7/15/2021                    
    20,000    -   $11.61   10/31/2027                    

 

49
 

 

2023 Director Compensation

 

The following table sets forth a summary of the compensation we paid to our non-employee directors in 2023.

 

 

Name

 

Fees Earned or

Paid in Cash

   Option Awards   Restricted Stock Awards  

 

Total

 
                 
Lawrence J. Waldman  $113,000    -   $40,000   $153,000 
Raymond A. Nielsen   50,000    -    40,000    90,000 
Robert M. Brill   50,000    -    40,000    90,000 
Debra Wasser   18,696    -    40,000    38,696 
Ashraf Lotfi   14,783    -    14,783    29,566 
Conrad J. Gunther   26,766    -    20,000    46,766 

 

On October 11, 2021, the Board of Directors, following the unanimous recommendation of the Board’s Compensation Committee, unanimously approved a director compensation plan, effective October 1, 2021 (the “Plan”). The Plan is based on the recommendations of an independent compensation consultant engaged by the Board’s Compensation Committee. Pursuant to the Plan, each director is entitled to Director Compensation, divided into the following pay components: (i) Annual Board Cash Compensation in the amount of $40,000 and (ii) an Annual Equity Retainer in the amount of $40,000, to be automatically granted on the date of the Company’s annual meeting of shareholders. Additionally, a director serving as a chairman for the Board’s Compensation Committee, Nominating & Governance Committee, or Strategic Planning Committee is entitled to Chair Compensation in the amount of $10,000. The director serving as the chairman for the Board’s Audit Committee is entitled to Chair Compensation in the amount of $25,000. Furthermore, the director serving as the Non-Executive Chairman is entitled to Board Leadership Compensation in the amount of $48,000.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

 

The following table sets forth, as of March 25, 2024, information regarding the beneficial ownership of our common stock by (a) each person who is known to us to be the owner of more than five percent (5%) of our common stock, (b) each of our directors, (c) each of the named executive officers, and (d) all directors and executive officers and executive employees as a group. For purposes of the table, a person or group of persons is deemed to have beneficial ownership of any shares that such person has the right to acquire within 60 days of March 25, 2024.

 

Name and Address of Beneficial Owner (1)  Amounts and Nature of Beneficial Ownership (2)   Percent of Class (%) 
         
Andrew Africk / ADA Partners LP
Leviticus Partners, L.P.		   

1,076,834

660,000

    

15.9

9.7

 
Emmanuel Lakios   200,108(3)   3.0 
Kevin R. Collins   92,437(3)   1.4 
Lawrence J. Waldman   70,288(4)   1.0 
Raymond A. Nielsen   61,588(4)   * 
Jeffrey A. Brogan   42,019(3)   * 
Robert M. Brill   23,073(4)   * 
Maxim Shatalov   17,500(3)   * 
Richard Catalano   11,250(3)   * 
Warren Cheesman   7,500(3)   * 
Ashraf Lotfi   4,514(4)   * 
Debra Wasser   4,373(4)   * 
 All directors and executive officers and executive employees as a group (nine persons)   534,650    7.9 

 

 

* Less than 1% of the outstanding common stock or less than 1% of the voting power

 

(1)The address of Messrs. Lakios, Waldman, Nielsen, Brogan, Brill, Shatalov, Catalano, Cheesman. Lotfi and Ms. Wasser is c/o CVD Equipment Corporation, 355 South Technology Drive, Central Islip, New York 11722. The address of Mr. Collins is c/o Stainless Design Concepts, 1117 Old Kings Highway, Saugerties, NY 12477. The address of Andrew Africk / ADA Partners is c/o Searay Capital, 111 West 67th Street, New York, NY 10023. The address of Leviticus Partners, L.P. is 200 Park Avenue, Suite 1700, New York, NY 10166.

 

50
 

 

(2)All of such shares are owned directly with sole voting and investment power, unless otherwise noted below.

 

(3)Does not include unvested options to purchase the following shares of our common stock: Lakios – 181,250; Collins – 27,500; Brogan – 32,500; Shatalov – 32,500; Catalano – 33,750; and Cheesman – 22,500

 

(4)Does not include unvested restricted shares of our common stock: Waldman – 1,458; Nielsen – 1,458; Brill – 1,458; Lotfi – 1,822 and Wasser – 1,438

 

Does not include shares to be issued per Director compensation agreement related to the Annual Equity Retainer in the amount of $40,000, to be determined at the 2024 Annual Meeting of Shareholders.

 

Equity Compensation Plan Information Table

 

The following table provides information about shares of our common stock that may be issued upon the exercise of options under all of our existing compensation plans as of December 31, 2023.

 

 

   Number of securities to be issued upon exercise of outstanding options, warrants and rights (1)   Weighted-average exercise price of outstanding options, warrants and rights (2)   Number of securities remaining available for future issuance 

Plan Category

               
Equity compensation plans approved by security holders
   846,875   $8.20    335,375 
Equity compensation plans not approved by security holders   —    

N/A

    — 
                
Total   846,875   $8.20    335,375 

 

(1) Reflects aggregate options outstanding under our 2007 Share Incentive Plan, 2016 Equity Incentive Plan and 2022 Equity Incentive Plan.
   
(2) Calculation is exclusive of the value of any unvested restricted stock awards.

 

Item 13.Certain Relationships and Related Transactions, and Director Independence.

 

Transactions with related persons, promoters and certain control persons.

 

None.

 

Director Independence

 

The current members of our Board of Directors are Lawrence J. Waldman, Emmanuel Lakios, Raymond A. Nielsen, Robert M. Brill, Debra Wasser and Ashraf Lotfi. Messrs. Waldman, Nielsen, Brill and Lotfi and Ms. Wasser have been determined to be “independent” as defined under Rule 4200 of the Nasdaq Stock Market.

 

51
 

 

Item 14.Principal Accountant Fees and Services.

 

The following presents fees for professional audit services rendered by Marcum, LLP, Certified Public Accountants, the Company’s independent registered public accounting firm for the years ended December 31, 2023 and 2022.

 

   2023   2022 
         
Audit fees  $198,275   $181,500 
Audit-related fees   55,002    20,500 
All other fees   -    - 
Total fees  $253,277   $202,000 

 

Audit Fees

 

Audit fees consisted of the review of the first three quarters and audit of the year-end.

 

Audit-related Fees

 

Consisted of the audit of the Company’s defined contribution 401(k) plan and fees associated with registration statements and comfort letter.

 

Audit Committee Approval

 

The engagement of the Company’s independent registered public accounting firm is pre-approved by the Company’s Audit Committee. The Audit Committee pre-approves all fees billed and all services rendered by the Company’s independent registered public accounting firm.

 

52
 

 

PART IV

 

Item 15. Exhibits, Financial Statement Schedules

 

3.1   Certificate of Incorporation dated October 12, 1982 (Incorporated herein by reference to the Company’s Form S-1 filed on July 3, 2007).
     
3.2   Certificate of Amendment of Certificate of Corporation, dated April 25, 1985 (Incorporated herein by reference to the Company’s Form S-1 filed on July 3, 2007).
     
3.3   Certificate of Amendment of Certificate of Corporation, dated August 12, 1985 (Incorporated herein by reference to the Company’s Form S-1 filed on July 3, 2007).
     
3.4   Certificate of Amendment of the Certificate of Incorporation, dated December 9, 2016 (Incorporated herein by reference the Company’s Current Report on Form 8-K filed on December 14, 2016).
     
3.5   Amended and restated By-laws of CVD Equipment Corporation, dated as of October 5, 2016 (Incorporated herein by reference to the Company’s Current Report on Form 8-K filed on October 11, 2016).
     
4.1   Description of the Company’s Securities (Incorporated herein by reference to the Company’s Annual Report on Form 10-K filed on March 30, 2020).
     
10.1   Lease Agreement, dated February 9, 2012, by and between FAE Holdings 411519R, LLC and the Company (Incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012).
     
10.2   Assignment Agreement, dated February 9, 2012, by and between FAE Holdings 411519R, LLC and the Company (Incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012).
     
10.3   Joint and Several Hazardous Material Guaranty and Indemnification Agreement, dated March 15, 2012, by and between FAE Holdings 411519R, LLC and the Company (Incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012).
     
10.4   Guaranty of Payment, dated March 15, 2012, by the Company (Incorporated by reference from the Company’s Report on Form 10-Q filed with the Commission on May 15, 2012).
     
10.5   Agreement to Purchase and Sale, the building and real estate property located at 555 N Research Place, Central Islip, NY, dated March 29, 2021, by and between 555 N Research Corporation, a wholly-owned subsidiary of the Company, and Steel K, LLC. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the Commission on May 13, 2021).
     
10.6   Employment Agreement, dated June 1, 2021, by and between Emmanuel Lakios, the Company’s President and Chief Executive Officer, and the Company. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the Commission on August 16, 2021).
     
10.7   Employment Agreement, dated June 1, 2021, by and between Thomas McNeill, the Company’s Executive Vice President and Chief Financial Officer, and the Company. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed with the Commission on August 16, 2021).

 

53
 

 

10.8   Assignment, Assumption and Amendment Agreement dated as of July 26, 2021, by and between Town of Islip Industrial Development Agency, 555N Research Corporation and Steel 555 NRP, LLC. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q/A filed with the Commission on March 1, 2022).
     
10.9   Second Amended and Restated Lease and Project Agreement, dated as of July 1, 2021, by and between Town of Islip Industrial Development Agency and FAE HOLDINGS 411519R, LLC. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q/A filed with the Commission on March 1, 2022).
     
10.10   Agency Compliance Agreement, dated as of July 1, 2021, by and between Town of Islip Industrial Development Agency, CVD Equipment Corporation and CVD Materials Corporation. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q/A filed with the Commission on March 1, 2022).
     
10.11   Amended and Restated Sublease Agreement, dated as of July 26, 2021, by and between FAE HOLDINGS 411519R, LLC, CVD Equipment Corporation and CVD Materials Corporation. (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q/A filed with the Commission on March 1, 2022).
     
21.1   List of Subsidiaries
     
23.1**   Consent of MARCUM, Certified Public Accountants and Advisors, A Professional Corporation (S-8).
     
31.1**   Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
     
31.2**   Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer.
     
32.1**   Section 1350 Certification of Principal Executive Officer.
     
32.2**   Section 1350 Certification of Principal Financial Officer.
     
97 **   CVD Equipment Corporation Executive Compensation Clawback Policy
     
101.INS***   XBRL Instance
     
101.SCH***   XBRL Taxonomy Extension Schema
     
101.CAL***   XBRL Taxonomy Extension Calculation
     
101.DEF***   XBRL Taxonomy Extension Definition
     
101.LAB***   XBRL Taxonomy Extension Labels
     
101.PRE***   XBRL Taxonomy Extension Presentation

 

 

* Management contract or compensatory plan or arrangement required

 

** Filed herewith

 

*** XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

 

54
 

 

SIGNATURES

 

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

DATE: March 28, 2024  
     
CVD EQUIPMENT CORPORATION  
     
By: /s/ Emmanuel Lakios  
Name: Emmanuel Lakios  
Title: President and Chief Executive Officer  

 

By: /s/ Richard Catalano  
Name: Richard Catalano  
Title: Vice President, Chief Financial Officer and Secretary  
   Principal Financial and Accounting Officer  

 

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated below.

 

NAME   POSITION   DATE
         
/s/ Emmanuel Lakios   President, Chief Executive Officer   3/28/2024
Emmanuel Lakios   (Principal Executive Officer)    
         
/s/ Lawrence J. Waldman   Director, Chairman of the Board   3/28/2024
Lawrence J. Waldman        
         
/s/ Raymond A. Nielsen   Director   3/28/2024
Raymond A. Nielsen        
         
/s/ Robert M. Brill   Director   3/28/2024
Robert M. Brill        
         

/s/ Debra Wasser

  

Director

  

3/28/2024

Debra Wasser        
         

/s/ Ashraf Lotfi

  

Director

  

3/28/2024

Ashraf Lotfi        

 

55
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARies

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

  Page No.
   
Report of Independent Registered Public Accounting Firm (PCAOB ID Number 688)

F-1

   
Financial Statements:  
   
Consolidated Balance Sheets as of December 31, 2023 and 2022 F-2
   
Consolidated Statements of Operations for the years ended December 31, 2023 and 2022 F-3
   
Consolidated Statements of Changes in Stockholders’ Equity for the years ended December 31, 2023 and 2022 F-4
   
Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 F-5
   
Notes to Consolidated Financial Statements F-6
   
56
 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Shareholders and Board of Directors of

CVD Equipment Corporation and Subsidiaries

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of CVD Equipment Corporation and Subsidiaries (the “Company”) as of December 31, 2023 and 2022, the related consolidated statements of operations, changes in stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

Revenue Recognition – Estimated Total Contract Costs

 

Description of the Matter

 

As discussed in Notes 2 and 3 to the consolidated financial statements, the Company recognizes revenue from the sale of systems (“System Projects”) over time by using an input method based on costs incurred as it best depicts the Company’s progress toward satisfaction of the performance obligation. Under this method, revenue arising from such contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. The estimation of these costs requires judgment by the Company given the unique product specifications and requirements for contracts related to the design, development, and manufacture of the system. During the year ended December 31, 2023, the Company recognized approximately $18.2 million of revenue recognized over time.

 

Subjective judgment is required by management in determining the assumptions in estimating the estimated costs to complete on contracts for which revenue is recognized over time using a cost-to-cost model. Complex auditor judgment was required in evaluating initial cost estimates and expected costs to complete.

 

How We Addressed the Matter in Our Audit

 

The primary procedures we performed to address this critical audit matter included the following:

 

  ● Obtaining an understanding of management’s process in developing the cost estimates;
     
  ● Obtain and review contracts to ensure that the recognition of revenue over time was appropriate;
     
  ● Evaluating management’s ability to reasonably estimate costs by performing a comparison of the actual costs to prior period estimates, including evaluating the timely identification of circumstances that may warrant a modification to the estimated costs;
     
  ● Evaluate management’s methodologies and the consistency of management’s methodologies over the life of the contracts;
     
  ● Tested the original estimated costs and profit margins on System Projects by obtaining the original estimates, comparing the actual costs and profit margins to the original estimates and investigating significant changes; and
     
  ● Tested the estimated costs to complete Systems Projects that were not completed during the year ended December 31, 2023 by comparing the estimated cost to complete at December 31, 2023 to actual cost incurred subsequent to December 31, 2023.

 

/s/ Marcum llp

 

Marcum LLP

 

We have served as the Company’s auditor since 2019.

 

Melville, NY
March 28, 2024

 

F-1
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Balance Sheets

As of December 31, 2023 and 2022

(in thousands, except share amounts)

 

           
   2023   2022 
ASSETS          
Current assets:          
Cash and cash equivalents  $14,025   $14,365 
Accounts receivable, net   1,906    3,788 
Contract assets   1,604    2,170 
Inventories, net   4,454    2,538 
Other current assets   852    797 
Total current assets   22,841    23,658 
           
Employee retention credit receivable   -    1,529 
Property, plant and equipment, net   12,166    12,596 
Intangible assets, net   9    119 
Other assets   9    10 
Total assets  $35,025   $37,912 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $1,203   $1,454 
Accrued expenses   1,765    2,591 
Current maturities of long-term debt   81    77 
Deposits from purchasers of MesoScribe assets – note 15   597    - 
Contract liabilities   4,908    4,042 
Total current liabilities   8,554    8,164 
           
Long-term debt, net of current portion   268    349 
           
Total liabilities   8,822    8,513 
           
Commitments and contingencies (see note 13)   -     -  
           
Stockholders’ equity:          
Common stock - $0.01 par value – 20,000,000 shares
authorized; issued and outstanding 6,824,511 at December 31,
2023 and 6,760,938 at December 31, 2022		   68    67 
Additional paid-in capital   28,695    27,712 
(Accumulated deficit) retained earnings   (2,560)   1,620 
Total stockholders’ equity   26,203    29,399 
           
Total liabilities and stockholders’ equity  $35,025   $37,912 

 

The accompanying notes are an integral part of the consolidated financial statements

 

F-2
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Statements of Operations

Years ended December 31, 2023 and 2022

(in thousands, except per share amounts)

 

           
   2023   2022 
         
Revenue  $24,109   $25,813 
Cost of revenue   19,038    19,186 
           
Gross profit   5,071    6,627 
           
Operating expenses:          
Research and development   2,596    1,906 
Selling   1,632    1,216 
General and administrative   5,451    5,328 
Loss on disposition of Tantaline   162    - 
Impairment charge   111    - 
           
Total operating expenses   9,952    8,450 
           
Operating loss   (4,881)   (1,823)
           
Other income (expense):          
Interest income   577    162 
Interest expenses   (23)   (8)
Employee retention credits   -    1,529 
Foreign exchange income (loss)   42    (95)
Other income   91    15 
Total other income, net   687    1,603 
           
Loss before income tax   (4,194)   (220)
           
Income tax (benefit) expense   (14)   4 
           
Net loss  $(4,180)  $(224)
           
Loss per common share:          
Basic  $(0.62)  $(0.03)
Diluted  $(0.62)  $(0.03)
           
Weighted average number of shares:          
Basic   6,788    6,734 
Diluted   6,788    6,734 

 

The accompanying notes are an integral part of the consolidated financial statements

 

F-3
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Statements of Changes in Stockholders’ Equity

Years ended December 31, 2023 and 2022

(in thousands, except share amounts)

 

                     
   Common stock   Additional paid-in   (Accumulated Deficit) / Retained      
   Shares   Par Value   Capital  

Earnings

   Total 
                     
Balance at January 1, 2022   6,723,438   $67   $27,277   $1,844   $29,188 
Net loss   -    -    -    (224)   (224)
Stock-based compensation   37,500    -    435    -    435 
Balance at December 31, 2022   6,760,938   $67   $27,712   $1,620   $29,399 
                          
Net loss   -    -    -    (4,180)   (4,180)
Stock-based compensation   41,320    1    907    -    908 
Exercise of stock options and
issuance of shares		   22,253    -    76    -    76 
Balance at December 31, 2023   6,824,511   $68   $28,695   $(2,560)  $26,203 

 

The accompanying notes are an integral part of the consolidated financial statements

 

F-4
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

Consolidated Statements of Cash Flows

Years ended December 31, 2023 and 2022

(in thousands)

 

           
   2023   2022 
Cash flows from operating activities:          
Net loss  $(4,180)  $(224)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:          
Loss on disposition of Tantaline   162    - 
Impairment charge   111    - 
Stock-based compensation   908    435 
Depreciation and amortization   792    867 
Changes in operating assets and liabilities, net of effects of disposition of Tantaline:          
Accounts receivable   1,841    (2,342)
Contract assets   566    368 
Inventories   (1,921)   (1,313)
Income tax receivable   -    716 
Employee retention credit receivable   1,529    (1,529)
Other current assets   (47)   (301)
Accounts payable   (154)   293 
Accrued expenses   (679)   832 
Contract liabilities   866    2,392 
Net cash (used in) provided by operating activities   (206)   194 
           
Cash flows from investing activities:          
Net cash used in disposition of Tantaline   (312)   - 
Deposits from purchaser of MesoScribe assets   597    - 
Purchases of property and equipment   (418)   (665)
Capitalized patent costs   -    (53)
Net proceeds from sale of assets   -    10 
Net cash used in investing activities   (133)   (708)
           
Cash flows from financing activities:          
Proceeds from exercise of stock options   76    - 
Payments of long-term debt   (77)   (1,772)
Net cash used in financing activities   (1)   (1,772)
           
Net decrease in cash and cash equivalents   (340)   (2,286)
           
Cash and cash equivalents at beginning of year   14,365    16,651 
           
Cash and cash equivalents at end of year  $14,025   $14,365 
           
Supplemental disclosure of cash flow information:          
Income taxes paid  $8   $1 
Interest paid  $24   $8 
           
Non-cash investing and financing activities:          
Loan obtained for new equipment
  $-   $432 

 

The accompanying notes are an integral part of the consolidated financial statements

 

F-5
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 1 – Business Description

 

CVD Equipment Corporation and its subsidiaries (the “Company”) is a New York corporation. Its principal business activities include designing, developing, and manufacturing a broad range of chemical vapor deposition, physical vapor transport, gas control, and other equipment and process solutions used to develop and manufacture materials and coatings for industrial applications and research. Its products are used in production environments as well as research and development centers, both academic and corporate.

 

We conduct our business through three reportable operating segments: i) CVD Equipment that supplies chemical vapor deposition, physical vapor transport and thermal process equipment; ii) SDC that designs and manufactures ultra-high purity gas and chemical delivery control systems; and iii) CVD Materials that provide products related to advanced materials and coatings.

 

Note 2 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Liquidity

 

At December 31, 2023, the Company had $14.0 million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of the accompanying Form 10-K.

 

Reclassifications

 

In addition, certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net (loss).

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of CVD Equipment Corporation and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

F-6
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

The Company’s significant estimates are the accounting for certain items such as revenues on long-term contracts recognized on the input method, valuation of inventories at the lower of cost or net realizable value; allowance for credit losses; valuation allowances for deferred tax assets, estimated lives and impairment considerations of long-lived assets and valuation of stock-based compensation.

 

Revenue Recognition

 

In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers (“ASC 606”), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606, the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:

 

Over time

 

The Company designs, manufactures and sells custom chemical vapor deposition, thermal process equipment and other equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that do not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognizes revenue based on point in time.

 

Under the over time method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to

 

F-7
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. There were no material impairment losses recognized on contract assets during the year ended December 31, 2023 and 2022.

 

The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.

 

Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because we believe these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide us with some measure of assurance that the customer will perform on its obligations under the contract.

 

Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.

 

Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.

 

Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.

 

Point in time

 

For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers.”

 

For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the year ended December 31, 2023 and 2022, all system equipment sales were recorded over time by using an input method.

 

F-8
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Inventories

 

Inventories (raw materials, work-in-process and finished goods) are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value. Work-in-process and finished goods inventory reflect all accumulated production costs, which are comprised of direct production costs and overhead, and is reduced by amounts recorded in cost of sales as the related revenue is recognized. Indirect costs relating to long-term contracts, which include expenses such as general and administrative, are charged to expense as incurred and are not included in our cost of sales or work-in-process and finished goods inventory.

 

Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated net realizable value if less than cost. The Company evaluates usage requirements by analyzing historical usage, anticipated demand, alternative uses of materials, and other qualitative factors. Unanticipated changes in demand for the Company’s products may require a write down of inventory, which would be reflected in cost of sales in the period the revision is made.

 

Product Warranty

 

The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period. The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.

 

Income Taxes

 

Deferred tax assets and liabilities are determined based on the estimated future tax effects of temporary differences between the financial statements and tax bases of assets and liabilities, as measured by using the future enacted tax rates. Deferred tax expense (benefit) is the result of changes in the deferred tax assets and liabilities. The Company records a valuation allowance against deferred tax assets when it is more likely than not that future tax benefits will not be utilized based on a lack of sufficient positive evidence.

 

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not the tax position will be sustained on examination by taxing authorities based on the technical merits of the position and (2) for those positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

 

F-9
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

The Company’s policy for global intangible low taxed income (“GILTI”) is to treat such amounts as a period cost when incurred.

 

Impairment of Long-Lived Assets and Intangibles

 

Long-lived assets consist primarily of property, plant, and equipment. Intangibles consist of patents, copyrights and intellectual property, licensing agreements and certifications. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable.When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists.If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value.

 

Property, Plant and Equipment

 

Property, plant and equipment are recorded at cost. Depreciation is determined on a straight-line basis for buildings and building improvements over 5 to 39 years and for machinery and equipment over 5 to 8 years. Depreciation and amortization of assets used in manufacturing are recorded in cost of revenue. Depreciation and amortization of all other assets are recorded as operating expenses.

 

Intangible Assets

 

The cost of intangible assets is being amortized on a straight-line basis over their estimated initial useful lives which ranged from 5 to 20 years.

 

Research and Development

 

Research and development costs are expensed as incurred and include charges for the development of new technology and transition of existing technology into new products.

 

Earnings Per Share

 

Basic earnings per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during each period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be adjusted upon exercise of common stock options, unvested restricted shares, and warrants.

 

F-10
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period.

 

Cash and Cash Equivalents

 

The Company had cash and cash equivalents of $14.0 million and $14.4 million at December 31, 2023 and 2022, respectively. The Company invests excess cash in treasury bills, certificates of deposit or deposit accounts, all with original maturities of less than three months. Cash equivalents were $12.1 million and $11.7 million at December 31, 2023 and 2022, respectively.

 

The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount in excess of the limit at both December 31, 2023 and 2022 was $1.5 million. The Company’s cash in our Denmark subsidiary exceeded the government guarantee limit by approximately $0.5 million at December 31, 2022.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in treasury bills, certificates of deposit or deposit accounts. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.

 

The Company routinely assesses the financial strength of its customers. In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects the best estimate of the amounts the Company does not expect to collect. In addition to reviewing delinquent accounts receivable, the Company consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts. The Company records an allowance for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided based upon the collection history, current economic trends and reasonable supportable forecasts.

 

The Company has accounts receivables from certain customers that exceed 10%. As of December 31, 2023, the accounts receivable balance includes amounts from three customers that represented 37.6%, 13.0% and 12.8% of total accounts receivable, and as of December 31, 2022, two customers that represented 35.7% and 30.3% of total accounts receivable.

 

F-11
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Accounts receivable is presented net of an allowance for credit losses of $36,000 as of both December 31, 2023 and 2022. The allowance is based on prior experience and management’s evaluation of future economic conditions. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for doubtful accounts could be material to our results of operations and financial condition.

 

Sales Concentrations

 

Revenue to a single customer in any one year can exceed 10% of our total sales. There were three customers in the year ended December 31, 2023 that represented 14.3%, 13.5% and 10.9% of our revenues, while there was one customer in the year ended December 31, 2022 that represented 29.2% of our revenues. The loss of a large customer could have a material adverse effect on the Company’s business and financial condition.

 

Export sales to customers represented approximately 17% of sales for both years ended December 31, 2023 and 2022. Export sales in both 2023 and 2022 were primarily to customers in Europe and Asia. All contracts except those entered into by the Company’s subsidiary in Denmark are denominated in U.S. dollars. The Company has not entered into any foreign exchange contracts.

 

Supplier Risk

 

The Company relies on suppliers to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products or cause it to carry excess or obsolete inventory and could cause it to redesign its products.

 

Fair Value of Financial Instruments

 

The carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, contract assets and contract liabilities approximate fair value due to the relatively short-term maturity of these instruments. The carrying value of long-term debt approximates fair value based on prevailing borrowing rates currently available for loans with similar terms and maturities.

 

F-12
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with the provisions set forth in ASC 718, “Stock Compensation”. ASC 718 requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards over the vesting period. The Company uses the Black-Scholes option-pricing model to compute the estimated fair value of option awards and includes assumptions regarding expected volatility, expected option term, dividend yields and risk-free interest rates.

 

Shipping and Handling

 

It is the Company’s policy to include freight charges billed to customers in total revenue. The amount included in revenue was $55,000 and $87,000 for the years ended December 31, 2023 and 2022, respectively.

 

Recently Adopted Accounting Standards

 

In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), which require that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the increase or decreases of expected credit losses that have taken place during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The adoption of the ASU 2016-3 as of January 1, 2023 did not have a material impact on the Company’s financial position.

 

Recently Issued Accounting Standards

 

In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate for federal, state, and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, the ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU also describes items that need to be disaggregated based on their nature, which is determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event that triggered the establishment of the reconciling item and the activity with which the reconciling item is associated. The ASU eliminates the historic requirement that entities disclose information concerning unrecognized tax benefits having a reasonable possibility of

 

F-13
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

significantly increasing or decreasing in the 12 months following the reporting date. This ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU should be applied on a prospective basis; however, retrospective application is permitted. We are currently evaluating the impact that ASU 2023 – 09 will have on our consolidated financial statements.

 

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segments,” which aims to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. Currently, Topic280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the CODM uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this ASU do not change or remove those disclosure requirements and do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We are currently evaluating the impact that ASU 2023 – 07 will have on our consolidated financial statements.

 

The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.

 

F-14
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 3 – Revenue

 

The following table represents a disaggregation of revenue from contracts by end markets for the years ended December 31, 2023 and 2022 (in thousands):

 

   Over time   Point in time   Total 
   Year Ended December 31, 2023 
             
   Over time   Point in time   Total 
Energy  $4,901   $189   $5,090 
Aerospace   3,427    1,469    4,896 
Industrial   6,123    2,821    8,944 
Research   3,700    1,479    5,179 
Total  $18,151   $5,958   $24,109 

 

   Over time   Point in time   Total 
   Year Ended December 31, 2022 
             
   Over time   Point in time   Total 
Energy  $9,094   $58   $9,152 
Aerospace   95    1,527    1,622 
Industrial   5,961    4,856    10,817 
Research   2,807    1,415    4,222 
Total  $17,957   $7,856   $25,813 

 

The energy market includes customers involved in the manufacture of silicon carbide wafers and batteries. Aerospace market includes customers that manufacture aircraft engines. Industrial end market consists of various end customers in diverse industries. Research market principally represents customers that are universities and other research institutions.

 

The Company has unrecognized contract revenue of approximately $16.3 million at December 31, 2023, which it expects to recognize as revenue within the next twelve months.

 

Judgment is required to evaluate assumptions including the amount of net contract revenues and the total estimated costs to determine our progress towards contract completion and to calculate the corresponding amount of revenue to recognize.

 

Changes in estimates for sales of systems occur for a variety of reasons, including but not limited to (i) build accelerations or delays, (ii) product cost forecast changes, (iii) cost related change orders or add-ons, or (iv) changes in other information used to estimate costs. Changes in estimates may have a material effect on the Company’s consolidated financial position and results of operations.

 

F-15
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 3 – Revenue (continued)

 

Contract assets and contract liabilities on input method type contracts in progress are summarized at December 31 as follows (in thousands):

 

   2023   2022 
Costs incurred on contracts in progress  $9,500   $14,390 
Estimated earnings   5,083    10,926 
Costs and estimated earnings on uncompleted contracts   14,583    25,316 
Billings to date   (17,553)   (26,925)
Net cost in excess of billings   (2,970)   (1,609)
Deferred revenue related to non-systems contracts   (334)   (263)
Contract liability in excess of contract assets  $(3,304)  $(1,872)

Included in accompanying consolidated balance sheets under the following captions (in thousands):

          
           
Contract assets  $1,604   $2,170 
Contract liabilities  $4,908   $4,042 

 

Of the contract liability balances at December 31, 2022 and December 31, 2021, $3.7 million and $1.7 million was recognized as revenue during the years ended December 31, 2023 and 2022, respectively. Contract assets at December 31, 2021 were $2.5 million.

 

Note 4 - Inventories

 

Inventories as of December 31 consist of (in thousands):

 

   2023   2022 
         
Raw materials  $2,351   $2,165 
Work-in-process   1,248    373 
Finished goods   855    - 
Total  $4,454   $2,538 

 

F-16
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 5 – Property, Plant and Equipment

 

Major classes of property, plant and equipment consist of the following as of December 31 (in thousands):

 

   2023   2022 
         
Land  $2,220   $2,220 
Buildings and improvements   12,798    12,530 
Machinery and equipment   7,536    7,810 
Construction in progress   167    12 
Totals at cost   22,721    22,572 
           
Less: accumulated depreciation   (10,555)   (9,976)
Property, plant and equipment, net  $12,166   $12,596 

 

Machinery and equipment also include furniture and fixtures and software.

 

Depreciation expense was $0.7 million and $0.8 million for the years ended December 31, 2023 and 2022, respectively.

 

The Company entered into an agreement with the Town of Islip Industrial Development Agency (Islip IDA) in July 2021 under which the Company was granted tax incentives whereby the Company agreed to make payments in lieu of all real estate taxes and assessments (PILOT payments). The agreement requires the Company to maintain certain employment levels at its Central Islip, New York facility. The agreement provides for the Islip IDA to recapture tax incentives provided to the Company in certain circumstances. Any recapture of such tax benefits could have a material adverse effect on the Company’s financial position and future results of operations and cash flows.

 

F-17
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 6 – Intangible Assets

 

Intangible assets consisted of the following (in thousands):

 

December 31, 2023

 

   Cost   Accumulated Amortization   Net 
Patents  $87   $78   $9 

 

December 31, 2022

 

   Cost   Accumulated Amortization   Net 
Patents  $565   $446   $119 

 

Amortization expense was $0.1 million and $0.1 million in years ended December 31, 2023 and 2022, respectively, including costs of abandoned patent applications.

 

The estimated amortization expense related to intangible assets for each of the five succeeding fiscal years and thereafter as of December 31, 2023 is approximately $1,000 per year.

 

Note 7 – Accrued Expenses

 

Accrued expenses consist of the following as of December 31 (in thousands):

 

   2023   2022 
         
Accrued wages and benefits  $358   $995 
Accrued vacation   729    905 
Other   678    691 
Total accrued expenses  $1,765   $2,591 

 

F-18
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 8 – Long-term Debt

 

Long-term debt as of December 31 consist of the following (in thousands, except percentages and amounts in notes):

 

   2023   2022 
 Equipment loan payable in monthly repayments of $8 including interest at 6% per annum  $349   $426 
Less: current maturities   81    77 
 Long-term debt, net of current maturities  $268   $349 

 

In September 2022, the Company entered into a loan agreement to fund the acquisition of machinery equipment in the amount of $0.4 million.

 

Future maturities of long-term debt as of December 31, 2023 are as follows (in thousands):

 

      
2024  $81 
2025   87 
2026   92 
2027   89 
      
Total  $349 

 

Note 9 – Earnings per Share

 

The calculation of basic and diluted weighted average common shares outstanding as of December 31 is as follows (in thousands):

 

   2023   2022 
         
Basic weighted average shares outstanding   6,788    6,734 
Effect of potentially dilutive share-based awards   -    - 
           
Diluted weighted average shares outstanding   6,788    6,734 

 

At December 31, 2023, stock options to purchase 846,875 shares of common stock were outstanding and 335,375 were exercisable. At December 31, 2022, stock options to purchase 673,000 shares of common stock were outstanding and 265,000 were exercisable.

 

At December 31, 2023 and 2022, 846,875 and 673,000 stock options, respectively, were not included in the computation of diluted earnings per share because their effect was antidilutive.

 

F-19
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

Note 10 – Income Taxes

 

Loss before income taxes are as follows:

 

   2023   2022 
         
Domestic  $(4,073)   (596)
Foreign   (121)   376 
Total  $(4,194)  $(220)

 

The expense/(benefit) for income taxes for the years ended December 31 includes the following (in thousands):

 

   2023   2022 
Current:          
Federal  $(16)  $1 
State   2    3 
Total current tax provision   (14)   4 
Deferred:          
Federal   -    - 
State   -    - 
Total deferred tax provision   -    - 
Income tax (benefit) expense  $(14)  $4 

 

The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31 is as follows (in thousands):

 

   2023    2022 
Expected provision at federal statutory tax rate at 21%  $(881)  $(46)
Increase (decrease) in valuation allowance   688    (33)
State and local taxes   21    84 
Foreign tax rate differential   (1)   4 
US taxation of foreign operations   -    80 
Federal research and development credits   (75)   (55)
Change in tax rates   -    10 
Non-deductible expenses   37    62 
Disposition of Tantaline   193    - 
Other   4    (102)
Income tax (benefit) expense  $(14)  $4 

 

F-20
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 10 – Income Taxes (continued)

 

The tax effects of temporary differences giving rise to significant portions of the net deferred taxes as of December 31 are as follows (in thousands):

 

   2023   2022 
Deferred income tax assets:          
Net operating loss carryforwards  $849   $482 
R&D tax credit carryforwards   1,863    1,723 
Compensation costs   113    10 
Vacation accrual   153    174 
Intangible assets   38    27 
Capitalized research and development   759    356 
Other items   303    263 
Deferred income tax assets   4,078    3,035 
Less: valuation allowance   (3,646)   (2,957)
Deferred income tax assets, net of valuation allowance   432    78 
Deferred incomes tax liability:          
Property, plant and equipment   (365)   (11)
Prepaid expenses   (67)   (67)
Deferred income tax asset, net  $-   $- 

 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that the deferred tax assets will be realized. The ultimate realization of deferred tax assets is based on the assessment of available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit the utilization of existing deferred tax assets. The Company considered all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, historical earnings, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the prior three-year period ended December 31, 2023. Such objective evidence limits the ability to consider subjective evidence such as our projections for future growth. Based on this assessment, we maintained a full valuation allowance against our net deferred tax assets as of December 31, 2023, and 2022. If these estimates and assumptions change in the future, we may be required to reduce our existing valuation allowance resulting in less income tax expense.

 

For the year ended December 31, 2023, the valuation allowance increased by approximately $0.7 million from the prior year primarily from current year operating losses for which no tax benefit was provided.

 

F-21
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 10 – Income Taxes (continued)

 

At December 31, 2023, the Company had $4.0 million of U.S. federal net operating loss carryforwards. These net operating losses have an indefinite carryforward period but are only available to offset 80% of future taxable income. The Company also has $1.9 million of federal research and development tax credits which expire in varying amounts in tax years 2028 through 2042.

 

The Company applies the applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2023 and 2022, the Company had no uncertain tax positions. The Company does not expect that its unrecognized tax benefits will significantly increase or decrease within twelve months.

 

The Company files federal income tax returns and income tax returns in various state and local tax jurisdictions and in Denmark. The federal tax years open to examination are 2020 to 2023. The Company’s state and local tax years that are open to tax examination are generally 2019 to 2023.

 

The Inflation Reduction Act (“IRA”) and Chips and Science Act (“CHIPS Act”) were both enacted in August 2022. The IRA introduced new provisions including a 15% corporate alternative minimum tax for certain large corporations that have at least an average of $1 billion adjusted financial statement income over a consecutive three-tax-year period and a 1% excise tax surcharge on stock repurchases. The CHIPS Act provides a variety of incentives associated with investments in domestic semiconductor manufacturing and related activities. Both the IRA and CHIPS Act are applicable for tax years beginning after December 31, 2022 and had no impact to the Company’s consolidated financial statements for the years ended December 31, 2023 and 2022.

 

Note 11 – Employee Retention Credit

 

During 2022, the Company conducted an analysis as to whether it was entitled to employee retention credits (“ERC”) under the CARES Act as amended by the Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Plan Act of 2021. Based on the analysis, the Company determined that it was entitled to an ERC of approximately $1.5 million related to payroll paid in the first and third quarters of 2021 under the applicable Internal Revenue Service regulations related to ERCs.

 

As ERCs are not within the scope of ASC 740, Income Taxes, the Company has chosen to account for the ERCs by analogizing to the International Standard IAS 20, Accounting for Government Grants and Disclosure of Government Assistance. In accordance with IAS 20, an entity recognizes government grants only when there is reasonable assurance that the entity will comply with the conditions attached to them and the grants will be received. Accordingly, the Company recognized a non-current receivable of $1.5 million as of December 31, 2022 and other income of $1.5 million for the year ended December 31, 2022. The Company received the ERC credit in July 2023.

 

F-22
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 12 – Stock-Based Compensation

 

A summary of the Company’s Share Incentive Plans are as follows:

 

2007 Share Incentive Plan

 

On December 12, 2007, shareholders approved the Company’s 2007 Share Incentive Plan (“2017 Incentive Plan”), in connection therewith, 750,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2017 Incentive Plan through December 12, 2017. The Plan expired in December 2017. As of December 31, 2023, there were 120,000 options outstanding under this plan.

 

2016 Share Incentive Plan

 

On December 9, 2016, shareholders approved the Company’s 2016 Share Incentive Plan (“2016 Incentive Plan”), in connection therewith, 750,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2016 Incentive Plan through December 9, 2026. As of December 31, 2023, there were 442,125 options outstanding under this plan.

 

2022 Share Incentive Plan

 

On July 14, 2022, shareholders approved the Company’s 2022 Share Incentive Plan (“2022 Incentive Plan”), in connection therewith, 515,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2022 Incentive Plan through July 14, 2032. As of December 31, 2023, there were 284,750 options outstanding under this plan.

 

Under the 2016 and 2022 Share Incentive Plans, the purchase price of the common stock under each option plan shall be determined by the Committee, provided, however, that such purchase price shall not be less than the fair market value of the shares on the date such option is granted. The stock options generally expire seven to ten years after the date of grant.

 

As of December 31, 2023, there were 26,948 shares available for grant under the 2016 Equity Incentive Plan and 188,930 shares available for grant under the 2022 Equity Incentive Plan.

 

F-23
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 12 – Stock-Based Compensation (continued)

 

The Company recorded stock-based compensation of $0.9 million and $0.4 million for the years ended December 31, 2023 and 2022, respectively, that were included in the following line items in our Consolidated Statements of Operations (in thousands):

 

   2023   2022 
         
Cost of revenue  $120   $34 
Research and development   159    57 
Selling   94    27 
General and administrative   535    317 
           
Total stock-based compensation expense  $908   $435 

 

Stock-based compensation expense in both years included approximately $0.2 million related to restricted stock awards pursuant to a Director Compensation plan discussed below. The Company recognizes forfeitures of stock awards as they occur.

 

For the year ended December 31, 2023, the Company granted 254,000 stock options, vesting 25% per year over four years, with a ten-year life. The Company determined the fair value of stock options granted during the year ended December 31, 2023 is based upon weighted average assumptions as provided below.

 

Stock price  $14.02 
Exercise price  $14.02 
Dividend yield   0%
Expected volatility   72%
Risk-free interest rate   3.39%
Expected life (in years)   6.00 

 

The expected life is the number of years the Company estimates that the awards will be outstanding based on the simplified method that considers the vesting period and contractual period of the option. The Company has 846,875 of outstanding stock options under the three plans at December 31, 2023.

 

F-24
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 12 – Stock-Based Compensation (continued)

 

The following table summarizes stock options awards for the years ended December 31, 2023 and 2022:

 

   Awards
(in Shares)		  

Weighted
Average

Exercise Price

 
Outstanding at December 31, 2021   618,500   $11.26 
           
Granted   198,500    5.04 
Expired / cancelled   (144,000)   11.72 
Exercised   -    - 
Outstanding at December 31, 2022   673,000    5.70 
Granted   254,000    14.02 
Expired / cancelled   (44,500)   6.57 
Exercised   (35,625)   4.53 
Outstanding at December 31, 2023   846,875    8.20 

 

The following table summarizes information about the outstanding and exercisable options at December 31, 2023:

 

   Options Outstanding   Options Exercisable 
       Weighted   Weighted           Weighted     
       Average   Average           Average     
Exercise  Number   Remaining   Exercise   Intrinsic   Number   Exercise   Intrinsic 
Price Range  Outstanding   Contractual   Price   Value   Exercisable   Price   Value 
$ 4.00-7.00   463,375    7.9   $4.55   $76,655    195,375   $4.47   $37,064 
$ 7.01-10.00   20,000    4.3   $8.07   $-    20,000   $8.07   $- 
$ 10.01-13.00   130,000    4.0   $11.51   $-    120,000   $10.52   $- 
$ 13.01-16.00   233,500    9.2   $14.11   $-    -   $-   $- 

 

As of December 31, 2023, there was $2.4 million of unrecognized compensation costs related to stock options expected to be recognized over a weighted average period of 2.6 years.

 

Restricted Stock Awards

 

Pursuant to the Director Compensation plan approved on October 11, 2021, each of the five independent directors is entitled to compensation for an annual equity retainer in the amount of $40,000 per director, to be automatically granted on the date of the Company’s annual meeting of shareholders.

 

F-25
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 12 – Stock-Based Compensation (continued)

 

The following table summarizes restricted stock awards for the years ended December 31, 2023 and 2022:

 

       Weighted 
       Average Grant 
   Shares of   Date Fair 
   Restricted Stock   Value 
Unvested outstanding at January 1, 2022   -   $- 
Granted   32,000    5.02 
Vested   (32,000)   5.02 
Forfeited or cancelled   -    - 
Unvested outstanding at December 31, 2022   -    - 
           
Granted   41,320    6.65 
Vested   (24,187)   6.81 
Forfeited or cancelled   -    - 
Unvested outstanding at December 31, 2023   17,133   $6.53 

 

The fair value of the restricted stock awards is recorded as stock-based compensation expense over the one-year vesting period and totaled $0.17 million $0.16 million for the years ending December 31, 2023 and 2022, respectively.

 

Restricted Stock Units

 

In prior years, the Company issued restricted stock units or RSUs. During the year ended December 31, 2022, 5,500 RSUs vested which had an intrinsic value of $22,745. No restricted stock units vested during the year ended December 31, 2023 and there were no RSUs outstanding as of December 31, 2023 and 2022.

 

Note 13 – Defined Contribution Plan

 

The Company maintains a 401(k) Plan for the benefit of all eligible employees. All employees as of the effective date of the 401(k) Plan became eligible. An employee is eligible to become a participant after three months of continuous service.

 

Participants may elect to contribute from their compensation any amount up to the maximum deferral allowed by the Internal Revenue Code. Employer contributions are optional.

 

Effective July 1, 2022, the Company implemented a matching contribution of 50% of an employee’s contributions up to 6% of their compensation. The Company recorded compensation expense of $243,000 and $90,000 during the years ended December 31, 2023 and 2022, respectively, for matching contributions to the 401(k) plan.

 

No discretionary employer contribution has been made for 2023 and 2022.

 

F-26
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 14 – Segment Reporting

 

The Company operates through three segments: CVD Equipment, Stainless Design Concepts (“SDC”) and CVD Materials. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport and similar equipment. SDC manufactures ultra-high purity gas control systems. The CVD Materials segment provides material coatings for aerospace, medical, electronic and other applications. The Company evaluates performance based on several factors, of which the primary financial measure is income (loss) before taxes.

 

The Company’s corporate administration activities are reported in the “Corporate” column. These activities primarily include expenses related to certain corporate officers and support staff, expenses related to the Company’s Board of Directors, stock option expense for shares granted to corporate administration employees, certain consulting expenses, investor and shareholder relations activities, and all of the Company’s legal, auditing and professional fees, and interest expense.

 

Elimination entries included in the “Eliminations” column represent intersegment revenues and cost of revenues that are eliminated in consolidation. Intersegment sales for the year ended December 31, 2023 and 2022 by the SDC segment to the CVD Equipment segment were $439,000 and $573,000, respectively. Intersegment sales by the CVD Equipment segment to the SDC segment for the year ended December 31, 2023 were $109,000. There were no intersegment sales by the CVD Equipment segment to the SDC segment during the year ended December 31, 2022.

 

The following table presents certain information regarding the Company’s segments as of and for the years ended December 31, 2023 and December 31, 2022 (in thousands, including amount in notes):

 

2023

 

   CVD Equipment   SDC   CVD Materials   Corporate   Eliminations   Consolidated 
Assets  $31,401   $3,468   $211   $-   $(55)  $35,025 
                               
Revenue  $16,334   $7,139   $1,184   $-   $(548)  $24,109 
Operating (loss)
income(1)		   (2,129)   1,677    (193)   (4,118)   (118)   (4,881)
Pretax (loss) income (1)   (2,070)   1,677    (141)   (3,542)   (118)   (4,194)
Depreciation and amortization  $620   $49   $123   $-   $-   $792 
Purchases of property,
plant & equipment		  $404   $14   $-   $-   $-   $418 

 

2022

 

   CVD Equipment    SDC   CVD Materials   Corporate   Eliminations   Consolidated 
Assets  $31,622   $4,149   $2,099   $-   $42   $37,912 
                               
Revenue  $16,674   $6,541   $3,171   $-   $(573)  $25,813 
Operating (loss) income   (1,430)   1,546    1,050    (2,989)   -    (1,823)
Pretax (loss) income (2)   (156)   1,849    1,076    (2,989)   -    (220)
Depreciation and amortization  $652   $49   $166   $-   $-   $867 
Purchases of property, plant & equipment (3)  $653   $3   $3   $-   $-   $- 

 

  (1) CVD Materials segment includes loss on sale of Tantaline of $0.2 million and an impairment charge related to MesoScribe fixed assets of $0.1 million.
  (2) Includes other income related to ERCs of $1,103, $303 and $123 for the CVD, SDC and Materials segments, respectively.
  (3) Include $0.4 million of purchased equipment financed with a loan

 

F-27
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 15 – CVD Materials – Tantaline and MesoScribe Subsidiaries

 

Tantaline Subsidiary

 

On May 26, 2023, the Company sold its Tantaline subsidiary located in Nordborg, Denmark in exchange for a nominal amount at closing and an earn-out provision based on any net income that Tantaline may earn during the five-year period ending December 31, 2027. The Company recorded a loss of $0.2 million upon the sale. Any earn-out amounts will be recognized when and if any such amounts become probable of receipt.

 

The decision to sell Tantaline was based on the Company’s ongoing strategy to focus on the equipment business consisting of the CVD Equipment and SDC segments and reduce its focus on the non-core CVD Materials business.

 

Including the loss on disposition of $0.2 million, the revenues and net income of Tantaline were $0.5 million and $0.1 million, respectively, for the year ended December 31, 2023. The total assets and total liabilities of the Tantaline subsidiary were $1.1 million and $0.4 million as of December 31, 2022.

 

MesoScribe Subsidiary

 

On August 8, 2023, the Company entered into a Purchase and License Agreement (the “Agreement”) with a third-party. Pursuant to the Agreement, the Company will sell certain proprietary assets relating to its plasma spray technology and material deposition system and grant a non-exclusive license to use certain of the Company’s related intellectual property as more fully described in the Agreement, for an aggregate purchase price of $0.9 million. The purchase price is payable in several installments and contingent upon certain performance metrics and other milestones.

 

The Company will continue to fulfill remaining orders for MesoScribe products through the end of 2024 at which time it plans to cease the remaining operations of MesoScribe and dispose of any remaining equipment. During the year ended December 31, 2023, the Company recorded an impairment charge of $0.1 million for certain equipment of MesoScribe based on its decision to cease the operations of MesoScribe upon fulfillment of remaining orders. There were no impairment charges recorded in 2022.

 

The Company received payments under the Agreement in the amount of $0.6 million which has been reflected as “deposits from purchaser” in the accompanying consolidated balance sheet as of December 31, 2023. The Company expects the transaction to be completed in 2024 with the shipment of the equipment to the purchaser.

 

The revenues and net income of MesoScribe were $0.7 million and $33,000 for the year ended December 31, 2023, including the impairment charge of $0.1 million.

 

The total assets and total liabilities of the MesoScribe subsidiary were $0.2 million and $0.7 million, respectively, as of December 31, 2023 and $0.9 million and $0.1 million, respectively, as of December 31, 2022.

 

F-28
 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 16 – Risks and Uncertainties

 

The Company currently operates in a challenging economic environment as the global economy continues to confront the remaining impacts from the pandemic, geopolitical conflicts, inflationary pressures, and adverse supply chain disruptions. The specific impacts on the Company have included:

 

  ● Significant geopolitical developments across Europe and Asia (including the war in Ukraine) have and may continue to restrict the Company’s ability to procure raw materials and components such as nickel and integrated circuits, as well as impact the Company’s ability to sell its products into China, Russia and other Eastern European and Asian regions.
     
  ● Supply chain disruptions have led to much longer lead times to acquire raw materials for production and has led to inflationary pressures in both materials and labor. These supply chain disruptions have impacted the Company’s ability to recognize revenue timelier as it delays the Company’s manufacturing processes.

 

While management has initiated actions to mitigate the potential negative impacts to its revenue and profitability, the Company is unable to predict the impact that the above uncertainties may have on its future results of operations and cash flows.

 

F-29

 

 EX-21.1 2 ex21-1.htm

 


 

Exhibit 21.1

 

CVD EQUIPMENT CORPORATION

SUBSIDIARIES OF REGISTRANT

 

SUBSIDIARY

NAME

  

STATE OR OTHER JURISDICTION

OF INCORPORATION OR ORGANIZATION

CVD Materials Corporation   New York
CVD MesoScribe Technologies Corporation   New York
FAE Holdings 411519R, LLC   New York

 

 

 

 EX-23.1 3 ex23-1.htm

 

Exhibit 23.1

 

Independent Registered Public Accounting Firm’s Consent

 

We consent to the incorporation by reference in the Registration Statement of CVD Equipment Corporation on Form S-8 (File No. 333-138903, 333-153186, and 333-217439) and Form S-3 (File No. 333-271066) of our report dated March 28, 2024 with respect to our audits of the consolidated financial statements of CVD Equipment Corporation and Subsidiaries as of December 31, 2023 and 2022 and for each of the two years in the period ended December 31, 2023, which report is included in this Annual Report on Form 10-K of CVD Equipment Corporation for the year ended December 31, 2023.

 

/s/ Marcum LLP

 

Marcum LLP

Melville, NY

March 28, 2024

 

 

 

 EX-31.1 4 ex31-1.htm

 

Exhibit 31.1

 

Certification of Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Emmanuel Lakios, certify that:

 

1. I have reviewed this annual report on Form 10-K of CVD Equipment Corporation;

 

2. Based upon my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3 Based upon my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: March 28, 2024 /s/ Emmanuel Lakios
  President, Chief Executive Officer

 

 

 

 EX-31.2 5 ex31-2.htm

 

Exhibit 31.2

Certification of Principal Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

I, Richard Catalano, certify that:

 

1. I have reviewed this annual report on Form 10-K of CVD Equipment Corporation;

 

2. Based upon my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3 Based upon my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial data; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: March 28, 2024 /s/ Richard Catalano
 

Executive Vice President and

Chief Financial Officer

 

 

 EX-32.1 6 ex32-1.htm

 

Exhibit 32.1

 

Certification of Principal Executive Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

 

I, Emmanuel Lakios, President and Chief Executive Officer of CVD Equipment Corporation, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, the annual report on Form 10-K for the period ending December 31, 2023 of CVD Equipment Corporation (the “Form 10-K”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of CVD Equipment Corporation.

 

Dated: March 28, 2024 /s/ Emmanuel Lakios
  Emmanuel Lakios
  Chief Executive Officer
  (Principal Executive Officer)

 

 

 EX-32.2 7 ex32-2.htm

 

Exhibit 32.2

 

Certification of Principal Financial Officer

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

 

I, Richard Catalano, Chief Financial Officer of CVD Equipment Corporation, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge, the annual report on Form 10-K for the period ending December 31, 2023 of CVD Equipment Corporation (the “Form 10-K”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of CVD Equipment Corporation.

 

Dated: March 28, 2024 /s/ Richard Catalano
  Richard Catalano
 

Executive Vice President and

Chief Financial Officer

  (Principal Financial Officer)

 

 

 EX-97.1 8 ex-97.htm

 

Exhibit 97

 

 

EXECUTIVE COMPENSATION CLAWBACK POLICY

 

A.Introduction

 

The Board of Directors (the “Board”) of CVD Equipment Corporation (the “Company”) and its wholly owned subsidiaries have adopted this policy (this “Policy”) to provide for the recovery or “clawback” of erroneously awarded incentive-based compensation from certain executive officers in accordance with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10D-1 thereunder and the applicable listing rules of the Nasdaq Stock Market (“Nasdaq”), including Nasdaq Listing Rule 5608.

 

In the event that the Company is required to prepare an Accounting Restatement (as defined below) due to the Company’s material noncompliance with any financial reporting requirement under the securities laws, the Company will reasonably promptly recover Incentive-Based Compensation (as defined below) from any of the Company’s current or former executive officers to the extent such Incentive-Based Compensation was: (i) “Received” (as defined below) during the three-year period preceding the date the Company is required to prepare the Accounting Restatement, and (ii) in excess of what would have been paid to the executive officer under the Accounting Restatement.

 

This Policy shall be effective as of the date it is adopted by the Board (the “Effective Date”) and shall apply to Incentive Compensation that is approved, awarded, or granted to Covered Executives (as defined below) on or after October 2, 2023.

 

B.Administration

 

This Policy shall be administered by the Compensation Committee of the Board (the “Committee”). The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. Any determinations made by the Compensation Committee shall be final and binding on all affected individuals.

 

C.Covered Executives

 

This Policy applies to the Company’s current and former executive officers, as determined by the Board in accordance with Section 10D of the Exchange Act and the applicable Nasdaq listing standards, and such other senior executives/employees who may from time to time be deemed subject to the Policy by the Committee (“Covered Executives”). For the avoidance of doubt, the term “Covered Executives” shall include (i) any individual currently of previously designated as an “officer” of the Company as defined in Rule 16a-1(f) under the Exchange Act, and (ii) shall include each “executive officer” who is or was identified pursuant to Item 401(b) of Regulation S-K.

 

D.Accounting Restatement

 

For the purposes of this Policy, an “Accounting Restatement” shall mean an accounting restatement of the Company’s financial statements due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error (i) in previously issued financial statements that is material to the previously issued financial statements, or (ii) that is not material to previously issued financial statements, but would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period, within the meaning of Rule 10D-1 and Rule 5608.

 

 
 

 

E.Incentive Compensation; Financial Reporting Measure

 

For purposes of this Policy, “Incentive Compensation” means any compensation granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure (including cash and stock options awarded as compensation). Financial Reporting Measures are measures that are determined and presented in accordance with the accounting principles used in the Company’s financial statements, and any measures that are derived wholly or in part from such measures, as well as the Company’s stock price and total stockholder return.

 

F.Application

 

In the event the Company is required to prepare and file an Accounting Restatement, the Committee will require the recovery of any excess Incentive Compensation “Received”1 by any Covered Executive during the three (3) completed fiscal years immediately preceding the date on which the Company is required to prepare an Accounting Restatement.

 

G.Excess Incentive Compensation

 

The amount to be recovered will be the excess of the Incentive Compensation paid to the Covered Executive based on the erroneous data over the Incentive Compensation that would have been paid to the Covered Executive had it been based on the restated results, as determined by the Committee. These determinations are made on a pre-tax basis. If the Committee cannot determine the amount of excess Incentive Compensation received by the Covered Executive directly from the information in the Accounting Restatement, then it will make its determination based on a reasonable estimate of the effect of the Accounting Restatement.

 

H.Recovery; Clawback

 

The Committee shall recover any excess Incentive Compensation in accordance with this Policy unless such recovery would be impracticable, as determined by the Committee in accordance with Rule 10D-1 of the Exchange Act and any applicable listing rules or standards adopted by Nasdaq. The Committee will determine, in its sole discretion, the method for recovering Incentive Compensation hereunder which shall include, without limitation any remedial and recovery method permitted by applicable law and shall be applied to the fullest extent of applicable law. Any right of recovery hereunder is in addition to, and not in lieu of, any other remedies or rights that may be available to the Company under applicable law, regulation or rule, and pursuant to the terms of any similar policy or recovery provision in any applicable employment agreement, severance agreement, equity award agreement, bonus plan, or similar agreement or plan, and any other legal remedies available to the Company. The provisions of this Policy are in addition to, and not in lieu of, any rights of recovery the Company may have under Section 304 of Sarbanes-Oxley Act of 2002.

 

I.Prohibition on Indemnification and Insurance

 

The Company, its subsidiaries, and its affiliates shall not indemnify any Covered Executives against the loss of any erroneously awarded Incentive Compensation, nor shall they pay for, or reimburse any Covered Executive for any insurance policy entered into by a Covered Executive that provides for coverage (full or partial) in connection with any recovery obligation pursuant to this Policy.

 

 

1 Incentive Compensation is deemed “Received” in the Company’s fiscal period during which the Financial Reporting Measure specified in the Incentive Compensation award is attained, even if the payment or grant of the Incentive Compensation occurs after the end of that period.

 

2
 

 

J.Interpretation

 

The Committee is authorized to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this Policy. It is intended that this Policy be interpreted in a manner that is consistent with the requirements of Section 10D of the Exchange Act and any applicable rules or standards adopted by the Securities and Exchange Commission and any applicable listing rules or standards adopted by Nasdaq.

 

K.Amendment; Termination

 

The Committee may amend this Policy from time to time in its discretion and shall amend this Policy as it deems necessary to reflect final regulations adopted by the Securities and Exchange Commission under Section 10D of the Exchange Act and to comply with any applicable listing rules or standards adopted by Nasdaq. The Committee may terminate this Policy at any time.

 

L.Successors

 

This Policy shall be binding and enforceable against all Covered Executives and their beneficiaries, heirs, executors, administrators or other legal representatives.

 

M.Mandatory Disclosures

 

The Company shall file this Policy as an exhibit to its Annual Report on Form 10-K and, if applicable, disclose information relating to the occurrence of an Accounting Restatement in accordance with applicable law, including, but not limited to, the Exchange Act and any applicable listing rules or standards adopted by Nasdaq. In the event the Company is required to clawback any erroneously awarded incentive-based compensation from any executive officer in accordance with the Exchange Act and any applicable listing rules or standards adopted by Nasdaq, and the occurrence of such is disclosed by the Company in a public filing required by the Exchange Act, the Company will disclose (i) the aggregate amount recovered, or (ii) if no amount was recovered, the absence of a recoverable amount.

 

3

 

 GRAPHIC 9 ex97_001.jpg begin 644 ex97_001.jpg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cvv-20231231.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Business Description link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Property, Plant and Equipment link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Long-term Debt link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Earnings per Share link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Employee Retention Credit link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Defined Contribution Plan link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - CVD Materials – Tantaline and MesoScribe Subsidiaries link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Risks and Uncertainties link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Property, Plant and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Long-term Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Earnings per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Schedule of Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Schedule of Cost and Estimated Earnings in Excess of Billings (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Revenue (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Schedule of Inventories, net (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Schedule of Property, Plant and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Property, Plant and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Schedule of Finite Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Schedule of Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Schedule of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Schedule of Long Term Debt (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Schedule of Maturities of Long Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Long-term Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Schedule of Basic and Diluted Weighted Average Common Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Earnings per Share (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Schedule of Loss Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Schedule of Components of Income Tax Expense (Benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - Employee Retention Credit (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - Schedule of Stock Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - Schedule of Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - Schedule of Stock Options Awards (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices (Details) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - Schedule of Restricted Stock Awards (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - Stock-Based Compensation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - Defined Contribution Plan (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - Schedule of Segments (Details) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - Schedule of Segments (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - Segment Reporting (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - CVD Materials – Tantaline and MesoScribe Subsidiaries (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 cvv-20231231_cal.xml XBRL CALCULATION FILE EX-101.DEF 12 cvv-20231231_def.xml XBRL DEFINITION FILE EX-101.LAB 13 cvv-20231231_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Long-Lived Tangible Asset [Axis] Building and Building Improvements [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Machinery and Equipment [Member] Geographical [Axis] DENMARK Concentration Risk Benchmark [Axis] Accounts Receivable [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer [Axis] Customer [Member] Customer One [Member] Customer Two [Member] Customer Three [Member] Revenue Benchmark [Member] Customer A [Member] Customer B [Member] Customer C [Member] Export Sales [Member] Geographic Distribution [Axis] Geographic Distribution, Foreign [Member] Product and Service [Axis] Cargo and Freight [Member] Timing of Transfer of Good or Service [Axis] Transferred over Time [Member] Energy [Member] Transferred at Point in Time [Member] Aerospace [Member] Industrial [Member] Research [Member] Land [Member] Construction in Progress [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Income Tax Authority [Axis] Domestic Tax Authority [Member] Income Tax Authority, Name [Axis] Internal Revenue Service (IRS) [Member] Tax Credit Carryforward [Axis] Research Tax Credit Carryforward [Member] Plan Name [Axis] 2007 Share Incentive Plan [Member] 2016 Share Incentive Plan [Member] 2022 Share Incentive Plan [Member] Award Type [Axis] Restricted Stock [Member] Title of Individual [Axis] Director [Member] Share-Based Payment Arrangement, Option [Member] Five Directors [Member] Restricted Stock Units (RSUs) [Member] Income Statement Location [Axis] Cost of Revenue [Member] Research and Development Expense [Member] Selling Expense [Member] General and Administrative Expense [Member] Exercise Price Range [Axis] Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Exercise Price Range Four [Member] Consolidation Items [Axis] Intersegment Eliminations [Member] Segments [Axis] SDC [Member] CVD Equipment [Member] Operating Segments [Member] CVD Materials [Member] Corporate, Non-Segment [Member] Disposal Group Name [Axis] Tantaline A/S of Nordborg [Member] Consolidated Entities [Axis] Meso Scribe Technologies Inc [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] ICFR Auditor Attestation Flag Document Financial Statement Error Correction [Flag] Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS Current assets: Cash and cash equivalents Accounts receivable, net Contract assets Inventories, net Other current assets Total current assets Employee retention credit receivable Property, plant and equipment, net Intangible assets, net Other assets Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable Accrued expenses Current maturities of long-term debt Deposits from purchasers of MesoScribe assets – note 15 Contract liabilities Total current liabilities Long-term debt, net of current portion Total liabilities Commitments and contingencies (see note 13) Stockholders’ equity: Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,824,511 at December 31, 2023 and 6,760,938 at December 31, 2022 Additional paid-in capital (Accumulated deficit) retained earnings Total stockholders’ equity Total liabilities and stockholders’ equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Revenue Cost of revenue Gross profit Operating expenses: Research and development Selling General and administrative Loss on disposition of Tantaline Impairment charge Total operating expenses Operating loss Other income (expense): Interest income Interest expenses Employee retention credits Foreign exchange income (loss) Other income Total other income, net Loss before income tax Income tax (benefit) expense Net loss Loss per common share: Basic Diluted Weighted average number of shares: Basic Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Net loss Stock-based compensation Stock-based compensation, shares Exercise of stock options and issuance of shares Exercise of stock options and issuance of shares, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash (used in) provided by operating activities: Stock-based compensation Depreciation and amortization Changes in operating assets and liabilities, net of effects of disposition of Tantaline: Accounts receivable Contract assets Inventories Income tax receivable Employee retention credit receivable Other current assets Accounts payable Accrued expenses Contract liabilities Net cash (used in) provided by operating activities Cash flows from investing activities: Net cash used in disposition of Tantaline Deposits from purchaser of MesoScribe assets Purchases of property and equipment Capitalized patent costs Net proceeds from sale of assets Net cash used in investing activities Cash flows from financing activities: Proceeds from exercise of stock options Payments of long-term debt Net cash used in financing activities Net decrease in cash and cash equivalents Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Supplemental disclosure of cash flow information: Income taxes paid Interest paid Non-cash investing and financing activities: Loan obtained for new equipment Accounting Policies [Abstract] Business Description Summary of Significant Accounting Policies Revenue from Contract with Customer [Abstract] Revenue Inventory Disclosure [Abstract] Inventories Property, Plant and Equipment [Abstract] Property, Plant and Equipment Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Payables and Accruals [Abstract] Accrued Expenses Debt Disclosure [Abstract] Long-term Debt Earnings Per Share [Abstract] Earnings per Share Income Tax Disclosure [Abstract] Income Taxes Employee Retention Credit Employee Retention Credit Share-Based Payment Arrangement [Abstract] Stock-Based Compensation Retirement Benefits [Abstract] Defined Contribution Plan Segment Reporting [Abstract] Segment Reporting Discontinued Operations and Disposal Groups [Abstract] CVD Materials – Tantaline and MesoScribe Subsidiaries Risks And Uncertainties Risks and Uncertainties Basis of Presentation Liquidity Reclassifications Principles of Consolidation Use of Estimates Revenue Recognition Inventories Product Warranty Income Taxes Impairment of Long-Lived Assets and Intangibles Property, Plant and Equipment Intangible Assets Research and Development Earnings Per Share Cash and Cash Equivalents Concentration of Credit Risk Sales Concentrations Supplier Risk Fair Value of Financial Instruments Stock-Based Compensation Shipping and Handling Recently Adopted Accounting Standards Recently Issued Accounting Standards Schedule of Disaggregation of Revenue Schedule of Cost and Estimated Earnings in Excess of Billings Schedule of Inventories, net Schedule of Property, Plant and Equipment Schedule of Finite Lived Intangible Assets Schedule of Accrued Expenses Schedule of Long Term Debt Schedule of Maturities of Long Term Debt Schedule of Basic and Diluted Weighted Average Common Shares Outstanding Schedule of Loss Before Income Taxes Schedule of Components of Income Tax Expense (Benefit) Schedule of Effective Income Tax Rate Reconciliation Schedule of Deferred Tax Assets and Liabilities Schedule of Stock Based Compensation Schedule of Weighted Average Assumptions Schedule of Stock Options Awards Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices Schedule of Restricted Stock Awards Schedule of Segments Schedule of Product Information [Table] Product Information [Line Items] Contract assets, impairment loss Standard product warranty description Income tax examination, description Property plant and equipment useful life Intangible assets estimated useful life Cash equivalents Cash uninsured amount Concentration risk percentage Allowance for credit loss Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Total Costs incurred on contracts in progress Estimated earnings Costs and estimated earnings on uncompleted contracts Billings to date Net cost in excess of billings Deferred revenue related to non-systems contracts Contract liability in excess of contract assets Unrecognized contract revenue Deferred revenue recognized Raw materials Work-in-process Finished goods Total Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Totals at cost Less: accumulated depreciation Property, plant and equipment, net Depreciation expense Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Intangible assets, Cost Intangible assets, Accumulated Amortization Intangible assets, Net Amortization expense Estimated amortization expense, 2024 Estimated amortization expense, 2025 Estimated amortization expense, 2026 Estimated amortization expense, 2027 Estimated amortization expense, 2028 Estimated amortization expense, thereafter Accrued wages and benefits Accrued vacation Other Total accrued expenses  Equipment loan payable in monthly repayments of $8 including interest at 6% per annum Less: current maturities  Long-term debt, net of current maturities Debt instrument monthly payments Debt instrument interest rate 2024 2025 2026 2027 Total Loan to fund acquisition of machinery equipment Basic weighted average shares outstanding Effect of potentially dilutive share-based awards Diluted weighted average shares outstanding Stock option outstanding Stock option exercisable Antidilutive shares from computation of diluted earnings per share Domestic Foreign Total Federal State Total current tax provision Federal State Total deferred tax provision Income tax (benefit) expense Expected provision at federal statutory tax rate at 21% Increase (decrease) in valuation allowance State and local taxes Foreign tax rate differential US taxation of foreign operations Federal research and development credits Change in tax rates Non-deductible expenses Disposition of Tantaline Other Federal statutory tax rate Net operating loss carryforwards R&D tax credit carryforwards Compensation costs Vacation accrual Intangible assets Capitalized research and development Other items Deferred income tax assets Less: valuation allowance Deferred income tax assets, net of valuation allowance Property, plant and equipment Prepaid expenses Deferred income tax asset, net Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Increase in valuation allowance Operating loss carryforwards Operating loss carryforwards, limitations Tax credit carryforward. Tax credit carryforward expiration Uncertain tax positions Income tax examination, year Employee retention credit eligible amount Employee retention credit receivable noncurrent Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total stock-based compensation expense Stock price Exercise price Dividend yield Expected volatility Risk-free interest rate Expected life (in years) Stock option awards outstanding, beginning balance Weighted average exercise price outstanding, beginning balance Stock option awards, granted Weighted average exercise price, granted Stock option awards, expired / cancelled Weighted average exercise price, expired / cancelled Stock option awards, exercised Weighted average exercise price, exercised Stock option awards outstanding, ending balance Weighted average exercise price outstanding, ending balance Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise price range, lower limit Exercise price range, upper limit Number of options outstanding Number of options outstanding, weighted average remaining contractual term Number of options outstanding, weighted average exercise price Number of options outstanding, intrinsic value Number of options exercisable Number of options exercisable, weighted average exercise price Number of options exercisable, intrinsic value Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Shares of restricted stock, unvested outstanding Weighted average grant date fair value, unvested outstanding Shares of restricted stock, granted Weighted average grant date fair value, granted Shares of restricted stock, vested Weighted average grant date fair value, vested Shares of restricted stock, forfeited or cancelled Weighted average grant date fair value, forfeited or cancelled Shares of restricted stock, unvested outstanding Weighted average grant date fair value, unvested outstanding Common shares reserved for future issuance. Outstanding stock options Expiration period Number of shares available for grant Stock based compensation Stock option granted Stock option vesting percentage Vesting period Unrecognized compensation costs Unrecognized compensation costs, recoginition period Annual equity retainer amount Restricted stock units, vested Restricted stock units vested, intrinsic value Restricted stock units outstanding Defined contribution plan percentage Defined contribution plan percentage of employees contribution Defined contribution plan, compensation expense Defined contribution plan, employer discretionary contribution amount Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Assets Operating (loss) income Pretax (loss) income Purchases of property, plant & equipment Loss on disposition of tantaline Asset impairment charges Other income related to ERC Number of operating segments Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Revenues Net income Liabilities Aggregate purchase price Deposits from purchaser of equipment Liquidity [Policy Text Block] Employee retention credit receivable noncurrent. Employee Retention Credit [Text Block] Sales Concentrations Policy [Policy Text Block] Payments for capitalized patent costs. Customer [Member] Export Sales [Member] Supplier Risk [Policy Text Block] Shipping And Handling Policy [Policy Text Block] Recently Issued Accounting Standards [Policy Text Block] Customer A [Member] Customer B [Member] Customer C [Member] Schedule Of Cost And Estimated Earnings In Excess Of Billings [Table Text Block] Costs incurred on uncompleted contracts. Estimated earnings. Costs and estimated earnings on uncompleted contracts. Billings to date. Net cost in excess of billings. Deferred revenues related to contracts. Contract liability in excess of contract assets. Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Exercise Price Range Four [Member] Increase decrease in employee retention credit receivable. Deposits from purchaser of MesoScribe assets. Employee retention tax credits income. 2007 Share Incentive Plan [Member] 2016 Share Incentive Plan [Member] 2022 Share Incentive Plan [Member] Share based payment arrangement annual equity retainer amount. Five Directors [Member] SDC [Member] CVD Equipment [Member] CVD Materials [Member] Tantaline A/S of Nordborg [Member] Meso Scribe Technologies Inc [Member] Effective income tax rate reconciliation US taxation of foreign operations amount. Sale of proprietary assets and license certain propriety information aggregate purchase price. Risks And Uncertainties [Text Block] Deferred tax assets capitalized research and development. Selling Expense [Member] Cost of Revenue [Member] Energy [Member] Aerospace [Member] Industrial [Member] Proceeds from deposits from purchaser of mesoscribe assets. Loan to fund acquisition of machinery equipment. Research [Member] Customer Two [Member] Customer Three [Member] Assets, Current Liabilities, Current Equity, Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Interest Expense Nonoperating Income (Expense) Shares, Outstanding Share-Based Payment Arrangement, Noncash Expense Increase (Decrease) in Accounts Receivable Increase (Decrease) in Contract with Customer, Asset Increase (Decrease) in Inventories Increase (Decrease) in Income Taxes Receivable Increase (Decrease) in Other Current Assets Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Liabilities Increase (Decrease) in Contract with Customer, Liability Net Cash Provided by (Used in) Operating Activities Cash Divested from Deconsolidation Payments to Acquire Property, Plant, and Equipment PaymentsForCapitalizedPatentCosts Net Cash Provided by (Used in) Investing Activities Repayments of Long-Term Debt Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Revenue from Contract with Customer [Text Block] EmployeeRetentionCreditTextBlock Inventory, Policy [Policy Text Block] Income Tax, Policy [Policy Text Block] Property, Plant and Equipment, Policy [Policy Text Block] Intangible Assets, Finite-Lived, Policy [Policy Text Block] Share-Based Payment Arrangement [Policy Text Block] CostsAndEstimatedEarningsOnUncompletedContracts BillingsToDate NetCostInExcessOfBillings Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Long-Term Debt Current Income Tax Expense (Benefit) Deferred Federal Income Tax Expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Deferred Tax Assets, Gross Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Deferred Tax Liabilities, Property, Plant and Equipment Deferred Tax Liabilities, Prepaid Expenses Deferred Tax Assets, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value EX-101.PRE 14 cvv-20231231_pre.xml XBRL PRESENTATION FILE XML 16 R1.htm IDEA: XBRL DOCUMENT v3.24.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2023
Mar. 25, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --12-31    
Entity File Number 1-16525    
Entity Registrant Name CVD EQUIPMENT CORPORATION    
Entity Central Index Key 0000766792    
Entity Tax Identification Number 11-2621692    
Entity Incorporation, State or Country Code NY    
Entity Address, Address Line One 355 South Technology Drive    
Entity Address, City or Town Central Islip    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 11722    
City Area Code (631)    
Local Phone Number 981-7081    
Title of 12(b) Security Common Stock, Par value $0.01    
Trading Symbol CVV    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 48,002,094
Entity Common Stock, Shares Outstanding   6,824,511  
Documents Incorporated by Reference [Text Block] None    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Auditor Firm ID 688    
Auditor Name Marcum LLP    
Auditor Location Melville, NY    
XML 17 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 14,025 $ 14,365
Accounts receivable, net 1,906 3,788
Contract assets 1,604 2,170
Inventories, net 4,454 2,538
Other current assets 852 797
Total current assets 22,841 23,658
Employee retention credit receivable 1,529
Property, plant and equipment, net 12,166 12,596
Intangible assets, net 9 119
Other assets 9 10
Total assets 35,025 37,912
Current liabilities:    
Accounts payable 1,203 1,454
Accrued expenses 1,765 2,591
Current maturities of long-term debt 81 77
Deposits from purchasers of MesoScribe assets – note 15 597
Contract liabilities 4,908 4,042
Total current liabilities 8,554 8,164
Long-term debt, net of current portion 268 349
Total liabilities 8,822 8,513
Commitments and contingencies (see note 13)
Stockholders’ equity:    
Common stock - $0.01 par value – 20,000,000 shares authorized; issued and outstanding 6,824,511 at December 31, 2023 and 6,760,938 at December 31, 2022 68 67
Additional paid-in capital 28,695 27,712
(Accumulated deficit) retained earnings (2,560) 1,620
Total stockholders’ equity 26,203 29,399
Total liabilities and stockholders’ equity $ 35,025 $ 37,912
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 20,000,000 20,000,000
Common stock, shares issued 6,824,511 6,760,938
Common stock, shares outstanding 6,824,511 6,760,938
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
Revenue $ 24,109 $ 25,813
Cost of revenue 19,038 19,186
Gross profit 5,071 6,627
Operating expenses:    
Research and development 2,596 1,906
Selling 1,632 1,216
General and administrative 5,451 5,328
Loss on disposition of Tantaline 162
Impairment charge 111
Total operating expenses 9,952 8,450
Operating loss (4,881) [1] (1,823)
Other income (expense):    
Interest income 577 162
Interest expenses (23) (8)
Employee retention credits 1,529
Foreign exchange income (loss) 42 (95)
Other income 91 15
Total other income, net 687 1,603
Loss before income tax (4,194) [1] (220) [2]
Income tax (benefit) expense (14) 4
Net loss $ (4,180) $ (224)
Loss per common share:    
Basic $ (0.62) $ (0.03)
Diluted $ (0.62) $ (0.03)
Weighted average number of shares:    
Basic 6,788 6,734
Diluted 6,788 6,734
[1] CVD Materials segment includes loss on sale of Tantaline of $0.2 million and an impairment charge related to MesoScribe fixed assets of $0.1 million.
[2] Includes other income related to ERCs of $1,103, $303 and $123 for the CVD, SDC and Materials segments, respectively.
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Statements of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2021 $ 67 $ 27,277 $ 1,844 $ 29,188
Balance, shares at Dec. 31, 2021 6,723,438      
Net loss (224) (224)
Stock-based compensation 435 $ 435
Stock-based compensation, shares 37,500      
Exercise of stock options and issuance of shares, shares      
Balance at Dec. 31, 2022 $ 67 27,712 1,620 $ 29,399
Balance, shares at Dec. 31, 2022 6,760,938      
Net loss (4,180) (4,180)
Stock-based compensation $ 1 907 908
Stock-based compensation, shares 41,320      
Exercise of stock options and issuance of shares 76 $ 76
Exercise of stock options and issuance of shares, shares 22,253     35,625
Balance at Dec. 31, 2023 $ 68 $ 28,695 $ (2,560) $ 26,203
Balance, shares at Dec. 31, 2023 6,824,511      
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows from operating activities:    
Net loss $ (4,180) $ (224)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Loss on disposition of Tantaline 162
Impairment charge 111
Stock-based compensation 908 435
Depreciation and amortization 792 867
Changes in operating assets and liabilities, net of effects of disposition of Tantaline:    
Accounts receivable 1,841 (2,342)
Contract assets 566 368
Inventories (1,921) (1,313)
Income tax receivable 716
Employee retention credit receivable 1,529 (1,529)
Other current assets (47) (301)
Accounts payable (154) 293
Accrued expenses (679) 832
Contract liabilities 866 2,392
Net cash (used in) provided by operating activities (206) 194
Cash flows from investing activities:    
Net cash used in disposition of Tantaline (312)
Deposits from purchaser of MesoScribe assets 597
Purchases of property and equipment (418) (665)
Capitalized patent costs (53)
Net proceeds from sale of assets 10
Net cash used in investing activities (133) (708)
Cash flows from financing activities:    
Proceeds from exercise of stock options 76
Payments of long-term debt (77) (1,772)
Net cash used in financing activities (1) (1,772)
Net decrease in cash and cash equivalents (340) (2,286)
Cash and cash equivalents at beginning of year 14,365 16,651
Cash and cash equivalents at end of year 14,025 14,365
Supplemental disclosure of cash flow information:    
Income taxes paid 8 1
Interest paid 24 8
Non-cash investing and financing activities:    
Loan obtained for new equipment $ 432
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.24.1
Business Description
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Business Description

Note 1 – Business Description

 

CVD Equipment Corporation and its subsidiaries (the “Company”) is a New York corporation. Its principal business activities include designing, developing, and manufacturing a broad range of chemical vapor deposition, physical vapor transport, gas control, and other equipment and process solutions used to develop and manufacture materials and coatings for industrial applications and research. Its products are used in production environments as well as research and development centers, both academic and corporate.

 

We conduct our business through three reportable operating segments: i) CVD Equipment that supplies chemical vapor deposition, physical vapor transport and thermal process equipment; ii) SDC that designs and manufactures ultra-high purity gas and chemical delivery control systems; and iii) CVD Materials that provide products related to advanced materials and coatings.

 
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

Note 2 - Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 

Liquidity

 

At December 31, 2023, the Company had $14.0 million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of the accompanying Form 10-K.

 

Reclassifications

 

In addition, certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net (loss).

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of CVD Equipment Corporation and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

The Company’s significant estimates are the accounting for certain items such as revenues on long-term contracts recognized on the input method, valuation of inventories at the lower of cost or net realizable value; allowance for credit losses; valuation allowances for deferred tax assets, estimated lives and impairment considerations of long-lived assets and valuation of stock-based compensation.

 

Revenue Recognition

 

In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers (“ASC 606”), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606, the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:

 

Over time

 

The Company designs, manufactures and sells custom chemical vapor deposition, thermal process equipment and other equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that do not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognizes revenue based on point in time.

 

Under the over time method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. There were no material impairment losses recognized on contract assets during the year ended December 31, 2023 and 2022.

 

The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.

 

Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because we believe these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide us with some measure of assurance that the customer will perform on its obligations under the contract.

 

Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.

 

Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.

 

Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.

 

Point in time

 

For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers.”

 

For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the year ended December 31, 2023 and 2022, all system equipment sales were recorded over time by using an input method.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Inventories

 

Inventories (raw materials, work-in-process and finished goods) are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value. Work-in-process and finished goods inventory reflect all accumulated production costs, which are comprised of direct production costs and overhead, and is reduced by amounts recorded in cost of sales as the related revenue is recognized. Indirect costs relating to long-term contracts, which include expenses such as general and administrative, are charged to expense as incurred and are not included in our cost of sales or work-in-process and finished goods inventory.

 

Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated net realizable value if less than cost. The Company evaluates usage requirements by analyzing historical usage, anticipated demand, alternative uses of materials, and other qualitative factors. Unanticipated changes in demand for the Company’s products may require a write down of inventory, which would be reflected in cost of sales in the period the revision is made.

 

Product Warranty

 

The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period. The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.

 

Income Taxes

 

Deferred tax assets and liabilities are determined based on the estimated future tax effects of temporary differences between the financial statements and tax bases of assets and liabilities, as measured by using the future enacted tax rates. Deferred tax expense (benefit) is the result of changes in the deferred tax assets and liabilities. The Company records a valuation allowance against deferred tax assets when it is more likely than not that future tax benefits will not be utilized based on a lack of sufficient positive evidence.

 

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not the tax position will be sustained on examination by taxing authorities based on the technical merits of the position and (2) for those positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

The Company’s policy for global intangible low taxed income (“GILTI”) is to treat such amounts as a period cost when incurred.

 

Impairment of Long-Lived Assets and Intangibles

 

Long-lived assets consist primarily of property, plant, and equipment. Intangibles consist of patents, copyrights and intellectual property, licensing agreements and certifications. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable.When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists.If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value.

 

Property, Plant and Equipment

 

Property, plant and equipment are recorded at cost. Depreciation is determined on a straight-line basis for buildings and building improvements over 5 to 39 years and for machinery and equipment over 5 to 8 years. Depreciation and amortization of assets used in manufacturing are recorded in cost of revenue. Depreciation and amortization of all other assets are recorded as operating expenses.

 

Intangible Assets

 

The cost of intangible assets is being amortized on a straight-line basis over their estimated initial useful lives which ranged from 5 to 20 years.

 

Research and Development

 

Research and development costs are expensed as incurred and include charges for the development of new technology and transition of existing technology into new products.

 

Earnings Per Share

 

Basic earnings per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during each period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be adjusted upon exercise of common stock options, unvested restricted shares, and warrants.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period.

 

Cash and Cash Equivalents

 

The Company had cash and cash equivalents of $14.0 million and $14.4 million at December 31, 2023 and 2022, respectively. The Company invests excess cash in treasury bills, certificates of deposit or deposit accounts, all with original maturities of less than three months. Cash equivalents were $12.1 million and $11.7 million at December 31, 2023 and 2022, respectively.

 

The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount in excess of the limit at both December 31, 2023 and 2022 was $1.5 million. The Company’s cash in our Denmark subsidiary exceeded the government guarantee limit by approximately $0.5 million at December 31, 2022.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in treasury bills, certificates of deposit or deposit accounts. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.

 

The Company routinely assesses the financial strength of its customers. In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects the best estimate of the amounts the Company does not expect to collect. In addition to reviewing delinquent accounts receivable, the Company consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts. The Company records an allowance for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided based upon the collection history, current economic trends and reasonable supportable forecasts.

 

The Company has accounts receivables from certain customers that exceed 10%. As of December 31, 2023, the accounts receivable balance includes amounts from three customers that represented 37.6%, 13.0% and 12.8% of total accounts receivable, and as of December 31, 2022, two customers that represented 35.7% and 30.3% of total accounts receivable.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Accounts receivable is presented net of an allowance for credit losses of $36,000 as of both December 31, 2023 and 2022. The allowance is based on prior experience and management’s evaluation of future economic conditions. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for doubtful accounts could be material to our results of operations and financial condition.

 

Sales Concentrations

 

Revenue to a single customer in any one year can exceed 10% of our total sales. There were three customers in the year ended December 31, 2023 that represented 14.3%, 13.5% and 10.9% of our revenues, while there was one customer in the year ended December 31, 2022 that represented 29.2% of our revenues. The loss of a large customer could have a material adverse effect on the Company’s business and financial condition.

 

Export sales to customers represented approximately 17% of sales for both years ended December 31, 2023 and 2022. Export sales in both 2023 and 2022 were primarily to customers in Europe and Asia. All contracts except those entered into by the Company’s subsidiary in Denmark are denominated in U.S. dollars. The Company has not entered into any foreign exchange contracts.

 

Supplier Risk

 

The Company relies on suppliers to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products or cause it to carry excess or obsolete inventory and could cause it to redesign its products.

 

Fair Value of Financial Instruments

 

The carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, contract assets and contract liabilities approximate fair value due to the relatively short-term maturity of these instruments. The carrying value of long-term debt approximates fair value based on prevailing borrowing rates currently available for loans with similar terms and maturities.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with the provisions set forth in ASC 718, “Stock Compensation”. ASC 718 requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards over the vesting period. The Company uses the Black-Scholes option-pricing model to compute the estimated fair value of option awards and includes assumptions regarding expected volatility, expected option term, dividend yields and risk-free interest rates.

 

Shipping and Handling

 

It is the Company’s policy to include freight charges billed to customers in total revenue. The amount included in revenue was $55,000 and $87,000 for the years ended December 31, 2023 and 2022, respectively.

 

Recently Adopted Accounting Standards

 

In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), which require that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the increase or decreases of expected credit losses that have taken place during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The adoption of the ASU 2016-3 as of January 1, 2023 did not have a material impact on the Company’s financial position.

 

Recently Issued Accounting Standards

 

In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate for federal, state, and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, the ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU also describes items that need to be disaggregated based on their nature, which is determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event that triggered the establishment of the reconciling item and the activity with which the reconciling item is associated. The ASU eliminates the historic requirement that entities disclose information concerning unrecognized tax benefits having a reasonable possibility of

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

significantly increasing or decreasing in the 12 months following the reporting date. This ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU should be applied on a prospective basis; however, retrospective application is permitted. We are currently evaluating the impact that ASU 2023 – 09 will have on our consolidated financial statements.

 

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segments,” which aims to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. Currently, Topic280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the CODM uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this ASU do not change or remove those disclosure requirements and do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We are currently evaluating the impact that ASU 2023 – 07 will have on our consolidated financial statements.

 

The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.24.1
Revenue
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Revenue

Note 3 – Revenue

 

The following table represents a disaggregation of revenue from contracts by end markets for the years ended December 31, 2023 and 2022 (in thousands):

 

   Over time   Point in time   Total 
   Year Ended December 31, 2023 
             
   Over time   Point in time   Total 
Energy  $4,901   $189   $5,090 
Aerospace   3,427    1,469    4,896 
Industrial   6,123    2,821    8,944 
Research   3,700    1,479    5,179 
Total  $18,151   $5,958   $24,109 

 

   Over time   Point in time   Total 
   Year Ended December 31, 2022 
             
   Over time   Point in time   Total 
Energy  $9,094   $58   $9,152 
Aerospace   95    1,527    1,622 
Industrial   5,961    4,856    10,817 
Research   2,807    1,415    4,222 
Total  $17,957   $7,856   $25,813 

 

The energy market includes customers involved in the manufacture of silicon carbide wafers and batteries. Aerospace market includes customers that manufacture aircraft engines. Industrial end market consists of various end customers in diverse industries. Research market principally represents customers that are universities and other research institutions.

 

The Company has unrecognized contract revenue of approximately $16.3 million at December 31, 2023, which it expects to recognize as revenue within the next twelve months.

 

Judgment is required to evaluate assumptions including the amount of net contract revenues and the total estimated costs to determine our progress towards contract completion and to calculate the corresponding amount of revenue to recognize.

 

Changes in estimates for sales of systems occur for a variety of reasons, including but not limited to (i) build accelerations or delays, (ii) product cost forecast changes, (iii) cost related change orders or add-ons, or (iv) changes in other information used to estimate costs. Changes in estimates may have a material effect on the Company’s consolidated financial position and results of operations.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 3 – Revenue (continued)

 

Contract assets and contract liabilities on input method type contracts in progress are summarized at December 31 as follows (in thousands):

 

   2023   2022 
Costs incurred on contracts in progress  $9,500   $14,390 
Estimated earnings   5,083    10,926 
Costs and estimated earnings on uncompleted contracts   14,583    25,316 
Billings to date   (17,553)   (26,925)
Net cost in excess of billings   (2,970)   (1,609)
Deferred revenue related to non-systems contracts   (334)   (263)
Contract liability in excess of contract assets  $(3,304)  $(1,872)

Included in accompanying consolidated balance sheets under the following captions (in thousands):

          
           
Contract assets  $1,604   $2,170 
Contract liabilities  $4,908   $4,042 

 

Of the contract liability balances at December 31, 2022 and December 31, 2021, $3.7 million and $1.7 million was recognized as revenue during the years ended December 31, 2023 and 2022, respectively. Contract assets at December 31, 2021 were $2.5 million.

 
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.24.1
Inventories
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Inventories

Note 4 - Inventories

 

Inventories as of December 31 consist of (in thousands):

 

   2023   2022 
         
Raw materials  $2,351   $2,165 
Work-in-process   1,248    373 
Finished goods   855    - 
Total  $4,454   $2,538 

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.24.1
Property, Plant and Equipment
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Property, Plant and Equipment

Note 5 – Property, Plant and Equipment

 

Major classes of property, plant and equipment consist of the following as of December 31 (in thousands):

 

   2023   2022 
         
Land  $2,220   $2,220 
Buildings and improvements   12,798    12,530 
Machinery and equipment   7,536    7,810 
Construction in progress   167    12 
Totals at cost   22,721    22,572 
           
Less: accumulated depreciation   (10,555)   (9,976)
Property, plant and equipment, net  $12,166   $12,596 

 

Machinery and equipment also include furniture and fixtures and software.

 

Depreciation expense was $0.7 million and $0.8 million for the years ended December 31, 2023 and 2022, respectively.

 

The Company entered into an agreement with the Town of Islip Industrial Development Agency (Islip IDA) in July 2021 under which the Company was granted tax incentives whereby the Company agreed to make payments in lieu of all real estate taxes and assessments (PILOT payments). The agreement requires the Company to maintain certain employment levels at its Central Islip, New York facility. The agreement provides for the Islip IDA to recapture tax incentives provided to the Company in certain circumstances. Any recapture of such tax benefits could have a material adverse effect on the Company’s financial position and future results of operations and cash flows.
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.24.1
Intangible Assets
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets

Note 6 – Intangible Assets

 

Intangible assets consisted of the following (in thousands):

 

December 31, 2023

 

   Cost   Accumulated Amortization   Net 
Patents  $87   $78   $9 

 

December 31, 2022

 

   Cost   Accumulated Amortization   Net 
Patents  $565   $446   $119 

 

Amortization expense was $0.1 million and $0.1 million in years ended December 31, 2023 and 2022, respectively, including costs of abandoned patent applications.

 

The estimated amortization expense related to intangible assets for each of the five succeeding fiscal years and thereafter as of December 31, 2023 is approximately $1,000 per year.

 
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.24.1
Accrued Expenses
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Accrued Expenses

Note 7 – Accrued Expenses

 

Accrued expenses consist of the following as of December 31 (in thousands):

 

   2023   2022 
         
Accrued wages and benefits  $358   $995 
Accrued vacation   729    905 
Other   678    691 
Total accrued expenses  $1,765   $2,591 

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.24.1
Long-term Debt
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Long-term Debt

Note 8 – Long-term Debt

 

Long-term debt as of December 31 consist of the following (in thousands, except percentages and amounts in notes):

 

   2023   2022 
 Equipment loan payable in monthly repayments of $8 including interest at 6% per annum  $349   $426 
Less: current maturities   81    77 
 Long-term debt, net of current maturities  $268   $349 

 

In September 2022, the Company entered into a loan agreement to fund the acquisition of machinery equipment in the amount of $0.4 million.

 

Future maturities of long-term debt as of December 31, 2023 are as follows (in thousands):

 

      
2024  $81 
2025   87 
2026   92 
2027   89 
      
Total  $349 

 
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.24.1
Earnings per Share
 12 Months Ended
Dec. 31, 2023
Loss per common share:  
Earnings per Share

Note 9 – Earnings per Share

 

The calculation of basic and diluted weighted average common shares outstanding as of December 31 is as follows (in thousands):

 

   2023   2022 
         
Basic weighted average shares outstanding   6,788    6,734 
Effect of potentially dilutive share-based awards   -    - 
           
Diluted weighted average shares outstanding   6,788    6,734 

 

At December 31, 2023, stock options to purchase 846,875 shares of common stock were outstanding and 335,375 were exercisable. At December 31, 2022, stock options to purchase 673,000 shares of common stock were outstanding and 265,000 were exercisable.

 

At December 31, 2023 and 2022, 846,875 and 673,000 stock options, respectively, were not included in the computation of diluted earnings per share because their effect was antidilutive.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Income Taxes

Note 10 – Income Taxes

 

Loss before income taxes are as follows:

 

   2023   2022 
         
Domestic  $(4,073)   (596)
Foreign   (121)   376 
Total  $(4,194)  $(220)

 

The expense/(benefit) for income taxes for the years ended December 31 includes the following (in thousands):

 

   2023   2022 
Current:          
Federal  $(16)  $1 
State   2    3 
Total current tax provision   (14)   4 
Deferred:          
Federal   -    - 
State   -    - 
Total deferred tax provision   -    - 
Income tax (benefit) expense  $(14)  $4 

 

The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31 is as follows (in thousands):

 

   2023    2022 
Expected provision at federal statutory tax rate at 21%  $(881)  $(46)
Increase (decrease) in valuation allowance   688    (33)
State and local taxes   21    84 
Foreign tax rate differential   (1)   4 
US taxation of foreign operations   -    80 
Federal research and development credits   (75)   (55)
Change in tax rates   -    10 
Non-deductible expenses   37    62 
Disposition of Tantaline   193    - 
Other   4    (102)
Income tax (benefit) expense  $(14)  $4 

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 10 – Income Taxes (continued)

 

The tax effects of temporary differences giving rise to significant portions of the net deferred taxes as of December 31 are as follows (in thousands):

 

   2023   2022 
Deferred income tax assets:          
Net operating loss carryforwards  $849   $482 
R&D tax credit carryforwards   1,863    1,723 
Compensation costs   113    10 
Vacation accrual   153    174 
Intangible assets   38    27 
Capitalized research and development   759    356 
Other items   303    263 
Deferred income tax assets   4,078    3,035 
Less: valuation allowance   (3,646)   (2,957)
Deferred income tax assets, net of valuation allowance   432    78 
Deferred incomes tax liability:          
Property, plant and equipment   (365)   (11)
Prepaid expenses   (67)   (67)
Deferred income tax asset, net  $-   $- 

 

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that the deferred tax assets will be realized. The ultimate realization of deferred tax assets is based on the assessment of available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit the utilization of existing deferred tax assets. The Company considered all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, historical earnings, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the prior three-year period ended December 31, 2023. Such objective evidence limits the ability to consider subjective evidence such as our projections for future growth. Based on this assessment, we maintained a full valuation allowance against our net deferred tax assets as of December 31, 2023, and 2022. If these estimates and assumptions change in the future, we may be required to reduce our existing valuation allowance resulting in less income tax expense.

 

For the year ended December 31, 2023, the valuation allowance increased by approximately $0.7 million from the prior year primarily from current year operating losses for which no tax benefit was provided.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 10 – Income Taxes (continued)

 

At December 31, 2023, the Company had $4.0 million of U.S. federal net operating loss carryforwards. These net operating losses have an indefinite carryforward period but are only available to offset 80% of future taxable income. The Company also has $1.9 million of federal research and development tax credits which expire in varying amounts in tax years 2028 through 2042.

 

The Company applies the applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2023 and 2022, the Company had no uncertain tax positions. The Company does not expect that its unrecognized tax benefits will significantly increase or decrease within twelve months.

 

The Company files federal income tax returns and income tax returns in various state and local tax jurisdictions and in Denmark. The federal tax years open to examination are 2020 to 2023. The Company’s state and local tax years that are open to tax examination are generally 2019 to 2023.

 

The Inflation Reduction Act (“IRA”) and Chips and Science Act (“CHIPS Act”) were both enacted in August 2022. The IRA introduced new provisions including a 15% corporate alternative minimum tax for certain large corporations that have at least an average of $1 billion adjusted financial statement income over a consecutive three-tax-year period and a 1% excise tax surcharge on stock repurchases. The CHIPS Act provides a variety of incentives associated with investments in domestic semiconductor manufacturing and related activities. Both the IRA and CHIPS Act are applicable for tax years beginning after December 31, 2022 and had no impact to the Company’s consolidated financial statements for the years ended December 31, 2023 and 2022.

 
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.24.1
Employee Retention Credit
 12 Months Ended
Dec. 31, 2023
Employee Retention Credit  
Employee Retention Credit

Note 11 – Employee Retention Credit

 

During 2022, the Company conducted an analysis as to whether it was entitled to employee retention credits (“ERC”) under the CARES Act as amended by the Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Plan Act of 2021. Based on the analysis, the Company determined that it was entitled to an ERC of approximately $1.5 million related to payroll paid in the first and third quarters of 2021 under the applicable Internal Revenue Service regulations related to ERCs.

 

As ERCs are not within the scope of ASC 740, Income Taxes, the Company has chosen to account for the ERCs by analogizing to the International Standard IAS 20, Accounting for Government Grants and Disclosure of Government Assistance. In accordance with IAS 20, an entity recognizes government grants only when there is reasonable assurance that the entity will comply with the conditions attached to them and the grants will be received. Accordingly, the Company recognized a non-current receivable of $1.5 million as of December 31, 2022 and other income of $1.5 million for the year ended December 31, 2022. The Company received the ERC credit in July 2023.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

Note 12 – Stock-Based Compensation

 

A summary of the Company’s Share Incentive Plans are as follows:

 

2007 Share Incentive Plan

 

On December 12, 2007, shareholders approved the Company’s 2007 Share Incentive Plan (“2017 Incentive Plan”), in connection therewith, 750,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2017 Incentive Plan through December 12, 2017. The Plan expired in December 2017. As of December 31, 2023, there were 120,000 options outstanding under this plan.

 

2016 Share Incentive Plan

 

On December 9, 2016, shareholders approved the Company’s 2016 Share Incentive Plan (“2016 Incentive Plan”), in connection therewith, 750,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2016 Incentive Plan through December 9, 2026. As of December 31, 2023, there were 442,125 options outstanding under this plan.

 

2022 Share Incentive Plan

 

On July 14, 2022, shareholders approved the Company’s 2022 Share Incentive Plan (“2022 Incentive Plan”), in connection therewith, 515,000 shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2022 Incentive Plan through July 14, 2032. As of December 31, 2023, there were 284,750 options outstanding under this plan.

 

Under the 2016 and 2022 Share Incentive Plans, the purchase price of the common stock under each option plan shall be determined by the Committee, provided, however, that such purchase price shall not be less than the fair market value of the shares on the date such option is granted. The stock options generally expire seven to ten years after the date of grant.

 

As of December 31, 2023, there were 26,948 shares available for grant under the 2016 Equity Incentive Plan and 188,930 shares available for grant under the 2022 Equity Incentive Plan.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 12 – Stock-Based Compensation (continued)

 

The Company recorded stock-based compensation of $0.9 million and $0.4 million for the years ended December 31, 2023 and 2022, respectively, that were included in the following line items in our Consolidated Statements of Operations (in thousands):

 

   2023   2022 
         
Cost of revenue  $120   $34 
Research and development   159    57 
Selling   94    27 
General and administrative   535    317 
           
Total stock-based compensation expense  $908   $435 

 

Stock-based compensation expense in both years included approximately $0.2 million related to restricted stock awards pursuant to a Director Compensation plan discussed below. The Company recognizes forfeitures of stock awards as they occur.

 

For the year ended December 31, 2023, the Company granted 254,000 stock options, vesting 25% per year over four years, with a ten-year life. The Company determined the fair value of stock options granted during the year ended December 31, 2023 is based upon weighted average assumptions as provided below.

 

Stock price  $14.02 
Exercise price  $14.02 
Dividend yield   0%
Expected volatility   72%
Risk-free interest rate   3.39%
Expected life (in years)   6.00 

 

The expected life is the number of years the Company estimates that the awards will be outstanding based on the simplified method that considers the vesting period and contractual period of the option. The Company has 846,875 of outstanding stock options under the three plans at December 31, 2023.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 12 – Stock-Based Compensation (continued)

 

The following table summarizes stock options awards for the years ended December 31, 2023 and 2022:

 

   Awards
(in Shares)		  

Weighted
Average

Exercise Price

 
Outstanding at December 31, 2021   618,500   $11.26 
           
Granted   198,500    5.04 
Expired / cancelled   (144,000)   11.72 
Exercised   -    - 
Outstanding at December 31, 2022   673,000    5.70 
Granted   254,000    14.02 
Expired / cancelled   (44,500)   6.57 
Exercised   (35,625)   4.53 
Outstanding at December 31, 2023   846,875    8.20 

 

The following table summarizes information about the outstanding and exercisable options at December 31, 2023:

 

   Options Outstanding   Options Exercisable 
       Weighted   Weighted           Weighted     
       Average   Average           Average     
Exercise  Number   Remaining   Exercise   Intrinsic   Number   Exercise   Intrinsic 
Price Range  Outstanding   Contractual   Price   Value   Exercisable   Price   Value 
$ 4.00-7.00   463,375    7.9   $4.55   $76,655    195,375   $4.47   $37,064 
$ 7.01-10.00   20,000    4.3   $8.07   $-    20,000   $8.07   $- 
$ 10.01-13.00   130,000    4.0   $11.51   $-    120,000   $10.52   $- 
$ 13.01-16.00   233,500    9.2   $14.11   $-    -   $-   $- 

 

As of December 31, 2023, there was $2.4 million of unrecognized compensation costs related to stock options expected to be recognized over a weighted average period of 2.6 years.

 

Restricted Stock Awards

 

Pursuant to the Director Compensation plan approved on October 11, 2021, each of the five independent directors is entitled to compensation for an annual equity retainer in the amount of $40,000 per director, to be automatically granted on the date of the Company’s annual meeting of shareholders.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 12 – Stock-Based Compensation (continued)

 

The following table summarizes restricted stock awards for the years ended December 31, 2023 and 2022:

 

       Weighted 
       Average Grant 
   Shares of   Date Fair 
   Restricted Stock   Value 
Unvested outstanding at January 1, 2022   -   $- 
Granted   32,000    5.02 
Vested   (32,000)   5.02 
Forfeited or cancelled   -    - 
Unvested outstanding at December 31, 2022   -    - 
           
Granted   41,320    6.65 
Vested   (24,187)   6.81 
Forfeited or cancelled   -    - 
Unvested outstanding at December 31, 2023   17,133   $6.53 

 

The fair value of the restricted stock awards is recorded as stock-based compensation expense over the one-year vesting period and totaled $0.17 million $0.16 million for the years ending December 31, 2023 and 2022, respectively.

 

Restricted Stock Units

 

In prior years, the Company issued restricted stock units or RSUs. During the year ended December 31, 2022, 5,500 RSUs vested which had an intrinsic value of $22,745. No restricted stock units vested during the year ended December 31, 2023 and there were no RSUs outstanding as of December 31, 2023 and 2022.

 
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.24.1
Defined Contribution Plan
 12 Months Ended
Dec. 31, 2023
Retirement Benefits [Abstract]  
Defined Contribution Plan

Note 13 – Defined Contribution Plan

 

The Company maintains a 401(k) Plan for the benefit of all eligible employees. All employees as of the effective date of the 401(k) Plan became eligible. An employee is eligible to become a participant after three months of continuous service.

 

Participants may elect to contribute from their compensation any amount up to the maximum deferral allowed by the Internal Revenue Code. Employer contributions are optional.

 

Effective July 1, 2022, the Company implemented a matching contribution of 50% of an employee’s contributions up to 6% of their compensation. The Company recorded compensation expense of $243,000 and $90,000 during the years ended December 31, 2023 and 2022, respectively, for matching contributions to the 401(k) plan.

 

No discretionary employer contribution has been made for 2023 and 2022.
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.24.1
Segment Reporting
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Segment Reporting

Note 14 – Segment Reporting

 

The Company operates through three segments: CVD Equipment, Stainless Design Concepts (“SDC”) and CVD Materials. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport and similar equipment. SDC manufactures ultra-high purity gas control systems. The CVD Materials segment provides material coatings for aerospace, medical, electronic and other applications. The Company evaluates performance based on several factors, of which the primary financial measure is income (loss) before taxes.

 

The Company’s corporate administration activities are reported in the “Corporate” column. These activities primarily include expenses related to certain corporate officers and support staff, expenses related to the Company’s Board of Directors, stock option expense for shares granted to corporate administration employees, certain consulting expenses, investor and shareholder relations activities, and all of the Company’s legal, auditing and professional fees, and interest expense.

 

Elimination entries included in the “Eliminations” column represent intersegment revenues and cost of revenues that are eliminated in consolidation. Intersegment sales for the year ended December 31, 2023 and 2022 by the SDC segment to the CVD Equipment segment were $439,000 and $573,000, respectively. Intersegment sales by the CVD Equipment segment to the SDC segment for the year ended December 31, 2023 were $109,000. There were no intersegment sales by the CVD Equipment segment to the SDC segment during the year ended December 31, 2022.

 

The following table presents certain information regarding the Company’s segments as of and for the years ended December 31, 2023 and December 31, 2022 (in thousands, including amount in notes):

 

2023

 

   CVD Equipment   SDC   CVD Materials   Corporate   Eliminations   Consolidated 
Assets  $31,401   $3,468   $211   $-   $(55)  $35,025 
                               
Revenue  $16,334   $7,139   $1,184   $-   $(548)  $24,109 
Operating (loss)
income(1)		   (2,129)   1,677    (193)   (4,118)   (118)   (4,881)
Pretax (loss) income (1)   (2,070)   1,677    (141)   (3,542)   (118)   (4,194)
Depreciation and amortization  $620   $49   $123   $-   $-   $792 
Purchases of property,
plant & equipment		  $404   $14   $-   $-   $-   $418 

 

2022

 

   CVD Equipment    SDC   CVD Materials   Corporate   Eliminations   Consolidated 
Assets  $31,622   $4,149   $2,099   $-   $42   $37,912 
                               
Revenue  $16,674   $6,541   $3,171   $-   $(573)  $25,813 
Operating (loss) income   (1,430)   1,546    1,050    (2,989)   -    (1,823)
Pretax (loss) income (2)   (156)   1,849    1,076    (2,989)   -    (220)
Depreciation and amortization  $652   $49   $166   $-   $-   $867 
Purchases of property, plant & equipment (3)  $653   $3   $3   $-   $-   $- 

 

  (1) CVD Materials segment includes loss on sale of Tantaline of $0.2 million and an impairment charge related to MesoScribe fixed assets of $0.1 million.
  (2) Includes other income related to ERCs of $1,103, $303 and $123 for the CVD, SDC and Materials segments, respectively.
  (3) Include $0.4 million of purchased equipment financed with a loan

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.24.1
CVD Materials – Tantaline and MesoScribe Subsidiaries
 12 Months Ended
Dec. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]  
CVD Materials – Tantaline and MesoScribe Subsidiaries

Note 15 – CVD Materials – Tantaline and MesoScribe Subsidiaries

 

Tantaline Subsidiary

 

On May 26, 2023, the Company sold its Tantaline subsidiary located in Nordborg, Denmark in exchange for a nominal amount at closing and an earn-out provision based on any net income that Tantaline may earn during the five-year period ending December 31, 2027. The Company recorded a loss of $0.2 million upon the sale. Any earn-out amounts will be recognized when and if any such amounts become probable of receipt.

 

The decision to sell Tantaline was based on the Company’s ongoing strategy to focus on the equipment business consisting of the CVD Equipment and SDC segments and reduce its focus on the non-core CVD Materials business.

 

Including the loss on disposition of $0.2 million, the revenues and net income of Tantaline were $0.5 million and $0.1 million, respectively, for the year ended December 31, 2023. The total assets and total liabilities of the Tantaline subsidiary were $1.1 million and $0.4 million as of December 31, 2022.

 

MesoScribe Subsidiary

 

On August 8, 2023, the Company entered into a Purchase and License Agreement (the “Agreement”) with a third-party. Pursuant to the Agreement, the Company will sell certain proprietary assets relating to its plasma spray technology and material deposition system and grant a non-exclusive license to use certain of the Company’s related intellectual property as more fully described in the Agreement, for an aggregate purchase price of $0.9 million. The purchase price is payable in several installments and contingent upon certain performance metrics and other milestones.

 

The Company will continue to fulfill remaining orders for MesoScribe products through the end of 2024 at which time it plans to cease the remaining operations of MesoScribe and dispose of any remaining equipment. During the year ended December 31, 2023, the Company recorded an impairment charge of $0.1 million for certain equipment of MesoScribe based on its decision to cease the operations of MesoScribe upon fulfillment of remaining orders. There were no impairment charges recorded in 2022.

 

The Company received payments under the Agreement in the amount of $0.6 million which has been reflected as “deposits from purchaser” in the accompanying consolidated balance sheet as of December 31, 2023. The Company expects the transaction to be completed in 2024 with the shipment of the equipment to the purchaser.

 

The revenues and net income of MesoScribe were $0.7 million and $33,000 for the year ended December 31, 2023, including the impairment charge of $0.1 million.

 

The total assets and total liabilities of the MesoScribe subsidiary were $0.2 million and $0.7 million, respectively, as of December 31, 2023 and $0.9 million and $0.1 million, respectively, as of December 31, 2022.
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.24.1
Risks and Uncertainties
 12 Months Ended
Dec. 31, 2023
Risks And Uncertainties  
Risks and Uncertainties

Note 16 – Risks and Uncertainties

 

The Company currently operates in a challenging economic environment as the global economy continues to confront the remaining impacts from the pandemic, geopolitical conflicts, inflationary pressures, and adverse supply chain disruptions. The specific impacts on the Company have included:

 

  ● Significant geopolitical developments across Europe and Asia (including the war in Ukraine) have and may continue to restrict the Company’s ability to procure raw materials and components such as nickel and integrated circuits, as well as impact the Company’s ability to sell its products into China, Russia and other Eastern European and Asian regions.
     
  ● Supply chain disruptions have led to much longer lead times to acquire raw materials for production and has led to inflationary pressures in both materials and labor. These supply chain disruptions have impacted the Company’s ability to recognize revenue timelier as it delays the Company’s manufacturing processes.

 

While management has initiated actions to mitigate the potential negative impacts to its revenue and profitability, the Company is unable to predict the impact that the above uncertainties may have on its future results of operations and cash flows.
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2023
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).

 
Liquidity

Liquidity

 

At December 31, 2023, the Company had $14.0 million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of the accompanying Form 10-K.

 
Reclassifications

Reclassifications

 

In addition, certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net (loss).

 
Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of CVD Equipment Corporation and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

The Company’s significant estimates are the accounting for certain items such as revenues on long-term contracts recognized on the input method, valuation of inventories at the lower of cost or net realizable value; allowance for credit losses; valuation allowances for deferred tax assets, estimated lives and impairment considerations of long-lived assets and valuation of stock-based compensation.

 
Revenue Recognition

Revenue Recognition

 

In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers (“ASC 606”), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606, the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:

 

Over time

 

The Company designs, manufactures and sells custom chemical vapor deposition, thermal process equipment and other equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that do not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognizes revenue based on point in time.

 

Under the over time method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. There were no material impairment losses recognized on contract assets during the year ended December 31, 2023 and 2022.

 

The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.

 

Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because we believe these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide us with some measure of assurance that the customer will perform on its obligations under the contract.

 

Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.

 

Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.

 

Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.

 

Point in time

 

For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers.”

 

For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the year ended December 31, 2023 and 2022, all system equipment sales were recorded over time by using an input method.
Inventories

Inventories

 

Inventories (raw materials, work-in-process and finished goods) are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value. Work-in-process and finished goods inventory reflect all accumulated production costs, which are comprised of direct production costs and overhead, and is reduced by amounts recorded in cost of sales as the related revenue is recognized. Indirect costs relating to long-term contracts, which include expenses such as general and administrative, are charged to expense as incurred and are not included in our cost of sales or work-in-process and finished goods inventory.

 

Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated net realizable value if less than cost. The Company evaluates usage requirements by analyzing historical usage, anticipated demand, alternative uses of materials, and other qualitative factors. Unanticipated changes in demand for the Company’s products may require a write down of inventory, which would be reflected in cost of sales in the period the revision is made.

 
Product Warranty

Product Warranty

 

The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period. The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.

 
Income Taxes

Income Taxes

 

Deferred tax assets and liabilities are determined based on the estimated future tax effects of temporary differences between the financial statements and tax bases of assets and liabilities, as measured by using the future enacted tax rates. Deferred tax expense (benefit) is the result of changes in the deferred tax assets and liabilities. The Company records a valuation allowance against deferred tax assets when it is more likely than not that future tax benefits will not be utilized based on a lack of sufficient positive evidence.

 

The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not the tax position will be sustained on examination by taxing authorities based on the technical merits of the position and (2) for those positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be realized upon ultimate settlement with the related tax authority.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

The Company’s policy for global intangible low taxed income (“GILTI”) is to treat such amounts as a period cost when incurred.

 
Impairment of Long-Lived Assets and Intangibles

Impairment of Long-Lived Assets and Intangibles

 

Long-lived assets consist primarily of property, plant, and equipment. Intangibles consist of patents, copyrights and intellectual property, licensing agreements and certifications. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable.When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists.If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value.

 
Property, Plant and Equipment

Property, Plant and Equipment

 

Property, plant and equipment are recorded at cost. Depreciation is determined on a straight-line basis for buildings and building improvements over 5 to 39 years and for machinery and equipment over 5 to 8 years. Depreciation and amortization of assets used in manufacturing are recorded in cost of revenue. Depreciation and amortization of all other assets are recorded as operating expenses.

 
Intangible Assets

Intangible Assets

 

The cost of intangible assets is being amortized on a straight-line basis over their estimated initial useful lives which ranged from 5 to 20 years.

 
Research and Development

Research and Development

 

Research and development costs are expensed as incurred and include charges for the development of new technology and transition of existing technology into new products.

 
Earnings Per Share

Earnings Per Share

 

Basic earnings per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during each period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be adjusted upon exercise of common stock options, unvested restricted shares, and warrants.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company had cash and cash equivalents of $14.0 million and $14.4 million at December 31, 2023 and 2022, respectively. The Company invests excess cash in treasury bills, certificates of deposit or deposit accounts, all with original maturities of less than three months. Cash equivalents were $12.1 million and $11.7 million at December 31, 2023 and 2022, respectively.

 

The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount in excess of the limit at both December 31, 2023 and 2022 was $1.5 million. The Company’s cash in our Denmark subsidiary exceeded the government guarantee limit by approximately $0.5 million at December 31, 2022.

 
Concentration of Credit Risk

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in treasury bills, certificates of deposit or deposit accounts. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity.

 

The Company routinely assesses the financial strength of its customers. In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects the best estimate of the amounts the Company does not expect to collect. In addition to reviewing delinquent accounts receivable, the Company consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts. The Company records an allowance for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided based upon the collection history, current economic trends and reasonable supportable forecasts.

 

The Company has accounts receivables from certain customers that exceed 10%. As of December 31, 2023, the accounts receivable balance includes amounts from three customers that represented 37.6%, 13.0% and 12.8% of total accounts receivable, and as of December 31, 2022, two customers that represented 35.7% and 30.3% of total accounts receivable.

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

Accounts receivable is presented net of an allowance for credit losses of $36,000 as of both December 31, 2023 and 2022. The allowance is based on prior experience and management’s evaluation of future economic conditions. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for doubtful accounts could be material to our results of operations and financial condition.

 
Sales Concentrations

Sales Concentrations

 

Revenue to a single customer in any one year can exceed 10% of our total sales. There were three customers in the year ended December 31, 2023 that represented 14.3%, 13.5% and 10.9% of our revenues, while there was one customer in the year ended December 31, 2022 that represented 29.2% of our revenues. The loss of a large customer could have a material adverse effect on the Company’s business and financial condition.

 

Export sales to customers represented approximately 17% of sales for both years ended December 31, 2023 and 2022. Export sales in both 2023 and 2022 were primarily to customers in Europe and Asia. All contracts except those entered into by the Company’s subsidiary in Denmark are denominated in U.S. dollars. The Company has not entered into any foreign exchange contracts.

 
Supplier Risk

Supplier Risk

 

The Company relies on suppliers to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products or cause it to carry excess or obsolete inventory and could cause it to redesign its products.

 
Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, contract assets and contract liabilities approximate fair value due to the relatively short-term maturity of these instruments. The carrying value of long-term debt approximates fair value based on prevailing borrowing rates currently available for loans with similar terms and maturities.
Stock-Based Compensation

Stock-Based Compensation

 

The Company records stock-based compensation in accordance with the provisions set forth in ASC 718, “Stock Compensation”. ASC 718 requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards over the vesting period. The Company uses the Black-Scholes option-pricing model to compute the estimated fair value of option awards and includes assumptions regarding expected volatility, expected option term, dividend yields and risk-free interest rates.

 
Shipping and Handling

Shipping and Handling

 

It is the Company’s policy to include freight charges billed to customers in total revenue. The amount included in revenue was $55,000 and $87,000 for the years ended December 31, 2023 and 2022, respectively.

 
Recently Adopted Accounting Standards

Recently Adopted Accounting Standards

 

In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326), which require that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the increase or decreases of expected credit losses that have taken place during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The adoption of the ASU 2016-3 as of January 1, 2023 did not have a material impact on the Company’s financial position.

 
Recently Issued Accounting Standards

Recently Issued Accounting Standards

 

In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures,” which requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate for federal, state, and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, the ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU also describes items that need to be disaggregated based on their nature, which is determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event that triggered the establishment of the reconciling item and the activity with which the reconciling item is associated. The ASU eliminates the historic requirement that entities disclose information concerning unrecognized tax benefits having a reasonable possibility of

 

 

CVD EQUIPMENT CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 2023 and 2022

 

Note 2 - Summary of Significant Accounting Policies (continued)

 

significantly increasing or decreasing in the 12 months following the reporting date. This ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU should be applied on a prospective basis; however, retrospective application is permitted. We are currently evaluating the impact that ASU 2023 – 09 will have on our consolidated financial statements.

 

In November 2023, the FASB issued ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segments,” which aims to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. Currently, Topic280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the CODM uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this ASU do not change or remove those disclosure requirements and do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We are currently evaluating the impact that ASU 2023 – 07 will have on our consolidated financial statements.

 

The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.24.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue

The following table represents a disaggregation of revenue from contracts by end markets for the years ended December 31, 2023 and 2022 (in thousands):

 

   Over time   Point in time   Total 
   Year Ended December 31, 2023 
             
   Over time   Point in time   Total 
Energy  $4,901   $189   $5,090 
Aerospace   3,427    1,469    4,896 
Industrial   6,123    2,821    8,944 
Research   3,700    1,479    5,179 
Total  $18,151   $5,958   $24,109 

 

   Over time   Point in time   Total 
   Year Ended December 31, 2022 
             
   Over time   Point in time   Total 
Energy  $9,094   $58   $9,152 
Aerospace   95    1,527    1,622 
Industrial   5,961    4,856    10,817 
Research   2,807    1,415    4,222 
Total  $17,957   $7,856   $25,813 
Schedule of Cost and Estimated Earnings in Excess of Billings

Contract assets and contract liabilities on input method type contracts in progress are summarized at December 31 as follows (in thousands):

 

   2023   2022 
Costs incurred on contracts in progress  $9,500   $14,390 
Estimated earnings   5,083    10,926 
Costs and estimated earnings on uncompleted contracts   14,583    25,316 
Billings to date   (17,553)   (26,925)
Net cost in excess of billings   (2,970)   (1,609)
Deferred revenue related to non-systems contracts   (334)   (263)
Contract liability in excess of contract assets  $(3,304)  $(1,872)

Included in accompanying consolidated balance sheets under the following captions (in thousands):

          
           
Contract assets  $1,604   $2,170 
Contract liabilities  $4,908   $4,042 
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.24.1
Inventories (Tables)
 12 Months Ended
Dec. 31, 2023
Inventory Disclosure [Abstract]  
Schedule of Inventories, net

Inventories as of December 31 consist of (in thousands):

 

   2023   2022 
         
Raw materials  $2,351   $2,165 
Work-in-process   1,248    373 
Finished goods   855    - 
Total  $4,454   $2,538 
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.24.1
Property, Plant and Equipment (Tables)
 12 Months Ended
Dec. 31, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment

Major classes of property, plant and equipment consist of the following as of December 31 (in thousands):

 

   2023   2022 
         
Land  $2,220   $2,220 
Buildings and improvements   12,798    12,530 
Machinery and equipment   7,536    7,810 
Construction in progress   167    12 
Totals at cost   22,721    22,572 
           
Less: accumulated depreciation   (10,555)   (9,976)
Property, plant and equipment, net  $12,166   $12,596 
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.24.1
Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite Lived Intangible Assets

Intangible assets consisted of the following (in thousands):

 

December 31, 2023

 

   Cost   Accumulated Amortization   Net 
Patents  $87   $78   $9 

 

December 31, 2022

 

   Cost   Accumulated Amortization   Net 
Patents  $565   $446   $119 
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.24.1
Accrued Expenses (Tables)
 12 Months Ended
Dec. 31, 2023
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses

Accrued expenses consist of the following as of December 31 (in thousands):

 

   2023   2022 
         
Accrued wages and benefits  $358   $995 
Accrued vacation   729    905 
Other   678    691 
Total accrued expenses  $1,765   $2,591 
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.24.1
Long-term Debt (Tables)
 12 Months Ended
Dec. 31, 2023
Debt Disclosure [Abstract]  
Schedule of Long Term Debt

Long-term debt as of December 31 consist of the following (in thousands, except percentages and amounts in notes):

 

   2023   2022 
 Equipment loan payable in monthly repayments of $8 including interest at 6% per annum  $349   $426 
Less: current maturities   81    77 
 Long-term debt, net of current maturities  $268   $349 
Schedule of Maturities of Long Term Debt

Future maturities of long-term debt as of December 31, 2023 are as follows (in thousands):

 

      
2024  $81 
2025   87 
2026   92 
2027   89 
      
Total  $349 
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.24.1
Earnings per Share (Tables)
 12 Months Ended
Dec. 31, 2023
Loss per common share:  
Schedule of Basic and Diluted Weighted Average Common Shares Outstanding

The calculation of basic and diluted weighted average common shares outstanding as of December 31 is as follows (in thousands):

 

   2023   2022 
         
Basic weighted average shares outstanding   6,788    6,734 
Effect of potentially dilutive share-based awards   -    - 
           
Diluted weighted average shares outstanding   6,788    6,734 
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2023
Income Tax Disclosure [Abstract]  
Schedule of Loss Before Income Taxes

Loss before income taxes are as follows:

 

   2023   2022 
         
Domestic  $(4,073)   (596)
Foreign   (121)   376 
Total  $(4,194)  $(220)
Schedule of Components of Income Tax Expense (Benefit)

The expense/(benefit) for income taxes for the years ended December 31 includes the following (in thousands):

 

   2023   2022 
Current:          
Federal  $(16)  $1 
State   2    3 
Total current tax provision   (14)   4 
Deferred:          
Federal   -    - 
State   -    - 
Total deferred tax provision   -    - 
Income tax (benefit) expense  $(14)  $4 
Schedule of Effective Income Tax Rate Reconciliation

The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31 is as follows (in thousands):

 

   2023    2022 
Expected provision at federal statutory tax rate at 21%  $(881)  $(46)
Increase (decrease) in valuation allowance   688    (33)
State and local taxes   21    84 
Foreign tax rate differential   (1)   4 
US taxation of foreign operations   -    80 
Federal research and development credits   (75)   (55)
Change in tax rates   -    10 
Non-deductible expenses   37    62 
Disposition of Tantaline   193    - 
Other   4    (102)
Income tax (benefit) expense  $(14)  $4 
Schedule of Deferred Tax Assets and Liabilities

The tax effects of temporary differences giving rise to significant portions of the net deferred taxes as of December 31 are as follows (in thousands):

 

   2023   2022 
Deferred income tax assets:          
Net operating loss carryforwards  $849   $482 
R&D tax credit carryforwards   1,863    1,723 
Compensation costs   113    10 
Vacation accrual   153    174 
Intangible assets   38    27 
Capitalized research and development   759    356 
Other items   303    263 
Deferred income tax assets   4,078    3,035 
Less: valuation allowance   (3,646)   (2,957)
Deferred income tax assets, net of valuation allowance   432    78 
Deferred incomes tax liability:          
Property, plant and equipment   (365)   (11)
Prepaid expenses   (67)   (67)
Deferred income tax asset, net  $-   $- 
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock Based Compensation

 

   2023   2022 
         
Cost of revenue  $120   $34 
Research and development   159    57 
Selling   94    27 
General and administrative   535    317 
           
Total stock-based compensation expense  $908   $435 
Schedule of Weighted Average Assumptions

 

Stock price  $14.02 
Exercise price  $14.02 
Dividend yield   0%
Expected volatility   72%
Risk-free interest rate   3.39%
Expected life (in years)   6.00 
Schedule of Stock Options Awards

The following table summarizes stock options awards for the years ended December 31, 2023 and 2022:

 

   Awards
(in Shares)		  

Weighted
Average

Exercise Price

 
Outstanding at December 31, 2021   618,500   $11.26 
           
Granted   198,500    5.04 
Expired / cancelled   (144,000)   11.72 
Exercised   -    - 
Outstanding at December 31, 2022   673,000    5.70 
Granted   254,000    14.02 
Expired / cancelled   (44,500)   6.57 
Exercised   (35,625)   4.53 
Outstanding at December 31, 2023   846,875    8.20 
Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices

The following table summarizes information about the outstanding and exercisable options at December 31, 2023:

 

   Options Outstanding   Options Exercisable 
       Weighted   Weighted           Weighted     
       Average   Average           Average     
Exercise  Number   Remaining   Exercise   Intrinsic   Number   Exercise   Intrinsic 
Price Range  Outstanding   Contractual   Price   Value   Exercisable   Price   Value 
$ 4.00-7.00   463,375    7.9   $4.55   $76,655    195,375   $4.47   $37,064 
$ 7.01-10.00   20,000    4.3   $8.07   $-    20,000   $8.07   $- 
$ 10.01-13.00   130,000    4.0   $11.51   $-    120,000   $10.52   $- 
$ 13.01-16.00   233,500    9.2   $14.11   $-    -   $-   $- 
Schedule of Restricted Stock Awards

The following table summarizes restricted stock awards for the years ended December 31, 2023 and 2022:

 

       Weighted 
       Average Grant 
   Shares of   Date Fair 
   Restricted Stock   Value 
Unvested outstanding at January 1, 2022   -   $- 
Granted   32,000    5.02 
Vested   (32,000)   5.02 
Forfeited or cancelled   -    - 
Unvested outstanding at December 31, 2022   -    - 
           
Granted   41,320    6.65 
Vested   (24,187)   6.81 
Forfeited or cancelled   -    - 
Unvested outstanding at December 31, 2023   17,133   $6.53 
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.24.1
Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2023
Segment Reporting [Abstract]  
Schedule of Segments

The following table presents certain information regarding the Company’s segments as of and for the years ended December 31, 2023 and December 31, 2022 (in thousands, including amount in notes):

 

2023

 

   CVD Equipment   SDC   CVD Materials   Corporate   Eliminations   Consolidated 
Assets  $31,401   $3,468   $211   $-   $(55)  $35,025 
                               
Revenue  $16,334   $7,139   $1,184   $-   $(548)  $24,109 
Operating (loss)
income(1)		   (2,129)   1,677    (193)   (4,118)   (118)   (4,881)
Pretax (loss) income (1)   (2,070)   1,677    (141)   (3,542)   (118)   (4,194)
Depreciation and amortization  $620   $49   $123   $-   $-   $792 
Purchases of property,
plant & equipment		  $404   $14   $-   $-   $-   $418 

 

2022

 

   CVD Equipment    SDC   CVD Materials   Corporate   Eliminations   Consolidated 
Assets  $31,622   $4,149   $2,099   $-   $42   $37,912 
                               
Revenue  $16,674   $6,541   $3,171   $-   $(573)  $25,813 
Operating (loss) income   (1,430)   1,546    1,050    (2,989)   -    (1,823)
Pretax (loss) income (2)   (156)   1,849    1,076    (2,989)   -    (220)
Depreciation and amortization  $652   $49   $166   $-   $-   $867 
Purchases of property, plant & equipment (3)  $653   $3   $3   $-   $-   $- 

 

  (1) CVD Materials segment includes loss on sale of Tantaline of $0.2 million and an impairment charge related to MesoScribe fixed assets of $0.1 million.
  (2) Includes other income related to ERCs of $1,103, $303 and $123 for the CVD, SDC and Materials segments, respectively.
  (3) Include $0.4 million of purchased equipment financed with a loan
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.24.1
Summary of Significant Accounting Policies (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Product Information [Line Items]    
Cash and cash equivalents $ 14,025,000 $ 14,365,000
Contract assets, impairment loss $ 0 0
Standard product warranty description The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period  
Income tax examination, description tax benefit that is more than 50% likely to be realized upon ultimate settlement  
Cash equivalents $ 12,100,000 11,700,000
Cash uninsured amount 1,500,000 1,500,000
Allowance for credit loss 36,000 36,000
Revenue 24,109,000 25,813,000
Cargo and Freight [Member]    
Product Information [Line Items]    
Revenue $ 55,000 $ 87,000
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer [Member]    
Product Information [Line Items]    
Concentration risk percentage 10.00%  
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer One [Member]    
Product Information [Line Items]    
Concentration risk percentage 37.60% 35.70%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Two [Member]    
Product Information [Line Items]    
Concentration risk percentage 13.00% 30.30%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Customer Three [Member]    
Product Information [Line Items]    
Concentration risk percentage 12.80%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer [Member]    
Product Information [Line Items]    
Concentration risk percentage 10.00%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer A [Member]    
Product Information [Line Items]    
Concentration risk percentage 14.30% 29.20%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer B [Member]    
Product Information [Line Items]    
Concentration risk percentage 13.50%  
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Customer C [Member]    
Product Information [Line Items]    
Concentration risk percentage 10.90%  
Export Sales [Member] | Customer Concentration Risk [Member] | Geographic Distribution, Foreign [Member]    
Product Information [Line Items]    
Concentration risk percentage 17.00% 17.00%
DENMARK    
Product Information [Line Items]    
Cash uninsured amount   $ 500,000
Minimum [Member]    
Product Information [Line Items]    
Intangible assets estimated useful life 5 years  
Maximum [Member]    
Product Information [Line Items]    
Intangible assets estimated useful life 20 years  
Building and Building Improvements [Member] | Minimum [Member]    
Product Information [Line Items]    
Property plant and equipment useful life 5 years  
Building and Building Improvements [Member] | Maximum [Member]    
Product Information [Line Items]    
Property plant and equipment useful life 39 years  
Machinery and Equipment [Member] | Minimum [Member]    
Product Information [Line Items]    
Property plant and equipment useful life 5 years  
Machinery and Equipment [Member] | Maximum [Member]    
Product Information [Line Items]    
Property plant and equipment useful life 8 years  
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]    
Total $ 24,109 $ 25,813
Energy [Member]    
Disaggregation of Revenue [Line Items]    
Total 5,090 9,152
Aerospace [Member]    
Disaggregation of Revenue [Line Items]    
Total 4,896 1,622
Industrial [Member]    
Disaggregation of Revenue [Line Items]    
Total 8,944 10,817
Research [Member]    
Disaggregation of Revenue [Line Items]    
Total 5,179 4,222
Transferred over Time [Member]    
Disaggregation of Revenue [Line Items]    
Total 18,151 17,957
Transferred over Time [Member] | Energy [Member]    
Disaggregation of Revenue [Line Items]    
Total 4,901 9,094
Transferred over Time [Member] | Aerospace [Member]    
Disaggregation of Revenue [Line Items]    
Total 3,427 95
Transferred over Time [Member] | Industrial [Member]    
Disaggregation of Revenue [Line Items]    
Total 6,123 5,961
Transferred over Time [Member] | Research [Member]    
Disaggregation of Revenue [Line Items]    
Total 3,700 2,807
Transferred at Point in Time [Member]    
Disaggregation of Revenue [Line Items]    
Total 5,958 7,856
Transferred at Point in Time [Member] | Energy [Member]    
Disaggregation of Revenue [Line Items]    
Total 189 58
Transferred at Point in Time [Member] | Aerospace [Member]    
Disaggregation of Revenue [Line Items]    
Total 1,469 1,527
Transferred at Point in Time [Member] | Industrial [Member]    
Disaggregation of Revenue [Line Items]    
Total 2,821 4,856
Transferred at Point in Time [Member] | Research [Member]    
Disaggregation of Revenue [Line Items]    
Total $ 1,479 $ 1,415
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Cost and Estimated Earnings in Excess of Billings (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]      
Costs incurred on contracts in progress $ 9,500 $ 14,390  
Estimated earnings 5,083 10,926  
Costs and estimated earnings on uncompleted contracts 14,583 25,316  
Billings to date (17,553) (26,925)  
Net cost in excess of billings (2,970) (1,609)  
Deferred revenue related to non-systems contracts (334) (263)  
Contract liability in excess of contract assets (3,304) (1,872)  
Contract assets 1,604 2,170 $ 2,500
Contract liabilities $ 4,908 $ 4,042  
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.24.1
Revenue (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]      
Unrecognized contract revenue $ 16,300    
Deferred revenue recognized 3,700 $ 1,700  
Contract assets $ 1,604 $ 2,170 $ 2,500
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Inventories, net (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Inventory Disclosure [Abstract]    
Raw materials $ 2,351 $ 2,165
Work-in-process 1,248 373
Finished goods 855
Total $ 4,454 $ 2,538
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Property, Plant and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Totals at cost $ 22,721 $ 22,572
Less: accumulated depreciation (10,555) (9,976)
Property, plant and equipment, net 12,166 12,596
Land [Member]    
Property, Plant and Equipment [Line Items]    
Totals at cost 2,220 2,220
Building and Building Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Totals at cost 12,798 12,530
Machinery and Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Totals at cost 7,536 7,810
Construction in Progress [Member]    
Property, Plant and Equipment [Line Items]    
Totals at cost $ 167 $ 12
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.24.1
Property, Plant and Equipment (Details Narrative) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 0.7 $ 0.8
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Finite Lived Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, Net $ 9 $ 119
Patents [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible assets, Cost 87 565
Intangible assets, Accumulated Amortization 78 446
Intangible assets, Net $ 9 $ 119
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.24.1
Intangible Assets (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]    
Amortization expense $ 100,000 $ 100,000
Estimated amortization expense, 2024 1,000  
Estimated amortization expense, 2025 1,000  
Estimated amortization expense, 2026 1,000  
Estimated amortization expense, 2027 1,000  
Estimated amortization expense, 2028 1,000  
Estimated amortization expense, thereafter $ 1,000  
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Accrued Expenses (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accrued wages and benefits $ 358 $ 995
Accrued vacation 729 905
Other 678 691
Total accrued expenses $ 1,765 $ 2,591
XML 59 R44.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Long Term Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
 Equipment loan payable in monthly repayments of $8 including interest at 6% per annum $ 349 $ 426
Less: current maturities 81 77
 Long-term debt, net of current maturities $ 268 $ 349
XML 60 R45.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Long Term Debt (Details) (Parenthetical)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
Debt Disclosure [Abstract]  
Debt instrument monthly payments $ 8
Debt instrument interest rate 6.00%
XML 61 R46.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Maturities of Long Term Debt (Details)
$ in Thousands
Dec. 31, 2023
USD ($)
Debt Disclosure [Abstract]  
2024 $ 81
2025 87
2026 92
2027 89
Total $ 349
XML 62 R47.htm IDEA: XBRL DOCUMENT v3.24.1
Long-term Debt (Details Narrative) - USD ($)
$ in Millions
Dec. 31, 2022
Sep. 30, 2022
Debt Disclosure [Abstract]    
Loan to fund acquisition of machinery equipment $ 0.4 $ 0.4
XML 63 R48.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Basic and Diluted Weighted Average Common Shares Outstanding (Details) - shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Loss per common share:    
Basic weighted average shares outstanding 6,788 6,734
Effect of potentially dilutive share-based awards
Diluted weighted average shares outstanding 6,788 6,734
XML 64 R49.htm IDEA: XBRL DOCUMENT v3.24.1
Earnings per Share (Details Narrative) - shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Loss per common share:      
Stock option outstanding 846,875 673,000 618,500
Stock option exercisable 335,375 265,000  
Antidilutive shares from computation of diluted earnings per share 846,875 673,000  
XML 65 R50.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Loss Before Income Taxes (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Domestic $ (4,073) $ (596)
Foreign (121) 376
Total $ (4,194) [1] $ (220) [2]
[1] CVD Materials segment includes loss on sale of Tantaline of $0.2 million and an impairment charge related to MesoScribe fixed assets of $0.1 million.
[2] Includes other income related to ERCs of $1,103, $303 and $123 for the CVD, SDC and Materials segments, respectively.
XML 66 R51.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Federal $ (16) $ 1
State 2 3
Total current tax provision (14) 4
Federal
State
Total deferred tax provision
Income tax (benefit) expense $ (14) $ 4
XML 67 R52.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Expected provision at federal statutory tax rate at 21% $ (881) $ (46)
Increase (decrease) in valuation allowance 688 (33)
State and local taxes 21 84
Foreign tax rate differential (1) 4
US taxation of foreign operations 80
Federal research and development credits (75) (55)
Change in tax rates 10
Non-deductible expenses 37 62
Disposition of Tantaline 193
Other 4 (102)
Income tax (benefit) expense $ (14) $ 4
XML 68 R53.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Federal statutory tax rate 21.00% 21.00%
XML 69 R54.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Net operating loss carryforwards $ 849 $ 482
R&D tax credit carryforwards 1,863 1,723
Compensation costs 113 10
Vacation accrual 153 174
Intangible assets 38 27
Capitalized research and development 759 356
Other items 303 263
Deferred income tax assets 4,078 3,035
Less: valuation allowance (3,646) (2,957)
Deferred income tax assets, net of valuation allowance 432 78
Property, plant and equipment (365) (11)
Prepaid expenses (67) (67)
Deferred income tax asset, net
XML 70 R55.htm IDEA: XBRL DOCUMENT v3.24.1
Income Taxes (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating Loss Carryforwards [Line Items]    
Increase in valuation allowance $ 700,000  
Uncertain tax positions $ 0 $ 0
Income tax examination, year The federal tax years open to examination are 2020 to 2023. The Company’s state and local tax years that are open to tax examination are generally 2019 to 2023  
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]    
Operating Loss Carryforwards [Line Items]    
Operating loss carryforwards $ 4,000,000.0  
Operating loss carryforwards, limitations These net operating losses have an indefinite carryforward period but are only available to offset 80% of future taxable income  
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]    
Operating Loss Carryforwards [Line Items]    
Tax credit carryforward. $ 1,900,000  
Tax credit carryforward expiration expire in varying amounts in tax years 2028 through 2042  
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.24.1
Employee Retention Credit (Details Narrative) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Employee Retention Credit    
Employee retention credit eligible amount $ (1,529) $ 1,529
Employee retention credit receivable noncurrent 1,529
Employee retention credits $ 1,529
XML 72 R57.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Stock Based Compensation (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 908 $ 435
Cost of Revenue [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 120 34
Research and Development Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 159 57
Selling Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 94 27
General and Administrative Expense [Member]    
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 535 $ 317
XML 73 R58.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Weighted Average Assumptions (Details)
 12 Months Ended
Dec. 31, 2023
$ / shares
Share-Based Payment Arrangement [Abstract]  
Stock price $ 14.02
Exercise price $ 14.02
Dividend yield 0.00%
Expected volatility 72.00%
Risk-free interest rate 3.39%
Expected life (in years) 6 years
XML 74 R59.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Stock Options Awards (Details) - $ / shares
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]    
Stock option awards outstanding, beginning balance 673,000 618,500
Weighted average exercise price outstanding, beginning balance $ 5.70 $ 11.26
Stock option awards, granted 254,000 198,500
Weighted average exercise price, granted $ 14.02 $ 5.04
Stock option awards, expired / cancelled (44,500) (144,000)
Weighted average exercise price, expired / cancelled $ 6.57 $ 11.72
Stock option awards, exercised (35,625)
Weighted average exercise price, exercised $ 4.53
Stock option awards outstanding, ending balance 846,875 673,000
Weighted average exercise price outstanding, ending balance $ 8.20 $ 5.70
XML 75 R60.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices (Details)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2023
USD ($)
$ / shares
shares
Exercise Price Range One [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price range, lower limit $ 4.00
Exercise price range, upper limit $ 7.00
Number of options outstanding | shares 463,375
Number of options outstanding, weighted average remaining contractual term 7 years 10 months 24 days
Number of options outstanding, weighted average exercise price $ 4.55
Number of options outstanding, intrinsic value | $ $ 76,655
Number of options exercisable | shares 195,375
Number of options exercisable, weighted average exercise price $ 4.47
Number of options exercisable, intrinsic value | $ $ 37,064
Exercise Price Range Two [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price range, lower limit $ 7.01
Exercise price range, upper limit $ 10.00
Number of options outstanding | shares 20,000
Number of options outstanding, weighted average remaining contractual term 4 years 3 months 18 days
Number of options outstanding, weighted average exercise price $ 8.07
Number of options outstanding, intrinsic value | $
Number of options exercisable | shares 20,000
Number of options exercisable, weighted average exercise price $ 8.07
Number of options exercisable, intrinsic value | $
Exercise Price Range Three [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price range, lower limit $ 10.01
Exercise price range, upper limit $ 13.00
Number of options outstanding | shares 130,000
Number of options outstanding, weighted average remaining contractual term 4 years
Number of options outstanding, weighted average exercise price $ 11.51
Number of options outstanding, intrinsic value | $
Number of options exercisable | shares 120,000
Number of options exercisable, weighted average exercise price $ 10.52
Number of options exercisable, intrinsic value | $
Exercise Price Range Four [Member]  
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]  
Exercise price range, lower limit $ 13.01
Exercise price range, upper limit $ 16.00
Number of options outstanding | shares 233,500
Number of options outstanding, weighted average remaining contractual term 9 years 2 months 12 days
Number of options outstanding, weighted average exercise price $ 14.11
Number of options outstanding, intrinsic value | $
Number of options exercisable | shares
Number of options exercisable, weighted average exercise price
Number of options exercisable, intrinsic value | $
XML 76 R61.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Restricted Stock Awards (Details) - Restricted Stock [Member] - $ / shares
shares in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Shares of restricted stock, unvested outstanding
Weighted average grant date fair value, unvested outstanding
Shares of restricted stock, granted 41,320 32,000
Weighted average grant date fair value, granted $ 6.65 $ 5.02
Shares of restricted stock, vested (24,187) (32,000)
Weighted average grant date fair value, vested $ 6.81 $ 5.02
Shares of restricted stock, forfeited or cancelled
Weighted average grant date fair value, forfeited or cancelled
Shares of restricted stock, unvested outstanding 17,133
Weighted average grant date fair value, unvested outstanding $ 6.53
XML 77 R62.htm IDEA: XBRL DOCUMENT v3.24.1
Stock-Based Compensation (Details Narrative) - USD ($)
 12 Months Ended
Jul. 14, 2022
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Oct. 11, 2021
Dec. 09, 2016
Dec. 12, 2007
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Outstanding stock options   846,875 673,000 618,500      
Stock based compensation   $ 908,000 $ 435,000        
Stock option granted   254,000 198,500        
Five Directors [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Annual equity retainer amount         $ 40,000    
Restricted Stock [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Stock based compensation   $ 170,000 $ 160,000        
Vesting period   1 year          
Restricted stock units, vested   24,187,000 32,000,000        
Restricted stock units outstanding   17,133,000      
Restricted Stock [Member] | Director [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Stock based compensation   $ 200,000 $ 200,000        
Share-Based Payment Arrangement, Option [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Expiration period   10 years          
Stock option granted   254,000          
Stock option vesting percentage   25.00%          
Vesting period   4 years          
Unrecognized compensation costs   $ 2,400,000          
Unrecognized compensation costs, recoginition period   2 years 7 months 6 days          
Restricted Stock Units (RSUs) [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Restricted stock units, vested   0 5,500        
Restricted stock units vested, intrinsic value     $ 22,745        
Restricted stock units outstanding   0 0        
2007 Share Incentive Plan [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Common shares reserved for future issuance.             750,000
Outstanding stock options   120,000          
2016 Share Incentive Plan [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Common shares reserved for future issuance.           750,000  
Outstanding stock options   442,125          
Number of shares available for grant   26,948          
2022 Share Incentive Plan [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Common shares reserved for future issuance. 515,000            
Outstanding stock options   284,750          
Number of shares available for grant   188,930          
2022 Share Incentive Plan [Member] | Minimum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Expiration period 7 years            
2022 Share Incentive Plan [Member] | Maximum [Member]              
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]              
Expiration period 10 years            
XML 78 R63.htm IDEA: XBRL DOCUMENT v3.24.1
Defined Contribution Plan (Details Narrative) - USD ($)
 12 Months Ended
Jul. 01, 2022
Dec. 31, 2023
Dec. 31, 2022
Retirement Benefits [Abstract]      
Defined contribution plan percentage 50.00%    
Defined contribution plan percentage of employees contribution 6.00%    
Defined contribution plan, compensation expense   $ 243,000 $ 90,000
Defined contribution plan, employer discretionary contribution amount   $ 0 $ 0
XML 79 R64.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Segments (Details) - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]    
Assets $ 35,025,000 $ 37,912,000
Revenue 24,109,000 25,813,000
Operating (loss) income (4,881,000) [1] (1,823,000)
Pretax (loss) income (4,194,000) [1] (220,000) [2]
Depreciation and amortization 792,000 867,000
Purchases of property, plant & equipment 418,000 [3]
Operating Segments [Member] | CVD Equipment [Member]    
Segment Reporting Information [Line Items]    
Assets 31,401,000 31,622,000
Revenue 16,334,000 16,674,000
Operating (loss) income (2,129,000) [1] (1,430,000)
Pretax (loss) income (2,070,000) [1] (156,000) [2]
Depreciation and amortization 620,000 652,000
Purchases of property, plant & equipment 404,000 653,000 [3]
Operating Segments [Member] | SDC [Member]    
Segment Reporting Information [Line Items]    
Assets 3,468,000 4,149,000
Revenue 7,139,000 6,541,000
Operating (loss) income 1,677,000 [1] 1,546,000
Pretax (loss) income 1,677,000 [1] 1,849,000 [2]
Depreciation and amortization 49,000 49,000
Purchases of property, plant & equipment 14,000 3,000 [3]
Operating Segments [Member] | CVD Materials [Member]    
Segment Reporting Information [Line Items]    
Assets 211,000 2,099,000
Revenue 1,184,000 3,171,000
Operating (loss) income (193,000) [1] 1,050,000
Pretax (loss) income (141,000) [1] 1,076,000 [2]
Depreciation and amortization 123,000 166,000
Purchases of property, plant & equipment 3,000 [3]
Corporate, Non-Segment [Member]    
Segment Reporting Information [Line Items]    
Assets
Revenue
Operating (loss) income (4,118,000) [1] (2,989,000)
Pretax (loss) income (3,542,000) [1] (2,989,000) [2]
Depreciation and amortization
Purchases of property, plant & equipment [3]
Intersegment Eliminations [Member]    
Segment Reporting Information [Line Items]    
Assets (55,000) 42,000
Revenue (548,000) (573,000)
Operating (loss) income (118,000) [1]
Pretax (loss) income (118,000) [1] [2]
Depreciation and amortization
Purchases of property, plant & equipment [3]
Intersegment Eliminations [Member] | CVD Equipment [Member]    
Segment Reporting Information [Line Items]    
Revenue 109,000 0
Intersegment Eliminations [Member] | SDC [Member]    
Segment Reporting Information [Line Items]    
Revenue $ 439,000 $ 573,000
[1] CVD Materials segment includes loss on sale of Tantaline of $0.2 million and an impairment charge related to MesoScribe fixed assets of $0.1 million.
[2] Includes other income related to ERCs of $1,103, $303 and $123 for the CVD, SDC and Materials segments, respectively.
[3] Include $0.4 million of purchased equipment financed with a loan
XML 80 R65.htm IDEA: XBRL DOCUMENT v3.24.1
Schedule of Segments (Details) (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
May 26, 2023
Dec. 31, 2023
Dec. 31, 2022
Sep. 30, 2022
Segment Reporting Information [Line Items]        
Loss on disposition of tantaline   $ (162)  
Asset impairment charges   111  
Loan to fund acquisition of machinery equipment     400 $ 400
Meso Scribe Technologies Inc [Member]        
Segment Reporting Information [Line Items]        
Asset impairment charges   100    
Tantaline A/S of Nordborg [Member]        
Segment Reporting Information [Line Items]        
Loss on disposition of tantaline $ 200      
CVD Materials [Member]        
Segment Reporting Information [Line Items]        
Other income related to ERC     123  
CVD Materials [Member] | Meso Scribe Technologies Inc [Member]        
Segment Reporting Information [Line Items]        
Asset impairment charges   100    
CVD Materials [Member] | Tantaline A/S of Nordborg [Member]        
Segment Reporting Information [Line Items]        
Loss on disposition of tantaline   $ 200    
CVD Equipment [Member]        
Segment Reporting Information [Line Items]        
Other income related to ERC     1,103  
SDC [Member]        
Segment Reporting Information [Line Items]        
Other income related to ERC     $ 303  
XML 81 R66.htm IDEA: XBRL DOCUMENT v3.24.1
Segment Reporting (Details Narrative)
 12 Months Ended
Dec. 31, 2023
USD ($)
Segment
Dec. 31, 2022
USD ($)
Segment Reporting Information [Line Items]    
Number of operating segments | Segment 3  
Revenue $ 24,109,000 $ 25,813,000
Intersegment Eliminations [Member]    
Segment Reporting Information [Line Items]    
Revenue (548,000) (573,000)
Intersegment Eliminations [Member] | SDC [Member]    
Segment Reporting Information [Line Items]    
Revenue 439,000 573,000
Intersegment Eliminations [Member] | CVD Equipment [Member]    
Segment Reporting Information [Line Items]    
Revenue $ 109,000 $ 0
XML 82 R67.htm IDEA: XBRL DOCUMENT v3.24.1
CVD Materials – Tantaline and MesoScribe Subsidiaries (Details Narrative) - USD ($)
 12 Months Ended
May 26, 2023
Dec. 31, 2023
Dec. 31, 2022
Aug. 08, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Loss on disposition of tantaline   $ (162,000)  
Revenues   24,109,000 25,813,000  
Net income   (4,180,000) (224,000)  
Assets   35,025,000 37,912,000  
Liabilities   8,822,000 8,513,000  
Asset impairment charges   111,000  
Deposits from purchaser of equipment   597,000  
Meso Scribe Technologies Inc [Member]        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Revenues   700,000    
Net income   33,000    
Assets   200,000 900,000  
Liabilities   700,000 100,000  
Aggregate purchase price       $ 900,000
Asset impairment charges   100,000    
Deposits from purchaser of equipment   600,000    
Tantaline A/S of Nordborg [Member]        
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]        
Loss on disposition of tantaline $ 200,000      
Revenues   500,000    
Net income   $ 100,000    
Assets     1,100,000  
Liabilities     $ 400,000  
EXCEL 83 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
    N=5 LR#RO]MJL4X5(DMP%V, M(M9@J[F+S*/<3":SK;#D'E82ED5J0JO4HLWGSNL7.88"R*!KPA_&PL&3ZM+C MOK<:\3$^0G "W75M0,I]>SXH5@U.B*^-]*'Y6)/E/-4MY^-URQNZ\_R:EGN9 MW7D>%*?O*%!F](N<_F![PK$+V$/]"1ZDA<9<+%4!\UH,\KEW8?8\=A73(GK; M\U7C*3Y:P*,B Y^X)LVNO%_-#U4!M=G69J]4:K:.-UTXLD\-VG)'-ZAQ$-!O M]SUMX8U2LA#K;2O,0G&'4R9)))S8H!!(^:*"P%"2$*?/!N6A7Q>"K=?8*W)R M4ZX--2E2UNL$DTQTUV@@'@CWA[+0"DGNM:J9>8/A^LK1*\;TD[*+P'4!C4ZP+Q(B\#&*:LHW ('._HV(7)BO&)L.W(OQW!QA^?CI[RF5J?,]!R#\/#!%?MJ1ZZ?T$ M7V)K"1(YF9U-COA(.L?9RY#4>L\Q]L//9JO+XFS^]-$HEU,A;_[-URHQEZ^. M;F*8R7^.;#%"%MD9LY+I]5'?_YZ)< XW7XCF+:*Q%WC7IN8B=:(]^**ZR M*C/J0GI2O(EOA'%_OZQ.=A6QQOIDB2E JC1ACB_^Y;'[;"["FR ,QOGWWC]# M/@2M 9@;Y##\CR,*ZJ"F#MF&.G'(Z4;>CV%7.(%X;C3V3GM],E4O)46 M<4KES3:_5F"#+>953G'XQ5F8C*-P!]MJ]JKEN_!>!/ B/+Z4JX^!\$?IVQBU M*W 7@-Q\TH+*BJ'P#A*!&1+:&Y7=7XJUV6'_#T8';?:KKT;>V\!4_*JX(A4! M62'82!#9J/6G+[AED78X=#%XB"G80E5\0%D^T*C<2$7E>):4 MXT:M?'$]'+;7D/EST!!QJ"'\&+'5C^R77?Q-5L=A*;*E,7G$A67R[ U#F$+F MOE>VO1,(3MMXK$G(0F=CS)A%( Y';3F]U-EBF#,_A^/C-=']"["TUG0NE.VW MQN$]9;Y#EO<$4.%F@FU-5-G#(K3O(9Y0G.FC[M[+P^APP\FE)45U&@3:C[.7 M8<+:5O3*3TJL-2V_%S-^&U\K>L$OTTR/\SM)?P$7#[!0U&H)0T^GS\ I6G[- M)__1FBV]6G-A6G#]]'%-C,0'X/>E ?OC_\ )XLM67_T?4$L#!!0 ( !V M?%A[*"3#H@0 !(+ 9 >&PO=V]R:W-H965T4 MI7@;Q[OMBR5>YLPYHSDT)QNIGO4*T7 M?N1W$P_5>P>K9"[ELQW0"[BM-%LN%2Z9:VF:V6D[1/HH[&'23ROT%I*34RNQ!&-;@ISG MUH71P*!\1T#M%[?8%5?#? LH2NI4]8PTI-,#S IABTQINX(ET&?&>DZU[SXU M,(J@EQA.*^&9E6PTS>BS"^AJX!VK@??S"RK/T)$!][(2QJL$N-&3-(Q[OU-J M;W8X\Q="9P+5<@LGD 9Y&-$S&N?TFP5A'GI7J*0K)"1!&H\@"M)A3CO'^="[ M$R4UF*H8AV$0D<(X&,<1C(,\3;T'JBI3Q8KB1F%HXT8Y84:CW'-I79X@RB*7 M*L_&](S3( KS_Z\T_EJE.6E+;>*Q&T19O":*,=L04V,LO=D7^V>&ZF-Z[&9 M)LG,4'UF3 EJ=0U4AMEK@5K;C=<5YW;VD*N.ICOLJN[(\9C6U@R60N<4X!6; M5[PR%5)J03S6C8$:J?M+,-LU[GF*.*Z5I-8GEDSA[H^T^IMT,+/_J8%9QUD; M:VLE^,A*_[D@GK.IZR,;:W<5C5)8>D3],%';/1FU-WWE-$C(+WTN#[M<9*1Q M8OLECX<[8,L*>U;=3INF$86LUQSM_%M* L\(@QHGB89>S]=(* D!3JG%LBR! M,SB-AY0F@S/O)[KR%+8"1!=[J?-=*&T,\E%H(ZC+PYP";G&!3FQWYBGDCAYE M$5)\I[?:8*WW6)TF2=KFI-1>WP?=-]]^GKKOB5V?G%!\D(06X<2R&(]B0KD3 M!6_(V]:YK+"U8&)KCVL*UY)7I:,T9YP)LJJ[&6@J6HGM"?QVO!=L;4_0=RWB M_;M?3ZS/0WL:Q'0ZA>]UV-YM#\>Q>X9I?-"[@[U["OWI+MUMS-:K$::]LO2S M_87OJKWGO&UO;XN?F%I6Q)WC@D+#\Q'Y4K4WL'9@Y-K=>N;2T#^\>UW1I165 MW4#K"RE--[ )^FOP]!]02P,$% @ '8!\6"V>J)B# @ =@4 !D !X M;"]W;W)K&ULA91=3]LP%(;O^RN.LFD"J9#F"ZJN MC41A""Z0$+!Q,>W"34X;"\?.?!P*_WZVTV:=5+J;^.N@LK!F703[U M<_VU'84\I M>8V2N)*@<3D++J+)/'7Q/N 'QS7M],%5LE#JQ0UNRUDPR,GYOF$&_I4O<[6_IU[YV6\N"$5XJ\EAL M*/..$G] B6*X4])4!-]DB>6_@-!*ZG7%6UWS^"#Q"HM32*(AQ*,X.D!NVLM-#]'S1VN^LA4(:@D[5S0$B6:?UH.T_5IWL -&;B-[YE@O4-MS MAT)9WY%QTT=<@JE42TR6=#R!K;;!'FT#=UWNSN+! UO;']6@YDP0?(9XF&21 M;Z.S;/!LO7K"Y4FC58%$$ WC= S)>3*XYI+;_[F$E5(EP3C+X&3PI P3-CD= MIEGJ(5DRAGT''>YXH4:]\HXG6T\K36>+?K9_5"XZ+_T-[UZD.Z977!((7-K4 MT>EY%H#N7-X-C&J\LQ;*6)_Z;F4?1M0NP*XOE3+;@=N@?VKS/U!+ P04 M" =@'Q8._0Y6>D" !_!@ &0 'AL+W=O37(A7QTYMI[3_ M?M<)9&RB3-I+_'7ON>?XXV2Z4_K!Y "6/!="FIF?6UM.@L"D.13,7*H2)*YL ME"Z8Q:'>!J;4P+(ZJ1 !#<,D*!B7_GQ:SZWT?*HJ*[B$E2:F*@JF7Q8@U&[F M1_YAXI9O<^LF@OFT9%NX _NE7&D]YA^6](E'OHOV36Q ^J3M#)6%?MD9%!P MV;3L>;\/1PFC\)4$ND^@->^F4,WRAEDVGVJU(]I%(YKKU%+K;"3'I3N4.ZMQ ME6.>G:\TGJ^V+SVR$DQ:PF1&WC]6O,2-MZ1SS]8"3'<:6*SE,H)TC[MH<.DK MN!$E2R5M;LA[F4'V)T" )%NF],!T0<\BWD!Z2?I1C]"0]L_@]5OE_1JO_U_* MOU^MC=5X9WZ;C0S&@G\"?OWT3)>&[,[P'+>_!.?3Y M';[+K!) U(:HT7B#C)W")AD2T-QR/7!/W0V_)TASW0+_\)6*(JPE^1U'H M7:,@JZO&1) Q@FUQ&PO=V]R:W-H965TU-OZ!(4W:3:%!Q)-9EO2P,\ M:8(*Z8=!,/8++I07S1K;RD0S7:$4"E:&V:HHN/FU!*GKN=?WMH9;D>7H#'XT M*WD&=X!?RI4AS>]0$E& LD(K9B"=>XO^=#ET_HW#5P&UW3DS5\E:ZWNG7"=S M+W"$0$*,#H'3YP'.04H'1#1^;C"]+J4+W#UOT2^;VJF6-;=PKN4WD6 ^]R8> M2R#EE<1;77^ 33TCAQ=K:1O)ZM9W-/!87%G4Q2:8&!1"M5_^N.G#3L D>"$@ MW 2$#>\V4EWXA;"RUK0RP[XNU M14/_S(]]?6BS#/=G<7,TM26/8>[1H%@P#^!%;U[UQ\&[ S4,NQJ&A]"C.YK+ MI"+2.F670@D$]I%^[#WU[&-^$'L_\R?<'F_[%&L:2HN4DSA@#BS5DJ9;J(P= M"44675GJL#V>LBW;WC_9,GIL*-9@>ML'[YUKBVP1QU5124[I>HM"&Q2_>3/0 MGP![*S(KBGW-)JNLW>I:M!/[Y-[NO1MN,J$LDY!2:'!R.O*8:7=)JZ NF_E=:Z1MT!QS M6K]@G /=IUKC5G$)NH4>_0%02P,$% @ '8!\6,@>PI&. @ H04 !D M !X;"]W;W)K&UL?53;;MLP#'W/5Q!>,;1 4=]R M7V(@Z07;0[&@[;:'80^*3<=&92F3Y*;]^U&RXV5#FA=+I,BC0]&'LYU4S[I M-/!:<:'G7F',=NK[.BVP8OI*;E'022Y5Q0R9:N/KK4*6N:2*^U$0#/V*E<)+ M9LZW4LE,UH:7 E<*=%U53+TMD.AW!3&.OQDMF4;?$3S;;M29/D= M2E96*'0I!2C,Y]XBG"[[-MX%?"]QIP_V8"M92_ELC2_9W LL(>28&HO :'G! M:^3< A&-WRVFUUUI$P_W>_0[5SO5LF8:KR7_46:FF'MC#S+,6 M@<5+)=?N"[LF-HX]2&MM9-4F$X.J%,W*7MMW.$@8!^\D1&U"Y'@W%SF6-\RP M9*;D#I2-)C2[<:6Z;")7"MN41Z/HM*0\DRS25-68P>TKM5FCAO,GMN:H+V:^ M(7@;Y*W++Z"3B#:97$(>7$ 51 M? (O[HJ-'5[\#MZ*O;GB@(D,7.6,:_BY6&NCZ/?X=:SF!K%_'-%*9JJW+,6Y M1YK0J%[02SY^"(?!IQ-\^QW?_BGTY)$DF-4<0>;P?Z..<3V)=IQK"]O#??]3 M28+3QEYI"H1<KMCW8D^J85:Q28ET;#&<2#,7TGDT$7]L)2Y@0\BB8P"0:]K\1+P7 TAN$D M[#U)PWB/M<%=&6<07HZ& UJCR\$DA&/=\ ]D4Z':N.%@7Z 6IE%0Y^WFSZ*1 MW=_P9GC=,[4IA0:..:4&5Z.!!ZH9"(UAY-:)<"T-2=IM"YJAJ&P G>=2FKUA M+^BF&PO=V]R:W-H M965T,Y-+)0I-,*?TX6QFJ[%WWW95EC]_5BN5"8F9S'.?*H%@_H)_>CSI^ZP M\ZV%:;]AVF]#C^ZH]))"(*@E.('@?B/0/J:M6/N9-JI[B3L49EPD.F_,%JCI MS"%65';&NF6;(BR5H.KEQ.202UI1A6$R,4> SS'F%G+4,4I+56R -H!EJI#6 M !E+9>D^36"3D__X2^_7#H7:$Q$RH5$:]R%TXN\2-/8IGC M'OL#"(?C&KI%TD$CZ>##DEZ_1OF0P*W(^P6^+"@$>ME.)+&3_%O5JTH#1K5! M>Y7F9E?Q_X1LR\3)VG<*==UH ..1^P_A)'3_$8Q/O'MEF6@YXV"KKV6H5V7W M-G0YZ7)5+:Y9;1Z(TZHOOII7K\LUTRLN#0A$2'JJN.74VLRLLNN5"6 M>FXY3.F10^T,:'^IZ"+7$Q>@>3:C?U!+ P04 " =@'Q8B4\N^[," !4 M!@ &0 'AL+W=O/932Z-A6-GMD/@W^_LI*'3VK[L);&=N\_?=_9] MF35*/YL"T<)K*:29!X6UU30,35I@R@ZG+DNFW!0K5S(-1L%UXX)O"NH4PF55L@RNT M/ZM[3;.P1\EXB=)P)4%C/@^N1]/%V,7[@%\<&[,S!J=DK=2SFWS+YL'0$4*! MJ74(C%XO>(-".""B\;O##/HM7>+N>(O^Q6LG+6MF\$:))Y[98AY, L@P9[6P M#ZKYBIV>"X>7*F'\$YHV]BH.(*V-56673 Q*+MLW>^WJL),P&1Y(B+J$R/-N M-_(LE\RR9*95 ]I%$YH;>*D^F\AQZ0YE935]Y91GDUNF)9<; Q5J6!5,(YP\ MLK5 \VD66MK A85I![9HP:(#8*,([I2TA8%;F6'V-T!(S'IZT9;>(CJ*N,3T M'.+1*43#*#Z"%_=R8X\7'\#[KDPK-55E29?".,73?4I;G/%^'-3G6?KJ,[[]?U6. @92*M!?.=1*S6/:NL8]5L M6;&.U6Z%#:AW5L",@Z"CQ7)-1Q&/@!NWF"M!'F'@A$NPA:H-Q9M/4]B68_"? MY1BX2^1N4C1H8?[AO(?LY>G59.*>\7APF^=D)HY\I2Q*RYD0;P-? ;*6-OO, M>00A-DQG!L[@;+ \5*'CN\&^BQ3N='J)>N/]S%"M:VG;IN]7>\N\;IWB/;SU MVSNF-UP:$)A3ZO#\ZB( W7I8.[&J\KZQ5I9&PO=V]R:W-H965T MCTRM4>1N4EF,XO$X'95"5H/%L1N[ MU(MCU=A"5GBIP31E*?3#&1;J[F00#;8#5W*]L3PP6AS78HW7:+_6EYK>1AU* M+DNLC%05:%R=#$ZCH[,9VSN#;Q+O3.\9.)*E4O_PR\?\9#!FA[# S#*"H'^W M>(Y%P4#DQO<6<] MR1/[SUOT#RYVBF4I#)ZKXD^9V\W)8#Z '%>B*>R5NOL= MVWBFC)>IPKA?N/.VT^D LL985;:3R8-25OZ_N&_ST)LP'S\S(6XGQ,YOOY#S M\D)8L3C6Z@XT6Q,:/[A0W6QR3E97;QL".6!9J# MXY$E:#8892W,F8>)GX&)8OBL*KLQ\+[*,7\*,"*?.L?BK6-G\5[$"\S>0A(- M(1['R1Z\I LT<7C)+P.%"VFR0IE&(_QUNC16$S7^WA6S1YSL1F2Y')E:9'@R M(#T8U+Q#7UR3_/*F0% K^*2,@3,D"2+T"[;+Y_VH MC!0L/9+T2-:57M" ,+!2!WU-3,PCA&5:XDG8GX_>NL[OZ-QL,T&./PF6+34G53Y/- W:# M\(!"&T!6#!#?L5RB)LZS<='D9,A&OB2R6D,H*QI1C1%5;@Z>UNCEH?:J=MYH M35..@@^8H_8EB5)7CRBXML(BQ)"TY\?NQBR=Y7G&:*? +,3KLYMW@SEK+%*/_0X YH=L@I4HP$[ MC[LOOR24Z8E[+X]>FHX>BYAAF:45'PLJ[,_A!)VW])5: =5T/H^\^"?<*&A! M.E8P57/T3P>4 K@51>,3)=A]464(Z7P.84)-IF48!0*%RF@Y+S""GT^ZSM,M MG$N*CDDLR3*,''&_7O/WKA*K=@Z=>K0;-,3.^;AC-1=2Z&SCELSQEDXU=H+9U/7^^@W.-^(:LV-MG.!T:)Q\$55;ZAB:-EQH:6ZH.4)*S52: M6AFY=>E&5*0=(A=$APDIY0^JM"8AA-$X]FG[W\*9=<*9O5@X6\4[AIP:@Q0\ M)^63%$MBB96[]Z>]"SRO&0[/$]\U.(O4[C2=(KN:9I2^M;SE/JFE<6(Q5$BY MDAGE#\C:5[-56T7GW7XW0J<0%]:C;)YNBJR;X#G=O" ;_>UR:]V3N'"3CH(O MY%G+OFH=%+SW9D+K!V+FG="YH5K.)X=(\@5GBN9\J0BU&4,!^_B:R56);IAF@>36E\-B%R6:*P(ZGW#Y(YQ+/@ M7-222?DOQ="71-"7Q&QZ",DT]80-)-6,IH\I!6FR)P/ YX: MBV(?AE 73"@N+GYOI \U3%(G^XB:"IEB+60>=+(.TQE_3/=ZZ9U\10V"_W:) M==0[YI>HU^XR0^Q0367]B;\;[>Y+I_Z:\&CN+UN?A5Y+4D.!*YHZ?CNCPX[V M%QC_8E7M+@U+9>D*XAXW=.=#S0;T?:64W;[P MTM&PO=V]R:W-H965T"]( %O6N^PL,> D;=N^/=/23/=UP\R"6 (H^KHI07O:52Z[/A4&9+6%'I\C64 M^&7.Q8HJ?!6+H5P+H+E16A7#P/.2X8JRLCK%15/ MEU#PW47/[]43MVRQ5'IB.#E?TP7<@?JTOA'X-FQ0$@'SB][4/[L< M:7DC\)G!3K;&1$=@@*R)1&H/BWA2LH"@V$;OQ58?8:DUJQ M/:[1WYK8,989E7#%BR\L5\N+WJA'Y7J.*)-5[&"VF>9&=ETZA' MLHU4?%4IHP7E-%)^>"[XC0THBF!R94 MHXW.L5(GY4X)_,I03TWN%,\>!I<85TZN^ IS+:E9KI-[.BM GIX/%9K1PL.L M@KRTD,$+D'Y /O!2+25Y4^:0'P(,T;_&R:!V\C+H1+R&S"6AWR>!%X0=>&$3 M=&CPPI>"7E(!5= W] EK3)&I$+1<@!G_,9U));!@_CP6O<6.CF/K)CJ3:YK! M10^[1(+80F_R\P]^XOW2X7G4>!YUH4_NL"GS30&$SXE)'7F>NF,^=Z(>]YG4 MMIP.6X[.B$Y+X%QQJ;1; K90;H#\2/S PV<8.;>(246V)+3,L66V2 5KL]!^ M/"9QZMQA4[)R0<81"5+G'90@:&&$:8XUSW0R=/.2.(RQ#E+GGBL4D*9V9\:I MK.T4/.JQ=F'LC? 9H5K'XL?-XL>O7OPOIMW1\'2+SBZ 3"7RVEJ;E\<2T(G\ MB@1TV7-L=M:"96;9(]<+G#>/(#*&BW X?](UJ#3M57L4^QNDK3+" M*\O46":X&Q*U!!LQ F?))XH_ZL:?[S??=(''>(9OIW/AC.Q^[7J0SQ@1.#DE&RPR; M#L<&9ZZ3%GR?SD.+<>;2CZRFH>%^I_" M=VJ)-DH]UT)J2IX\&S@-UQW^[[GM]XUQ_Q;T\5,;:+Z\+Y5@>'3,:IGG7VQK MV0@.O+S"TXO>_3>XQUB9S[3 ':T=?VO>P0U&,UZJ'U$2]D,LQ]0=ZXW'C6/\ M2Y-^@@-_')MO>CY*]=:8]KTD0GU4]8GO:8# ,YT3N2$*C%Q/RPWJV?T,*FEY MU JUEA_6:A4%Q+[1\QM%E(Z#6C,TFH:G@S TC3AV [M)^%9S8)[ZU]%4HZ:I M1J]N*CP,8 +,QF&9\&4R[P3]KG81>^.6U_\'/G\A(.=9&1MV=,SATW3,M=Y, MWU(FG#U$M9?;POI4;O$#XO)#%OR-EAN\09&:@TV>&O(-@XJ0D7H_6_V3:N[4 MSN)]9@[, (L6)VN^?\GD<^(?M$Q&?C]$^DW<)&Y,!E'?'Z6&X$?^MYITCG*] MG_;]4/<%[AGAT;H#KBIK9YDHYM3>IO;B]CWZ@8H$\ M00J8HZKGIGB$$_:.9U\47YM[U8PKO*69X1*OQ2"T 'Z? D !D !X;"]W;W)K&ULK59-;^,V$+WK5Q#:(' ;2Q2GTYL _DJNH>@09)N#T4/M#6V MA95$+4G'27]]9RA9Z[1)L(<>*(GDS..;>1Q2TYW2W\P&P++GNFK,S-]8VYZ- MQV:Y@5J:4]5"@S,KI6MIL:O78]-JD(5SJJNQ",-T7,NR\>=3-W:GYU.UM579 MP)UF9EO74K]<0J5V,Y_[^X'[3UNYA@>PO[=W&GOC :4H:VA,J1JF M837S+_C994SVSN!K"3MS\,THDH52WZCSI9CY(1&""I:6$"2^GN *JHJ D,;W M'M,?EB3'P^\]^B\N=HQE(0UJ/LK";F9_[K("5W%;V7NU^A3Z>A/"6JC+N MR7:=K9CX;+DU5M6],S*HRZ9[R^<^#P<.>?B.@^@=A./=+>187DLKYU.M=DR3 M-:+1APO5>2.YLB%1'JS&V1+][/P!UIABR^ZA5=J6S9J-'N6B G,R'5O$)ZOQ MLL>Z[+#$.UA(U+$]9Q ,F0A%]@!<- MT48.+_KI:/^\6!BK<6_\]5:\'5K\-AK5RYEIY1)F/A:$ ?T$_OSX$T_#\P^X MQ@/7^"/T^0/67[&M@*D5ZWF;MSA^C/*X 6^E*JP]BM:2M,R1132V!&VQ;EG9 M=-7=%=I:ZL(9;X!=J;J5S@%ZT(XLO7^/"C;"Q>U&;0U.FP!Y+*NM6UO6:HLZX72C+&[&,[9/AW>0#@?M M77V]]FZ^;\O62?MP?<5HY%9:T*6L#,:@46WLLINJQ!)R<=)P8U15%CA1>!?& M .(=$;4XY/01Q&F.;\&I]QG;*$G8"H-D"#O TB*(8/[* 1Q,: M"'@>#UYQ[MQ$'/!PXOW6 G)QA58I8T[8B&,3 1<3-.-!FF4X-(FP,T(/3LZC M_A4'><[9B7>GPP"HI9-A'>WU_1 YBSJY MDB#GT7_E&K(=Q%&7Z21.\1DF(:5_DI.,GVD^QY2]IY4@,9+4^>?(&_VS])6_ MP-S_A$*)&!1*TX-LYVGVGD)M)3'OQ[)NSQD,.HRB$X=',N_;()]'F^NU2OU) MT-(JDHXCZARQ\%1@XQZ%_J7W\10>''J?% T5:V2/(^*US=GQP&]:@U^[.Q\..3I3N8AQ&A]^*B^XV M_6'>_9/<2KTN<>]5L$+7\#1+?*:[>[[K6-6ZNW6A+-[4[G.#OT:@R0#G5PJ/ MK[Y#"PP_6_-_ %!+ P04 " =@'Q8UVV,[H,( ""/@ &0 'AL+W=O M.B:VJFQY M9N-*O''9N\G#5AX@"I)0PVL!R$B\ZI2E M_<#S!OV,\KPWN:BNW8O)1;%6*<_9O2!RG654O%ZSM'B^[/F]MPL/?+E2YD)_ M_*_SP=!*9#U>)?G#W+K<_$N#(K MBF_FR^W\LN<9BUC*$F4DJ/[UQ*8L38V2MN/WC6BON:?IN/WY3?UKY;QV9D8E MFQ;IO_E/X;VS@4&[VD2&7UDSQOVGH]DJRE*K)-9VU! MQO/Z-WW9!.*4#L&F0[#3P8\.= @W'<+*T=JRRJT;JNCD0A3/1)C66LU\J&)3 M]=;>\-P,XZ,2^J]<]U.3QWKX2+$@CWR9\P5/:*[(59(4ZUSQ?$GNBY0GG$GR MPPU3E*>2_$R%H";Z/Y*_D%\?;\@/?_SQHJ^T-4:SGVSN?%W?.3AP9S\@=T6N M5I)\R>=L[@KTM1N-+\&;+] MT+L7Q7R=*'*;U]5FLO:W?^A&Y%:Q3/ZG+62U8M2N:$KZLRQIPBY[NF8E$T^L M-_GS'_R!]]CQOD(4I],J5P1FL])8CZPW]?\B:8L5[+-ZUHJKJ3, MO/,T\2,OB#W/N^@_;7O4UC <. T=:^/&VABV5B>BT#,*H5(R)3\2GI64"SU= M*9(6LM7H>,^676OK%H/6%HZ9@\;, 6CFH](1I6).RDUJ/9M*S-6KGKAD(GAI MF-"3/-$9S95N M\2I-1A.=Y_H2(Z^,"K(014;4BI$Y5TU3/VPDKM6*BK^E&?*$8RTE6 MS00?]OK(%2^K49B]&62FI)3.=%^37245^OXY2YB49AI3A7ZVF*&K5-[LFJ^% MZ68N-3Z43/!BWE8V8+#>63;#9H2'X%#T?K^T&WH&#EN MC!P?-W*=\URNA8XMS)0(/M/0JU6Q7%:BIYT1; MRP_/@ANM;3/"P;ZQ1YNYMF[1BP_:^L">6+YFK9;Y>[<,(M\;MQC7TC(>^>%A M^P)K7W!DU,6RJ&:JKZ(B2O+;':2IL%6[VN]T38#?_)WT_P<\.!;>O!A?$"NAG_F#*X(T)K. M"8&DYL;.0HT_QJ\($)0Z!P!)S5UQL+ 4P+#4N2(V>F.G(L+A8* MMDW_X6ZNAVVY[H4';+*J&A/=@3TA^WH MG SG@,3 0F(PPJ\&5-+#4G,#8$DO.+)^U;D:QB>@/WS3=SH56GH+87I#K84K ML!I@2SIO[2"IN7&S%!GZ^%M;J"B(I>8&P*)@>&1=KVLU;/1VG@W1+@JU-@O& M03L*A5M;D3"YH2;Z-9SHN'N8YUC#"RU"AA%^HJ-2()::&P!+@>'1G=&.B1ZW M)7H8[R;Z.=@NM&P7PFR'6@]3N!Y0%P"QU-RX67@,A_CU@,J!6&IN "P'AD?V M&CO7PZBM'KSQ;CV<@^Y"2W:>>K%$&7GH!1*AHB&6FAL BX81O,#8N4 V>CO_ M)PQW3_X<:>5::SDN@CGNYLO/=U-H)YQ'.^7X!:S3V>N6C5[@D$9DN2R"N>R.YSQ;9^#$"DMT=N4^G1JC\A*7FGL.U_!3# M*W+?D>5'E /O<)K#7=_KM&6F&&:FZS5/JX.MYJ!8\^4V,R=>JQ.7#I.?,O7# M-^R:$UAJ;G@LI,7X^ZXQ*KUAJ;D!L/06PZMW.@":H[W7:$EL,$UO'HCCA20'?L'-.G&-A+MYZ8P%_>S9&!4(L-3< M%@AC> GONXH"E@['0%6<@P)C2X$QS&IW-%GI2^*U5 BP-/1_.08H#2XH#F.=.J803'@KP7;HF M I::&Q,+D@/\?=D!*BIBJ;D!L*@X@-?SOJ<2CDB/#E<"W+.KT_VMMWDS)I;5 M2\Z25&?9ZI=AFZO-B]17U>O#.]>O_<_3^G5H*U._G7U'Q9+GDJ1LH26]3T/] M*!?U"\_U%U64U3O#LT*I(JL^KAB=,V$:Z+\OBD*]?3$W:%X[G_P?4$L#!!0 M ( !V ?%A[-=-KO@4 +8J 9 >&PO=V]R:W-H965TLDWTV3'J;_*G:)PBBS+F49^$$\6\_S>(U_,V5Z$ M04P?.4CV4>3S'SCK8S/ '+?2)85#BG$41!?/SO?R\*<>( G18'5#B@ MJ@-I<<"% \X3/4:6IW7G"W\QY^P-\,PZ1K/8A!6P-[H+$WVPXW?AYA=,[3_1 XST%'^^H\(,P^01^!5^>[\#'#Y_ M!Q#$X&7+]HD?KY+Y5*319)C393'RS7%DU#(R1."!Q6*;@,_QBJY4@&F:1ID+ M>L_E!FD1[^CR F#X"T 6P@T!W?9W1YIP<%E:G./A-KS6S\);V:I+_?'HX#;W!RG8A+JV4F.PR)EL;T^>8\LT/\/6!1J^4 M-]9?"S"T_H; E%R=,E=G) HZ)DM@"$PIP:PLP>P\"A[=G!-RV99G51A8-_*@ MC9H)Z)81N=J(KBEG>;Y:#FHQADZ (3 E7:],UQN)@Y[)$A@"4TH +?F6M%WRC#B>DZ%A@U6T$$M/(0G[WZHC>H^7J4*@P=^J*6B'F7H1)A"4W-&,F?+ MK9Z/6HS!$V$(3E+H0+=L;AI5+Z80E/+ M( 4,U(H##3>]^E/0A3:LDK/!;.;9+0]+)$4%ZA 56G:"_T"/I8Y^B*$390I- M+8C4,PB.Q%=D5.*80E/+("4.TFJ'=KX6?LI3TK.J=&VP\BR/M+!5*@[4H3BZ MV-IO7:0?9?!,C;$[@J3<060LPAK50*;0U#)(#83T6S+MA+5K5,0$S:J$K5MY M=@M=I2!!'8*DBZX]%T_Z809/U!A;*4CJ(30;BZ]&=9$I-+4,4A+;&V*W!4ASAL?I*V*@<,H6FED'*(7QF;PG7^T;0K>Y9 M-1B=\%H-24H3W"%->C*VWV)+/]C@V1IC&P=+?83':D1AHYK(%)K:D9>:B)S9 MBB(-32;BU'KR#58V:A$#1$H4TB%1>O*VYZI+/]K0&3.%IM9&"B4R5LN*&%5* MIM#4,DBE1,YL69%Z,PJYJ+JMU6!%6B4".3GATB%<>A*WU^)+/];@^1IC5X=( M\43&ZFP1HUK)%)I:!JF5R)F=K<+/5IZWM5^S?P\O9XA%+"'$]T/OA\$\0)".DZA;0N9FE(_'A( M\G@AV"X_9_C*A&!1_G%+_17EF4'Z_9HQ\7Z1#5 >55W\#U!+ P04 " = M@'Q89?N7.JX# -#@ &0 'AL+W=O\>]B"R#18U52,7>V4M8WKBN*+5187+,:J'JR M9KS"4DWYQA4U![PR3E7I!IZ7N!4FU,EF9NV.9S/6R))0N.-(-%6%^=,ME&P_ M=WSG>>&>;+92+[C9K,8;> #YI;[C:N9V*"M2 16$4<1A/7<^^#>Y;QR,Q=\$ M]N)HC#25)6/?]>2/U=SQ=$100B$U!%9_.UA 66HD%<>_+:C3O5,['H^?T3\9 M\HK,$@M8L/(?LI+;N3-UT K6N"GE/=O_#BVA6.,5K!3F%^U;6\]!12,DJUIG M%4%%Z.$?/[9"'#GXT0L.0>L0G.L0M@[AN0Y1ZQ 990Y4C XYECB;<;9'7%LK M-#TP8AIO19]0G?<'R=53HOQD]J *:=64@-@:+9B0"-,5^B@D49*"&F%."=T( M1"CZ^%B $-KPEI2E67V3@\2D%&_1%?KRD*,WK]ZB5]KVKRUKA((2,U>J*/6[ MW**-Z/804?!"1#D4URCTWZ' "T*+^^)\]\#BGI_O[I^ZNTK:3M^@TS

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end XML 84 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 85 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 87 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1 html 162 315 1 true 57 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://cvdequipment.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://cvdequipment.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://cvdequipment.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://cvdequipment.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders' Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated statements of Cash Flows Sheet http://cvdequipment.com/role/StatementsOfCashFlows Consolidated statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - Business Description Sheet http://cvdequipment.com/role/BusinessDescription Business Description Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://cvdequipment.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Revenue Sheet http://cvdequipment.com/role/Revenue Revenue Notes 9 false false R10.htm 00000010 - Disclosure - Inventories Sheet http://cvdequipment.com/role/Inventories Inventories Notes 10 false false R11.htm 00000011 - Disclosure - Property, Plant and Equipment Sheet http://cvdequipment.com/role/PropertyPlantAndEquipment Property, Plant and Equipment Notes 11 false false R12.htm 00000012 - Disclosure - Intangible Assets Sheet http://cvdequipment.com/role/IntangibleAssets Intangible Assets Notes 12 false false R13.htm 00000013 - Disclosure - Accrued Expenses Sheet http://cvdequipment.com/role/AccruedExpenses Accrued Expenses Notes 13 false false R14.htm 00000014 - Disclosure - Long-term Debt Sheet http://cvdequipment.com/role/Long-termDebt Long-term Debt Notes 14 false false R15.htm 00000015 - Disclosure - Earnings per Share Sheet http://cvdequipment.com/role/EarningsPerShare Earnings per Share Notes 15 false false R16.htm 00000016 - Disclosure - Income Taxes Sheet http://cvdequipment.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 00000017 - Disclosure - Employee Retention Credit Sheet http://cvdequipment.com/role/EmployeeRetentionCredit Employee Retention Credit Notes 17 false false R18.htm 00000018 - Disclosure - Stock-Based Compensation Sheet http://cvdequipment.com/role/Stock-basedCompensation Stock-Based Compensation Notes 18 false false R19.htm 00000019 - Disclosure - Defined Contribution Plan Sheet http://cvdequipment.com/role/DefinedContributionPlan Defined Contribution Plan Notes 19 false false R20.htm 00000020 - Disclosure - Segment Reporting Sheet http://cvdequipment.com/role/SegmentReporting Segment Reporting Notes 20 false false R21.htm 00000021 - Disclosure - CVD Materials ??? Tantaline and MesoScribe Subsidiaries Sheet http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiaries CVD Materials ??? Tantaline and MesoScribe Subsidiaries Notes 21 false false R22.htm 00000022 - Disclosure - Risks and Uncertainties Sheet http://cvdequipment.com/role/RisksAndUncertainties Risks and Uncertainties Notes 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://cvdequipment.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 00000024 - Disclosure - Revenue (Tables) Sheet http://cvdequipment.com/role/RevenueTables Revenue (Tables) Tables http://cvdequipment.com/role/Revenue 24 false false R25.htm 00000025 - Disclosure - Inventories (Tables) Sheet http://cvdequipment.com/role/InventoriesTables Inventories (Tables) Tables http://cvdequipment.com/role/Inventories 25 false false R26.htm 00000026 - Disclosure - Property, Plant and Equipment (Tables) Sheet http://cvdequipment.com/role/PropertyPlantAndEquipmentTables Property, Plant and Equipment (Tables) Tables http://cvdequipment.com/role/PropertyPlantAndEquipment 26 false false R27.htm 00000027 - Disclosure - Intangible Assets (Tables) Sheet http://cvdequipment.com/role/IntangibleAssetsTables Intangible Assets (Tables) Tables http://cvdequipment.com/role/IntangibleAssets 27 false false R28.htm 00000028 - Disclosure - Accrued Expenses (Tables) Sheet http://cvdequipment.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://cvdequipment.com/role/AccruedExpenses 28 false false R29.htm 00000029 - Disclosure - Long-term Debt (Tables) Sheet http://cvdequipment.com/role/Long-termDebtTables Long-term Debt (Tables) Tables http://cvdequipment.com/role/Long-termDebt 29 false false R30.htm 00000030 - Disclosure - Earnings per Share (Tables) Sheet http://cvdequipment.com/role/EarningsPerShareTables Earnings per Share (Tables) Tables http://cvdequipment.com/role/EarningsPerShare 30 false false R31.htm 00000031 - Disclosure - Income Taxes (Tables) Sheet http://cvdequipment.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://cvdequipment.com/role/IncomeTaxes 31 false false R32.htm 00000032 - Disclosure - Stock-Based Compensation (Tables) Sheet http://cvdequipment.com/role/Stock-basedCompensationTables Stock-Based Compensation (Tables) Tables http://cvdequipment.com/role/Stock-basedCompensation 32 false false R33.htm 00000033 - Disclosure - Segment Reporting (Tables) Sheet http://cvdequipment.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://cvdequipment.com/role/SegmentReporting 33 false false R34.htm 00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies 34 false false R35.htm 00000035 - Disclosure - Schedule of Disaggregation of Revenue (Details) Sheet http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails Schedule of Disaggregation of Revenue (Details) Details 35 false false R36.htm 00000036 - Disclosure - Schedule of Cost and Estimated Earnings in Excess of Billings (Details) Sheet http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails Schedule of Cost and Estimated Earnings in Excess of Billings (Details) Details 36 false false R37.htm 00000037 - Disclosure - Revenue (Details Narrative) Sheet http://cvdequipment.com/role/RevenueDetailsNarrative Revenue (Details Narrative) Details http://cvdequipment.com/role/RevenueTables 37 false false R38.htm 00000038 - Disclosure - Schedule of Inventories, net (Details) Sheet http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails Schedule of Inventories, net (Details) Details 38 false false R39.htm 00000039 - Disclosure - Schedule of Property, Plant and Equipment (Details) Sheet http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails Schedule of Property, Plant and Equipment (Details) Details 39 false false R40.htm 00000040 - Disclosure - Property, Plant and Equipment (Details Narrative) Sheet http://cvdequipment.com/role/PropertyPlantAndEquipmentDetailsNarrative Property, Plant and Equipment (Details Narrative) Details http://cvdequipment.com/role/PropertyPlantAndEquipmentTables 40 false false R41.htm 00000041 - Disclosure - Schedule of Finite Lived Intangible Assets (Details) Sheet http://cvdequipment.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails Schedule of Finite Lived Intangible Assets (Details) Details 41 false false R42.htm 00000042 - Disclosure - Intangible Assets (Details Narrative) Sheet http://cvdequipment.com/role/IntangibleAssetsDetailsNarrative Intangible Assets (Details Narrative) Details http://cvdequipment.com/role/IntangibleAssetsTables 42 false false R43.htm 00000043 - Disclosure - Schedule of Accrued Expenses (Details) Sheet http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails Schedule of Accrued Expenses (Details) Details 43 false false R44.htm 00000044 - Disclosure - Schedule of Long Term Debt (Details) Sheet http://cvdequipment.com/role/ScheduleOfLongTermDebtDetails Schedule of Long Term Debt (Details) Details 44 false false R45.htm 00000045 - Disclosure - Schedule of Long Term Debt (Details) (Parenthetical) Sheet http://cvdequipment.com/role/ScheduleOfLongTermDebtDetailsParenthetical Schedule of Long Term Debt (Details) (Parenthetical) Details 45 false false R46.htm 00000046 - Disclosure - Schedule of Maturities of Long Term Debt (Details) Sheet http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails Schedule of Maturities of Long Term Debt (Details) Details 46 false false R47.htm 00000047 - Disclosure - Long-term Debt (Details Narrative) Sheet http://cvdequipment.com/role/Long-termDebtDetailsNarrative Long-term Debt (Details Narrative) Details http://cvdequipment.com/role/Long-termDebtTables 47 false false R48.htm 00000048 - Disclosure - Schedule of Basic and Diluted Weighted Average Common Shares Outstanding (Details) Sheet http://cvdequipment.com/role/ScheduleOfBasicAndDilutedWeightedAverageCommonSharesOutstandingDetails Schedule of Basic and Diluted Weighted Average Common Shares Outstanding (Details) Details 48 false false R49.htm 00000049 - Disclosure - Earnings per Share (Details Narrative) Sheet http://cvdequipment.com/role/EarningsPerShareDetailsNarrative Earnings per Share (Details Narrative) Details http://cvdequipment.com/role/EarningsPerShareTables 49 false false R50.htm 00000050 - Disclosure - Schedule of Loss Before Income Taxes (Details) Sheet http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails Schedule of Loss Before Income Taxes (Details) Details 50 false false R51.htm 00000051 - Disclosure - Schedule of Components of Income Tax Expense (Benefit) (Details) Sheet http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails Schedule of Components of Income Tax Expense (Benefit) (Details) Details 51 false false R52.htm 00000052 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) Sheet http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails Schedule of Effective Income Tax Rate Reconciliation (Details) Details 52 false false R53.htm 00000053 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical) Sheet http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetailsParenthetical Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical) Details 53 false false R54.htm 00000054 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details) Sheet http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails Schedule of Deferred Tax Assets and Liabilities (Details) Details 54 false false R55.htm 00000055 - Disclosure - Income Taxes (Details Narrative) Sheet http://cvdequipment.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://cvdequipment.com/role/IncomeTaxesTables 55 false false R56.htm 00000056 - Disclosure - Employee Retention Credit (Details Narrative) Sheet http://cvdequipment.com/role/EmployeeRetentionCreditDetailsNarrative Employee Retention Credit (Details Narrative) Details http://cvdequipment.com/role/EmployeeRetentionCredit 56 false false R57.htm 00000057 - Disclosure - Schedule of Stock Based Compensation (Details) Sheet http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails Schedule of Stock Based Compensation (Details) Details 57 false false R58.htm 00000058 - Disclosure - Schedule of Weighted Average Assumptions (Details) Sheet http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails Schedule of Weighted Average Assumptions (Details) Details 58 false false R59.htm 00000059 - Disclosure - Schedule of Stock Options Awards (Details) Sheet http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails Schedule of Stock Options Awards (Details) Details 59 false false R60.htm 00000060 - Disclosure - Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices (Details) Sheet http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices (Details) Details 60 false false R61.htm 00000061 - Disclosure - Schedule of Restricted Stock Awards (Details) Sheet http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails Schedule of Restricted Stock Awards (Details) Details 61 false false R62.htm 00000062 - Disclosure - Stock-Based Compensation (Details Narrative) Sheet http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative Stock-Based Compensation (Details Narrative) Details http://cvdequipment.com/role/Stock-basedCompensationTables 62 false false R63.htm 00000063 - Disclosure - Defined Contribution Plan (Details Narrative) Sheet http://cvdequipment.com/role/DefinedContributionPlanDetailsNarrative Defined Contribution Plan (Details Narrative) Details http://cvdequipment.com/role/DefinedContributionPlan 63 false false R64.htm 00000064 - Disclosure - Schedule of Segments (Details) Sheet http://cvdequipment.com/role/ScheduleOfSegmentsDetails Schedule of Segments (Details) Details 64 false false R65.htm 00000065 - Disclosure - Schedule of Segments (Details) (Parenthetical) Sheet http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical Schedule of Segments (Details) (Parenthetical) Details 65 false false R66.htm 00000066 - Disclosure - Segment Reporting (Details Narrative) Sheet http://cvdequipment.com/role/SegmentReportingDetailsNarrative Segment Reporting (Details Narrative) Details http://cvdequipment.com/role/SegmentReportingTables 66 false false R67.htm 00000067 - Disclosure - CVD Materials ??? Tantaline and MesoScribe Subsidiaries (Details Narrative) Sheet http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative CVD Materials ??? Tantaline and MesoScribe Subsidiaries (Details Narrative) Details http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiaries 67 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod - form10-k.htm 65, 66, 85 cvv-20231231.xsd cvv-20231231_cal.xml cvv-20231231_def.xml cvv-20231231_lab.xml cvv-20231231_pre.xml form10-k.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-k.htm": { "nsprefix": "CVV", "nsuri": "http://cvdequipment.com/20231231", "dts": { "schema": { "local": [ "cvv-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "cvv-20231231_cal.xml" ] }, "definitionLink": { "local": [ "cvv-20231231_def.xml" ] }, "labelLink": { "local": [ "cvv-20231231_lab.xml" ] }, "presentationLink": { "local": [ "cvv-20231231_pre.xml" ] }, "inline": { "local": [ "form10-k.htm" ] } }, "keyStandard": 289, "keyCustom": 26, "axisStandard": 23, "axisCustom": 0, "memberStandard": 30, "memberCustom": 27, "hidden": { "total": 79, "http://fasb.org/us-gaap/2023": 70, "http://cvdequipment.com/20231231": 6, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 162, "entityCount": 1, "segmentCount": 57, "elementCount": 500, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 687, "http://xbrl.sec.gov/dei/2023": 38 }, "report": { "R1": { "role": "http://cvdequipment.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R2": { "role": "http://cvdequipment.com/role/BalanceSheets", "longName": "00000002 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R3": { "role": "http://cvdequipment.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R4": { "role": "http://cvdequipment.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CostOfRevenue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R5": { "role": "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' Equity", "shortName": "Consolidated Statements of Changes in Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R6": { "role": "http://cvdequipment.com/role/StatementsOfCashFlows", "longName": "00000006 - Statement - Consolidated statements of Cash Flows", "shortName": "Consolidated statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R7": { "role": "http://cvdequipment.com/role/BusinessDescription", "longName": "00000007 - Disclosure - Business Description", "shortName": "Business Description", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R8": { "role": "http://cvdequipment.com/role/SummaryOfSignificantAccountingPolicies", "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R9": { "role": "http://cvdequipment.com/role/Revenue", "longName": "00000009 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R10": { "role": "http://cvdequipment.com/role/Inventories", "longName": "00000010 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R11": { "role": "http://cvdequipment.com/role/PropertyPlantAndEquipment", "longName": "00000011 - Disclosure - Property, Plant and Equipment", "shortName": "Property, Plant and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R12": { "role": "http://cvdequipment.com/role/IntangibleAssets", "longName": "00000012 - Disclosure - Intangible Assets", "shortName": "Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R13": { "role": "http://cvdequipment.com/role/AccruedExpenses", "longName": "00000013 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R14": { "role": "http://cvdequipment.com/role/Long-termDebt", "longName": "00000014 - Disclosure - Long-term Debt", "shortName": "Long-term Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R15": { "role": "http://cvdequipment.com/role/EarningsPerShare", "longName": "00000015 - Disclosure - Earnings per Share", "shortName": "Earnings per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R16": { "role": "http://cvdequipment.com/role/IncomeTaxes", "longName": "00000016 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R17": { "role": "http://cvdequipment.com/role/EmployeeRetentionCredit", "longName": "00000017 - Disclosure - Employee Retention Credit", "shortName": "Employee Retention Credit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "CVV:EmployeeRetentionCreditTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "CVV:EmployeeRetentionCreditTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R18": { "role": "http://cvdequipment.com/role/Stock-basedCompensation", "longName": "00000018 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R19": { "role": "http://cvdequipment.com/role/DefinedContributionPlan", "longName": "00000019 - Disclosure - Defined Contribution Plan", "shortName": "Defined Contribution Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R20": { "role": "http://cvdequipment.com/role/SegmentReporting", "longName": "00000020 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R21": { "role": "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiaries", "longName": "00000021 - Disclosure - CVD Materials \u2013 Tantaline and MesoScribe Subsidiaries", "shortName": "CVD Materials \u2013 Tantaline and MesoScribe Subsidiaries", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R22": { "role": "http://cvdequipment.com/role/RisksAndUncertainties", "longName": "00000022 - Disclosure - Risks and Uncertainties", "shortName": "Risks and Uncertainties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "CVV:RisksAndUncertaintiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "CVV:RisksAndUncertaintiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R23": { "role": "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "longName": "00000023 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R24": { "role": "http://cvdequipment.com/role/RevenueTables", "longName": "00000024 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R25": { "role": "http://cvdequipment.com/role/InventoriesTables", "longName": "00000025 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R26": { "role": "http://cvdequipment.com/role/PropertyPlantAndEquipmentTables", "longName": "00000026 - Disclosure - Property, Plant and Equipment (Tables)", "shortName": "Property, Plant and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R27": { "role": "http://cvdequipment.com/role/IntangibleAssetsTables", "longName": "00000027 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R28": { "role": "http://cvdequipment.com/role/AccruedExpensesTables", "longName": "00000028 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R29": { "role": "http://cvdequipment.com/role/Long-termDebtTables", "longName": "00000029 - Disclosure - Long-term Debt (Tables)", "shortName": "Long-term Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R30": { "role": "http://cvdequipment.com/role/EarningsPerShareTables", "longName": "00000030 - Disclosure - Earnings per Share (Tables)", "shortName": "Earnings per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R31": { "role": "http://cvdequipment.com/role/IncomeTaxesTables", "longName": "00000031 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R32": { "role": "http://cvdequipment.com/role/Stock-basedCompensationTables", "longName": "00000032 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R33": { "role": "http://cvdequipment.com/role/SegmentReportingTables", "longName": "00000033 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R34": { "role": "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName": "00000034 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Summary of Significant Accounting Policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CapitalizedContractCostImpairmentLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R35": { "role": "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails", "longName": "00000035 - Disclosure - Schedule of Disaggregation of Revenue (Details)", "shortName": "Schedule of Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R36": { "role": "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails", "longName": "00000036 - Disclosure - Schedule of Cost and Estimated Earnings in Excess of Billings (Details)", "shortName": "Schedule of Cost and Estimated Earnings in Excess of Billings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "CVV:CostsIncurredOnUncompletedContracts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "CVV:ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "CVV:CostsIncurredOnUncompletedContracts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "CVV:ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R37": { "role": "http://cvdequipment.com/role/RevenueDetailsNarrative", "longName": "00000037 - Disclosure - Revenue (Details Narrative)", "shortName": "Revenue (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R38": { "role": "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails", "longName": "00000038 - Disclosure - Schedule of Inventories, net (Details)", "shortName": "Schedule of Inventories, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:InventoryRawMaterials", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R39": { "role": "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "longName": "00000039 - Disclosure - Schedule of Property, Plant and Equipment (Details)", "shortName": "Schedule of Property, Plant and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R40": { "role": "http://cvdequipment.com/role/PropertyPlantAndEquipmentDetailsNarrative", "longName": "00000040 - Disclosure - Property, Plant and Equipment (Details Narrative)", "shortName": "Property, Plant and Equipment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R41": { "role": "http://cvdequipment.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails", "longName": "00000041 - Disclosure - Schedule of Finite Lived Intangible Assets (Details)", "shortName": "Schedule of Finite Lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31_us-gaap_PatentsMember", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R42": { "role": "http://cvdequipment.com/role/IntangibleAssetsDetailsNarrative", "longName": "00000042 - Disclosure - Intangible Assets (Details Narrative)", "shortName": "Intangible Assets (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R43": { "role": "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails", "longName": "00000043 - Disclosure - Schedule of Accrued Expenses (Details)", "shortName": "Schedule of Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:AccruedSalariesCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R44": { "role": "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetails", "longName": "00000044 - Disclosure - Schedule of Long Term Debt (Details)", "shortName": "Schedule of Long Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LoansPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LoansPayable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R45": { "role": "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetailsParenthetical", "longName": "00000045 - Disclosure - Schedule of Long Term Debt (Details) (Parenthetical)", "shortName": "Schedule of Long Term Debt (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtInstrumentPeriodicPayment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:DebtInstrumentPeriodicPayment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R46": { "role": "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails", "longName": "00000046 - Disclosure - Schedule of Maturities of Long Term Debt (Details)", "shortName": "Schedule of Maturities of Long Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "us-gaap:LongTermDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R47": { "role": "http://cvdequipment.com/role/Long-termDebtDetailsNarrative", "longName": "00000047 - Disclosure - Long-term Debt (Details Narrative)", "shortName": "Long-term Debt (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "CVV:LoanToFundAcquisitionOfMachineryEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R48": { "role": "http://cvdequipment.com/role/ScheduleOfBasicAndDilutedWeightedAverageCommonSharesOutstandingDetails", "longName": "00000048 - Disclosure - Schedule of Basic and Diluted Weighted Average Common Shares Outstanding (Details)", "shortName": "Schedule of Basic and Diluted Weighted Average Common Shares Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R49": { "role": "http://cvdequipment.com/role/EarningsPerShareDetailsNarrative", "longName": "00000049 - Disclosure - Earnings per Share (Details Narrative)", "shortName": "Earnings per Share (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R50": { "role": "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails", "longName": "00000050 - Disclosure - Schedule of Loss Before Income Taxes (Details)", "shortName": "Schedule of Loss Before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R51": { "role": "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails", "longName": "00000051 - Disclosure - Schedule of Components of Income Tax Expense (Benefit) (Details)", "shortName": "Schedule of Components of Income Tax Expense (Benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R52": { "role": "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "longName": "00000052 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details)", "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R53": { "role": "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetailsParenthetical", "longName": "00000053 - Disclosure - Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical)", "shortName": "Schedule of Effective Income Tax Rate Reconciliation (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R54": { "role": "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "longName": "00000054 - Disclosure - Schedule of Deferred Tax Assets and Liabilities (Details)", "shortName": "Schedule of Deferred Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R55": { "role": "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative", "longName": "00000055 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R56": { "role": "http://cvdequipment.com/role/EmployeeRetentionCreditDetailsNarrative", "longName": "00000056 - Disclosure - Employee Retention Credit (Details Narrative)", "shortName": "Employee Retention Credit (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "CVV:IncreaseDecreaseInEmployeeRetentionCreditReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": null }, "R57": { "role": "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails", "longName": "00000057 - Disclosure - Schedule of Stock Based Compensation (Details)", "shortName": "Schedule of Stock Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_CostOfRevenueMember", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R58": { "role": "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails", "longName": "00000058 - Disclosure - Schedule of Weighted Average Assumptions (Details)", "shortName": "Schedule of Weighted Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:SharePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R59": { "role": "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails", "longName": "00000059 - Disclosure - Schedule of Stock Options Awards (Details)", "shortName": "Schedule of Stock Options Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R60": { "role": "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails", "longName": "00000060 - Disclosure - Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices (Details)", "shortName": "Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_custom_ExercisePriceRangeOneMember", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_ExercisePriceRangeOneMember", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R61": { "role": "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "longName": "00000061 - Disclosure - Schedule of Restricted Stock Awards (Details)", "shortName": "Schedule of Restricted Stock Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_us-gaap_RestrictedStockMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R62": { "role": "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative", "longName": "00000062 - Disclosure - Stock-Based Compensation (Details Narrative)", "shortName": "Stock-Based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2021-10-11_custom_FiveDirectorsMember", "name": "CVV:SharebasedPaymentArrangementAnnualEquityRetainerAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R63": { "role": "http://cvdequipment.com/role/DefinedContributionPlanDetailsNarrative", "longName": "00000063 - Disclosure - Defined Contribution Plan (Details Narrative)", "shortName": "Defined Contribution Plan (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "From2022-07-012022-07-01", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-012022-07-01", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R64": { "role": "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "longName": "00000064 - Disclosure - Schedule of Segments (Details)", "shortName": "Schedule of Segments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:SegmentExpenditureAdditionToLongLivedAssets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R65": { "role": "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical", "longName": "00000065 - Disclosure - Schedule of Segments (Details) (Parenthetical)", "shortName": "Schedule of Segments (Details) (Parenthetical)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GainLossOnSaleOfBusiness", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-01-012022-12-31_custom_CVDMaterialsMember", "name": "us-gaap:OtherIncome", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } }, "R66": { "role": "http://cvdequipment.com/role/SegmentReportingDetailsNarrative", "longName": "00000066 - Disclosure - Segment Reporting (Details Narrative)", "shortName": "Segment Reporting (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true, "unique": true } }, "R67": { "role": "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative", "longName": "00000067 - Disclosure - CVD Materials \u2013 Tantaline and MesoScribe Subsidiaries (Details Narrative)", "shortName": "CVD Materials \u2013 Tantaline and MesoScribe Subsidiaries (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "From2023-01-01to2023-12-31", "name": "us-gaap:GainLossOnSaleOfBusiness", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_MesoScribeTechnologiesIncMember", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-k.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/AccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r21" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r20", "r653" ] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": [ "r606" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r282", "r283" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued expenses", "totalLabel": "Total accrued expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23" ] }, "us-gaap_AccruedSalariesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedSalariesCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued wages and benefits", "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23", "r624" ] }, "us-gaap_AccruedVacationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedVacationCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued vacation", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r23", "r62" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r57", "r190", "r498" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r101" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r411", "r412", "r413", "r534", "r701", "r702", "r703", "r752", "r771" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:" } } }, "auth_ref": [] }, "CVV_AerospaceMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "AerospaceMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Aerospace [Member]", "documentation": "Aerospace [Member]" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total stock-based compensation expense", "verboseLabel": "Stock based compensation", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r406", "r418" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Allowance for credit loss", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r196", "r284", "r288" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Amortization expense", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r4", "r50", "r54" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r680" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://cvdequipment.com/role/EarningsPerShareDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Antidilutive shares from computation of diluted earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r243" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 }, "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical", "http://cvdequipment.com/role/StatementsOfCashFlows", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Impairment charge", "verboseLabel": "Asset impairment charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r4", "r55" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r144", "r193", "r215", "r252", "r267", "r273", "r285", "r316", "r317", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r450", "r453", "r464", "r492", "r561", "r653", "r665", "r714", "r715", "r755" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r185", "r200", "r215", "r285", "r316", "r317", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r450", "r453", "r464", "r653", "r714", "r715", "r755" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r680" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r677", "r679", "r680" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r677", "r679", "r680" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r677", "r679", "r680" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r377", "r378", "r379", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r401", "r402", "r403", "r404", "r405" ] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "CVV_BillingsToDate": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "BillingsToDate", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails": { "parentTag": "CVV_NetCostInExcessOfBillings", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Billings to date", "documentation": "Billings to date.", "label": "BillingsToDate" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://cvdequipment.com/role/BusinessDescription" ], "lang": { "en-us": { "role": { "label": "Business Description", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r88", "r124", "r125" ] }, "CVV_CVDEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "CVDEquipmentMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical", "http://cvdequipment.com/role/SegmentReportingDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "CVD Equipment [Member]", "documentation": "CVD Equipment [Member]" } } }, "auth_ref": [] }, "CVV_CVDMaterialsMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "CVDMaterialsMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "CVD Materials [Member]", "documentation": "CVD Materials [Member]" } } }, "auth_ref": [] }, "us-gaap_CapitalizedContractCostImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalizedContractCostImpairmentLoss", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Contract assets, impairment loss", "documentation": "Amount of impairment loss for asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": [ "r292" ] }, "us-gaap_CargoAndFreightMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CargoAndFreightMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cargo and Freight [Member]", "documentation": "Product transported between locations." } } }, "auth_ref": [ "r720" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r31", "r188", "r622" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r32" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents at beginning of year", "periodEndLabel": "Cash and cash equivalents at end of year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r31", "r121", "r213" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r121" ] }, "us-gaap_CashDivestedFromDeconsolidation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashDivestedFromDeconsolidation", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Net cash used in disposition of Tantaline", "label": "Cash Divested from Deconsolidation", "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash." } } }, "auth_ref": [ "r119" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r692", "r765" ] }, "us-gaap_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash uninsured amount", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and contingencies (see note 13)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r27", "r83", "r493", "r548" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common shares reserved for future issuance.", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r28" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r656", "r657", "r658", "r660", "r661", "r662", "r663", "r701", "r702", "r752", "r768", "r771" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://cvdequipment.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r100" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://cvdequipment.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r100", "r549" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://cvdequipment.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r100" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://cvdequipment.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r10", "r100", "r549", "r567", "r771", "r772" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock - $0.01 par value \u2013 20,000,000 shares authorized; issued and outstanding 6,824,511 at December 31, 2023 and 6,760,938 at December 31, 2022", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r100", "r494", "r653" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r39", "r41", "r77", "r78", "r281", "r606" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r39", "r41", "r77", "r78", "r281", "r528", "r606" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r39", "r41", "r77", "r78", "r281", "r606", "r688" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r86", "r154" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Concentration risk percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r39", "r41", "r77", "r78", "r281" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r39", "r41", "r77", "r78", "r281", "r606" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "auth_ref": [ "r218", "r450", "r451", "r453", "r454", "r477", "r616", "r713", "r716", "r717" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesDomain", "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical" ], "auth_ref": [ "r218", "r450", "r451", "r453", "r454", "r477", "r616", "r713", "r716", "r717" ] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/SegmentReportingDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]" } } }, "auth_ref": [ "r218", "r254", "r265", "r266", "r267", "r268", "r269", "r271", "r275", "r316", "r317", "r318", "r319", "r321", "r322", "r324", "r326", "r327", "r714", "r715" ] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidationItemsDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/SegmentReportingDetailsNarrative" ], "auth_ref": [ "r218", "r254", "r265", "r266", "r267", "r268", "r269", "r271", "r275", "r316", "r317", "r318", "r319", "r321", "r322", "r324", "r326", "r327", "r714", "r715" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r76", "r625" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "CVV_ContractLiabilityInExcessOfContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "ContractLiabilityInExcessOfContractAssets", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "label": "Contract liability in excess of contract assets", "documentation": "Contract liability in excess of contract assets." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/RevenueDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "label": "Contract assets", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r334", "r336", "r355" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "label": "Contract liabilities", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r334", "r335", "r355" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred revenue recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r356" ] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateNonSegmentMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Corporate, Non-Segment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": [ "r15", "r266", "r267", "r268", "r269", "r275", "r706" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r113", "r215", "r285", "r316", "r317", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r464", "r714" ] }, "CVV_CostOfRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "CostOfRevenueMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Member]", "documentation": "Cost of Revenue [Member]" } } }, "auth_ref": [] }, "CVV_CostsAndEstimatedEarningsOnUncompletedContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "CostsAndEstimatedEarningsOnUncompletedContracts", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails": { "parentTag": "CVV_NetCostInExcessOfBillings", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Costs and estimated earnings on uncompleted contracts", "documentation": "Costs and estimated earnings on uncompleted contracts.", "label": "CostsAndEstimatedEarningsOnUncompletedContracts" } } }, "auth_ref": [] }, "CVV_CostsIncurredOnUncompletedContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "CostsIncurredOnUncompletedContracts", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails": { "parentTag": "CVV_CostsAndEstimatedEarningsOnUncompletedContracts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "label": "Costs incurred on contracts in progress", "documentation": "Costs incurred on uncompleted contracts." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Federal", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r690", "r699", "r751" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total current tax provision", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r142", "r438", "r444", "r699" ] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "label": "State", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r690", "r699", "r751" ] }, "CVV_CustomerAMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "CustomerAMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer A [Member]", "documentation": "Customer A [Member]" } } }, "auth_ref": [] }, "CVV_CustomerBMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "CustomerBMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer B [Member]", "documentation": "Customer B [Member]" } } }, "auth_ref": [] }, "CVV_CustomerCMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "CustomerCMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer C [Member]", "documentation": "Customer C [Member]" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r40", "r281" ] }, "CVV_CustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "CustomerMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Member]", "documentation": "Customer [Member]" } } }, "auth_ref": [] }, "CVV_CustomerOneMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "CustomerOneMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer One [Member]" } } }, "auth_ref": [] }, "CVV_CustomerThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "CustomerThreeMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Three [Member]", "documentation": "Customer Three [Member]" } } }, "auth_ref": [] }, "CVV_CustomerTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "CustomerTwoMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer Two [Member]", "documentation": "Customer Two [Member]" } } }, "auth_ref": [] }, "country_DK": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "DK", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "DENMARK" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt instrument interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r25", "r329" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Debt instrument monthly payments", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r26", "r85" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r699", "r750", "r751" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total deferred tax provision", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r4", "r142", "r161", "r443", "r444", "r699" ] }, "CVV_DeferredRevenuesRelatedToContracts": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "DeferredRevenuesRelatedToContracts", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "label": "Deferred revenue related to non-systems contracts", "documentation": "Deferred revenues related to contracts." } } }, "auth_ref": [] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r699", "r750", "r751" ] }, "CVV_DeferredTaxAssetsCapitalizedResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Capitalized research and development", "documentation": "Deferred tax assets capitalized research and development." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income tax assets", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r433" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income tax asset, net", "label": "Deferred Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r748" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred income tax assets, net of valuation allowance", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r748" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r75", "r749" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other items", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r75", "r749" ] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "R&D tax credit carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r74", "r75", "r749" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Vacation accrual", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensated absences (includes, but not limited to, sick and personal days)." } } }, "auth_ref": [ "r75", "r749" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Compensation costs", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation." } } }, "auth_ref": [ "r75", "r749" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r434" ] }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses", "label": "Deferred Tax Liabilities, Prepaid Expenses", "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Property, plant and equipment", "label": "Deferred Tax Liabilities, Property, Plant and Equipment", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment." } } }, "auth_ref": [ "r75", "r749" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/DefinedContributionPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined contribution plan, compensation expense", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r370" ] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/DefinedContributionPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined contribution plan, employer discretionary contribution amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://cvdequipment.com/role/DefinedContributionPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined contribution plan percentage of employees contribution", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://cvdequipment.com/role/DefinedContributionPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Defined contribution plan percentage", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "CVV_DepositsFromPurchaserOfMesoscribeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "DepositsFromPurchaserOfMesoscribeAssets", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deposits from purchasers of MesoScribe assets \u2013 note 15", "verboseLabel": "Deposits from purchaser of equipment", "documentation": "Deposits from purchaser of MesoScribe assets." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r56" ] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r4", "r56" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [ "r707", "r769" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r354", "r640", "r641", "r642", "r643", "r644", "r645", "r646" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r354", "r640", "r641", "r642", "r643", "r644", "r645", "r646" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://cvdequipment.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Disaggregation of Revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r719" ] }, "CVV_DisclosureEmployeeRetentionCreditAbstract": { "xbrltype": "stringItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "DisclosureEmployeeRetentionCreditAbstract", "lang": { "en-us": { "role": { "label": "Employee Retention Credit" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r372", "r376", "r407", "r408", "r410", "r651" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "CVV_DisclosureRisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "DisclosureRisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks And Uncertainties" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiaries" ], "lang": { "en-us": { "role": { "label": "CVD Materials \u2013 Tantaline and MesoScribe Subsidiaries", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r89", "r129" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Name of disposal group." } } }, "auth_ref": [ "r648", "r649" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r679" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r677", "r679", "r680" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r677", "r679", "r680", "r682" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r678" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r666" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r679" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r679" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r681" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r669" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DomesticCountryMember", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Authority [Member]", "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss per common share:", "verboseLabel": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r208", "r224", "r225", "r226", "r227", "r228", "r233", "r235", "r240", "r241", "r242", "r246", "r462", "r463", "r488", "r502", "r628" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r208", "r224", "r225", "r226", "r227", "r228", "r235", "r240", "r241", "r242", "r246", "r462", "r463", "r488", "r502", "r628" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r37", "r38" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://cvdequipment.com/role/EarningsPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r232", "r243", "r244", "r245" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Federal statutory tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r217", "r427", "r446" ] }, "CVV_EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperationsAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperationsAmount", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "US taxation of foreign operations", "documentation": "Effective income tax rate reconciliation US taxation of foreign operations amount." } } }, "auth_ref": [] }, "CVV_EmployeeRetentionCreditReceivableNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "EmployeeRetentionCreditReceivableNoncurrent", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/EmployeeRetentionCreditDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employee retention credit receivable", "verboseLabel": "Employee retention credit receivable noncurrent", "documentation": "Employee retention credit receivable noncurrent." } } }, "auth_ref": [] }, "CVV_EmployeeRetentionCreditTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "EmployeeRetentionCreditTextBlock", "presentation": [ "http://cvdequipment.com/role/EmployeeRetentionCredit" ], "lang": { "en-us": { "role": { "verboseLabel": "Employee Retention Credit", "documentation": "Employee Retention Credit [Text Block]", "label": "EmployeeRetentionCreditTextBlock" } } }, "auth_ref": [] }, "CVV_EmployeeRetentionTaxCreditsIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "EmployeeRetentionTaxCreditsIncome", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/EmployeeRetentionCreditDetailsNarrative", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Employee retention credits", "documentation": "Employee retention tax credits income." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation costs", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r409" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation costs, recoginition period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r409" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "CVV_EnergyMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "EnergyMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Energy [Member]", "documentation": "Energy [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r672" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r668" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r668" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r686" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r668" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r683" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r680" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r668" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r668" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r668" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r668" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r684" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r10", "r182", "r204", "r205", "r206", "r219", "r220", "r221", "r223", "r229", "r231", "r247", "r286", "r287", "r333", "r411", "r412", "r413", "r439", "r440", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r469", "r470", "r471", "r472", "r473", "r474", "r476", "r523", "r524", "r525", "r534", "r590" ] }, "CVV_EstimatedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "EstimatedEarnings", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails": { "parentTag": "CVV_CostsAndEstimatedEarningsOnUncompletedContracts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "label": "Estimated earnings", "documentation": "Estimated earnings." } } }, "auth_ref": [] }, "CVV_ExercisePriceRangeFourMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "ExercisePriceRangeFourMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range Four [Member]", "documentation": "Exercise Price Range Four [Member]" } } }, "auth_ref": [] }, "CVV_ExercisePriceRangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "ExercisePriceRangeOneMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range One [Member]", "documentation": "Exercise Price Range One [Member]" } } }, "auth_ref": [] }, "CVV_ExercisePriceRangeThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "ExercisePriceRangeThreeMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range Three [Member]", "documentation": "Exercise Price Range Three [Member]" } } }, "auth_ref": [] }, "CVV_ExercisePriceRangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "ExercisePriceRangeTwoMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range Two [Member]", "documentation": "Exercise Price Range Two [Member]" } } }, "auth_ref": [] }, "CVV_ExportSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "ExportSalesMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Export Sales [Member]", "documentation": "Export Sales [Member]" } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfFinancialInstrumentsPolicy", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments", "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments." } } }, "auth_ref": [ "r7", "r16" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intangible assets estimated useful life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r191", "r305" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated amortization expense, thereafter", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated amortization expense, 2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r128" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated amortization expense, 2028", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r128" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated amortization expense, 2027", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r128" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated amortization expense, 2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r128" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/IntangibleAssetsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Estimated amortization expense, 2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r128" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r303", "r304", "r305", "r306", "r486", "r487" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets, Cost", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r127", "r487" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r486" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r51", "r53" ] }, "CVV_FiveDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "FiveDirectorsMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Five Directors [Member]", "documentation": "Five Directors [Member]" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Foreign exchange income (loss)", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r465", "r466", "r467", "r468", "r587" ] }, "us-gaap_GainLossOnSaleOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSaleOfBusiness", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 }, "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical", "http://cvdequipment.com/role/StatementsOfCashFlows", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposition of Tantaline", "label": "Loss on disposition of tantaline", "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant." } } }, "auth_ref": [ "r452", "r697" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r114", "r572" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r111" ] }, "us-gaap_GeographicDistributionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicDistributionAxis", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographic Distribution [Axis]", "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities." } } }, "auth_ref": [ "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r489", "r490", "r633" ] }, "us-gaap_GeographicDistributionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicDistributionDomain", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities." } } }, "auth_ref": [ "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r489", "r490" ] }, "us-gaap_GeographicDistributionForeignMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicDistributionForeignMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographic Distribution, Foreign [Member]", "documentation": "Allocation of business activity identified as foreign." } } }, "auth_ref": [ "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r489", "r490", "r634" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r112", "r215", "r252", "r266", "r272", "r275", "r285", "r316", "r317", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r464", "r630", "r714" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r677", "r679", "r680" ] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets and Intangibles", "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Domestic", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations." } } }, "auth_ref": [ "r216", "r445" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Loss before income tax", "totalLabel": "Total", "verboseLabel": "Pretax (loss) income", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r109", "r147", "r252", "r266", "r272", "r275", "r490", "r500", "r630" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfLossBeforeIncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Foreign", "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile." } } }, "auth_ref": [ "r216", "r445" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r648", "r649" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r8", "r14", "r18", "r90", "r91", "r92", "r93", "r94", "r95", "r96", "r97", "r98", "r131" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r307", "r309", "r573" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "auth_ref": [ "r309", "r573" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority [Axis]", "documentation": "Information by tax jurisdiction." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxAuthorityNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameAxis", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income Tax Authority, Name [Axis]", "documentation": "Information by name of taxing authority." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncomeTaxAuthorityNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxAuthorityNameDomain", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r217", "r421", "r428", "r430", "r436", "r441", "r447", "r448", "r449", "r533" ] }, "us-gaap_IncomeTaxExaminationDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationDescription", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income tax examination, year", "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings." } } }, "auth_ref": [ "r72" ] }, "us-gaap_IncomeTaxExaminationLikelihoodOfUnfavorableSettlement": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExaminationLikelihoodOfUnfavorableSettlement", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Income tax examination, description", "documentation": "Description of the likelihood that an uncertainty in income taxes will not be sustained as a result of the examination by the taxing authority." } } }, "auth_ref": [ "r72", "r141" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfComponentsOfIncomeTaxExpenseBenefitDetails", "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income tax (benefit) expense", "totalLabel": "Income tax (benefit) expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r150", "r162", "r230", "r231", "r260", "r426", "r442", "r504" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r203", "r424", "r425", "r430", "r431", "r435", "r437", "r530" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r747" ] }, "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Change in tax rates", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates." } } }, "auth_ref": [ "r423", "r427" ] }, "us-gaap_IncomeTaxReconciliationDispositionOfBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationDispositionOfBusiness", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Disposition of Tantaline", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the disposition of a business not qualifying as a discontinued operation." } } }, "auth_ref": [ "r747" ] }, "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Foreign tax rate differential", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)." } } }, "auth_ref": [ "r747" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Expected provision at federal statutory tax rate at 21%", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r427" ] }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationNondeductibleExpense", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "Non-deductible expenses", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r747" ] }, "us-gaap_IncomeTaxReconciliationOtherAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationOtherAdjustments", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r747" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "label": "State and local taxes", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r747" ] }, "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationTaxCreditsResearch", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Federal research and development credits", "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit." } } }, "auth_ref": [ "r747" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income taxes paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r33" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerAsset", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Contract assets", "label": "Increase (Decrease) in Contract with Customer, Asset", "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r696" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Contract liabilities", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r480", "r696" ] }, "CVV_IncreaseDecreaseInEmployeeRetentionCreditReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "IncreaseDecreaseInEmployeeRetentionCreditReceivable", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://cvdequipment.com/role/EmployeeRetentionCreditDetailsNarrative", "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Employee retention credit receivable", "label": "Employee retention credit eligible amount", "documentation": "Increase decrease in employee retention credit receivable." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax receivable", "label": "Increase (Decrease) in Income Taxes Receivable", "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities, net of effects of disposition of Tantaline:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other current assets", "label": "Increase (Decrease) in Other Current Assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r696" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "presentation": [ "http://cvdequipment.com/role/ScheduleOfBasicAndDilutedWeightedAverageCommonSharesOutstandingDetails" ], "lang": { "en-us": { "role": { "label": "Effect of potentially dilutive share-based awards", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r236", "r237", "r238", "r242", "r375" ] }, "CVV_IndustrialMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "IndustrialMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Industrial [Member]", "documentation": "Industrial [Member]" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [ "r302" ] }, "us-gaap_IntangibleAssetsFiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsFiniteLivedPolicy", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible Assets", "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r53", "r482", "r483", "r484", "r486", "r626" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets, net", "verboseLabel": "Intangible assets, Net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r49", "r52" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expenses", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r81", "r149", "r207", "r256", "r475", "r574", "r664", "r770" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r209", "r211", "r212" ] }, "us-gaap_InternalRevenueServiceIRSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InternalRevenueServiceIRSMember", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Internal Revenue Service (IRS) [Member]", "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity." } } }, "auth_ref": [] }, "us-gaap_IntersegmentEliminationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntersegmentEliminationMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/SegmentReportingDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Intersegment Eliminations [Member]", "documentation": "Eliminating entries used in operating segment consolidation." } } }, "auth_ref": [ "r254", "r265", "r266", "r267", "r268", "r269", "r271", "r275" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/Inventories" ], "lang": { "en-us": { "role": { "label": "Inventories", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r289" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r693" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails" ], "lang": { "en-us": { "role": { "label": "Inventories, net", "totalLabel": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r198", "r623", "r653" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r151", "r187", "r197", "r289", "r290", "r291", "r481", "r627" ] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails" ], "lang": { "en-us": { "role": { "label": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r695" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfInventoriesNetDetails" ], "lang": { "en-us": { "role": { "label": "Work-in-process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r694" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r115", "r255" ] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r720" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r22", "r215", "r285", "r316", "r317", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r451", "r453", "r454", "r464", "r547", "r629", "r665", "r714", "r755", "r756" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r105", "r146", "r496", "r653", "r698", "r708", "r753" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r24", "r186", "r215", "r285", "r316", "r317", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r451", "r453", "r454", "r464", "r653", "r714", "r755", "r756" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "CVV_LiquidityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "LiquidityPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Liquidity", "documentation": "Liquidity [Policy Text Block]" } } }, "auth_ref": [] }, "CVV_LoanToFundAcquisitionOfMachineryEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "LoanToFundAcquisitionOfMachineryEquipment", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/Long-termDebtDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Loan to fund acquisition of machinery equipment", "documentation": "Loan to fund acquisition of machinery equipment." } } }, "auth_ref": [] }, "us-gaap_LoansAssumed1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansAssumed1", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Loan obtained for new equipment", "documentation": "The fair value of loans assumed in noncash investing or financing activities." } } }, "auth_ref": [ "r34", "r35", "r36" ] }, "us-gaap_LoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayable", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Equipment loan payable in monthly repayments of $8 including interest at 6% per annum", "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r17", "r145", "r764" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r17", "r145", "r330", "r332", "r636", "r637", "r764" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Current maturities of long-term debt", "verboseLabel": "Less: current maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r194" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "2024", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r6", "r218", "r331" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "2027", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r6", "r218", "r331" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "2026", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r6", "r218", "r331" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfMaturitiesOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "2025", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r6", "r218", "r331" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfLongTermDebtDetails" ], "lang": { "en-us": { "role": { "label": "Long-term debt, net of current portion", "verboseLabel": "Long-term debt, net of current maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r195" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://cvdequipment.com/role/Long-termDebt" ], "lang": { "en-us": { "role": { "label": "Long-term Debt", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r132" ] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "auth_ref": [ "r281", "r642", "r719", "r766", "r767" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r312", "r313", "r314", "r315", "r371", "r479", "r522", "r539", "r540", "r593", "r595", "r597", "r598", "r600", "r617", "r618", "r632", "r639", "r650", "r655", "r718", "r757", "r758", "r759", "r760", "r761", "r762" ] }, "CVV_MesoScribeTechnologiesIncMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "MesoScribeTechnologiesIncMember", "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Meso Scribe Technologies Inc [Member]", "documentation": "Meso Scribe Technologies Inc [Member]" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r312", "r313", "r314", "r315", "r371", "r479", "r522", "r539", "r540", "r593", "r595", "r597", "r598", "r600", "r617", "r618", "r632", "r639", "r650", "r655", "r718", "r757", "r758", "r759", "r760", "r761", "r762" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r281", "r642", "r719", "r766", "r767" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r210" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r210" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r121", "r122", "r123" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "CVV_NetCostInExcessOfBillings": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "NetCostInExcessOfBillings", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cost in excess of billings", "documentation": "Net cost in excess of billings.", "label": "NetCostInExcessOfBillings" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative", "http://cvdequipment.com/role/StatementsOfCashFlows", "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "label": "Net loss", "verboseLabel": "Net income", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r110", "r123", "r148", "r184", "r201", "r202", "r206", "r215", "r222", "r224", "r225", "r226", "r227", "r230", "r231", "r239", "r252", "r266", "r272", "r275", "r285", "r316", "r317", "r319", "r320", "r321", "r323", "r325", "r327", "r328", "r463", "r464", "r501", "r569", "r588", "r589", "r630", "r664", "r714" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Adopted Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income, net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r116" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income (expense):" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://cvdequipment.com/role/SegmentReportingDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r705" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating loss", "verboseLabel": "Operating (loss) income", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r252", "r266", "r272", "r275", "r630" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r74" ] }, "us-gaap_OperatingLossCarryforwardsLimitationsOnUse": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLimitationsOnUse", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating loss carryforwards, limitations", "documentation": "A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r73" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingSegmentsMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r269", "r275" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r23" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r199", "r653" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r192" ] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherIncome", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Other income related to ERC", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r503", "r570", "r601", "r602", "r603" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other income", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r117" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r679" ] }, "us-gaap_PatentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PatentsMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Patents [Member]", "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law." } } }, "auth_ref": [ "r143" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "CVV_PaymentsForCapitalizedPatentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "PaymentsForCapitalizedPatentCosts", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Capitalized patent costs", "documentation": "Payments for capitalized patent costs.", "label": "PaymentsForCapitalizedPatentCosts" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r120" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/DefinedContributionPlan" ], "lang": { "en-us": { "role": { "label": "Defined Contribution Plan", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r647" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r673" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r674" ] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassifications", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r691" ] }, "CVV_ProceedsFromDepositsFromPurchaserOfMesoscribeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "ProceedsFromDepositsFromPurchaserOfMesoscribeAssets", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deposits from purchaser of MesoScribe assets", "documentation": "Proceeds from deposits from purchaser of mesoscribe assets." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfMachineryAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfMachineryAndEquipment", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net proceeds from sale of assets", "documentation": "The cash inflow from sale of machinery and equipment." } } }, "auth_ref": [ "r118" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r2", "r13" ] }, "us-gaap_ProductInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductInformationLineItems", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r277", "r485", "r516", "r517", "r518", "r519", "r520", "r521", "r620", "r640", "r654", "r689", "r710", "r711", "r719", "r766" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r277", "r485", "r516", "r517", "r518", "r519", "r520", "r521", "r620", "r640", "r654", "r689", "r710", "r711", "r719", "r766" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/PropertyPlantAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r129", "r155", "r159", "r160" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Totals at cost", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r130", "r189", "r499" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 }, "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r491", "r499", "r653" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, Plant and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r5", "r155", "r159", "r497" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://cvdequipment.com/role/PropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Property, Plant and Equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r130" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property plant and equipment useful life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r312", "r313", "r314", "r315", "r359", "r371", "r402", "r403", "r404", "r478", "r479", "r522", "r539", "r540", "r593", "r595", "r597", "r598", "r600", "r617", "r618", "r632", "r639", "r650", "r655", "r658", "r709", "r718", "r758", "r759", "r760", "r761", "r762" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r312", "r313", "r314", "r315", "r359", "r371", "r402", "r403", "r404", "r478", "r479", "r522", "r539", "r540", "r593", "r595", "r597", "r598", "r600", "r617", "r618", "r632", "r639", "r650", "r655", "r658", "r709", "r718", "r758", "r759", "r760", "r761", "r762" ] }, "CVV_RecentlyIssuedAccountingStandardsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "RecentlyIssuedAccountingStandardsPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Standards", "documentation": "Recently Issued Accounting Standards [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Payments of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r30", "r531" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r87", "r420", "r763" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchMember", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Research Tax Credit Carryforward [Member]", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r73" ] }, "CVV_ResearchOneMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "ResearchOneMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Research [Member]", "documentation": "Research [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r37" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "(Accumulated deficit) retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r102", "r135", "r495", "r526", "r527", "r532", "r550", "r653" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r182", "r219", "r220", "r221", "r223", "r229", "r231", "r286", "r287", "r411", "r412", "r413", "r439", "r440", "r455", "r457", "r458", "r460", "r461", "r523", "r525", "r534", "r771" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/SegmentReportingDetailsNarrative", "http://cvdequipment.com/role/StatementsOfOperations", "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue", "verboseLabel": "Revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r253", "r254", "r265", "r270", "r271", "r277", "r279", "r281", "r353", "r354", "r485" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Total", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r253", "r254", "r265", "r270", "r271", "r277", "r279", "r281", "r353", "r354", "r485" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r163", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r619" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://cvdequipment.com/role/Revenue" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r163", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r357" ] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/RevenueDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized contract revenue", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r158" ] }, "CVV_RisksAndUncertaintiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "RisksAndUncertaintiesTextBlock", "presentation": [ "http://cvdequipment.com/role/RisksAndUncertainties" ], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties", "documentation": "Risks And Uncertainties [Text Block]" } } }, "auth_ref": [] }, "CVV_SDCMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "SDCMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical", "http://cvdequipment.com/role/SegmentReportingDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "SDC [Member]", "documentation": "SDC [Member]" } } }, "auth_ref": [] }, "CVV_SaleOfProprietaryAssetsAndLicenseCertainProprietyInformationAggregatePurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "SaleOfProprietaryAssetsAndLicenseCertainProprietyInformationAggregatePurchasePrice", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate purchase price", "documentation": "Sale of proprietary assets and license certain propriety information aggregate purchase price." } } }, "auth_ref": [] }, "CVV_SalesConcentrationsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "SalesConcentrationsPolicyPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Sales Concentrations", "documentation": "Sales Concentrations Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r281", "r687" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://cvdequipment.com/role/AccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Components of Income Tax Expense (Benefit)", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r140" ] }, "CVV_ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsTableTextBlock", "presentation": [ "http://cvdequipment.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cost and Estimated Earnings in Excess of Billings", "documentation": "Schedule Of Cost And Estimated Earnings In Excess Of Billings [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDebtInstrumentsTextBlock", "presentation": [ "http://cvdequipment.com/role/Long-termDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Long Term Debt", "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer." } } }, "auth_ref": [ "r26", "r60", "r61", "r79", "r80", "r82", "r84", "r133", "r134", "r636", "r638", "r700" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r139" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://cvdequipment.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Basic and Diluted Weighted Average Common Shares Outstanding", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r704" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r138" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock Based Compensation", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r71" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfFiniteLivedIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r51", "r53", "r486" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://cvdequipment.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite Lived Intangible Assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r51", "r53" ] }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Loss Before Income Taxes", "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions." } } }, "auth_ref": [ "r699" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://cvdequipment.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventories, net", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r19", "r106", "r107", "r108" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://cvdequipment.com/role/Long-termDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Maturities of Long Term Debt", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ScheduleOfProductInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductInformationTable", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Product Information [Table]", "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfPropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical", "http://cvdequipment.com/role/SegmentReportingDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r45", "r46", "r47", "r48" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://cvdequipment.com/role/SegmentReportingTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segments", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r45", "r46", "r47", "r48" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r373", "r374", "r377", "r378", "r379", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r401", "r402", "r403", "r404", "r405" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r63" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": [ "r63" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock Options Awards", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r11", "r12", "r64" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Weighted Average Assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r137" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Awards", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r667" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r671" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r670" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r675" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical", "http://cvdequipment.com/role/SegmentReportingDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r249", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r275", "r281", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r310", "r311", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r635", "r689", "r766" ] }, "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentExpenditureAdditionToLongLivedAssets", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails" ], "lang": { "en-us": { "role": { "label": "Purchases of property, plant & equipment", "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets." } } }, "auth_ref": [ "r263", "r631" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "auth_ref": [ "r279", "r280", "r536", "r537", "r538", "r594", "r596", "r599", "r604", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r621", "r641", "r658", "r719", "r766" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://cvdequipment.com/role/SegmentReporting" ], "lang": { "en-us": { "role": { "label": "Segment Reporting", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r264", "r269", "r273", "r274", "r275", "r276", "r277", "r278", "r281" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical", "http://cvdequipment.com/role/SegmentReportingDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingExpense", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling", "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services." } } }, "auth_ref": [ "r114" ] }, "CVV_SellingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "SellingExpenseMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Selling Expense [Member]", "documentation": "Selling Expense [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://cvdequipment.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r651" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Shares of restricted stock, forfeited or cancelled", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r394" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, forfeited or cancelled", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r394" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Shares of restricted stock, granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r392" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r392" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Shares of restricted stock, unvested outstanding", "periodEndLabel": "Shares of restricted stock, unvested outstanding", "label": "Restricted stock units outstanding", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r389", "r390" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average grant date fair value, unvested outstanding", "periodEndLabel": "Weighted average grant date fair value, unvested outstanding", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r389", "r390" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "negatedLabel": "Shares of restricted stock, vested", "label": "Restricted stock units, vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r393" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value, vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r393" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "presentation": [ "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price", "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r403" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r402" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r404" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r373", "r374", "r377", "r378", "r379", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r401", "r402", "r403", "r404", "r405" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares available for grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r63" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://cvdequipment.com/role/EarningsPerShareDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock option exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r383" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Stock option awards, expired / cancelled", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r727" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, expired / cancelled", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r727" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock option awards, granted", "verboseLabel": "Stock option granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r385" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r63" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://cvdequipment.com/role/EarningsPerShareDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock option outstanding", "periodStartLabel": "Stock option awards outstanding, beginning balance", "periodEndLabel": "Stock option awards outstanding, ending balance", "verboseLabel": "Outstanding stock options", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r381", "r382" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average exercise price outstanding, beginning balance", "periodEndLabel": "Weighted average exercise price outstanding, ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r381", "r382" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfRestrictedStockAwardsDetails", "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r377", "r378", "r379", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r401", "r402", "r403", "r404", "r405" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r386" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, granted", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r385" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-Based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r372", "r380", "r399", "r400", "r401", "r402", "r405", "r414", "r415", "r416", "r417" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r69" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price range, lower limit", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r67" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": [ "r65" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price range, upper limit", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r70" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Stock price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock option vesting percentage", "documentation": "Percentage of vesting of award under share-based payment arrangement." } } }, "auth_ref": [ "r721" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted stock units vested, intrinsic value", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Expiration period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r652" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://cvdequipment.com/role/ScheduleOfWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected life (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r401" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options exercisable, intrinsic value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r63" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options exercisable, weighted average exercise price", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": [ "r66" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, weighted average exercise price", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": [ "r65" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://cvdequipment.com/role/ScheduleOfOutstandingAndExercisableOptionsRangesOfExercisePricesDetails" ], "lang": { "en-us": { "role": { "label": "Number of options outstanding, weighted average remaining contractual term", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r136" ] }, "CVV_SharebasedPaymentArrangementAnnualEquityRetainerAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "SharebasedPaymentArrangementAnnualEquityRetainerAmount", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Annual equity retainer amount", "documentation": "Share based payment arrangement annual equity retainer amount." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "CVV_ShippingAndHandlingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "ShippingAndHandlingPolicyPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Shipping and Handling", "documentation": "Shipping And Handling Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r124", "r214" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r676" ] }, "us-gaap_StandardProductWarrantyDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyDescription", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Standard product warranty description", "documentation": "Describes the nature of the product warranty, including the approximate term of the product warranty, how the product warranty arose, and the events or circumstances that would require the warrantor to perform under the product warranty." } } }, "auth_ref": [ "r58", "r59" ] }, "us-gaap_StandardProductWarrantyPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StandardProductWarrantyPolicy", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Product Warranty", "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability." } } }, "auth_ref": [ "r712" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfSegmentsDetails", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical", "http://cvdequipment.com/role/SegmentReportingDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r183", "r249", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r275", "r281", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r308", "r310", "r311", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r635", "r689", "r766" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r10", "r29", "r182", "r204", "r205", "r206", "r219", "r220", "r221", "r223", "r229", "r231", "r247", "r286", "r287", "r333", "r411", "r412", "r413", "r439", "r440", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r469", "r470", "r471", "r472", "r473", "r474", "r476", "r523", "r524", "r525", "r534", "r590" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r279", "r280", "r536", "r537", "r538", "r594", "r596", "r599", "r604", "r605", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r621", "r641", "r658", "r719", "r766" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r219", "r220", "r221", "r247", "r485", "r529", "r535", "r541", "r542", "r543", "r544", "r545", "r546", "r549", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r562", "r563", "r564", "r565", "r566", "r568", "r571", "r572", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r590", "r659" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r219", "r220", "r221", "r247", "r485", "r529", "r535", "r541", "r542", "r543", "r544", "r545", "r546", "r549", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r562", "r563", "r564", "r565", "r566", "r568", "r571", "r572", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r590", "r659" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation, shares", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r10", "r99", "r100", "r135" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://cvdequipment.com/role/ScheduleOfStockOptionsAwardsDetails", "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of stock options and issuance of shares, shares", "negatedLabel": "Stock option awards, exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r10", "r99", "r100", "r135", "r386" ] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r68", "r99", "r100", "r135" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of stock options and issuance of shares", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r10", "r29", "r135" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://cvdequipment.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://cvdequipment.com/role/BalanceSheets", "http://cvdequipment.com/role/StatementsOfChangesInStockholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r100", "r103", "r104", "r126", "r551", "r567", "r591", "r592", "r653", "r665", "r698", "r708", "r753", "r771" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://cvdequipment.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "CVV_SupplierRiskPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "SupplierRiskPolicyTextBlock", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Supplier Risk", "documentation": "Supplier Risk [Policy Text Block]" } } }, "auth_ref": [] }, "CVV_TantalineASOfNordborgMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "TantalineASOfNordborgMember", "presentation": [ "http://cvdequipment.com/role/CvdMaterialsTantalineAndMesoscribeSubsidiariesDetailsNarrative", "http://cvdequipment.com/role/ScheduleOfSegmentsDetailsParenthetical" ], "lang": { "en-us": { "role": { "label": "Tantaline A/S of Nordborg [Member]", "documentation": "Tantaline A/S of Nordborg [Member]" } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax credit carryforward.", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r74" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r73" ] }, "us-gaap_TaxCreditCarryforwardLimitationsOnUse": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardLimitationsOnUse", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tax credit carryforward expiration", "documentation": "Description of the limitation related to use of the tax credit carryforward." } } }, "auth_ref": [] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r73" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceAxis", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Timing of Transfer of Good or Service [Axis]", "documentation": "Information by timing of transfer of good or service to customer." } } }, "auth_ref": [ "r645", "r719" ] }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TimingOfTransferOfGoodOrServiceDomain", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time." } } }, "auth_ref": [ "r645", "r719" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r707", "r754" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransferredAtPointInTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferredAtPointInTimeMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Transferred at Point in Time [Member]", "documentation": "Contract with customer in which good or service is transferred at point in time." } } }, "auth_ref": [ "r645" ] }, "us-gaap_TransferredOverTimeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransferredOverTimeMember", "presentation": [ "http://cvdequipment.com/role/ScheduleOfDisaggregationOfRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Transferred over Time [Member]", "documentation": "Contract with customer in which good or service is transferred over time." } } }, "auth_ref": [ "r645" ] }, "CVV_TwoThousandSevenShareIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "TwoThousandSevenShareIncentivePlanMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2007 Share Incentive Plan [Member]", "documentation": "2007 Share Incentive Plan [Member]" } } }, "auth_ref": [] }, "CVV_TwoThousandSixteenShareIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "TwoThousandSixteenShareIncentivePlanMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2016 Share Incentive Plan [Member]", "documentation": "2016 Share Incentive Plan [Member]" } } }, "auth_ref": [] }, "CVV_TwoThousandTwentyTwoShareIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://cvdequipment.com/20231231", "localname": "TwoThousandTwentyTwoShareIncentivePlanMember", "presentation": [ "http://cvdequipment.com/role/Stock-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "2022 Share Incentive Plan [Member]", "documentation": "2022 Share Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Uncertain tax positions", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r422", "r429" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://cvdequipment.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r42", "r43", "r44", "r152", "r153", "r156", "r157" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://cvdequipment.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increase in valuation allowance", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r432" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://cvdequipment.com/role/ScheduleOfBasicAndDilutedWeightedAverageCommonSharesOutstandingDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted", "label": "Diluted weighted average shares outstanding", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r234", "r242" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted average number of shares:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://cvdequipment.com/role/ScheduleOfBasicAndDilutedWeightedAverageCommonSharesOutstandingDetails", "http://cvdequipment.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic", "label": "Basic weighted average shares outstanding", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r233", "r242" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://cvdequipment.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r685" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "825", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "60", "Paragraph": "1", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-3" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)-(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205-20/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482669/740-10-15-2" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(4)", "Publisher": "SEC" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(5)", "Publisher": "SEC" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(1)(i)", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(1)(ii)", "Publisher": "SEC" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Subsection": "Instruction 5", "Publisher": "SEC" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(a)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(a)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(a)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(a)", "Subparagraph": "(4)", "Publisher": "SEC" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(a)", "Subparagraph": "(5)", "Publisher": "SEC" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1406", "Paragraph": "(c)", "Publisher": "SEC" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//280/tableOfContent" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479483/340-40-50-3" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-30/tableOfContent" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-15" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1B" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "920", "SubTopic": "350", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-48" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 91 0001493152-24-011730-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-011730-xbrl.zip M4$L#!!0 ( "* ?%A: QAF( \ $>O 0 8W9V+3(P,C,Q,C,Q+GAS M9.U=6W/CMA5^[TS_ ZK.M)N9R%K;VI"\9B(0DC"E M"Y"VE%]? +R() @*I.V6,\4^)#)P<"[X<' Y (%/_]BL O"(&,>4G/8.#][V M "(>]3%9G/:^3/IGD^'550_\X^<__PF(?Y_^TN^#2XP"_P2,J->_(G/Z$_@, M5^@$_(((8C"D["=P#X-(IM!+'" &AG2U#E"(1$8LZ02\.S@Z@J#?M^![CXA/ MV9>[JXSO,@S7_&0P>'IZ.B#T$3Y1]L //+JR8S@)81CQC-O;S=ODGUWQ&\R] MK/#']S=K_N/F#O^Z0.1#-(+DB7^%WV[^-;O]^,>[?W]8H8?EX]?S'V>3X-OC M]K>UM_+\K\,S=#T;?_UM''CQ\'*C0SY33)., C%GH4XH$LM$_7"[1KR2-,XJ%/!#5BI0J#61/9#9LLQ1_^UQ M__@P+3F\O\_*>(\^^A;A]0J14#9H)>+P2!*C ,G42\I6(S2'42"L^!;! ,\Q M\GL@A&R!0ME"^1IZR()CVM0A(51XA'#+)$6FK==8-/DL023))G+":("FP@P@ M?PB7-(N1!(,A%5U+#V#_M!?_S#%,6?IHC@E6XA,W/ 1]Z721Y"5^JI*?!F5B MG5/$D3\F/ZO?:X:X**[,NA8)2?F$I+ZL!P,O"EH5W>E75S))3ROSN;5\#@/I MBY,E0B&/:[N89%7K1Z*J9<^(LFHGG ;8%RD^2/B!F*$#PQ*,6\A$YA*%6)A1 M@4PQWPJF8WN8P)L"_^\<;&;8LBKEX_EX+>)\A+C'\%I*3\:W MB@PKB'Z4LSZQM HHCQ@2?Z2<0(Z5@Z3&#[!"R)6!1XDX9GGT8B$ M8C5_*YJ[AU'J2G:T5L!]* .7,)?.E&,/=OQ!*L#!:8;S#CTB$J$8K_0/*T ^ ME@%)2KO:-M?V%1%5%%*6>4@^P:;6#]^6:SW'P=6\N>9O&143WW![&\@^B/@7 M*4F,@SG;"I7#,BHIO^^!X@@@\4'&T^%4YR&AF-3B68#..,\"#5JJ%2I'NJ^D M;$#,QR%A1D(,I"Q"_L5FC0A/^ZMRHA4.QV4<$BX@9>-@,,-P3 @?J(IW.RF3[L$*P#>ZT."Y 4"U?U-5ZP6@=TB] ="D6ZD#UDR,=) MAV3*M()$6Y&GW$#&#L3\'#YU 2WJ/?3EYJHO]\'%L IWT1)3IA4^^L);<3N7 MW$">G8/'#,]("I6U3T*&9Y&4+A<&,3RF3"MXM&5XP@WDV:E5B,.GQGW00B;< MH35E,G:4^$TYU0:1(VV)GK !&1^'1,UF_J-_ \7$%,. 3\72&0HF2*S(;Q"G M,D [0Y-HQK&/X2Z*TK",%8K:DGYX/P*9%/"WOWXX.CS\"63BU!)?"IPH@2 O MT>%=$X#$_($+K+X0#[$08C'@I[!69UFAIRW]%2^%48&;0^:YD?XV$?]&D?\C M+7Q@'_D';])?[EC"_DV *9P%F>\5DJQPTF(,"0_P)N;B(+#;&G M.LL*'"U,4=YD<-@TW6W((U.5886+%I\H[CPX5%IL0>2!,>398'.L12KT[0B' M3[-]B>)84TZV0D6+/.3W*!P>[8/A>6SJ2:QPTF(,IL"XPZQ%!+8 5G6>%4IZ M]* +!4,+I?QXG@1ZDNI,0+>EMH)9"VBD["7.10$R)8L\)4(XI7\9B&=#EZ1BXV'.!_/SW$0R!0#U,T96*&OQ4CRZ$N9<9 DE;J; MQF("8L&2,!7M6D6#F'!UCV[*M$)3"Z.4O=7UQPW]-A?=_8Q"@V]6$UDAIA\! MR?E?CN_W@*#0N5^FM(-7",GE(]X2@';[/V$"H[E#MR6W0_4$+ M[-@AZCK>AKY[*86C:U%A?GECP>"]%B6L$-:"1'G_C84 ):5JD\(Y;^#U66C M^\BMX*T- ^TD..]]@;W_ZNE./8D5B%KTIWP>P$UTVGGD.>38$TO'$0ZB$/E? M$5XLQ?_/'A&#"S2DJQ4E:DN?CZ-0WJLH;]\TN.NS>%DU@]J0DA*OUJB) B#5 M "0J@%B'^(P"!SDMG*^W.5%2[>Y[J:R@UD)-5:=,G->WG6AQ?H[FE*'<:1/C M1+F&U@;*=_JG384)%N<@YE\ZLN(\LMDNW&I-27P!6094LGX\1T0H9YIE-2AI M!7=MD&DG+-X%2 %/E[K@32+R.]< FC6 B_D<>;(/S#"\@R&Z0QXE'@ZP,LG0 M IH4M6H"^B&G7!/(I.7AEP)!4:)K *_6 &I7U:WY6#6-VKA7\Z;AUN&MCN*@ M.6(,^:)ZXTBQF+5?8S@3]1MBXTS LI15,ZB-HJ6"%/Q)*%O.ZW/"7.?0\(BQ M:2?"3&"%8\4W8Q5S.#=!MUM?5=^(8EAF61);P:@%R8S7J3A,VW:ZZJ#W>?GL MN*&OK2>VPE2+F>6[6,4?5)TZ=_UJ$U!+02XQ6$4K=1NP:1#=7\ *W-I(F!;W MRDEQ +?PVG%<=V=/D/DF8,V$5H#6'JV*O35A#F+N#LAF0.:BO?*HU 8Q#W/Y M"4=2K7?J6GRQ_(EST"W#GG$J_#QF-@WB?6W4+!^Z5J>R=AIDS23602VK$BU MK(9K.-:2VQ%:0:G&LA+M^@Y[#M/7<*_[HTCCC*F5;X58;>$HYNO[T M64#5AI=K::T@K#VPI4/H0L3MOZWSLIV^L M_BZL/MBL@I1""JAY55] M:X56EAF@(.1I2FL5I)?PY^N@V#128O^SXB9U]I54?_-6C4!=X<*V31I"ODCZ M1SLT=F^WVP&1TL<@R.?=5'7\VI=S[NHZ[!:UV&7=+W8R$YU @/$B]I6971!7X+8 M8EM2M9C6 2W/$*-JC"HJJB=W0-PT&164KTCN@[9U8(XMUR5(;QZHR M.J"O&*:F2QIQ2/R)O+I)?<)S)58:1,9LY$9)T8P&]!VS#F]"U,R^O26Z9>'T M261L14(#&VW*=,#*2Z'3"#/DA925QH'JK [H+.^RRRY(+(VTE5D=T'F"U+5Z MR5<_1:4->1W0NG"<1YVOT7K?>I).VJ"M+.I)NFF#OMK81]1).RYIQ/:94:#I M@!6346E^GT_H@'[#^U%V:UFI>ZS*Z8;&V7:8IK&>TP&-=UN%D_'\,V7^C+)% M:3)02](!&W8[C%/D+0D-Z (C+J8J13OVDW7 %L/7(7?(0_A1*O>9$B]B\EQ$ MUM$T*K+7QG@C(4RS9C"0VPK"5C23+P#'AL=Y*TI0"-GV^6:/T)IR'/)+1E>W MD5@$08[8>+[;O(Z_)DM-MB=O;:Z7O'C\.O9JF$WA)H:-QQ]B&<&M(&S0;/^K M1@H%&1+(C%#\_RNRMZGNENYMBG:U(FX9]1#R57-MV-+;%6U?$:_JY;=PJ\YX M75(VA&LL1Y4_D'\+):)RQ;.SVH*PJV#O#L@8FNR9X,N@E_7?#0K Y%=J=/,1 M*Z:043&R>+71:HHVX7E O8<]0U2>[AEC;YBR>4GP*I^C-4.WA[QKP%6JJ\&V MEZH;H%UCL180S6FKWOK8:F;4Y'?# +5',:0JMA:+BQ_--1G4@+XC!D;K=8 1 MDPW*9%,M24?,6&)YU$=^.O9/2/P@?<_&B),]?3<,E+,I$@;;*\XCY.]>T9G( M;];D!TL&0UN4ZX;!;1XS4>]'Z5B_!*=N5(J:85W%:T9_3+[(=<8Z$$-W_ F. M&,:RB9H=:3?7G!I V6RE(J.;)JCJKVIK%J@U*M9-\S,_HB-A16J=EMK1&,!G MI-8R>K>0&E)'T$U T@N DHTK?H<"V;RF5&N"5I0=!2Y5,;W6:+M#*,TJ+N*; M%.BHS=<4DBF]C(@8W<5LFJO#T/*F9V^)"6+;+!R?3;H;%.BHS387JGV9B&08 MVW9)&<(+,A::QY/RLY6[20^WR&N&AHCDFHS\^3(-898W+S3_TD)(*!;/GA]DY^_20%4KQ< - W 0 4 8W9V+3(P,C,Q,C,Q M7V-A;"YX;6SM7>MOXSB2_W[ _@^Z###H!=:=3OHQ_9B^16(G@P!Y(4GW['T: M,!+M\%J6O**4Q_SU1U*2+8EO6S+IP0X6.SUN5K&J?B2K2):*O_[S>1X'CS## M*$V^[AV\?K,7P"1,(Y3,ONY]NQT=W8[/SO8"G(,D G&:P*][2;KWS__YVW\% MY)]?_WLT"DX1C*//P20-1V?)-/T27((Y_!S\!A.8@3S-O@3?05S07])3%,,L M&*?S10QS2/ZB[/AS\/[UX2$(1B,#OM]A$J79MYNS)=^'/%_@S_O[3T]/KY/T M$3REV0_\.DSG9@QO,GMS?.;ZI^2_-<8)3\^T_^[!Q@&Q%X)_OR,T=<] MVF_5[=/;UVDVVS]\\^9@_U\7Y[?A YR#$4JHW4*X5U-1+B*Z@T^?/NVSOZV; M>AB!GL&N[":0MZ'^-ZF8C^M/H MX'#T]N#U,X[V:N,S"V9I#&_@-*#_)N@M>PT?(_CO BWF,,DI:/NTP?XX)8.2 M2,M('S(X_;H7/CZ2#@[?'AR6[']JM9K,1CG,YA-X MKX--V+8_44Y EI!)BZ]A=OM /*%&&EGS/L<.^2.\ \\&LXQKV:-="(OT!1** MG/Q.UN)Q!B.D TM#U:?G(]YU1*/*B.X7R#@%!BY&0]6?>!,X);Z,=)+D&;HO M:"=TV=&(IZ'JT7IP1G^X@8LTHRY+9S9)\_X$&C]&%R0LR1"(\1U9G@'A WA;W&,4(6#@?=9CUJ.;1O@')OU](R%VE@-$)H)69B7-ML.?7L.@ MP<.A.T S&14$FW;P4T@<;$QO@09/5EZ MU 7]FS'M4;GP 49%#*^F$X3!;);!&4/Z:EJYMTH$G3J6;(908)QBYE9PCN8D M5HOJJ7^6G#R'$..KZ3&*8_J+K4YK<^X],+$<91JJ(5!HA"&7,+>UM))Z"'&E M08FMY*:,MA"-60X2:SY#X'"*$I3#<])+U(W ;)$P9S5(.6RCZ MZ&2XC9TE5*;DPTQPC(_A-,U@8T-GORCIF0P3,,\7:5)>VRY[KA;R8YC *;*> MX_8LAU#L9#J%(85^*<(-"=MO8)@F(8H1VYG8:K8&3\>JK>=I-NU@D*TIG,(L M@Q$1IHR/R-)UCL ]D2=']O/-CMT@9T36\:&6+$9\,:^!EF M(<+TA+$2Y(;E9)'ULOP;>)VAT'XIZJ67(=2_@3@G?9%!PZR_'G F3 8_[[8] MF+7C,OC]OJ7XEEP&F?#EN;S]-!?3;4'$]2(E$R;#79'8#FM#4YRBE!E?1_$(SH%P(%)2!_K%H. M*HTXB;PEU2$199G7R\1*QBS'O^H MVG6:[3N1E29%D]%)_T5/UQ]!3!>.HWQ,1N0+F8WL0Q"Y#H;D7=T:@^8H"X,T MBV#V=>^@[@=D86NH\)]:5"WV,;VLI&Q&B(R'FGZ:I7.5J2NSINNHTH2$2+$7 M/+$0EDGO!L+JD1U%1^.&S)7#%1V"> NJDJ1,R3YS NZ!'F M;VD:/:$X5KEN$VH_7+K4EYL;P"?@&OY/N1+R[M)^W1O:T^M=O-^K7..V41MO MB=JZW0)?@Q?J2(PWO]WVKF,7N?4E>U^QPCX-J"H+SV9<*4AQN^87UZ\B<=#U-;50LQRP:D\NDM*KJ7KV:PHE]5=8,5*^C1\ MCJ((495!? U0=):,P0+E(&Z(K@CU#6A=3W5CL,P-X1-\-S0%)5E].DIV+L6< MVA=&-&4K1(K5V836]=; &#YS0_@$7\,1'261S5*NIW2]3)KJ)H^$?$2,K@'IPTV^NJ*9,K4_'6_J^4Y^>^M M9>&)TT=;*7EOS5/R@EMHVA0C0PMX!1I ":VA<)7< E;=HJKZKD!+2N'Z M8L\8)HW.7KE.=L]X-E\ E-$5>/P LIG*?\K:N[ZQ,P5'K:]/4V>I45EA@(XH M@["FV=B;8(#7H#ME!$'H!@D6ENT\+6BV;=H1Q#5W/>GM4A)KV.?/-OK.X M \_E-P:X%%M@<]%W"3R9ZQ#9& $S=?R;'*=I1D1(RL25\.4N PD&(96^#B?+ M,F3*\T$K)J[#:=M)M8:%? *8)<"OX6YU=*X#;UL8S>S@$W*K4*\^H49)001? M78%P%0)/GLG6G)@>)2![.2/F8Q\]T+/ME!VSF(0H W;J.LK9@D5ET;@@;O=R MH[%]$^W4G+R$N$3KR6H^ [#A\1]O8+5@6&+3]=C"%<>C MQ7W[MS^#+N^;H?6?:R$7YT:;HK8[]T6LP#Y7#%F1J2!I[_Q<:%/(U(;P";() M7&0P+ NWTUO].2T ^J<&-R61\].@3<$S,(E/"!+_FT$RU":P_/=9PA?E4^YE M#*C-,/W@+Z8V1O+*"_*"2XOWV8"L8&*&]2^[A+769)Y#WGCWS@;D%ID9K!]W M"5:!6;P';25\\07VVLQ,CP6>.,AGNNJ MO!/3EUT<5H4==*4XS:@-D?;X!,C&2I[#VRGHM4[0O"0U!-;CPR)C^WB_&>H4 M ;/$E:,VA-;C$R4;*_F-KK+XT:8;H@8C0\P]/I):TW8^P2^Q09F NME-DI"' MN]= )HB* R-Z_SZACRM6EWO*4SDMH:>W30K\!,^#&)AF\-T!T2"$,,*E#!M4 M%%R+D:?74 8PKJNQ?TL1"8'8!?M=>A3^NT 9E!;JEL]7&QZ>7F*93UU[@PT_ MBRN13M.LJA*%_H31-:![5/K!N6S.ZLD\O;\RG*&F9O%J-]=<5\K+[0L0/J $ M9B^&L]&4@:?W6Q93T-VV?N8U,AS%8E)/ MHT %AJKQJS*/3R/W!BZJ=?5JVJQ**H=23N%I &B.H,X87GD6JFKG0<+5R\75 M@X7M'QHMKV&&THC?>U?EA$Z>0Y9V>D.\Z\ET"D-5V>HMR^%ZG7!C=SZ_T?;8 MQM$YQ6LOLO] EDA,,XQ44& MR7_4E$&+=-CKZ2V:)6B*0KIK+>]#B+&OTQBU2F:VY/_8E;]B1K/S M&^R"%;]@Q7!0K;H5U5IB?^J*S16,&T0F459'4ZZ#-UVYA'DN@\BF/[1H27K0 ME;2F_T? . 0@B0+!UG(@N[9?)A.+?,@;MR8+N@>0@XA9W41Q)4M:4K[M2EE1 M!7Q)O4&$I$'K*.]&K2T1WW5%7-($[2A^$ 'K^MG$V[!<9+&,[[LRUF0!&:5! M13CPH%QF^8A%_,"/1TH15"3#&E&8*NJ@21Z4],.:&L[H M#V0[2U/$DYE0W$/.7U5D08-N4#''C]$%"2*_51"6=1"T>Q@VJ$'X!ZT)_BT) MB:\%*,FE6G'>CM$RV3O4'@27RB#SD'.)YD%F\*K^T]"5P*L(\HZF#TGTX/QF M11.\*JF&%K$13*K$Y%QG@VY;HDJC497@G$-5QJ3;LWH[.%5IP'E:+D3=EM2= M6%4E-.=HNQ'KMF1NA:XJB3DOVPY@MR5O-Y)5B/R6\[1\/+N] ;T,;%42RRK_E41B73GO6[.CRK89TE^6 M(43%='O*T80)ZIEQCN:T-D>]()TE)\\AQ/AJ>HQ8@1RLU)=SVDU]:1^EUZY[ M6:U[* G*CFC#NJN&'7I+IF&9(2)-KY)O=$E;Q#"O]G<@E*766#/I+QF(=7U6 MOA 96YK].$M8=J&J/IBLO>L4 M'QM,A*IZ"M4(1M0A*KZEK2S\B72TV>E6^%.%9MN M17,4[=;'2/55^APUE;/\EOSCKMB,5NS76QVJ#_-X3GI M,^I>+ZI,JNGC/KD/J> =:Y3E2#Q=S@-D/B[ M5;>A U]=HRJ/HUR$923._ X5Z!;$+(?'5 &NO>L@08L%[Q 4>GL6&5!)OX.0 MF<$4(:Z]:Z^])D(2O7U"B%7&6F,QT-&YWN7:(F9F!W^WOLUO%I5>BK^3;W@I MRB6X6^73;/UR6J#&-: (/)!0E_0JUDEY]R[3*7C5XKP]'2] 7F1L=%G IKQN M7W%4@NAD@3'[LEC]-?'V)5U9M/EA\'6&DA M0'R67)(A&_CE%*X7^%X+L[BGM:0 LN;D.>?K&O6.FW8:;=*RHQ;DN M/]#QU M## *CY)H@N(BA]'OS,0P.GJ$&9C!<3J?IPG+,<=718YSD-#O^95QIC+'@G7' MCE.K#H.ZQZ#J,BC[+!/;<=#H=6N;B6YVOAG*W"6@*$_?(=*KEYP;:?PJ)-_S MW_BU-D48!R6_3GZ_ZZR9O_JKPM[:<4+^@,E6N%<[K9BZWL=L_^G@'C#P*6!: M0YWJ1]22I^L-TDX,J X"OH5CS:]2YHLT*>-)R7O 2F^GO"%=,2\S16M_ M5]_&!:^J+O[NVO]5Y\W6[S_KZ!S5J2NE.H5D*H+87ATYH6MO8H93MU:XF3E\ M6O0KD=F[SF2?<4XZ60-'';GKI7P3-,U,XQ.F$SB%]+,IZT5&2^A6GVI>K:V6 MCM[UFF.(&_=TJ(UU?!RGK1FV-KIF7%RO1)MA;&,IGY"V!M7;.;J6"^D%*3?; M']L1NI&J+O%3]+C:7-%RJ#?TM9<0Q75&KF*#PI>G:&Q0EMR;FQ/:0=#N MP?7V9+B)NF7YVV:52'E4A^IT72WH]S M\ VT[J>;W5K4!K&QE]ZJK>"8%4D^ M2^JECC0H$YB_@[@HP8KC] DDH?W(L>*]6YZA/VONP!@1!VB:]Q_M&+E.(N@% M?9V==@#JZN2UM9I-$/'S-.)#JTQ&8\CU#%TG$_0"O:G=!B_K8A#P?;LE/X.R M1E0E]^HL_FA.:UH)8*:U4_IB[OKE)T/(^U1Y9U8 \D-979D^Q0")J _6E[F=+#@H*L M6? _);"!LTH_K0^*-Q\GF1OYK#*/ESS Z MNL4N#2&%BK\<0K=GXA.*8J")[9]$D3%)Q<7WZO-D(,##0 MT)<,G$QCL$#TM;(_853[/?IY'WR$<2JKD4<8KPZ,LH2IN[=T>2UY34H.BS\#8I-/L1+[,)K!99<.XNT?C MY&Z<)-E-M"ZA=W-.K)D.QV93/R=?0Z\U"OA:,_)N4MKB:F,O7^=J2P>X (A[ M ]TY7 5:IIW.8Q?('H%<^O%'3OE:8A0C3IT@KR6YH MG@^^FE9_ Z\S%*HO'S\H2],T:P:QRNVK'I?&*/MDU[55KT'9K0/[W$"+>^Q!+?C9+JE3QT7U"V-" S M4XQ+&:BX!4UV[+D!M\ZC?#58/?R45_\U!Q=K9UMX?2+'!V7=7UZ3;2=J=-Y_ M-AMI?*%?_B7HK8^P\6.T?##MCFQB "&DWV=<0)SBD(Q_>%O<8Q0A5I#>3%$N M:AE_GP3+7H*??_IX>'#P)5AVQYP![?"6=1@T>Y2;I(JRZ?_1-8W\\O]02P,$ M% @ (H!\6'9FNTO[) @V(" !0 !C=G8M,C R,S$R,S%?9&5F+GAM M;.U=ZV_DN)'_?L#]#[H)$&R >#WVC.>UV0O\'!BQQX;MF;W[U) E=C=OU&*' ME/S8O_Y(/;JEEOCJ%D7*[B!(QC:+K*I?D2P5B\5__/-I%GD/ !.(XM_?[/WZ M]HT'X@"%,)[\_N;[[<[A[?'Y^1N/)'X<^A&*P>]O8O3FG__]G__AT?_\X[]V M=KPS"*+PBW>"@IWS>(Q^\[[Y,_#%^PIB@/T$X=^\'WZ4LM^@,Q@![!VCV3P" M":!_R ?^XAW\NK_O>SL["OW^ '&(\/>;\T6_TR29DR^[NX^/C[_&Z,%_1/@G M^35 ,[4.;Q,_2 O"FI&*]M-'M??[\>3?[:]FTT?+I M'D?E&.]V2W86/=._ALF"H-KX8#?_8[4I%'1=89K +R23Y (%?I)9B)0CC]N" M_;13-MMAO]K9V]]YM_?K$PG?E#AERL8H C=@[+'_IT O1@T>0O#O%,YG($X8 MOKNLP>XQHO9+NWGW?^EUB9YGE,S)I!9X1MO=X.A MC_R(J>IV"D!")"RTMC7$RK6/Z1^G((&!'^GPU4K8'9-LJ@'V*W(UOIJSY8$: ME4QQ8B(SS!U/_7@"R'E\FZ#@YQ1%(5VI3BE-\JS!K4(OAMCWR?0L0H\ZJFW0 M=&B;*8$Q(.0$D ##.<-/9I1\B@XUELYF/GZ^&M_"20S'U.3CY# (4!HG=/N[ M1A$,()"J4*N3[IB_ 0\@3H&$NY56W0U_'M..Z>8N5U!+R^[8N,:(K@C)\W7$ MU!Z'IV43"5-2NBXU1;?3";R/P"$A\FV"U[P[AJAUXA2$IT]S$!,I?)S6W;%S M@>+)3@+P[ 3\2]NA_P1W_I/"+&NT M[% OM OT#"A%0G]/U^)C#$(H TM"U>7.1W?7'>95ANS3@MJIK[#%2*BZ8^\$ MC.E>1@>)$PSO4S8(6W8D[$FH.M0>F+!?W( YPFS+DJF-T[P[AHX?PDOJEF#H M1^2.+L\^[0/0-?H2$,2\@7MPF]X3&$)?8?=9K[,.MVE(?A(ZWG?J8N/$AW0B M2'D6TO3M_G3J!AEWA^Y\NG%*]=O6UHAKI,0.MWT/;I(2@XK4YEPF136*B(RY M3TJ\"6D,N5)*C DHS+E52IR)B8RX6(IFQFEOW)]18D^)UISSH,:CD*CO#>X$ MT"TV(M]\S")+#S*G?[-..Q0NF((PC<#5^ 02?S+!8)(A?34NMK>"!9DXFMV8 M$. 8D6Q;(0F<45\M+*?^>7SZ% !"KL9',(K8;W1E6KOGSAT332N34)E H>*& M? .)KJ:%U";8Y3HENIRK=M2#-Z9I)-K]F,#A#,8P 1=TE'#5 ]-%0KTK9LWA6^IBZW MJ>6-4Y4]/OR(00EWZ28LB"!YOI M7K$?0]\QFC-2B=:$MH]\ @.Z"I_ **6NQA\ 3J;T_P\? /8G@#KC,Q1G7S+D M*DVR? KJ=^A"T<4@YC[L-*%2)36#3G]1DG=BQF&>S5&<']LN M1BX6\B,0@S'4GN/Z79H0['0\!@&#?L'"#77;;T" X@!&,/LRT95LC3XMB[;> M3K/I $8^3<$88 Q"RDSN']&EZP+Z]Y2?!.K/-[WNC,2(M/U#*:7Q8SK=55FO M%Q-FDP6QCE9C6+K6HM2+"?97=F5JJNDL2V'1-GCEGHRA<)4/=_CHXU";?6D/ M)MBN.#[LF_@)X 2%F$L&+G)IG_!5QC&.@O19V,8D+\&T 2.A8UFDS[ MZP>HGQ>+=N8%:O%^/G^YKL:_9B9,+G<7G]:=Y.UP.+ZWE**IV8.R+1-6M% M9:C?I!Q/:5=X""]!SLAI,HB69Y0 M,5!5H8M>8)SLTJ:[19O=U@[,\[T8;"=$,Q]J,MVD[H'C;*2=&9C=LX1]+7;K MI.9Y]:-(C\.,P#Q?,4H.=5DK:7JU23#VTRA9VRA+\CK/(=M((=L_+^B/-;[! M$_VD"4%80>^5'?3&:_L66V/\G3KCWB^U_OYF5A#)]9.:$.]%0BP[\M#8 MJW;5%_LJ]U%J\ARHRU/T[<'8J_;^5W^.R&]>,4@A9REIA(*:>!&[9H9P*&E2_@7P+Z94+M[S3*1J.; M0.Z8EIR-,9I)55FH#0DEJ.J6,O+&0YA:TN]O]MXN>8D0_P8H MM^UE /WP":I86#M9I_"U>ITRN.HH<* 2R=R"G"V,5M@\*=Q8'C: MXF'7:#KJ'+;ZAQ\'$O'<0'*>G5O=#L,P4YD?7?LP/(^/_3E,_$@&B)#,P*3J M'!VY %RHK&%UPR)9\3(#5092>_M1VXKM&#H"SKG[D#58^!]";9[;:MO1@1TX M-%SK5I:=6\D:*4L"%%:;N@]"*\?R MN@2=$Y*"\"3%[ X)P!"%636BS'0:*0R2)4JK+^<17%,D'LSO'8,Y7QPZPEG4 MV5"!ELK$0_K ,:1SBZUDQ)2I(>&:\[FMJZ&B+)&(A_$'QS NC+43D 5]#15E MF4@\F#]6CDAV5X2EK/SLZ_BD42&K=ECR07180NJ');0GK^C*Z"&/ M["P3$A973S&@/Y247HW4Z$&57B&M&ON?5MDO.F.ZKG3G+?OSEAV:%&JU_E:- MZ\^K7"]:FV2IK1Y7E:V]MZMLU2A,LB:ORE5C=&^5T9+^[U[6@T<_M[Q*'V:U MRBG;5>-XOZG:DLPKZ4QRR2OF56/RW2J3!96W)#/)8WN-KQJ'[U M@MPKZ/5R4WR+"LB5N.YL1T5U%Z5W,OIC2J:5V&L MRNU^8Y.%6M6!:53ZLQW-A;ZQYK3^Q*:JI5.7[7V%^;#FQOQLRK MN%9CN+&95OW9GEA5J[Y68[NQ7?(\Q;Y$$!=GJ_'>W"!7?;"^F-ZL*%M-J,9V MJ;/K%T-XBS'^9B?GF6Y"81HD[)D3//,+-*"Z]S0#*>91F^2L1V M$K%UT%#$L:D1EY*S30/I8^2F%4%+(H_WD^FV/TD!]8RE)5E+U<&2M,P71FF)Q$;6V%%_ZP90Z$/BY*K$,1P&1K82#]=&3"[8$JU?4I7-TIE([[4FO>^X'&-% O:XFNUU>;CTGZ2: MK389O7=.LPWV>)I]WZMF%^EP7P&:8'\^9?4:^/N=H/F@]C^IV*:O'\A@R1?& M*G?+Z./G'++B MAR5BQ2]&)_]J@:?XX\F_*+O];P]R2T>M;/)CQ-:^78]1'%!1\N(X+'?DZ/D( MQ,%TYN.?XF"PG'(XNXBR2-R-WAW\2H9EH4,YI9T L#((,NS:%>%2Z-<<>$YN M468!=C3<6QQ M-R"-X+8V'^U]'!1( B&X"'U<%Z%F?=H?/T:G3RQ[)>.#JW':KM%LM&^I/(>N MIOG,R4Z6A9G>5Z D.@E>('R/ !K]Y\;W*H<&PN)G''[)$? "I([[>QM M"-3 7+SUP734L3M.28)F #CT?._P?PB7#O*JA M67"_V6XX6QA' !X&W59TD"#PS9]ESQM6V!.%7P7-^X^#"Y2*5#AV(P#>%0). M;CT;HV1FGVG]YBD'%GWPU-OTORLH&302LLM?^M<]@!-J\RKFQU8J'"Z:C?;Z M_H)<4Z/2$6MBV:C/0NY$.NH=85CKEK?F5$K;:-DKY6&HST+ MR1!KJ7:59ZYRWQM1[J&*8@]+!C\-0ZDU?KD*_61$H4:U5_UR>V)] LJBR(0YNBFB&\V&H( P/KX]N MH24+F8FI[ 0W%=2N@I.[P.TV!.N\"W #S 0W'EI;SF<;8TK @^)3Q9P8*6<"N:(*-XF M:-Y_Q%.HUH;V^2+:CGEVA8&3^U$'.#FZ_1S[>((HLV=LC9U*;J3( M7GU\/PY]'!92_\'*(<7)GSX%49H58:-[-?UO2!UL/M!K=#8@N->6CAL< MJ$C>^[-JBV.5$TC\R02#2::$JW$A9E%(><%]K41SXZV LCM6H[G>(?O-XKV# MHE-+-9DYDC9P;QJVG-+.[.7P)2G,+*9RIB:S*EPKTU1%)^UST:&:S'=P1E>2 MJ_$=]F,R!OAJ_)5%,22GMP6U$K&U UTE?)"^0,Z%8"52)= [<>S ,BE9/@])X,Q/ M0%B^;GH>GSY1*R=7XR,81>PWPI.(QNN_U9,(-D;^_&\YRO(151A[^4"L83E4 MY81BJ2(#:JB?L4C>PVR\#[QZG%)][-(HVTOT*F]#?P.)$*'&4\%5A"K]_-V+ M0=(7 +5;1>T)9D*A&L\)5X62/$!M]Q",*V]C&=)(+;RP?1"F@*?.:Z7"'IPY M(%.'4O1VJ8*VG#\N>RU/F*I@M7W)=/N2J3.'9MN73%_72Z87U->1G;8LVU@Z M$%O_4SCNR?5]_WA@]F3 \S"Q>B$8QH034?4>S-T8-:DTW%"O>S[G5RR\]2RFLU:Z>^V/0Q5Y%"*+ MO3^ID\[2B(7X3L <@P!F,5;Z[PAD:H[9S1B+R^PT(S$%$-3R(Y=(H'!SW?98@B]R*P^KOWZZ&<-7"MA:"[?S+L\*SD?=[ MHB!UWJF7]>HMN_7R?FU'J04B*\2IU:AM1ZH%7"K'JN5].!.MUH&4&Z]6U9GS M$6N!($?/>87=R">\1TGD*FUVXD $6QD]U>(!7%TYY%\(N%_RSBHKR\*AVAW9 MB7&O@Y8RWB*-N13WM@6ZR_'PW@W#T1CY-?V24HC&UII9BI2O.Q.16)(AK=&2 MZ(^,LO>\ULV]+261G(L ";BN!#"J@8JU0.7T];)@%@GIW-Q=9?X;2!:E&-B% MJ4>8?;1PH%:A'B"XRF(Y&-?AQ#@DX9S]U6 '/Z9A(81#9Q3]V Q/G^;4F0+B ML,T[4=BFZ,@K>^H_8?("Q9,[@&VS.CU3 MD,# C]I%$M8]X8GD_5+KN3<1+_TDQ;1?0#1 $^93+WNT!R$;=2>IBR)9&AH) MU(L^ZIQ;6!>.? *#PS@\@5%*=]L_LH+?=-=] -B?@&,TFZ'X=DK-AURE"6&E M;.D"+@10F&Z=#9<%MHL!O7)$KQC2R\?T\D&]RJA] 5QFZ%\#G#&AAG$C(7N1 MZ#\'.)?&)LZL4O01&",,%G5JQ;O 0>-XHK[4$.+E_7EYAU[68__K*#67.8K9 MYQV[%+ HP9MM3D<@IJ,*UYL#X1G%LO/\KD I:+G[>;\40_RM?\%/QV,0,!M: M2'U#_>4;$* X@%%Y1"J0O.&P5"5?]%Z5F@W@U4=P6F[YAGH@]'7TE6!KJST! M>:T%RF#Q!16'%]"_IQRRW5)H!T(WJ>PX$[UP8]GR7>F\+Q-H+ESB)?F@X2RU MKE35Q=C*]^,5W2#H^/&$+:I9:5NZK#[Z.%0Y:50BMO-=S&=-+N$5UWT+A\Z-8)?(X>I%'F *&.WC&KN(SY)5N*]JW-;17WDLX4 MI,@[=\ES:,UC)X2Z^]*29O![TZKXINM];8R5_D)H/^U$0>TJ. UIO]H4JF'M M6QO Z>C^=4Y5@F,_*NIY% 5^SF]N93N9A-"=/4V:&J(B"7>'L[9J4A&/,0AA M4MT4)#6Y^20#V]^DPK=,,:> 4EDVI826RFY+=:^ E=O;G"G(7-[L.H;5T>VN MK$\GV]WJ[6PEWZA.G=5:;0W>N4!86Q79NVW9PSA- MMZ?1)SM@KA\H7DM"'N36IAY?_G6. 8:'HD06Y\+&(DEG,,D,DES%W\E:QSBK M?;PD/%MEHCLO[\]F=N=M@H*?1SX!(162:OJ?"#;M1ZZ$4BY+$2GPSF3[F7(_+C%)@R -I"$LEOJOF6@7!2RJ9S> M%6AI:*O&@-AN0C'/GUKCR)(9=KJ/,1BCSWHN+0ZI'4 )B6W60 MM?#2%(>[]*V+8NLDN0798SLR*&C3MI:V*ACKSA,N[]Q F+6I\A7$ /L1J^,9 MSJ@>29)_/RM.%B5R6R6,UYDNZ@)QPRW6L"R\6!"V.[F%"'PPU>BM53CMYQ-0 M1PD*9[WV'EE;N4]^2$@ZRX*%XBN)PCODC1OCE5[[OXZ:A)>\>L4_*WF[''&ABWS,[$YN,:J7#VL[(MD^0?/B!446*IWZWRD8N&(IK+XO MJ>DO$U A,&EJ/-OQR0WD.GIN2J8\:](Z.K-#&4(N!9.';H@N!ZX';:P] MALF;+"S>K&\/! H(+(7-3:X62%7NKG6 L"6T%S6VC5!>\GO-[" M!6VM.;TJ)+8"[M8P6Q&]\WB](FIG*,5ZH"TI;$7;;6&V(KE[8?EN P'H$> B M)#"#@AL#)D<=?7X!)B8-J9A6H,+IP8 -]?M\;L%05T;=&FH7"GS9 95O*8.R M=O92''WT9+-\!K;FV[$NN5ZX54N^[TCXIM K9\ W@*%/_WR,X@3[09+Z$2OB MOB^Q=/L,OIZ9X(BNN<&@US%3:B1'8 )CIJDC/V)5 /9+_-5.G>G;FFPR\8MLUHTMNI.]%N"A-H45[45\NB297K\?F;2J8 M-Q$^NC41FCO8/6<'JRBAOH-IFWD78[YB(^Y,?3P3_>1"IOP-()3C@.7\,SW* M4\D_"%^N6G979)4WLLD=\K,4W,J&Z73H\%^XG@9=D8'PA-@PXUEC",>3F]:.9LGK \0$LDYD+,G%:F7DL4AVZ55"AN;&#VJKF!Y)AU*OY*P.PK[3HY\1-PYD-LZN"J0^ZV%F]*J:]H(<\T0,[CO/"% M#8.O<[ UZDT4YV;:6@_2.[F4:[*X-7VCFG4S4GYD>YW-1;W.P=:R-U'< MRTD4TY3>R45=D\6MZ1O5[$"2U+I0SQG"8P MK^L-)K;VO:'NW$Q.,ZF %(/5 M7"4WEG8=_K9V;TZM"FEJO>< L4C_3B/M2>E]F@_[C22@K+=,D^U/MU2?IQG6 M(M PLVT.T#8':)L#U)4%E@>4XA2@>JL7FP'4I@R'@O:J21=N)-VT*K-=W^YF MRZRG,N>^LAF\'D<4'FHY\+8$I4F4J6VE% B M3@71Y+_KM4D*!Z0N[B: B.EM56C3PD1!!.X"9@J7NT?*QS/]Q=K(2'NP58E- M!QLU(;AQ[VYW=(*3RM9"?UIN*_2'T8V@OC/]>^7/+\_/JLO7S^&R"AS'2_])JMEJD]%'YS3;8(\;#K66U;.]B;3.321W$TVMY^IUB0F]OOFO.W3C;:^_3BD590 !?M3[W&P^Y8:L/5^#P. MX0,,4S_BQ\8X35_>=P!?5FX,TRID?\!D>@.B3&@RA?,[=!HG,'GF.F5M LHZ MZ3_V)L9 @)6:/FS'ZFS Z*3+; YJAV*$)Q"#@'8E"F75V_3O[VXPEY!0"+[O MNF[,J_5D[@P^@')X(CJ :VDXVCL8G+9%DG!5?F#-F:1[\PS%F4-T[,]AXD?9 MGDRHLP3P PC/$#Y+65[I.2$I*ZS,=S"UNQKMMTUW%YS.=9/EUE0!SR[+(5ZHE76GFGXR&?I8T\K* MU_E2?OC@PXA]H-*U/+M;86!IDXSX0FW/F*:<.RP\C+)^0=@N-YU0])\"3TN- M_N69B8[<_42%>O2IZO48OF)$3-S_X0_V\LS)F))XMF?WQO0Z>WOV/^S2./4= M;]B]0D*%9:FD_D1V?;3KX5ZH_9E1$\\"AW?CN2IK/M%D[PYT-,H+M;=.M<,S M,VN/72Q.]E!X?2\ MZR%?G@$:5A7/&C^].&O,)R']RBE^Q=H)EL5^^=C:;1?ZXQGSYRX/9YKNQ5)9 MAW&<^E%>>>*&E4R( 3Z,7S7HX56M$< MUW8'>)8@D_]P,L%@XBQ7T9M7[@9P[('Z^\6YGS<@#G"2?:F]1CAF5^H3%J53(G:>MTQ/I=T M-N9_5*\PIMZ9.[7$-$#F5PO3U:*=NF"2#%&ZC! 4P3#C.Q. MA>SZ&(>@[\IA*A,"J3+N7 ;D,<)TA:9?H-1[+]B5X<(E&?7]K:0/C9AW[J2Q M!L\Y73=PL5J<1G &XTQ0&41"LMYKB>G#).>?FVQE+_Z74+/*/J!30GU60LK9 M+RZG(B$;LBNG)B'7I[ &9,Z>M)9%O9F=4B9JND4BQGORZ0P#X*0WUQ5(/59_ M/?YQ M_5W2V8*A'PGO;C;;V2I?JV" ;9QR+=!>_3="0"(J_);]?;3?]PW9S6.$5K=8%.D!Q"DXH_)F1PA^D+#[O\.<_\3%:H[,A M KJVF,Y]?R]B!>=Q0%F_$-ZQ:&D\1/2X8CCW*;!DL#0U&*>4\4("^E%[!*C8 M(&]'K0R0TR=JCI1O^LF*GS,M?$,Q\QBI;J-,9KH7 "*XQ&=PT"%:BW%UIO@_JO.*B_;E!U,#'5OMYCV^" MQ-T =1NGW"6D4W4JGY'8RL-7/B-Q-8&$1466BY4?L2* MU, $O9977Q]^='R MJX0,TCFA7>315-8F#[^ -2-KMQS,5VQ(Y?=UB':6I^/'_MQXM-&X/#V:OR-#G%/X1 ^ MXLHGL.0[;SJAD:IL_>PCRGYL79SC*%>/@ZN693:%P]YQ+0-!M@.$]N /!-$81FE VZ,(MVGR/[T+R*'I_HG;SV[ZY*),/"0]MN10\ MY]YS3U;D5BM9\J&1=9)WXRWZ:2U5LDTVZ5:R;;+):TPVV9;[V);[V);[L ^! M^]&*-6%RM-R'DF7G5$=\*WYM/+%*+ O3+Q4M.Z)0'HWAAP)FAM MP;1[3Q!W(%[NU"1XY7<;^C8XM^Y#6(O'N9+'OKT/L;T/L;T/X9ZM;>]##.H^ MA*7SZH'>A[#DWAR>JQPJNUDW65Y5Q(Y!M(5 HDUYJ]7MB;:NC'@]6]GB4O-O]J M(:S(S]W";6%W ?U[&&6^"1_ 2J/7B^*J$GA0KENTN#T1*G,)KC&:8P@2'S_G MMD1%OH !_38 QP G5'UEB^?*H?[B0?+K% =3GX!K3&DX&56=C_,*#<6<'GFV M=F!UR=_\1N[KLQ&Y/GA8?^AR73D!5!:89&7X2W/#5^-E$@QW3Z?4BL2O$%U- MY?"@_BA/CRI^S_[GGHY ?_/_4$L#!!0 ( "* ?%A+>!;NWF, $W5!0 4 M 8W9V+3(P,C,Q,C,Q7VQA8BYX;6SEO7MSY+AR)_K_C=CO@#O>==B[47J-%5:WM)*Z9WTG-DY0)$JBAT76 5EJU?GT%P^211)OJ@I(]6QX M[1Y5)OA+X(?$*Y'XU__ULBK0,R9U7I7_]LV[[W_\!N$RK;*\?/RW;S[='2_N M3B\OOT%UDY194E0E_K=ORNJ;__4__]O_@^C_^]?_]_@87>2XR/Z,SJKT^+)< M5G]!'Y,5_C/Z&9>8)$U%_H(^)\6&_:6ZR M,T&FU6A>XP?0'\>$_HW_^_OW[ M!!T?.Y3[&9=913[=7O;E/C7-NO[S#S]\^?+E^[)Z3KY4Y+?Z^[1:N15XUR3- MINY+^_'EQ_;_"?5_+?+RMS^S__60U!C1^BKK/[_4^;]]P[[;?O;+3]]7Y/&' M]S_^^.Z'__/AZBY]PJOD."]9O:7XFTZ+E:+2>_>G/_WI!_YK)RI)OCR0HOO& M3S]T=V#'[T_&[]\<_O?O^ MI=FNZ94JG/&A&_:OST1O%2#*0CY@>G_4.+'I,$9 M^]"?V(?>_8%]Z!_:/U\E#[CX!C%)R@^M77\:E=4J_1 :[ TF>96=E_-03[4C MP:=]AS2O,&"H']R$^ZI)BEG@AYK!87_$\VI\IQ>^IJF?Q_-J>J!Y$-B-#-F[ M>M7U6K _7M%_C2#BEX8.8#CK0+(B#!Z8?X$/#&W9?>E5.BJW8-Z\(K+M;&3D M92Z3^H$7O*F/'Y-D33_P_J,GK[EO[;_ZG$$4[6?0KD_Z___K#[@M1*$81K:KRKJG2WS[@U0,F&J,5)NN(FR4NDI.O@VD@SG7!(?ID! M#XFEE@3#*".\*94Z8=1)PV'0#:G6F#3;&PJX6909&WS7;, ^V=[3SQHF3TZ: M(;GE8_IW_.' J-%7>,&RN3J9),7;"^/ M6M7]\W*U)M4SGSZ:/9NC;D@R>IDSI*.3(AA"^J"=4K)30$F9H?X_ANH'=I,U M:0;,I/^U8R7]C[_>4K J!SCY+02KE' 8:T8_1&>%"LVTU=F*,*^;/*7SJ \X MJ3>$M_5!W9"EH3_D9;[:K)0N1O%[J 97PNH:??0CB(97(9HV?BL3MU]_2%[, MS3W^/5ASJV#US3W\$49S*Q!)S2UDX,QV/R3I$YV(D^UP[F2<6A@U0DXH'* / MIQ$&\>CT<<N/^GW.'_&U2-)UD]L;-/,&PRRH?R,%6[G<[2" MT0GD@FY*G:'8(28;-4Z_?ZR>:>UORH9L!6':_]CQI?W#7\_^8V+2\(<03)"! ML&;?_35Z&TM0I@UZ=O[QP^+V/Z*/*:>LDBE4'J%PF]>_G6Q/<)D^K1+RFV'[ MQ*X6]LS S8CQ$8)9)SJ%/('*!PP#-<3T4*\&9==DD?)^4M_B%.?/R4.!S2<- M6O&@APP6T*/S!8TL&')9 $JG"JTXVLG#F1XK.HIE$]BH$=F!F39]#>)@F&7' MZ."QF 849W6ZJ9MJA8EDF/DTW:85E&9N)HRH9E:!0S+$9:6&_OQ/^GS,V_B=^]%T.X_G'[^W+-6 MZ4)4 B&:5P^,-:W\:_1FU4+2-^F>^K:Q4:]+]716(Q.Z:25XT];M!4 U\!25 MMHVI8)AVOO]26=MY(!.ZG25XTW;N!4"U\Q25MIVI8*!VIC+V'CV2"M[6,D2I MM7Q&K;$W/;G@!L MVQ.WMCT)T[:GUK8]C=6VI^:V/078MJ=N;7MZV+8]?UE7I.&#AK9U%3*AVE<+ MKVMA20!$&^M029>BN!SB@G F;KM#];.\;DC^L&&[?X;S I-"R"F<'?AP'J>7 MCLXA9XCZ> @TU(!R5J"VYZ(B.'\LC0L$)\WX7%.:8B?=2 TX^U18'6EXA%KE MN(<(-Z3*-FES3>XP>4H)*)SAX+L"E56E$>^M=*0_%6 MIPEYK!9E=L$X^V3>P-#(!CW%-,$=G5VJ!*/SQ@6=-$MFLIPZK32<2=1]OLK+ MQ^OE/4G*>HG)]?+GJLI,/L=+,R2Q/$P9TLQ!#0SIW+%.*2@T4;5$G2[[-]-& M%8'FT3J(!&?7SYA0[.;(,H-\4 +:8(]HIQ.&0S8+0HEB.WE4/;.-?JIQX&V! M$I/'K7Y'8/1SL,T !:A^'V#P6_2&U@"25O]/9HKFI\K*Y+'U8X%)5:^35'\J+$F$\B$::)T;F?P< MG0!Z3%((!#0?V MW:_1VU\+2:,+6:5P!='K. G-T>T M\F (Y !2<7>D5V%SOTX)#LTN\C)O,,]A=%DV;1(CGL.H/MF*H/0BJ4WY/KU* M"$G"&:8-.>FA#H:B_IBGC!4EM$FM=F6(M%8U>M@B7@SBY4#95[M)&FLZJXE, MT!QJ*GBC;&E# 3!D4J&2CH^$#!Q_=EFFU0K?)R^+3?-4D;S9&ER73C@D.O)QBPHA*HUXVK$RQ'M%.(ZHREPLT/JI,&PR@K1Q3$=\9=BH+@G.BG# MI$R*]O9 >\1Y>7MG=%16K; T"462>T4'G"2';946^)"0SQ5+HY8,>3-E@C\ZD=,)@.&9#*)U$46 M&ZWQ![^#(8@"E+3"I_^US_F/\M3K_DMU_U1MZJ3,[M@(>/>4$'S)&6"GK*(?^!?$=5"OA#C5#GJZ.D2=OS1X-M-L MRC&XYF:0BFUF37!\J6_F$>YQS4([#.V2@%[ZRZT)CG M"ECFWOOWA^7>ZW->LJF>)2_A1"9H=DL5O%%*RZ% =-Z84$F18WR2#2FE(%T1 M-"1/&YS9G^73R 9>GNGA3E9ILB 8KIC0*=9LK6R0I_HL%_KN\Z; U\O+,LN? M\VRCS=.ND0MUI<\(L[O3IQ2*SA$;,OE6#)5E%V%VTC'?@CG+"4YI44I/HA(( M10DUL(X+XU]!D$ )23H>:X7@S"[.5^NBVF+,G=7UFH5#&4<5@WS(D<4*>SBZ M:(6C$\<5H?2J%)NQ'I\D-1UF;I(M?Q1D00A[BXK]^PB),@Z[@+J@<^6.T/H< M*4JI4,LA \1NU:,0B4X+,RXY,(RN67I1.*YE,FWZ5.9-?7OWR6?2.M6).'E5 MPS=,8L<*T3GE@](ZJ>5:Z%NJ5P,Z Q41 OU+.5?L(^;\/$:-\.$=1NAR?(=2 M' S1[!@U$1Z]"NIT#II1NZJ;ZV5[NJ\=Q912P7*YZ2'V^=QDD>A$,..2 _+K MAJV+NC@+,%ZE.X5=E-D9Q594_ VV\Y:/ M57O:SBX;#711JWS8R?0=+JC(HXE6>K%0CL@$LO-$*IGH[+ DY970G3O+;^' M-'$E)DE!R;W(5GG),H@E[,C"Q1LYZH9-%>=ASCA9G(-B=-;-02LGC..ZW"F- MM>&QD^]*\$V)TVK%L/')&_]KW8;L_AUGG\H,D\%&!SMMJT^VYR^8I'F-;^A" M ^O>(C_HEX+F5#]<58TRLN__,V!ZU>%LDY/1"F'$I1$7/^221 9GRCE@E Z7 MCM@*>9>86"L:G5MN^)SX!!F*%X/+[(H/5TV<:G9I<-7NE>IM0)A@HW, /MP@[44M$Y8X6F2G[2 M"R,N#27"C=^WJ_$CW[4K6 K9Q!J38-$)?G_2!E^Z/:E3B,XL'Y3*FY.M#AHH M 3JA[D^:3C9U7N*ZOA-P34EU+#I!-Q%L14BAUR6WYWI MWWD:_!9L,WX*I]^!/X/TJM,4C=1R9P=^R.GT\]GYWS8Y/\O1G^\JA((=[VH! M]J>[D@2(IM7"DN8;G\]0+PG'_5^O,=M*+Q\[[V&<96BE0[I\"^2AL]>(1F>. M&[XIA7IIM'/U!_8:'^@PQ-+*ZF,;54(!O88&X,!K3"2BM[T1ELIK]))PO,9I M1=85Y2+^6)4M%XU^PR ?-O&G!?8XZZ=&.#J#7!'*2]Y6_@A1C>-6!0ZK)M%R M)PE%G^*[)XP;?FZ9T65;VA]7FRI?^QKNJD^)E4FW5-BR@V&761 M3*8JJ;/;"/1XRH/'"%&H(S#_1E,#TQJ+GRA1I1#N(%'3X; M1E(V"17"B[OKY<>*9 ^TGO17Q$W2P6Z$VR'W%\#UHM'9YH9/SJ_4:J#%#WR*JI'^D7J%[7.Q:H1RL$X0N^1KZ'Y3WSY@L'EC,8-I,+%7\'H(S6EB,(=*/ MT?F@0R2[#/8 W:^=5.B&/JO2#9M^L6P5"@O&/X=J9A6HKI6'OX%H9 4@.;NQ M$.$Y00(W\()^.&,?ORB21P7\R>^AFE@)JVOCT8\@&EF%2$K[TLD@)A2KF<]P M38<2'K-JLF,D%KS1%2"EMA_(P** #$S/A(%L),=^BQ_;T/^J[!?;!C>FD0_M M^HVPIV.!4A@$:5P0:D>+H=+N=FLD'BW**)QIP^B5)+Q^7*7=/N"C8C:RDM#L4E7!HMN@! M3_DB2X)BC!:>EC-< [4J<&AS_LQFYW2:Y&CL0#XF>238)O[TPF I-$7HR"*N MAIA>)";=8))7&9UF$QN'),G0[-% G?)F(@:*,6IL6JX(<<3EXY/DO,R<*-++ MQ2'(!*::'JT00'*,D=FH<ITDAL%S0OTW/9"VRH0FBA3LEB20( MBB@Z=%JR"(6.,UPE*F'^$R?$C2X#R3ADD:"JJ=*+ 23*%)N-)DP^"DE.-X2, M4.M''+UHL$-9"]C^?%8C!X(H%G#2J:T0'Q$ET@C$PTRV%WF!/VX4,1]JD5#< MT('K.#']'007-*"DN]-<##$Y) 2CM'QW2E V+(I1:\Y4+"P#U"#'+!C+ &*" M$IBM9'E0:A1&GU#.1I+@L,_SR'WBKM4N2"\L)#-11 [3QIY\0=WI1?8V8E%L[22<6Q\N,0:I=C)"!1Y(Q M,*MS$=(Q*7%3U4U2_'_YVK@05PM'H8<2L)(D(TEX5%'!LQ%&Z""J%&-AW=*5 M'6@HKY)-?@]W!5@!:W<%>/ C"!*H$,E7@,7NB1 *WM:>_H[B!;7@)JV M.A=#7"[2;OQ+@\M:[;X'OP4;V:=P^H&\^P%$ZT[1R#GSV]\#M^8O)&_HET^K MU6I3MJ<\JKA!C5RH5C;"[%I<*02B]4W(IDQH9=%8.# M[JHB3W.6XK1+>JFP M2B44BA!Z@!T;9 D05-#"DG)1]X)]XM' )+@AF)$0TX;@EP Q>[[L>KE4CO8F MX5"DL /NR*&7!$$2*[PI6:C"<3K00$(%<9VXM+FLZPTF7N11J$2BD!:\ADB2 M/$0ZZ4!:22448W+K#J<;.CYNW[U_N,^;0K6XE$6"C4D:PWEK3RW?MO'[Y#G5;@YO]8W9.$Y6:]VZX>JD*3?4HI%8H$!H@=#Q0B(*B@ MQS5EP\<*M:)(R,;(3C4"JS!G\GLH BAA=4T_^A%$HZL029U_U-:17/[Y2_K$ M7I+37$A0BX5V_2J04_<_E %! 0,P^6DC(8HZV1@7$G9#UJ-]$O 8;1+P:)D$ M/$*HTT"NL^*%"'4+UT_%/ECHDE.:)0.30H#Y"D_%**@J*+'I_49 MO0K:Z83.:,E3G%V6RXJL^/RFJDR*S?-B(&0OL<=",1A@$ MG5P0:D)GF-+Q;TP+=6KM3E@4)GVNBDW9)(3?)2T0_R6(.3YD"QBP>^+JV$?3DUK92%A!GC !U=[C;G!^[ MN;'0BG3%LL'LO8C\&9\E3=)BT]JK$P]]J=($>GJ;4B4+B$)&@-K[D[T.2Q63 M=)R*EC*&G-*IUF-EB!*?2(5/'"-!E'/']"* Z*'"9<@@0U G&X4+=ZND*+IW MT[4V3:3"4P&:[C.(C+!J^TMQWL M*J$8Y J^XY%-'@2;'$%..<75QHMKKHB89LQL1L/D]OHIWD@H\,Q8 7 R,1Y( M@."(%I9N6CQ\*R!.[KS-0Y&G%T65Z'=91C*!,^;)\";)\G8"@!@@H]*ER.." MB$M&:?^3I/R-;-9-NKTA58HQB[*J>V]EVW]SU [+&2^3QFQR4@7$,Q^\&@;N MBD"#,HX&(U;,S3P6-,ZRN57I;W=/":W ZTU3LQ&4 M/O@AN5 A\O.!@P.60P M: "BG@-,W8$#UT1<]0@)9330CK0^JW=9 '%VLKW%2TS8O8-[_-*C80'H@<6(M46@7UDAB)<2^OWRRW1)>"!) M119-@VG7X$%,ZML&)N%0M+,#[GBFEP1!+"N\*9,N3R]N4:N!!BHQ+B3LW@6A MGGG5G!-2D=.*#M^I@3XN2N'?9K$9(#_3HM, 02MGF(;'6Z1 ,L2+0;MRT*^L MI-#.JB7_14Y6EZI-S7'0':/_RU'U>NE_U@.F MMC!P*A22:VJ 0U:-)<#P1PE+\E-W=^?W=T!8T&Y&.I%!D@W/"0U3!\,P!I#02MBJ(]#I'J,3[/1J;Y>FJDCOF7_+FZ713-]4* M$^ZYK21ST@SJY=Q-&?DXNQH8YKECE5,J"\UVB(W.N\ORF8*MR)8BUQ@[%@G) M)!6X(66&OX/AA@*4=.#0BN2XAN%]>(C;:**H,4XE&)(1>J!#7LA28-BAA::. M.DQ'$_+H/'&A2$1V6(D1CQ--U23%E>LR39<[AQ6R9TZDS\^\G=_1_^%M??KY M\U_/5^NBVF)\BQOZI;PJ3PG.\F8PT:*-H62!MW8(?LPTB3''4S6ZGYF'5XKS M:4N@T^2V")3R,@;SYNC.Z(94:TR:[0V%WM#U)EMKKME^J'XJ8U8)Z:I

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form10-k_htm.xml IDEA: XBRL DOCUMENT 0000766792 2023-01-01 2023-12-31 0000766792 2023-06-30 0000766792 2024-03-25 0000766792 2023-12-31 0000766792 2022-12-31 0000766792 2022-01-01 2022-12-31 0000766792 us-gaap:CommonStockMember 2021-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000766792 us-gaap:RetainedEarningsMember 2021-12-31 0000766792 2021-12-31 0000766792 us-gaap:CommonStockMember 2022-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000766792 us-gaap:RetainedEarningsMember 2022-12-31 0000766792 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000766792 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000766792 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000766792 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000766792 us-gaap:CommonStockMember 2023-12-31 0000766792 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000766792 us-gaap:RetainedEarningsMember 2023-12-31 0000766792 srt:MinimumMember us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0000766792 srt:MaximumMember us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0000766792 srt:MinimumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0000766792 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2023-12-31 0000766792 srt:MinimumMember 2023-12-31 0000766792 srt:MaximumMember 2023-12-31 0000766792 country:DK 2022-12-31 0000766792 CVV:CustomerMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000766792 CVV:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000766792 CVV:CustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerBMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerCMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0000766792 CVV:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0000766792 CVV:ExportSalesMember us-gaap:CustomerConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2023-01-01 2023-12-31 0000766792 CVV:ExportSalesMember us-gaap:CustomerConcentrationRiskMember us-gaap:GeographicDistributionForeignMember 2022-01-01 2022-12-31 0000766792 us-gaap:CargoAndFreightMember 2023-01-01 2023-12-31 0000766792 us-gaap:CargoAndFreightMember 2022-01-01 2022-12-31 0000766792 CVV:EnergyMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000766792 CVV:EnergyMember us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0000766792 CVV:EnergyMember 2023-01-01 2023-12-31 0000766792 CVV:AerospaceMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000766792 CVV:AerospaceMember us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0000766792 CVV:AerospaceMember 2023-01-01 2023-12-31 0000766792 CVV:IndustrialMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000766792 CVV:IndustrialMember us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0000766792 CVV:IndustrialMember 2023-01-01 2023-12-31 0000766792 CVV:ResearchOneMember us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000766792 CVV:ResearchOneMember us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0000766792 CVV:ResearchOneMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredOverTimeMember 2023-01-01 2023-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember 2023-01-01 2023-12-31 0000766792 CVV:EnergyMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0000766792 CVV:EnergyMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-12-31 0000766792 CVV:EnergyMember 2022-01-01 2022-12-31 0000766792 CVV:AerospaceMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0000766792 CVV:AerospaceMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-12-31 0000766792 CVV:AerospaceMember 2022-01-01 2022-12-31 0000766792 CVV:IndustrialMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0000766792 CVV:IndustrialMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-12-31 0000766792 CVV:IndustrialMember 2022-01-01 2022-12-31 0000766792 CVV:ResearchOneMember us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0000766792 CVV:ResearchOneMember us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-12-31 0000766792 CVV:ResearchOneMember 2022-01-01 2022-12-31 0000766792 us-gaap:TransferredOverTimeMember 2022-01-01 2022-12-31 0000766792 us-gaap:TransferredAtPointInTimeMember 2022-01-01 2022-12-31 0000766792 us-gaap:LandMember 2023-12-31 0000766792 us-gaap:LandMember 2022-12-31 0000766792 us-gaap:BuildingAndBuildingImprovementsMember 2023-12-31 0000766792 us-gaap:BuildingAndBuildingImprovementsMember 2022-12-31 0000766792 us-gaap:MachineryAndEquipmentMember 2023-12-31 0000766792 us-gaap:MachineryAndEquipmentMember 2022-12-31 0000766792 us-gaap:ConstructionInProgressMember 2023-12-31 0000766792 us-gaap:ConstructionInProgressMember 2022-12-31 0000766792 us-gaap:PatentsMember 2023-12-31 0000766792 us-gaap:PatentsMember 2022-12-31 0000766792 2022-09-30 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2023-12-31 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2023-01-01 2023-12-31 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2023-12-31 0000766792 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember us-gaap:ResearchMember 2023-01-01 2023-12-31 0000766792 CVV:TwoThousandSevenShareIncentivePlanMember 2007-12-12 0000766792 CVV:TwoThousandSevenShareIncentivePlanMember 2023-12-31 0000766792 CVV:TwoThousandSixteenShareIncentivePlanMember 2016-12-09 0000766792 CVV:TwoThousandSixteenShareIncentivePlanMember 2023-12-31 0000766792 CVV:TwoThousandTwentyTwoShareIncentivePlanMember 2022-07-14 0000766792 CVV:TwoThousandTwentyTwoShareIncentivePlanMember 2023-12-31 0000766792 srt:MinimumMember CVV:TwoThousandTwentyTwoShareIncentivePlanMember 2022-07-14 2022-07-14 0000766792 srt:MaximumMember CVV:TwoThousandTwentyTwoShareIncentivePlanMember 2022-07-14 2022-07-14 0000766792 srt:DirectorMember us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0000766792 srt:DirectorMember us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000766792 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0000766792 us-gaap:EmployeeStockOptionMember 2023-12-31 0000766792 CVV:FiveDirectorsMember 2021-10-11 0000766792 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0000766792 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0000766792 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0000766792 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-12-31 0000766792 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000766792 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0000766792 CVV:CostOfRevenueMember 2023-01-01 2023-12-31 0000766792 CVV:CostOfRevenueMember 2022-01-01 2022-12-31 0000766792 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0000766792 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-12-31 0000766792 CVV:SellingExpenseMember 2023-01-01 2023-12-31 0000766792 CVV:SellingExpenseMember 2022-01-01 2022-12-31 0000766792 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0000766792 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-12-31 0000766792 CVV:ExercisePriceRangeOneMember 2023-01-01 2023-12-31 0000766792 CVV:ExercisePriceRangeOneMember 2023-12-31 0000766792 CVV:ExercisePriceRangeTwoMember 2023-01-01 2023-12-31 0000766792 CVV:ExercisePriceRangeTwoMember 2023-12-31 0000766792 CVV:ExercisePriceRangeThreeMember 2023-01-01 2023-12-31 0000766792 CVV:ExercisePriceRangeThreeMember 2023-12-31 0000766792 CVV:ExercisePriceRangeFourMember 2023-01-01 2023-12-31 0000766792 CVV:ExercisePriceRangeFourMember 2023-12-31 0000766792 us-gaap:RestrictedStockMember 2021-12-31 0000766792 us-gaap:RestrictedStockMember 2022-12-31 0000766792 us-gaap:RestrictedStockMember 2023-12-31 0000766792 2022-07-01 2022-07-01 0000766792 us-gaap:IntersegmentEliminationMember CVV:SDCMember 2023-01-01 2023-12-31 0000766792 us-gaap:IntersegmentEliminationMember CVV:SDCMember 2022-01-01 2022-12-31 0000766792 us-gaap:IntersegmentEliminationMember CVV:CVDEquipmentMember 2023-01-01 2023-12-31 0000766792 us-gaap:IntersegmentEliminationMember CVV:CVDEquipmentMember 2022-01-01 2022-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDEquipmentMember 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMaterialsMember 2023-12-31 0000766792 us-gaap:CorporateNonSegmentMember 2023-12-31 0000766792 us-gaap:IntersegmentEliminationMember 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDEquipmentMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMaterialsMember 2023-01-01 2023-12-31 0000766792 us-gaap:CorporateNonSegmentMember 2023-01-01 2023-12-31 0000766792 us-gaap:IntersegmentEliminationMember 2023-01-01 2023-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDEquipmentMember 2022-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2022-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMaterialsMember 2022-12-31 0000766792 us-gaap:CorporateNonSegmentMember 2022-12-31 0000766792 us-gaap:IntersegmentEliminationMember 2022-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDEquipmentMember 2022-01-01 2022-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:SDCMember 2022-01-01 2022-12-31 0000766792 us-gaap:OperatingSegmentsMember CVV:CVDMaterialsMember 2022-01-01 2022-12-31 0000766792 us-gaap:CorporateNonSegmentMember 2022-01-01 2022-12-31 0000766792 us-gaap:IntersegmentEliminationMember 2022-01-01 2022-12-31 0000766792 CVV:TantalineASOfNordborgMember CVV:CVDMaterialsMember 2023-01-01 2023-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember CVV:CVDMaterialsMember 2023-01-01 2023-12-31 0000766792 CVV:CVDEquipmentMember 2022-01-01 2022-12-31 0000766792 CVV:SDCMember 2022-01-01 2022-12-31 0000766792 CVV:CVDMaterialsMember 2022-01-01 2022-12-31 0000766792 CVV:TantalineASOfNordborgMember 2023-05-26 2023-05-26 0000766792 CVV:TantalineASOfNordborgMember 2023-01-01 2023-12-31 0000766792 CVV:TantalineASOfNordborgMember 2022-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2023-08-08 0000766792 CVV:MesoScribeTechnologiesIncMember 2023-01-01 2023-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2023-12-31 0000766792 CVV:MesoScribeTechnologiesIncMember 2022-12-31 iso4217:USD shares iso4217:USD shares CVV:Segment pure false FY 0000766792 P7Y P10Y P1Y 10-K true 2023-12-31 --12-31 2023 false 1-16525 CVD EQUIPMENT CORPORATION NY 11-2621692 355 South Technology Drive Central Islip NY 11722 (631) 981-7081 Common Stock, Par value $0.01 CVV NASDAQ No No Yes Yes Non-accelerated Filer true false false false false 48002094 6824511 None 688 Marcum LLP Melville, NY 14025000 14365000 1906000 3788000 1604000 2170000 4454000 2538000 852000 797000 22841000 23658000 1529000 12166000 12596000 9000 119000 9000 10000 35025000 37912000 1203000 1454000 1765000 2591000 81000 77000 597000 4908000 4042000 8554000 8164000 268000 349000 8822000 8513000 0.01 0.01 20000000 20000000 6824511 6824511 6760938 6760938 68000 67000 28695000 27712000 -2560000 1620000 26203000 29399000 35025000 37912000 24109000 25813000 19038000 19186000 5071000 6627000 2596000 1906000 1632000 1216000 5451000 5328000 -162000 111000 9952000 8450000 -4881000 -1823000 577000 162000 23000 8000 1529000 42000 -95000 91000 15000 687000 1603000 -4194000 -220000 -14000 4000 -4180000 -224000 -0.62 -0.03 -0.62 -0.03 6788 6734 6788 6734 6723438 67000 27277000 1844000 29188000 -224000 -224000 37500 435000 435000 6760938 67000 27712000 1620000 29399000 6760938 67000 27712000 1620000 29399000 -4180000 -4180000 41320 1000 907000 908000 22253 76000 76000 6824511 68000 28695000 -2560000 26203000 6824511 68000 28695000 -2560000 26203000 -4180000 -224000 -162000 111000 908000 435000 792000 867000 -1841000 2342000 -566000 -368000 1921000 1313000 -716000 -1529000 1529000 47000 301000 -154000 293000 -679000 832000 866000 2392000 -206000 194000 312000 597000 418000 665000 53000 10000 -133000 -708000 76000 77000 1772000 -1000 -1772000 -340000 -2286000 14365000 16651000 14025000 14365000 8000 1000 24000 8000 432000 <p id="xdx_803_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_z3tMg98pLrA1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 1 – <span id="xdx_828_zpKn9KBfKml1">Business Description</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CVD Equipment Corporation and its subsidiaries (the “Company”) is a New York corporation. Its principal business activities include <span style="background-color: white">designing, developing, and manufacturing a broad range of chemical vapor deposition, physical vapor transport, gas control, and other equipment and process solutions used to develop and manufacture materials and coatings for industrial applications and research. Its products are used in production environments as well as research and development centers, both academic and corporate. </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We conduct our business through three reportable operating segments: i) CVD Equipment that supplies chemical vapor deposition, physical vapor transport and thermal process equipment; ii) SDC that designs and manufactures ultra-high purity gas and chemical delivery control systems; and iii) CVD Materials that provide products related to advanced materials and coatings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zs4FqB3Hm35" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - <span id="xdx_82E_zEyDo6MFjX8a">Summary of Significant Accounting Policies</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zrki3aQaIsH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zHa4pWjJgTng">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--LiquidityPolicyTextBlock_zOzsrKfLdOm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_864_ztxQH9KtTiaa">Liquidity</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At December 31, 2023, the Company had $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zoT92Aoy1Qc1" title="Cash and cash equivalents">14.0</span> million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of the accompanying Form 10-K.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zZzI82UYxsFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_868_zpFOVRJqSdvk">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In addition, certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net (loss).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zpngO4VxvY3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_863_zXa7ZnUa3Syl">Principles of Consolidation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of CVD Equipment Corporation and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p id="xdx_855_zUMzYVr3sZLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_zVyWiev3tKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zquej73hHBo1">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s significant estimates are the accounting for certain items such as revenues on long-term contracts recognized on the input method, valuation of inventories at the lower of cost or net realizable value; allowance for credit losses; valuation allowances for deferred tax assets, estimated lives and impairment considerations of long-lived assets and valuation of stock-based compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zEvPahY1j0W2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zPlm82Ww8ixl">Revenue Recognition</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers (“ASC 606<i>”</i>), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606<i>,</i> the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Over time</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company designs, manufactures and sells custom chemical vapor deposition, thermal process equipment and other equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that do not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognizes revenue based on point in time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the over time method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. <span style="background-color: white">There were <span id="xdx_902_eus-gaap--CapitalizedContractCostImpairmentLoss_do_c20230101__20231231_z4mSBh7oMBmf" title="Contract assets, impairment loss"><span id="xdx_90F_eus-gaap--CapitalizedContractCostImpairmentLoss_do_c20220101__20221231_ziyNhujAodn8" title="Contract assets, impairment loss">no</span></span> material impairment losses recognized on contract assets during the year ended December 31, 2023 and 2022.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because we believe these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide us with some measure of assurance that the customer will perform on its obligations under the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Point in time</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the year ended December 31, 2023 and 2022, all system equipment sales were recorded over time by using an input method.</span></p> <p id="xdx_85D_za4enY5UeXD1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zQBkfEurwnD5" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_862_ze4ZACQK3Xki">Inventories</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Inventories (raw materials, work-in-process and finished goods) are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value. <span style="background-color: white">Work-in-process and finished goods inventory reflect all accumulated production costs, which are comprised of direct production costs and overhead, and is reduced by amounts recorded in cost of sales as the related revenue is recognized. Indirect costs relating to long-term contracts, which include expenses such as general and administrative, are charged to expense as incurred and are not included in our cost of sales or work-in-process and finished goods inventory.</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated net realizable value if less than cost. The Company evaluates usage requirements by analyzing historical usage, anticipated demand, alternative uses of materials, and other qualitative factors. Unanticipated changes in demand for the Company’s products may require a write down of inventory, which would be reflected in cost of sales in the period the revision is made.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--StandardProductWarrantyPolicy_z5GhTPNJfnRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zTnpxyzF6a1f">Product Warranty</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--StandardProductWarrantyDescription_c20230101__20231231_z3CPknbPO5Ih" title="Standard product warranty description">The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period</span>. The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zrYXh8MOt4g1" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_860_z3LuxPTGQol9">Income Taxes</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Deferred tax assets and liabilities are determined based on the estimated future tax effects of temporary differences between the financial statements and tax bases of assets and liabilities, as measured by using the future enacted tax rates. Deferred tax expense (benefit) is the result of changes in the deferred tax assets and liabilities. The Company records a valuation allowance against deferred tax assets when it is more likely than not that future tax benefits will not be utilized based on a lack of sufficient positive evidence.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not the tax position will be sustained on examination by taxing authorities based on the technical merits of the position and (2) for those positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of <span id="xdx_900_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20230101__20231231_zkGXh0606yNl" title="Income tax examination, description">tax benefit that is more than 50% likely to be realized upon ultimate settlement</span> with the related tax authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy for global intangible low taxed income (“GILTI”) is to treat such amounts as a period cost when incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zAdstr1iuV26" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zRbaVJj6jW7a">Impairment of Long-Lived Assets and Intangibles</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets consist primarily of property, plant, and equipment. Intangibles consist of patents, copyrights and intellectual property, licensing agreements and certifications. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable.When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists.If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zoqfcnHxrWP5" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_868_zaoO1Xnai0ba">Property, Plant and Equipment</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment are recorded at cost. Depreciation is determined on a straight-line basis for buildings and building improvements over <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember__srt--RangeAxis__srt--MinimumMember_zBni8BT5reC7" title="Property plant and equipment useful life">5</span> to <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember__srt--RangeAxis__srt--MaximumMember_zEGuWbQgTEHb" title="Property plant and equipment useful life">39</span> years and for machinery and equipment over <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zqc6TVS0MHG9" title="Property plant and equipment useful life">5</span> to <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zGErfgL6kkHj" title="Property plant and equipment useful life">8</span> years. Depreciation and amortization of assets used in manufacturing are recorded in cost of revenue. Depreciation and amortization of all other assets are recorded as operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zATzk8v46kNh" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_860_zDbRGpyHxO43">Intangible Assets</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The cost of intangible assets is being amortized on a straight-line basis over their estimated initial useful lives which ranged from <span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zx8SEzFYpckh" title="Intangible assets estimated useful life">5</span> to <span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_z1QMZcLLEDKf" title="Intangible assets estimated useful life">20</span> years.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zWCQtucDoPNc" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_865_z9OuGdJ4jX96">Research and Development</span> </span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Research and development costs are expensed as incurred and include charges for the development of new technology and transition of existing technology into new products. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_z5N6N9HxQn26" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_862_zJ1fCXdDyDj8">Earnings Per Share</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Basic earnings per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during each period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be adjusted upon exercise of common stock options, unvested restricted shares, and warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period. </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGWy1hK21wLg" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_868_za9ivpx9BPxk">Cash and Cash Equivalents</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The Company had cash and cash equivalents of $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zkwfJQbs6Qpb" title="Cash and cash equivalents">14.0</span> million and $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zNFG0MMTCtGh" title="Cash and cash equivalents">14.4</span> million at December 31, 2023 and 2022, respectively. The Company invests excess cash in treasury bills, certificates of deposit or deposit accounts, all with original maturities of less than three months. Cash equivalents were $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zkONF4ziZbA5" title="Cash equivalents">12.1</span> million and $<span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zsxXTPproauc" title="Cash equivalents">11.7</span> million at December 31, 2023 and 2022, respectively. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount in excess of the limit at both December 31, 2023 and 2022 was $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20231231_zBacMmsBSFK" title="Cash uninsured amount"><span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20221231_z01NoEeNwiHh" title="Cash uninsured amount">1.5</span></span> million. The Company’s cash in our Denmark subsidiary exceeded the government guarantee limit by approximately $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20221231__srt--StatementGeographicalAxis__country--DK_zbRj1Ek13g5b" title="Cash uninsured amount">0.5</span> million at December 31, 2022.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zgwzpO8pVhQ2" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zu2pmibBOxs9">Concentration of Credit Risk</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in treasury bills, certificates of deposit or deposit accounts. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company routinely assesses the financial strength of its customers<i>.</i> In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects the best estimate of the amounts the Company does not expect to collect. In addition to reviewing delinquent accounts receivable, the Company consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts<i>. </i>The Company records an allowance for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided based upon the collection history, current economic trends and reasonable supportable forecasts.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has accounts receivables from certain customers that exceed <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zA104u7YpLSk" title="Concentration risk percentage">10</span>%. As of December 31, 2023, the accounts receivable balance includes amounts from three customers that represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zPtP2fFbXBq5" title="Concentration risk percentage">37.6</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zRZvs7SwCpme" title="Concentration risk percentage">13.0</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zbnpJWf01vvk" title="Concentration risk percentage">12.8</span>% of total accounts receivable, and as of December 31, 2022, two customers that represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z1p2BHOaPDO8" title="Concentration risk percentage">35.7</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zzdbXFbbKSXd" title="Concentration risk percentage">30.3</span>% of total accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable is presented net of an allowance for credit losses of $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zwJ2hxRKgXZd" title="Allowance for credit loss"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zIbR2HhUcnSg" title="Allowance for credit loss">36,000</span></span> as of both December 31, 2023 and 2022. <span style="background-color: white">The allowance is based on prior experience and management’s evaluation of future economic conditions. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for doubtful accounts could be material to our results of operations and financial condition.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84E_ecustom--SalesConcentrationsPolicyPolicyTextBlock_z9XbqPgqQGM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zXYfIPkLkcEk">Sales Concentrations</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue to a single customer in any one year can exceed <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_z3WYi4625AU4" title="Concentration risk percentage">10</span>% of our total sales. There were three customers in the year ended December 31, 2023 that represented <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_znvTmxsFAsXh" title="Concentration risk percentage">14.3</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_z8f9jjEx1Cji" title="Concentration risk percentage">13.5</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zOHfSmFT5Ie7" title="Concentration risk percentage">10.9</span>% of our revenues, while there was one customer in the year ended December 31, 2022 that represented <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zFUgiCW6ij39" title="Concentration risk percentage">29.2</span>% of our revenues. The loss of a large customer could have a material adverse effect on the Company’s business and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Export sales to customers represented approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ExportSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--GeographicDistributionAxis__us-gaap--GeographicDistributionForeignMember_zYiY1Pohcef1" title="Concentration risk percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ExportSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--GeographicDistributionAxis__us-gaap--GeographicDistributionForeignMember_zjow0hnQRHjj" title="Concentration risk percentage">17</span></span>% of sales for both years ended December 31, 2023 and 2022. Export sales in both 2023 and 2022 were primarily to customers in Europe and Asia. All contracts except those entered into by the Company’s subsidiary in Denmark are denominated in U.S. dollars. The Company has not entered into any foreign exchange contracts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_ecustom--SupplierRiskPolicyTextBlock_z20dzLwHoKH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_z61GghIdUHJj">Supplier Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company relies on suppliers to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products or cause it to carry excess or obsolete inventory and could cause it to redesign its products.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zmRnlO8SKz03" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_863_zmvi6iXvCxx9">Fair Value of Financial Instruments</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, contract assets and contract liabilities approximate fair value due to the relatively short-term maturity of these instruments. The carrying value of long-term debt approximates fair value based on prevailing borrowing rates currently available for loans with similar terms and maturities.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_85F_zsMA1Au3C0l2" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zBvD6CO0ooK8" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_861_zbEPzCQT630a">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records stock-based compensation in accordance with the provisions set forth in ASC 718, “Stock Compensation”. ASC 718 requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards over the vesting period. The Company uses the Black-Scholes option-pricing model to compute the estimated fair value of option awards and includes assumptions regarding expected volatility, expected option term, dividend yields and risk-free interest rates.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84E_ecustom--ShippingAndHandlingPolicyPolicyTextBlock_zu2hbuhK3Gw5" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_862_zP1fXQd4W1gl">Shipping and Handling</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">It is the Company’s policy to include freight charges billed to customers in total revenue. The amount included in revenue was $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__us-gaap--CargoAndFreightMember_zIDHrwOcIbx3" title="Revenue">55,000</span> and $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--CargoAndFreightMember_zUpufx7DmZre" title="Revenue">87,000</span> for the years ended December 31, 2023 and 2022, respectively. </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zU5efAbh2dLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zVbJBfJqZtZi">Recently Adopted Accounting Standards</span> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, <i>Financial Instruments – Credit Losses (Topic 326)</i>, which require that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the increase or decreases of expected credit losses that have taken place during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The adoption of the ASU 2016-3 as of January 1, 2023 did not have a material impact on the Company’s financial position.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--RecentlyIssuedAccountingStandardsPolicyTextBlock_zyYKFTLXhVPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zsUiVhbIl8i9">Recently Issued Accounting Standards</span> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “<i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>,” which requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate for federal, state, and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, the ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU also describes items that need to be disaggregated based on their nature, which is determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event that triggered the establishment of the reconciling item and the activity with which the reconciling item is associated. The ASU eliminates the historic requirement that entities disclose information concerning unrecognized tax benefits having a reasonable possibility of</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significantly increasing or decreasing in the 12 months following the reporting date. This ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU should be applied on a prospective basis; however, retrospective application is permitted. We are currently evaluating the impact that ASU 2023 – 09 will have on our consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, “<i>Segment Reporting (Topic 280): Improvements to Reportable Segments</i>,” which aims to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. Currently, Topic280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the CODM uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this ASU do not change or remove those disclosure requirements and do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We are currently evaluating the impact that ASU 2023 – 07 will have on our consolidated financial statements.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.</span></p> <p id="xdx_84C_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zrki3aQaIsH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zHa4pWjJgTng">Basis of Presentation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--LiquidityPolicyTextBlock_zOzsrKfLdOm4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_864_ztxQH9KtTiaa">Liquidity</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">At December 31, 2023, the Company had $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zoT92Aoy1Qc1" title="Cash and cash equivalents">14.0</span> million in cash and cash equivalents. The Company anticipates that the existing cash and cash equivalents balance together with potential future income from operations, collections of existing accounts receivable, revenue from its existing backlog of products as of this filing date, the sale of inventory on hand, deposits and down payments against significant orders will be adequate to meet its working capital and capital equipment requirements, and its anticipated cash needs over the next 12 months from the date of issuance of the accompanying Form 10-K.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 14000000.0 <p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zZzI82UYxsFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_868_zpFOVRJqSdvk">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In addition, certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net (loss).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--ConsolidationPolicyTextBlock_zpngO4VxvY3j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_863_zXa7ZnUa3Syl">Principles of Consolidation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of CVD Equipment Corporation and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.</span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_zVyWiev3tKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zquej73hHBo1">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s significant estimates are the accounting for certain items such as revenues on long-term contracts recognized on the input method, valuation of inventories at the lower of cost or net realizable value; allowance for credit losses; valuation allowances for deferred tax assets, estimated lives and impairment considerations of long-lived assets and valuation of stock-based compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zEvPahY1j0W2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zPlm82Ww8ixl">Revenue Recognition</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606 - Revenue from Contracts with Customers (“ASC 606<i>”</i>), the Company records revenue in an amount that reflects the consideration to which the Company expects to be entitled in exchange for goods or services promised to its customers. Under ASC 606<i>,</i> the Company follows a five-step model to: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price for the contract; (4) allocate the transaction price to the performance obligations; and (5) recognize revenue using one of the following two methods:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i><span style="text-decoration: underline">Over time</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company designs, manufactures and sells custom chemical vapor deposition, thermal process equipment and other equipment through contractual agreements. These system sales require the Company to deliver functioning equipment that is generally completed within two to eighteen months from commencement of order acceptance. For systems sales that meet the criteria to recognize revenue over time, the Company recognizes revenue over time by using an input method based on costs incurred as it depicts the Company’s progress toward satisfaction of the performance obligation. For system sales that do not meet the criteria to recognize revenue over time based on the contract provisions, the Company recognizes revenue based on point in time.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the over time method, revenue arising from fixed price contracts is recognized as work is performed based on the ratio of costs incurred to date to the total estimated costs at completion of the performance obligations. Incurred costs include all direct material and labor costs and those indirect costs related to contract performance, such as supplies, tools, repairs and depreciation costs. Contract material costs are included in incurred costs when the project materials have been purchased or moved to work-in-process, and installed, as required by the project’s engineering design. Cost based input methods of revenue recognition require the Company to make estimates of costs to complete the projects. In making such estimates, significant judgment is required to</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluate assumptions related to the costs to complete the projects, including materials, labor and other system costs. If the estimated total costs on any contract are greater than the net contract revenues, the Company recognizes the entire estimated loss in the period the loss becomes known and can be reasonably estimated. <span style="background-color: white">There were <span id="xdx_902_eus-gaap--CapitalizedContractCostImpairmentLoss_do_c20230101__20231231_z4mSBh7oMBmf" title="Contract assets, impairment loss"><span id="xdx_90F_eus-gaap--CapitalizedContractCostImpairmentLoss_do_c20220101__20221231_ziyNhujAodn8" title="Contract assets, impairment loss">no</span></span> material impairment losses recognized on contract assets during the year ended December 31, 2023 and 2022.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The timing of revenue recognition, billings and collections results in accounts receivables, unbilled receivables or contract assets and contract liabilities on our consolidated balance sheet. Under typical payment terms for our contracts accounted for over time, amounts are billed as work progresses in accordance with agreed-upon contractual terms, either at periodic intervals or upon achievement of contractual milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under ASC 606, payments received from customers in excess of revenue recognized to-date results in a contract liability. These contract liabilities are not considered to represent a significant financing component of the contract because we believe these cash advances and deposits are generally used to meet working capital demands which can be higher in the earlier stages of a contract. Also, advanced payments and deposits provide us with some measure of assurance that the customer will perform on its obligations under the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract assets include unbilled amounts typically resulting from system sales under contracts and represents revenue recognized that exceeds the amount billed to the customer.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract liabilities include advance payments and billings in excess of revenue recognized. The Company typically receives down payments upon receipt of order and progress payments as the system is manufactured.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract assets and contract liabilities are classified as current as these contracts in progress are expected to be substantially completed within the next twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Point in time</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For non-system sales of products and services, revenue is recognized at the point in time when control of the promised products or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those products or services (the transaction price). A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under ASC 606, “Revenue from Contracts with Customers.”</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For any system equipment sales where the equipment would have an alternative use or where the contract provisions of the contract preclude the use of over time revenue recognition, revenue is recognized at the point in time when control of the equipment is transferred to the customer. For the year ended December 31, 2023 and 2022, all system equipment sales were recorded over time by using an input method.</span></p> 0 0 <p id="xdx_844_eus-gaap--InventoryPolicyTextBlock_zQBkfEurwnD5" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_862_ze4ZACQK3Xki">Inventories</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Inventories (raw materials, work-in-process and finished goods) are valued at the lower of cost (determined on the first-in, first-out method) or net realizable value. <span style="background-color: white">Work-in-process and finished goods inventory reflect all accumulated production costs, which are comprised of direct production costs and overhead, and is reduced by amounts recorded in cost of sales as the related revenue is recognized. Indirect costs relating to long-term contracts, which include expenses such as general and administrative, are charged to expense as incurred and are not included in our cost of sales or work-in-process and finished goods inventory.</span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Obsolete inventory or inventory in excess of management’s estimated usage requirement is written down to its estimated net realizable value if less than cost. The Company evaluates usage requirements by analyzing historical usage, anticipated demand, alternative uses of materials, and other qualitative factors. Unanticipated changes in demand for the Company’s products may require a write down of inventory, which would be reflected in cost of sales in the period the revision is made.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_846_eus-gaap--StandardProductWarrantyPolicy_z5GhTPNJfnRk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zTnpxyzF6a1f">Product Warranty</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--StandardProductWarrantyDescription_c20230101__20231231_z3CPknbPO5Ih" title="Standard product warranty description">The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period</span>. The Company records the estimated warranty cost when revenue is recognized on the related system. Warranty cost is included in “Cost of revenue” in the consolidated statements of operations. The estimated warranty cost is based on the Company’s historical cost. The Company updates its warranty estimates based on actual costs incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_zrYXh8MOt4g1" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_860_z3LuxPTGQol9">Income Taxes</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Deferred tax assets and liabilities are determined based on the estimated future tax effects of temporary differences between the financial statements and tax bases of assets and liabilities, as measured by using the future enacted tax rates. Deferred tax expense (benefit) is the result of changes in the deferred tax assets and liabilities. The Company records a valuation allowance against deferred tax assets when it is more likely than not that future tax benefits will not be utilized based on a lack of sufficient positive evidence.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1) we determine whether it is more likely than not the tax position will be sustained on examination by taxing authorities based on the technical merits of the position and (2) for those positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of <span id="xdx_900_eus-gaap--IncomeTaxExaminationLikelihoodOfUnfavorableSettlement_c20230101__20231231_zkGXh0606yNl" title="Income tax examination, description">tax benefit that is more than 50% likely to be realized upon ultimate settlement</span> with the related tax authority.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s policy for global intangible low taxed income (“GILTI”) is to treat such amounts as a period cost when incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> tax benefit that is more than 50% likely to be realized upon ultimate settlement <p id="xdx_846_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_zAdstr1iuV26" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zRbaVJj6jW7a">Impairment of Long-Lived Assets and Intangibles</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived assets consist primarily of property, plant, and equipment. Intangibles consist of patents, copyrights and intellectual property, licensing agreements and certifications. Long-lived assets are reviewed for impairment whenever events or circumstances indicate their carrying value may not be recoverable.When such events or circumstances arise, an estimate of the future undiscounted cash flows produced by the asset, or the appropriate grouping of assets, is compared to the asset’s carrying value to determine if impairment exists.If the asset is determined to be impaired, the impairment loss is measured on the excess of its carrying value over its fair value. Assets to be disposed of are reported at the lower of their carrying value or net realizable value.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_845_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zoqfcnHxrWP5" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_868_zaoO1Xnai0ba">Property, Plant and Equipment</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment are recorded at cost. Depreciation is determined on a straight-line basis for buildings and building improvements over <span id="xdx_903_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember__srt--RangeAxis__srt--MinimumMember_zBni8BT5reC7" title="Property plant and equipment useful life">5</span> to <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember__srt--RangeAxis__srt--MaximumMember_zEGuWbQgTEHb" title="Property plant and equipment useful life">39</span> years and for machinery and equipment over <span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_zqc6TVS0MHG9" title="Property plant and equipment useful life">5</span> to <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zGErfgL6kkHj" title="Property plant and equipment useful life">8</span> years. Depreciation and amortization of assets used in manufacturing are recorded in cost of revenue. Depreciation and amortization of all other assets are recorded as operating expenses.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> P5Y P39Y P5Y P8Y <p id="xdx_843_eus-gaap--IntangibleAssetsFiniteLivedPolicy_zATzk8v46kNh" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_860_zDbRGpyHxO43">Intangible Assets</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The cost of intangible assets is being amortized on a straight-line basis over their estimated initial useful lives which ranged from <span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MinimumMember_zx8SEzFYpckh" title="Intangible assets estimated useful life">5</span> to <span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20231231__srt--RangeAxis__srt--MaximumMember_z1QMZcLLEDKf" title="Intangible assets estimated useful life">20</span> years.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> P5Y P20Y <p id="xdx_843_eus-gaap--ResearchAndDevelopmentExpensePolicy_zWCQtucDoPNc" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_865_z9OuGdJ4jX96">Research and Development</span> </span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Research and development costs are expensed as incurred and include charges for the development of new technology and transition of existing technology into new products. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_846_eus-gaap--EarningsPerSharePolicyTextBlock_z5N6N9HxQn26" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_862_zJ1fCXdDyDj8">Earnings Per Share</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Basic earnings per common share is computed by dividing the net income by the weighted average number of shares of common stock outstanding during each period. When applicable, diluted earnings per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents, consisting of shares that might be adjusted upon exercise of common stock options, unvested restricted shares, and warrants.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Potential common shares issued are calculated using the treasury stock method, which recognizes the use of proceeds that could be obtained upon the exercise of options and warrants in computing diluted earnings per share. It assumes that any proceeds would be used to purchase common stock at the average market price of the common stock during the period. </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGWy1hK21wLg" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_868_za9ivpx9BPxk">Cash and Cash Equivalents</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The Company had cash and cash equivalents of $<span id="xdx_901_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zkwfJQbs6Qpb" title="Cash and cash equivalents">14.0</span> million and $<span id="xdx_902_eus-gaap--CashAndCashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zNFG0MMTCtGh" title="Cash and cash equivalents">14.4</span> million at December 31, 2023 and 2022, respectively. The Company invests excess cash in treasury bills, certificates of deposit or deposit accounts, all with original maturities of less than three months. Cash equivalents were $<span id="xdx_907_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20231231_zkONF4ziZbA5" title="Cash equivalents">12.1</span> million and $<span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_pn5n6_c20221231_zsxXTPproauc" title="Cash equivalents">11.7</span> million at December 31, 2023 and 2022, respectively. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company places most of its temporary cash investments with financial institutions, which from time to time may exceed the Federal Deposit Insurance Corporation limit. The amount in excess of the limit at both December 31, 2023 and 2022 was $<span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20231231_zBacMmsBSFK" title="Cash uninsured amount"><span id="xdx_902_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20221231_z01NoEeNwiHh" title="Cash uninsured amount">1.5</span></span> million. The Company’s cash in our Denmark subsidiary exceeded the government guarantee limit by approximately $<span id="xdx_909_eus-gaap--CashUninsuredAmount_iI_pn5n6_c20221231__srt--StatementGeographicalAxis__country--DK_zbRj1Ek13g5b" title="Cash uninsured amount">0.5</span> million at December 31, 2022.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> 14000000.0 14400000 12100000 11700000 1500000 1500000 500000 <p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zgwzpO8pVhQ2" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zu2pmibBOxs9">Concentration of Credit Risk</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in treasury bills, certificates of deposit or deposit accounts. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company routinely assesses the financial strength of its customers<i>.</i> In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects the best estimate of the amounts the Company does not expect to collect. In addition to reviewing delinquent accounts receivable, the Company consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts<i>. </i>The Company records an allowance for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided based upon the collection history, current economic trends and reasonable supportable forecasts.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has accounts receivables from certain customers that exceed <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zA104u7YpLSk" title="Concentration risk percentage">10</span>%. As of December 31, 2023, the accounts receivable balance includes amounts from three customers that represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zPtP2fFbXBq5" title="Concentration risk percentage">37.6</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zRZvs7SwCpme" title="Concentration risk percentage">13.0</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zbnpJWf01vvk" title="Concentration risk percentage">12.8</span>% of total accounts receivable, and as of December 31, 2022, two customers that represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z1p2BHOaPDO8" title="Concentration risk percentage">35.7</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zzdbXFbbKSXd" title="Concentration risk percentage">30.3</span>% of total accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable is presented net of an allowance for credit losses of $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zwJ2hxRKgXZd" title="Allowance for credit loss"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zIbR2HhUcnSg" title="Allowance for credit loss">36,000</span></span> as of both December 31, 2023 and 2022. <span style="background-color: white">The allowance is based on prior experience and management’s evaluation of future economic conditions. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for doubtful accounts could be material to our results of operations and financial condition.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.10 0.376 0.130 0.128 0.357 0.303 36000 36000 <p id="xdx_84E_ecustom--SalesConcentrationsPolicyPolicyTextBlock_z9XbqPgqQGM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zXYfIPkLkcEk">Sales Concentrations</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue to a single customer in any one year can exceed <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_z3WYi4625AU4" title="Concentration risk percentage">10</span>% of our total sales. There were three customers in the year ended December 31, 2023 that represented <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_znvTmxsFAsXh" title="Concentration risk percentage">14.3</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerBMember_z8f9jjEx1Cji" title="Concentration risk percentage">13.5</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerCMember_zOHfSmFT5Ie7" title="Concentration risk percentage">10.9</span>% of our revenues, while there was one customer in the year ended December 31, 2022 that represented <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerAMember_zFUgiCW6ij39" title="Concentration risk percentage">29.2</span>% of our revenues. The loss of a large customer could have a material adverse effect on the Company’s business and financial condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Export sales to customers represented approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ExportSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--GeographicDistributionAxis__us-gaap--GeographicDistributionForeignMember_zYiY1Pohcef1" title="Concentration risk percentage"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--ExportSalesMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--GeographicDistributionAxis__us-gaap--GeographicDistributionForeignMember_zjow0hnQRHjj" title="Concentration risk percentage">17</span></span>% of sales for both years ended December 31, 2023 and 2022. Export sales in both 2023 and 2022 were primarily to customers in Europe and Asia. All contracts except those entered into by the Company’s subsidiary in Denmark are denominated in U.S. dollars. The Company has not entered into any foreign exchange contracts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.10 0.143 0.135 0.109 0.292 0.17 0.17 <p id="xdx_842_ecustom--SupplierRiskPolicyTextBlock_z20dzLwHoKH6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_z61GghIdUHJj">Supplier Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company relies on suppliers to manufacture many of the components and subassemblies used in its products. Quality or performance failures of the Company’s products or changes in its manufacturers’ financial or business condition could disrupt the Company’s ability to supply quality products to its customers and thereby have a material and adverse effect on its business and operating results. Some of the components and technologies used in the Company’s products are purchased and licensed from a single source or a limited number of sources. The loss of any of these suppliers may cause the Company to incur additional transition costs, result in delays in the manufacturing and delivery of its products or cause it to carry excess or obsolete inventory and could cause it to redesign its products.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_841_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zmRnlO8SKz03" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_863_zmvi6iXvCxx9">Fair Value of Financial Instruments</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The carrying amounts of financial instruments including cash and cash equivalents, accounts receivable, accounts payable, contract assets and contract liabilities approximate fair value due to the relatively short-term maturity of these instruments. The carrying value of long-term debt approximates fair value based on prevailing borrowing rates currently available for loans with similar terms and maturities.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p id="xdx_848_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zBvD6CO0ooK8" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_861_zbEPzCQT630a">Stock-Based Compensation</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company records stock-based compensation in accordance with the provisions set forth in ASC 718, “Stock Compensation”. ASC 718 requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant date fair value of those awards over the vesting period. The Company uses the Black-Scholes option-pricing model to compute the estimated fair value of option awards and includes assumptions regarding expected volatility, expected option term, dividend yields and risk-free interest rates.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_84E_ecustom--ShippingAndHandlingPolicyPolicyTextBlock_zu2hbuhK3Gw5" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_862_zP1fXQd4W1gl">Shipping and Handling</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">It is the Company’s policy to include freight charges billed to customers in total revenue. The amount included in revenue was $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ProductOrServiceAxis__us-gaap--CargoAndFreightMember_zIDHrwOcIbx3" title="Revenue">55,000</span> and $<span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--ProductOrServiceAxis__us-gaap--CargoAndFreightMember_zUpufx7DmZre" title="Revenue">87,000</span> for the years ended December 31, 2023 and 2022, respectively. </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> 55000 87000 <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zU5efAbh2dLf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zVbJBfJqZtZi">Recently Adopted Accounting Standards</span> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued Accounting Standard Update (“ASU”) 2016-13, <i>Financial Instruments – Credit Losses (Topic 326)</i>, which require that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the increase or decreases of expected credit losses that have taken place during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. The adoption of the ASU 2016-3 as of January 1, 2023 did not have a material impact on the Company’s financial position.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--RecentlyIssuedAccountingStandardsPolicyTextBlock_zyYKFTLXhVPc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zsUiVhbIl8i9">Recently Issued Accounting Standards</span> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, “<i>Income Taxes (Topic 740): Improvements to Income Tax Disclosures</i>,” which requires public business entities to disclose additional information in specified categories with respect to the reconciliation of the effective tax rate to the statutory rate for federal, state, and foreign income taxes. It also requires greater detail about individual reconciling items in the rate reconciliation to the extent the impact of those items exceeds a specified threshold. In addition to new disclosures associated with the rate reconciliation, the ASU requires information pertaining to taxes paid (net of refunds received) to be disaggregated for federal, state, and foreign taxes and further disaggregated for specific jurisdictions to the extent the related amounts exceed a quantitative threshold. The ASU also describes items that need to be disaggregated based on their nature, which is determined by reference to the item’s fundamental or essential characteristics, such as the transaction or event that triggered the establishment of the reconciling item and the activity with which the reconciling item is associated. The ASU eliminates the historic requirement that entities disclose information concerning unrecognized tax benefits having a reasonable possibility of</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">significantly increasing or decreasing in the 12 months following the reporting date. This ASU is effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. This ASU should be applied on a prospective basis; however, retrospective application is permitted. We are currently evaluating the impact that ASU 2023 – 09 will have on our consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2023, the FASB issued ASU 2023-07, “<i>Segment Reporting (Topic 280): Improvements to Reportable Segments</i>,” which aims to improve financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities to enable investors to develop more decision-useful financial analyses. Currently, Topic280 requires that a public entity disclose certain information about its reportable segments. For example, a public entity is required to report a measure of segment profit or loss that the CODM uses to assess segment performance and make decisions about allocating resources. Topic 280 also requires other specified segment items and amounts, such as depreciation, amortization, and depletion expense, to be disclosed under certain circumstances. The amendments in this ASU do not change or remove those disclosure requirements and do not change how a public entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine its reportable segments. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. We are currently evaluating the impact that ASU 2023 – 07 will have on our consolidated financial statements.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company believes there is no additional new accounting guidance adopted, but not yet effective that is relevant to the readers of our financial statements. However, there are numerous new proposals under development which, if and when enacted, may have a significant impact on our financial reporting.</span></p> <p id="xdx_803_eus-gaap--RevenueFromContractWithCustomerTextBlock_z2fTnzKZQoEa" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 3 – <span id="xdx_826_zdBP8cgY5qfa">Revenue</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_z5FivSmDk2Xa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents a disaggregation of revenue from contracts by end markets for the years ended December 31, 2023 and 2022 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zXclbTHF9vK3" style="display: none">Schedule of Disaggregation of Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20230101__20231231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zYZaNezJU1F4" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Over time</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zGoAccQRi8Z4" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Point in time</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20230101__20231231_zwoIudgqlsd3" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Over time</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Point in time</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--EnergyMember_zd1RqIjyDfrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Energy</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,901</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">189</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,090</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--AerospaceMember_zJJT7Aycacea" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Aerospace</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,427</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,469</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,896</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--IndustrialMember_zVksWhDlMYbe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Industrial</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,123</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,821</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,944</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--ResearchOneMember_zrrZT4ZY1fSi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Research</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,700</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,479</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,179</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zFAaNBYmCAmd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,151</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,109</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20220101__20221231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_z94U3IQDPeZj" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Over time</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220101__20221231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_z7DiWqouQlH3" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Point in time</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220101__20221231_zA1xnB4tF7xj" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Over time</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Point in time</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--EnergyMember_zV7DUVPxULqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Energy</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,094</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">58</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,152</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--AerospaceMember_z4DFdegqpSfk" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Aerospace</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">95</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,527</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,622</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--IndustrialMember_zolZEn41vfva" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Industrial</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,961</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,856</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,817</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--ResearchOneMember_zmL82Wb2HCkc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Research</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,807</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,415</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,222</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zR95fCbha7N9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,957</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,856</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,813</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zRcBUbBkrRog" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The energy market includes customers involved in the manufacture of silicon carbide wafers and batteries. Aerospace market includes customers that manufacture aircraft engines. Industrial end market consists of various end customers in diverse industries. Research market principally represents customers that are universities and other research institutions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has unrecognized contract revenue of approximately $<span id="xdx_90F_eus-gaap--RevenueRemainingPerformanceObligation_iI_pn5n6_c20231231_zKT7s2h9gQEf" title="Unrecognized contract revenue">16.3</span> million at December 31, 2023, which it expects to recognize as revenue within the next twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Judgment is required to evaluate assumptions including the amount of net contract revenues and the total estimated costs to determine our progress towards contract completion and to calculate the corresponding amount of revenue to recognize.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in estimates for sales of systems occur for a variety of reasons, including but not limited to (i) build accelerations or delays, (ii) product cost forecast changes, (iii) cost related change orders or add-ons, or (iv) changes in other information used to estimate costs. Changes in estimates may have a material effect on the Company’s consolidated financial position and results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 3 – Revenue (continued)</b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_891_ecustom--ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsTableTextBlock_z2RPmBsNwQG5" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Contract assets and contract liabilities on input method type contracts in progress are summarized at December 31 as follows (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zUromaHegK8i" style="display: none">Schedule of Cost and Estimated Earnings in Excess of Billings</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-style: normal"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" id="xdx_496_20231231_zMG0SxEi3W75" style="border-bottom: Black 1.5pt solid; text-align: center; font-style: normal"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>2023</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-style: normal"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-style: normal"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" id="xdx_49B_20221231_z81VAnykZCW" style="border-bottom: Black 1.5pt solid; text-align: center; font-style: normal"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-style: normal"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr id="xdx_406_ecustom--CostsIncurredOnUncompletedContracts_iI_pn3n3_maCAEEOzw4R_zE6e4TAPaLW6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Costs incurred on contracts in progress</span></td><td style="width: 2%; font-style: normal"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,500</span></td><td style="width: 1%; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; font-style: normal"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,390</span></td><td style="width: 1%; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--EstimatedEarnings_iI_pn3n3_maCAEEOzw4R_zMZis2zZhZa5" style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Estimated earnings</span></td><td style="font-style: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,083</span></td><td style="padding-bottom: 1.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,926</span></td><td style="padding-bottom: 1.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_ecustom--CostsAndEstimatedEarningsOnUncompletedContracts_iTI_pn3n3_mtCAEEOzw4R_maNCIEOzQmN_zXqlX5ZzHZ5g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs and estimated earnings on uncompleted contracts</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font-style: normal"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,583</span></td><td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: normal"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,316</span></td><td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--BillingsToDate_iNI_pn3n3_di_msNCIEOzQmN_zLKHClaRY6Ai" style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Billings to date</span></td><td style="font-style: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(17,553</span></td><td style="padding-bottom: 1.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-style: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(26,925</span></td><td style="padding-bottom: 1.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40D_ecustom--NetCostInExcessOfBillings_iTI_pn3n3_mtNCIEOzQmN_ztpbaRzJxjta" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cost in excess of billings</span></span></td><td style="font-style: normal"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,970</span></td><td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-style: normal"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,609</span></td><td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_400_ecustom--DeferredRevenuesRelatedToContracts_iI_pn3n3_z1qFR8gRIsz5" style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deferred revenue related to non-systems contracts</span></td><td style="font-style: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(334</span></td><td style="padding-bottom: 1.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-style: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(263</span></td><td style="padding-bottom: 1.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40E_ecustom--ContractLiabilityInExcessOfContractAssets_iI_pn3n3_zo2ZhPSh2hSi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract liability in excess of contract assets</span></span></td><td style="font-style: normal; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,304</span></td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-style: normal; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,872</span></td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Included in accompanying consolidated balance sheets under the following captions (in thousands):</span></p></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--ContractWithCustomerAssetNetCurrent_iI_pn3n3_z0bi0J2ylgA2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-style: normal; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Contract assets</span></td><td style="font-style: normal; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,604</span></td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,170</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_zwMHnW6avr52" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-style: normal; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Contract liabilities</span></td><td style="font-style: normal; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,908</span></td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,042</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A0_zCiAR5higJoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Of the contract liability balances at December 31, 2022 and December 31, 2021, $<span id="xdx_900_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn5n6_c20230101__20231231_zd8m5sVw3sx6" title="Contract liability">3.7</span> million and $<span id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pn5n6_c20220101__20221231_z1rjxT0fW8n" title="Deferred revenue recognized">1.7</span> million was recognized as revenue during the years ended December 31, 2023 and 2022, respectively. Contract assets at December 31, 2021 were $<span id="xdx_90D_eus-gaap--ContractWithCustomerAssetNetCurrent_iI_pn5n6_c20211231_zEjRDVdvX3k5" title="Contract assets">2.5</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_896_eus-gaap--DisaggregationOfRevenueTableTextBlock_z5FivSmDk2Xa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table represents a disaggregation of revenue from contracts by end markets for the years ended December 31, 2023 and 2022 (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8BA_zXclbTHF9vK3" style="display: none">Schedule of Disaggregation of Revenue</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20230101__20231231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_zYZaNezJU1F4" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Over time</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20230101__20231231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_zGoAccQRi8Z4" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Point in time</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20230101__20231231_zwoIudgqlsd3" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Over time</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Point in time</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40C_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--EnergyMember_zd1RqIjyDfrj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Energy</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,901</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">189</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,090</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--AerospaceMember_zJJT7Aycacea" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Aerospace</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,427</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,469</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,896</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--IndustrialMember_zVksWhDlMYbe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Industrial</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,123</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,821</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">8,944</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--ResearchOneMember_zrrZT4ZY1fSi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Research</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,700</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,479</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,179</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zFAaNBYmCAmd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">18,151</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,958</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,109</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20220101__20221231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredOverTimeMember_z94U3IQDPeZj" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Over time</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220101__20221231__us-gaap--TimingOfTransferOfGoodOrServiceAxis__us-gaap--TransferredAtPointInTimeMember_z7DiWqouQlH3" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Point in time</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220101__20221231_zA1xnB4tF7xj" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Year Ended December 31, 2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Over time</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Point in time</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--EnergyMember_zV7DUVPxULqg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%"><span style="font-family: Times New Roman, Times, Serif">Energy</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,094</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">58</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 12%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,152</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--AerospaceMember_z4DFdegqpSfk" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Aerospace</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">95</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,527</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,622</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--IndustrialMember_zolZEn41vfva" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Industrial</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,961</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,856</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,817</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_hsrt--ProductOrServiceAxis__custom--ResearchOneMember_zmL82Wb2HCkc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Research</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,807</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,415</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,222</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pn3n3_zR95fCbha7N9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">17,957</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,856</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,813</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 4901000 189000 5090000 3427000 1469000 4896000 6123000 2821000 8944000 3700000 1479000 5179000 18151000 5958000 24109000 9094000 58000 9152000 95000 1527000 1622000 5961000 4856000 10817000 2807000 1415000 4222000 17957000 7856000 25813000 16300000 <p id="xdx_891_ecustom--ScheduleOfCostAndEstimatedEarningsInExcessOfBillingsTableTextBlock_z2RPmBsNwQG5" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Contract assets and contract liabilities on input method type contracts in progress are summarized at December 31 as follows (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zUromaHegK8i" style="display: none">Schedule of Cost and Estimated Earnings in Excess of Billings</span></span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-style: normal"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" id="xdx_496_20231231_zMG0SxEi3W75" style="border-bottom: Black 1.5pt solid; text-align: center; font-style: normal"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>2023</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-style: normal"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-style: normal"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" id="xdx_49B_20221231_z81VAnykZCW" style="border-bottom: Black 1.5pt solid; text-align: center; font-style: normal"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-style: normal"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr id="xdx_406_ecustom--CostsIncurredOnUncompletedContracts_iI_pn3n3_maCAEEOzw4R_zE6e4TAPaLW6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Costs incurred on contracts in progress</span></td><td style="width: 2%; font-style: normal"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">9,500</span></td><td style="width: 1%; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; font-style: normal"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,390</span></td><td style="width: 1%; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_ecustom--EstimatedEarnings_iI_pn3n3_maCAEEOzw4R_zMZis2zZhZa5" style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Estimated earnings</span></td><td style="font-style: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,083</span></td><td style="padding-bottom: 1.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">10,926</span></td><td style="padding-bottom: 1.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_ecustom--CostsAndEstimatedEarningsOnUncompletedContracts_iTI_pn3n3_mtCAEEOzw4R_maNCIEOzQmN_zXqlX5ZzHZ5g" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs and estimated earnings on uncompleted contracts</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="font-style: normal"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">14,583</span></td><td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: normal"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,316</span></td><td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--BillingsToDate_iNI_pn3n3_di_msNCIEOzQmN_zLKHClaRY6Ai" style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Billings to date</span></td><td style="font-style: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(17,553</span></td><td style="padding-bottom: 1.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-style: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(26,925</span></td><td style="padding-bottom: 1.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40D_ecustom--NetCostInExcessOfBillings_iTI_pn3n3_mtNCIEOzQmN_ztpbaRzJxjta" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Net cost in excess of billings</span></span></td><td style="font-style: normal"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,970</span></td><td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-style: normal"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,609</span></td><td style="font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_400_ecustom--DeferredRevenuesRelatedToContracts_iI_pn3n3_z1qFR8gRIsz5" style="vertical-align: bottom; background-color: White"> <td style="font-style: normal; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Deferred revenue related to non-systems contracts</span></td><td style="font-style: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(334</span></td><td style="padding-bottom: 1.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-style: normal; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(263</span></td><td style="padding-bottom: 1.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40E_ecustom--ContractLiabilityInExcessOfContractAssets_iI_pn3n3_zo2ZhPSh2hSi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract liability in excess of contract assets</span></span></td><td style="font-style: normal; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,304</span></td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="font-style: normal; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,872</span></td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Included in accompanying consolidated balance sheets under the following captions (in thousands):</span></p></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--ContractWithCustomerAssetNetCurrent_iI_pn3n3_z0bi0J2ylgA2" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-style: normal; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Contract assets</span></td><td style="font-style: normal; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,604</span></td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,170</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_pn3n3_zwMHnW6avr52" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-style: normal; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Contract liabilities</span></td><td style="font-style: normal; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font-style: normal; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,908</span></td><td style="padding-bottom: 2.5pt; font-style: normal; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,042</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 9500000 14390000 5083000 10926000 14583000 25316000 17553000 26925000 -2970000 -1609000 -334000 -263000 -3304000 -1872000 1604000 2170000 4908000 4042000 3700000 1700000 2500000 <p id="xdx_80D_eus-gaap--InventoryDisclosureTextBlock_zeB2gI8Ajgc1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 4 - <span id="xdx_824_ziUvkEVwxxS2">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zMj50oZdBzwb" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Inventories as of December 31 consist of (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zHYxpPj89jfa" style="display: none">Schedule of Inventories, net</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20231231_zaxzybLPeXn9" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20221231_zNQwwZ8pnWtg" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzesC_zZqxUPGG8LFe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,351</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,165</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzesC_zWt1wF7Q7zQ5" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Work-in-process</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,248</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">373</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzesC_zNcBQItqAqg2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">855</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINzesC_zh4CVN4nhlHa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,454</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,538</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AC_zHrdKJm9bwv3" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_891_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zMj50oZdBzwb" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Inventories as of December 31 consist of (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B8_zHYxpPj89jfa" style="display: none">Schedule of Inventories, net</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20231231_zaxzybLPeXn9" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20221231_zNQwwZ8pnWtg" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--InventoryRawMaterials_iI_pn3n3_maINzesC_zZqxUPGG8LFe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Raw materials</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,351</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,165</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--InventoryWorkInProcess_iI_pn3n3_maINzesC_zWt1wF7Q7zQ5" style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Work-in-process</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,248</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">373</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--InventoryFinishedGoods_iI_pn3n3_maINzesC_zNcBQItqAqg2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Finished goods</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">855</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0625">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--InventoryNet_iTI_pn3n3_mtINzesC_zh4CVN4nhlHa" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,454</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,538</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 2351000 2165000 1248000 373000 855000 4454000 2538000 <p id="xdx_807_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zOtGUuiWyaGi" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 5 – <span id="xdx_82C_z1MD99f8yii5">Property, Plant and Equipment</span></b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zqE5mmOQXcBa" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Major classes of property, plant and equipment consist of the following as of December 31 (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> <span id="xdx_8B2_zbbmHIsg5Se4" style="display: none">Schedule of Property, Plant and Equipment</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20231231_zL5RyhDJ0676" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20221231_zgoTfesFLNgj" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zATfmYMgAAMa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Land</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,220</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,220</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zJ9FN1toAgdh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Buildings and improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,798</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,530</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zkGMx402Pisi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Machinery and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,536</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,810</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zfP85yRjH3Pf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Construction in progress</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">167</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzCuC_zHnuR5molYQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Totals at cost</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,721</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,572</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzCuC_ztYXKFCN6Lk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,555</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,976</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzCuC_zmYqlYeqvvob" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property, plant and equipment, net</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,166</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,596</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AA_zvpJkspvoT76" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Machinery and equipment also include furniture and fixtures and software.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Depreciation expense was $<span id="xdx_904_eus-gaap--Depreciation_pn5n6_c20230101__20231231_zY1uAhSexGua" title="Depreciation expense">0.7</span> million and $<span id="xdx_904_eus-gaap--Depreciation_pn5n6_c20220101__20221231_zx3cTd36aNLk" title="Depreciation expense">0.8</span> million for the years ended December 31, 2023 and 2022, respectively. </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">The Company entered into an agreement with the Town of Islip Industrial Development Agency (Islip IDA) in July 2021 under which the Company was granted tax incentives whereby the Company agreed to make payments in lieu of all real estate taxes and assessments (PILOT payments). The agreement requires the Company to maintain certain employment levels at its Central Islip, New York facility. The agreement provides for the Islip IDA to recapture tax incentives provided to the Company in certain circumstances. Any recapture of such tax benefits could have a material adverse effect on the Company’s financial position and future results of operations and cash flows.</span></p> <p id="xdx_89C_eus-gaap--PropertyPlantAndEquipmentTextBlock_zqE5mmOQXcBa" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Major classes of property, plant and equipment consist of the following as of December 31 (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> <span id="xdx_8B2_zbbmHIsg5Se4" style="display: none">Schedule of Property, Plant and Equipment</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20231231_zL5RyhDJ0676" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_492_20221231_zgoTfesFLNgj" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LandMember_zATfmYMgAAMa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Land</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,220</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,220</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--BuildingAndBuildingImprovementsMember_zJ9FN1toAgdh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Buildings and improvements</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,798</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,530</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zkGMx402Pisi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Machinery and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,536</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,810</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ConstructionInProgressMember_zfP85yRjH3Pf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Construction in progress</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">167</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pn3n3_maPPAENzCuC_zHnuR5molYQi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Totals at cost</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,721</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">22,572</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzCuC_ztYXKFCN6Lk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Less: accumulated depreciation</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(10,555</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(9,976</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzCuC_zmYqlYeqvvob" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property, plant and equipment, net</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,166</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">12,596</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 2220000 2220000 12798000 12530000 7536000 7810000 167000 12000 22721000 22572000 10555000 9976000 12166000 12596000 700000 800000 <p id="xdx_80F_eus-gaap--IntangibleAssetsDisclosureTextBlock_zHZCU6d1gRq3" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 6 – <span id="xdx_82E_zNWPGI8kVBWl">Intangible Assets</span></b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zZYyW7BUSIDk" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Intangible assets consisted of the following (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> <span id="xdx_8B1_zOCQUSIwV0Hi" style="display: none">Schedule of Finite Lived Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">December 31, 2023</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Accumulated Amortization</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z2EEhuBXT9uf" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Finite-lived intangible assets, gross"><span style="font-family: Times New Roman, Times, Serif">87</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAtVKLJ8hFIb" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Finite-lived intangible assets, accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">78</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zeNtS0kqiUxd" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Intangible assets, net"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">December 31, 2022</span></b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Accumulated Amortization</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zQYTKWQYhsgk" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Intangible assets, Cost"><span style="font-family: Times New Roman, Times, Serif">565</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zG41Uu3PIKvk" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Intangible assets, Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">446</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ziBCDgquOTEi" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Intangible assets, Net"><span style="font-family: Times New Roman, Times, Serif">119</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AB_zafV0AWtjhf4" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Amortization expense was $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_pn5n6_c20230101__20231231_zv4yiV3rTC98" title="Amortization expense">0.1</span> million and $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_pn5n6_c20220101__20221231_zz2wewyYylx3" title="Amortization expense">0.1</span> million in years ended December 31, 2023 and 2022, respectively, including costs of abandoned patent applications. </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The estimated amortization expense related to intangible assets for each of the five succeeding fiscal years and thereafter as of December 31, 2023 is approximately $<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20231231_zkVIyeGcCxO2" title="Estimated amortization expense, 2024"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20231231_zoHQ8G3RFmc2" title="Estimated amortization expense, 2025"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20231231_zbeCfBdcMW94" title="Estimated amortization expense, 2026"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20231231_zdoWdqj1dEth" title="Estimated amortization expense, 2027"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_c20231231_zyheVeMxsSoi" title="Estimated amortization expense, 2028"><span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_c20231231_zFEprsbkTSFk" title="Estimated amortization expense, thereafter">1,000</span></span></span></span></span></span> per year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zZYyW7BUSIDk" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Intangible assets consisted of the following (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> <span id="xdx_8B1_zOCQUSIwV0Hi" style="display: none">Schedule of Finite Lived Intangible Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">December 31, 2023</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Accumulated Amortization</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z2EEhuBXT9uf" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Finite-lived intangible assets, gross"><span style="font-family: Times New Roman, Times, Serif">87</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAtVKLJ8hFIb" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Finite-lived intangible assets, accumulated amortization"><span style="font-family: Times New Roman, Times, Serif">78</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_986_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20231231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zeNtS0kqiUxd" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Intangible assets, net"><span style="font-family: Times New Roman, Times, Serif">9</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">December 31, 2022</span></b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Cost</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Accumulated Amortization</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Net</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Patents</span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zQYTKWQYhsgk" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Intangible assets, Cost"><span style="font-family: Times New Roman, Times, Serif">565</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zG41Uu3PIKvk" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Intangible assets, Accumulated Amortization"><span style="font-family: Times New Roman, Times, Serif">446</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_pn3n3_c20221231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_ziBCDgquOTEi" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Intangible assets, Net"><span style="font-family: Times New Roman, Times, Serif">119</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 87000 78000 9000 565000 446000 119000 100000 100000 1000 1000 1000 1000 1000 1000 <p id="xdx_807_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_zFAH7z5XxkQj" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b>Note 7 – <span id="xdx_826_zvO0vV8ilJd3">Accrued Expenses</span></b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zfF5RkHDzXc5" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Accrued expenses consist of the following as of December 31 (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> <span id="xdx_8B5_zdJ8PQPcde5d" style="display: none">Schedule of Accrued Expenses</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20231231_z3OwjHTy5Qc1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20221231_z3xcEBdHDul6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maALCz7TQ_zOkug24lua2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued wages and benefits</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">358</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">995</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--AccruedVacationCurrent_iI_pn3n3_maALCz7TQ_zRsXP9ALvvii" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued vacation</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">729</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">905</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCz7TQ_zti0ccu3STad" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">678</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">691</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz7TQ_zF0Gc1o4APL3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,765</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,591</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AA_zJvHKS4MEy27" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_898_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zfF5RkHDzXc5" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Accrued expenses consist of the following as of December 31 (in thousands):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><b> <span id="xdx_8B5_zdJ8PQPcde5d" style="display: none">Schedule of Accrued Expenses</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20231231_z3OwjHTy5Qc1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20221231_z3xcEBdHDul6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--AccruedSalariesCurrent_iI_pn3n3_maALCz7TQ_zOkug24lua2h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued wages and benefits</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">358</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">995</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--AccruedVacationCurrent_iI_pn3n3_maALCz7TQ_zRsXP9ALvvii" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Accrued vacation</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">729</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">905</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALCz7TQ_zti0ccu3STad" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">678</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">691</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--AccruedLiabilitiesCurrent_iTI_pn3n3_mtALCz7TQ_zF0Gc1o4APL3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total accrued expenses</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,765</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2,591</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 358000 995000 729000 905000 678000 691000 1765000 2591000 <p id="xdx_809_eus-gaap--LongTermDebtTextBlock_z0BtBEJs8uc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 8 – <span id="xdx_826_zY9P8uFwnWU6">Long-term Debt</span></b></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zmEZqeRt1icl" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Long-term debt as of December 31 consist of the following (in thousands, except percentages and amounts in notes):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_z5LqaNneDjK5" style="display: none">Schedule of Long Term Debt</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20231231_zseMbRniEpxf" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20221231_zsyNb2coUqH1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--LoansPayable_iI_pn3n3_zXbkpgPDGTP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> Equipment loan payable in monthly repayments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvbmcgVGVybSBEZWJ0IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20230101__20231231_zV3mlIkZ3SD" title="Debt instrument monthly payments">8</span> including interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvbmcgVGVybSBEZWJ0IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231_zrfrlzfbeKl4" title="Debt instrument interest rate">6</span>% per annum</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">349</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">426</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--LongTermDebtCurrent_iI_pn3n3_zrQuzeUOmlx1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: current maturities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">81</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">77</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zxRXp77cuHHb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> Long-term debt, net of current maturities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">268</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">349</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AB_zyhGKybzLNpk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2022<i>, </i>the Company entered into a loan agreement to fund the acquisition of machinery equipment in the amount of $<span id="xdx_902_ecustom--LoanToFundAcquisitionOfMachineryEquipment_iI_pn5n6_c20220930_zmKykWlPzNO" title="Loan to fund acquisition of machinery equipment">0.4</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zLPz4flkYub1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future maturities of long-term debt as of December 31, 2023 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zsJrbvkvZxI4" style="display: none">Schedule of Maturities of Long Term Debt</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20231231_zAaZcJRWe6e" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzMa5_zjeriY1V9tR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">81</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzMa5_zRhwq0oNEwqi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">87</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzMa5_zVlfeDuwZSUj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maLTDzMa5_zkktBZ69pfI8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">89</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzMa5_z18DrBWIpxp2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">349</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AE_zpULClA1eFwc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_893_eus-gaap--ScheduleOfDebtInstrumentsTextBlock_zmEZqeRt1icl" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif">Long-term debt as of December 31 consist of the following (in thousands, except percentages and amounts in notes):</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> <span id="xdx_8B3_z5LqaNneDjK5" style="display: none">Schedule of Long Term Debt</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_494_20231231_zseMbRniEpxf" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49F_20221231_zsyNb2coUqH1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--LoansPayable_iI_pn3n3_zXbkpgPDGTP6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> Equipment loan payable in monthly repayments of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvbmcgVGVybSBEZWJ0IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_905_eus-gaap--DebtInstrumentPeriodicPayment_pn3n3_c20230101__20231231_zV3mlIkZ3SD" title="Debt instrument monthly payments">8</span> including interest at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIExvbmcgVGVybSBEZWJ0IChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20231231_zrfrlzfbeKl4" title="Debt instrument interest rate">6</span>% per annum</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">349</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">426</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_406_eus-gaap--LongTermDebtCurrent_iI_pn3n3_zrQuzeUOmlx1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: current maturities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">81</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">77</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--LongTermDebtNoncurrent_iI_pn3n3_zxRXp77cuHHb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> Long-term debt, net of current maturities</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">268</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">349</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 8000 0.06 349000 426000 81000 77000 268000 349000 400000 <p id="xdx_893_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_zLPz4flkYub1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future maturities of long-term debt as of December 31, 2023 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zsJrbvkvZxI4" style="display: none">Schedule of Maturities of Long Term Debt</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20231231_zAaZcJRWe6e" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzMa5_zjeriY1V9tR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">2024</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">81</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pn3n3_maLTDzMa5_zRhwq0oNEwqi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2025</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">87</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pn3n3_maLTDzMa5_zVlfeDuwZSUj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">2026</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">92</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pn3n3_maLTDzMa5_zkktBZ69pfI8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">2027</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">89</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzMa5_z18DrBWIpxp2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">349</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 81000 87000 92000 89000 349000 <p id="xdx_806_eus-gaap--EarningsPerShareTextBlock_zA1iAQ1FPq53" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 9 – <span id="xdx_824_zHvjvNk4wGY1">Earnings per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zp6BdjejjpN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The calculation of basic and diluted weighted average common shares outstanding as of December 31 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zmo13Qd7sgEl" style="display: none">Schedule of Basic and Diluted Weighted Average Common Shares Outstanding</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20230101__20231231_zhlBGNz9AINg" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20220101__20221231_zbnD7q8EOs5j" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_z4GxHYLJvS98" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Basic weighted average shares outstanding</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,788</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,734</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_zwxlXJtjKKaf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Effect of potentially dilutive share-based awards</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0745">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zOKcnUS7Cjnk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Diluted weighted average shares outstanding</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,788</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,734</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AC_z70KnAKM71Q7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023, stock options to purchase <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20231231_zrsdQe94ATkk" title="Stock option outstanding">846,875</span> shares of common stock were outstanding and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20231231_zHluHREfKH62" title="Stock option exercisable">335,375</span> were exercisable. At December 31, 2022, stock options to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_c20221231_zdmcA4PZJ0xa" title="Stock option outstanding">673,000</span> shares of common stock were outstanding and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_c20221231_zEbW1dnxz421" title="Stock option exercisable">265,000</span> were exercisable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023 and 2022, <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20230101__20231231_zVk6lrkboHji" title="Antidilutive sharesfrom computation of diluted earnings per share">846,875</span> and <span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20220101__20221231_zrLyHQoMA2p1" title="Antidilutive shares from computation of diluted earnings per share">673,000</span> stock options, respectively, were not included in the computation of diluted earnings per share because their effect was antidilutive.</span></p> <p id="xdx_891_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zp6BdjejjpN6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The calculation of basic and diluted weighted average common shares outstanding as of December 31 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zmo13Qd7sgEl" style="display: none">Schedule of Basic and Diluted Weighted Average Common Shares Outstanding</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20230101__20231231_zhlBGNz9AINg" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20220101__20221231_zbnD7q8EOs5j" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_z4GxHYLJvS98" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Basic weighted average shares outstanding</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,788</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,734</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_pid_zwxlXJtjKKaf" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Effect of potentially dilutive share-based awards</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0745">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0746">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_zOKcnUS7Cjnk" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Diluted weighted average shares outstanding</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,788</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,734</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 6788 6734 6788 6734 846875 335375 673000 265000 846875 673000 <p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_z3iMqdrXZ5k5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – <span id="xdx_822_z9USkWGzSu8i">Income Taxes</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_z877JUzpUgX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before income taxes are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zJv3lIHWQIS8" style="display: none">Schedule of Loss Before Income Taxes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230101__20231231_zxZcrqlIQh8d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20220101__20221231_zNyxSrjdW0Le" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_maILFCOzXdM_zEWdHJb17S1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Domestic</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,073</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(596</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_maILFCOzXdM_zPrge4ig30O1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(121</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">376</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_mtILFCOzXdM_zG8JQfB1YMSf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,194</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(220</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> <p id="xdx_8AD_zuzkY7xno8dh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z8D5NLg9lU43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expense/(benefit) for income taxes for the years ended December 31 includes the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zR2Ykdm5AMZ7" style="display: none">Schedule of Components of Income Tax Expense (Benefit)</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20230101__20231231_zvzEzTK8dRE8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220101__20221231_z6D8X2msAYNa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Current:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzswH_zKGlHvpGkFhc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzswH_zyuARnHAadK3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzswH_maITEBzuuP_zYPRpJVYMXW6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current tax provision</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Deferred:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDITEBzJTX_zodxuH7iSu9a" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDITEBzJTX_zj5NvzgKc1dc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_pn3n3_mtDITEBzJTX_maITEBzuuP_zFTVIv8VQwxl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax provision</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0793">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzuuP_z72aNI4JiXKg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income tax (benefit) expense</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zSZtuBg2EGue" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z2wHHoZZqgWh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zeDKjMjspwF9" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20230101__20231231_z2rwqYtv9NZ3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220101__20221231_zFitVCVeTc2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> 2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzHAV_zcSx6iRpEAEc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected provision at federal statutory tax rate at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVmZmVjdGl2ZSBJbmNvbWUgVGF4IFJhdGUgUmVjb25jaWxpYXRpb24gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_z0tdeQ4gNDYe" title="Federal statutory tax rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVmZmVjdGl2ZSBJbmNvbWUgVGF4IFJhdGUgUmVjb25jaWxpYXRpb24gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zFqSsjJpQHg2" title="Federal statutory tax rate">21</span></span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(881</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(46</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzHAV_zjwTDSPTGVq4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (decrease) in valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">688</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzHAV_zVwgEW7snCT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State and local taxes</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">84</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzHAV_zxg03GBRWQJ2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign tax rate differential</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperationsAmount_pn3n3_maITEBzHAV_zcii4IrIk1q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">US taxation of foreign operations</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0817">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_pn3n3_di_msITEBzHAV_z8bMeCKMyVHe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal research and development credits</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(55</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_pn3n3_maITEBzHAV_znPUSiGmTLBi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in tax rates</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0823">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_pn3n3_maITEBzHAV_zDOTNenvAEZi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-deductible expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">62</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationDispositionOfBusiness_pn3n3_maITEBzHAV_zBCwDhx5Utej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Disposition of Tantaline</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">193</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maITEBzHAV_zfMJxefDaeR9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(102</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzHAV_zM9na2lCds89" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income tax (benefit) expense</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A8_zqX6W3FOlA16" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – Income Taxes (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zRvw7Plph6v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax effects of temporary differences giving rise to significant portions of the net deferred taxes as of December 31 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> <span id="xdx_8B1_znZFsfenrotf" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20231231_zzO8oya4Z7Hk" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20221231_zclMLNHV9rs3" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred income tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzjWa_zM2lZ3XeJQC4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carryforwards</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">849</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">482</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzjWa_zOM2uY9CkwQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">R&amp;D tax credit carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,863</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,723</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_pn3n3_maDTAGzjWa_zrVFUA5SRxzb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compensation costs</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">113</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_iI_pn3n3_maDTAGzjWa_ziTKeBycFYu8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vacation accrual</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">153</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">174</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzjWa_zokld4Eeo14j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">38</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopment_iI_pn3n3_maDTAGzjWa_zrYZPwszlaj2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capitalized research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">759</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">356</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzjWa_zPHytZ8RQDLb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other items</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">303</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">263</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzjWa_maDTANz0Q9_zKnB85pFFKb1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred income tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,078</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,035</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANz0Q9_zoJ7WogCiw61" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,646</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,957</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANz0Q9_maDTALNz5Um_zM5H2lNAMzii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred income tax assets, net of valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">432</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">78</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred incomes tax liability:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_msDTALNz5Um_zTVNC8l6ukte" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property, plant and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_pn3n3_di_msDTALNz5Um_zeTDd4T4ZZNe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(67</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(67</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNz5Um_zuPPeWrnG35a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred income tax asset, net</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0877">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A4_z0pKU7YVgdm1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that the deferred tax assets will be realized. The ultimate realization of deferred tax assets is based on the assessment of available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit the utilization of existing deferred tax assets. The Company considered all positive and negative evidence when determining the amount of the net deferred tax assets that are more likely than not to be realized. This evidence includes, but is not limited to, historical earnings, scheduled reversal of taxable temporary differences, tax planning strategies and projected future taxable income A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the prior three-year period ended December 31, 2023. Such objective evidence limits the ability to consider subjective evidence such as our projections for future growth. Based on this assessment, we maintained a full valuation allowance against our net deferred tax assets as of December 31, 2023, and 2022. If these estimates and assumptions change in the future, we may be required to reduce our existing valuation allowance resulting in less income tax expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023, the valuation allowance increased by approximately $<span id="xdx_904_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pn5n6_c20230101__20231231_zlCrT2eW7Sse" title="Increase in valuation allowance">0.7</span> million from the prior year primarily from current year operating losses for which no tax benefit was provided.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 10 – Income Taxes (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, 2023, the Company had $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember_zpRLpiRuD9Hg" title="Operating loss carryforwards">4.0</span> million of U.S. federal net operating loss carryforwards. <span id="xdx_90C_eus-gaap--OperatingLossCarryforwardsLimitationsOnUse_pid_dp_uPure_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember_zKb5UGfCsAE9" title="Operating loss carryforwards, limitations">These net operating losses have an indefinite carryforward period but are only available to offset 80% of future taxable income</span>. The Company also has $<span id="xdx_903_eus-gaap--TaxCreditCarryforwardAmount_iI_pn5n6_c20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_zCWJvoJLDDef" title="Tax credit carryforward.">1.9</span> million of federal research and development tax credits which <span id="xdx_907_eus-gaap--TaxCreditCarryforwardLimitationsOnUse_pn5n6_c20230101__20231231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember__us-gaap--IncomeTaxAuthorityNameAxis__us-gaap--InternalRevenueServiceIRSMember__us-gaap--TaxCreditCarryforwardAxis__us-gaap--ResearchMember_z1Mhi3Q6z6Fl" title="Tax credit carryforward expiration">expire in varying amounts in tax years 2028 through 2042</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies the applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2023 and 2022, the Company had <span id="xdx_90C_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20231231_zgGtEZbQ6wRk" title="Uncertain tax positions"><span id="xdx_90B_eus-gaap--UnrecognizedTaxBenefits_iI_do_c20221231_ziHDQhRmw4d7" title="Uncertain tax positions">no</span></span> uncertain tax positions. The Company does not expect that its unrecognized tax benefits will significantly increase or decrease within twelve months.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company files federal income tax returns and income tax returns in various state and local tax jurisdictions and in Denmark. <span id="xdx_905_eus-gaap--IncomeTaxExaminationDescription_c20230101__20231231_zJkdZP97oP12" title="Income tax examination, year">The federal tax years open to examination are 2020 to 2023. The Company’s state and local tax years that are open to tax examination are generally 2019 to 2023</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Inflation Reduction Act (“IRA”) and Chips and Science Act (“CHIPS Act”) were both enacted in August 2022. The IRA introduced new provisions including a 15% corporate alternative minimum tax for certain large corporations that have at least an average of $1 billion adjusted financial statement income over a consecutive three-tax-year period and a 1% excise tax surcharge on stock repurchases. The CHIPS Act provides a variety of incentives associated with investments in domestic semiconductor manufacturing and related activities. Both the IRA and CHIPS Act are applicable for tax years beginning after December 31, 2022 and had no impact to the Company’s consolidated financial statements for the years ended December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_894_eus-gaap--ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_z877JUzpUgX4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before income taxes are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zJv3lIHWQIS8" style="display: none">Schedule of Loss Before Income Taxes</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230101__20231231_zxZcrqlIQh8d" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20220101__20221231_zNyxSrjdW0Le" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_pn3n3_maILFCOzXdM_zEWdHJb17S1c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Domestic</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,073</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(596</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_pn3n3_maILFCOzXdM_zPrge4ig30O1" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Foreign</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(121</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">376</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_pn3n3_mtILFCOzXdM_zG8JQfB1YMSf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Total</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,194</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(220</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> </table> -4073000 -596000 -121000 376000 -4194000 -220000 <p id="xdx_895_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_z8D5NLg9lU43" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expense/(benefit) for income taxes for the years ended December 31 includes the following (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zR2Ykdm5AMZ7" style="display: none">Schedule of Components of Income Tax Expense (Benefit)</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_499_20230101__20231231_zvzEzTK8dRE8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_495_20220101__20221231_z6D8X2msAYNa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Current:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--CurrentFederalTaxExpenseBenefit_pn3n3_maCITEBzswH_zKGlHvpGkFhc" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(16</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--CurrentStateAndLocalTaxExpenseBenefit_pn3n3_maCITEBzswH_zyuARnHAadK3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">2</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--CurrentIncomeTaxExpenseBenefit_iT_pn3n3_mtCITEBzswH_maITEBzuuP_zYPRpJVYMXW6" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total current tax provision</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Deferred:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DeferredFederalIncomeTaxExpenseBenefit_pn3n3_maDITEBzJTX_zodxuH7iSu9a" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif">Federal</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0787">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0788">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredStateAndLocalIncomeTaxExpenseBenefit_pn3n3_maDITEBzJTX_zj5NvzgKc1dc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">State</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0790">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredIncomeTaxExpenseBenefit_iT_pn3n3_mtDITEBzJTX_maITEBzuuP_zFTVIv8VQwxl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Total deferred tax provision</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0793">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40B_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzuuP_z72aNI4JiXKg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income tax (benefit) expense</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> -16000 1000 2000 3000 -14000 4000 -14000 4000 <p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z2wHHoZZqgWh" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The reconciliation of the federal statutory income tax rate to our effective tax rate for the years ended December 31 is as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B2_zeDKjMjspwF9" style="display: none">Schedule of Effective Income Tax Rate Reconciliation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20230101__20231231_z2rwqYtv9NZ3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2023</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20220101__20221231_zFitVCVeTc2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> 2022</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_pn3n3_maITEBzHAV_zcSx6iRpEAEc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected provision at federal statutory tax rate at <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVmZmVjdGl2ZSBJbmNvbWUgVGF4IFJhdGUgUmVjb25jaWxpYXRpb24gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20230101__20231231_z0tdeQ4gNDYe" title="Federal statutory tax rate"><span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIEVmZmVjdGl2ZSBJbmNvbWUgVGF4IFJhdGUgUmVjb25jaWxpYXRpb24gKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20220101__20221231_zFqSsjJpQHg2" title="Federal statutory tax rate">21</span></span>%</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(881</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(46</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_pn3n3_maITEBzHAV_zjwTDSPTGVq4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Increase (decrease) in valuation allowance</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">688</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(33</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_407_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_pn3n3_maITEBzHAV_zVwgEW7snCT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">State and local taxes</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">21</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">84</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40D_eus-gaap--IncomeTaxReconciliationForeignIncomeTaxRateDifferential_maITEBzHAV_zxg03GBRWQJ2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Foreign tax rate differential</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_ecustom--EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperationsAmount_pn3n3_maITEBzHAV_zcii4IrIk1q8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">US taxation of foreign operations</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0817">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">80</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40A_eus-gaap--IncomeTaxReconciliationTaxCreditsResearch_iN_pn3n3_di_msITEBzHAV_z8bMeCKMyVHe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Federal research and development credits</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(75</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(55</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40E_eus-gaap--IncomeTaxReconciliationChangeInEnactedTaxRate_pn3n3_maITEBzHAV_znPUSiGmTLBi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Change in tax rates</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0823">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationNondeductibleExpense_pn3n3_maITEBzHAV_zDOTNenvAEZi" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Non-deductible expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">37</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">62</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--IncomeTaxReconciliationDispositionOfBusiness_pn3n3_maITEBzHAV_zBCwDhx5Utej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Disposition of Tantaline</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">193</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--IncomeTaxReconciliationOtherAdjustments_pn3n3_maITEBzHAV_zfMJxefDaeR9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Other</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(102</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_iT_pn3n3_mtITEBzHAV_zM9na2lCds89" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Income tax (benefit) expense</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(14</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 0.21 0.21 -881000 -46000 688000 -33000 21000 84000 -1000 4000 80000 75000 55000 10000 37000 62000 193000 4000 -102000 -14000 4000 <p id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zRvw7Plph6v1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The tax effects of temporary differences giving rise to significant portions of the net deferred taxes as of December 31 are as follows (in thousands):</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> <span id="xdx_8B1_znZFsfenrotf" style="display: none">Schedule of Deferred Tax Assets and Liabilities</span></b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20231231_zzO8oya4Z7Hk" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20221231_zclMLNHV9rs3" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred income tax assets:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pn3n3_maDTAGzjWa_zM2lZ3XeJQC4" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 60%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Net operating loss carryforwards</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">849</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">482</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_pn3n3_maDTAGzjWa_zOM2uY9CkwQ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">R&amp;D tax credit carryforwards</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,863</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,723</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_pn3n3_maDTAGzjWa_zrVFUA5SRxzb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Compensation costs</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">113</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">10</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences_iI_pn3n3_maDTAGzjWa_ziTKeBycFYu8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Vacation accrual</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">153</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">174</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_408_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_iI_pn3n3_maDTAGzjWa_zokld4Eeo14j" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Intangible assets</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">38</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_ecustom--DeferredTaxAssetsCapitalizedResearchAndDevelopment_iI_pn3n3_maDTAGzjWa_zrYZPwszlaj2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Capitalized research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">759</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">356</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_404_eus-gaap--DeferredTaxAssetsOther_iI_pn3n3_maDTAGzjWa_zPHytZ8RQDLb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other items</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">303</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">263</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGross_iTI_pn3n3_mtDTAGzjWa_maDTANz0Q9_zKnB85pFFKb1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred income tax assets</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,078</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,035</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pn3n3_di_msDTANz0Q9_zoJ7WogCiw61" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 20pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Less: valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,646</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,957</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsNet_iTI_pn3n3_mtDTANz0Q9_maDTALNz5Um_zM5H2lNAMzii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred income tax assets, net of valuation allowance</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">432</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">78</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred incomes tax liability:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxLiabilitiesPropertyPlantAndEquipment_iNI_pn3n3_di_msDTALNz5Um_zTVNC8l6ukte" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Property, plant and equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(365</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_eus-gaap--DeferredTaxLiabilitiesPrepaidExpenses_iNI_pn3n3_di_msDTALNz5Um_zeTDd4T4ZZNe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Prepaid expenses</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(67</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">(67</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_409_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pn3n3_mtDTALNz5Um_zuPPeWrnG35a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Deferred income tax asset, net</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0877">-</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 849000 482000 1863000 1723000 113000 10000 153000 174000 38000 27000 759000 356000 303000 263000 4078000 3035000 3646000 2957000 432000 78000 365000 11000 67000 67000 700000 4000000.0 These net operating losses have an indefinite carryforward period but are only available to offset 80% of future taxable income 1900000 expire in varying amounts in tax years 2028 through 2042 0 0 The federal tax years open to examination are 2020 to 2023. The Company’s state and local tax years that are open to tax examination are generally 2019 to 2023 <p id="xdx_806_ecustom--EmployeeRetentionCreditTextBlock_zYK16stfQS49" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 11 – <span id="xdx_828_zNWDKkJDAfa7">Employee Retention Credit</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2022, the Company conducted an analysis as to whether it was entitled to employee retention credits (“ERC”) under the CARES Act as amended by the Taxpayer Certainty and Disaster Tax Relief Act of 2020 and the American Plan Act of 2021. Based on the analysis, the Company determined that it was entitled to an ERC of approximately $<span id="xdx_90A_ecustom--IncreaseDecreaseInEmployeeRetentionCreditReceivable_pn5n6_c20220101__20221231_zsWrQRGpZZm" title="Employee retention credit eligible amount">1.5</span> million related to payroll paid in the first and third quarters of 2021 under the applicable Internal Revenue Service regulations related to ERCs.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As ERCs are not within the scope of ASC 740, <i>Income Taxes</i>, the Company has chosen to account for the ERCs by analogizing to the International Standard IAS 20, <i>Accounting for Government Grants and Disclosure of Government Assistance.</i> In accordance with IAS 20, an entity recognizes government grants only when there is reasonable assurance that the entity will comply with the conditions attached to them and the grants will be received. Accordingly, the Company recognized a non-current receivable of $<span id="xdx_901_ecustom--EmployeeRetentionCreditReceivableNoncurrent_iI_pn5n6_c20221231_zQ3oFjRWSOpl" title="Employee retention credit receivable noncurrent">1.5</span> million as of December 31, 2022 and other income of $<span id="xdx_905_ecustom--EmployeeRetentionTaxCreditsIncome_pn5n6_c20220101__20221231_zZnFiMFAFV1c" title="Employee retention credits">1.5</span> million for the year ended December 31, 2022. The Company received the ERC credit in July 2023.</span></p> 1500000 1500000 1500000 <p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z4KZOVz5achc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – <span id="xdx_827_zid4bzrt0uyf">Stock-Based Compensation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the Company’s Share Incentive Plans are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2007 Share Incentive Plan</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 12, 2007, shareholders approved the Company’s 2007 Share Incentive Plan (“2017 Incentive Plan”), in connection therewith, <span id="xdx_90A_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20071212__us-gaap--PlanNameAxis__custom--TwoThousandSevenShareIncentivePlanMember_zRaKyEmqkTb2" title="Common shares reserved for future issuance.">750,000</span> shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2017 Incentive Plan through December 12, 2017. The Plan expired in December 2017. As of December 31, 2023, there were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSevenShareIncentivePlanMember_zaIZlh4W8lYa" title="Number of options outstanding">120,000</span> options outstanding under this plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2016 Share Incentive Plan</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 9, 2016, shareholders approved the Company’s 2016 Share Incentive Plan (“2016 Incentive Plan”), in connection therewith, <span id="xdx_905_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20161209__us-gaap--PlanNameAxis__custom--TwoThousandSixteenShareIncentivePlanMember_zFHyRE7gALKf" title="Common shares reserved for future issuance.">750,000</span> shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2016 Incentive Plan through December 9, 2026. As of December 31, 2023, there were <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenShareIncentivePlanMember_zPWu4ofHth9i" title="Number of options outstanding">442,125</span> options outstanding under this plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">2022 Share Incentive Plan</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 14, 2022, shareholders approved the Company’s 2022 Share Incentive Plan (“2022 Incentive Plan”), in connection therewith, <span id="xdx_901_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20220714__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoShareIncentivePlanMember_zAfEC1ahM1N7" title="Common shares reserved for future issuance.">515,000</span> shares of the Company’s common stock are reserved for issuance pursuant to options or restricted stock that may be granted under the 2022 Incentive Plan through July 14, 2032. As of December 31, 2023, there were <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoShareIncentivePlanMember_zyD6qI4uyrD1" title="Number of options outstanding">284,750</span> options outstanding under this plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the 2016 and 2022 Share Incentive Plans, the purchase price of the common stock under each option plan shall be determined by the Committee, provided, however, that such purchase price shall not be less than the fair market value of the shares on the date such option is granted. The stock options generally expire <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dxL_c20220714__20220714__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoShareIncentivePlanMember__srt--RangeAxis__srt--MinimumMember_z7B6tP4bkTyc" title="Share based compensation arrangement by share based payment award expiration Period::XDX::P7Y"><span style="-sec-ix-hidden: xdx2ixbrl0917">seven</span></span> to <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20220714__20220714__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoShareIncentivePlanMember__srt--RangeAxis__srt--MaximumMember_zh7Lc2PlNZr7" title="Share based compensation arrangement by share based payment award expiration Period">ten years</span> after the date of grant.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As of December 31, 2023<i>, </i>there were <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandSixteenShareIncentivePlanMember_zLY5nuYSzxwa" title="Share based compensation arrangement by share based payment award, number of shares available for grant">26,948</span> shares available for grant under the 2016 Equity Incentive Plan and <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_c20231231__us-gaap--PlanNameAxis__custom--TwoThousandTwentyTwoShareIncentivePlanMember_zQu1IVtCtvKe" title="Number of shares available for grant">188,930</span> shares available for grant under the 2022 Equity Incentive Plan. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – Stock-Based Compensation (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recorded stock-based compensation of $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231_z0tQORJXY8rh" title="Stock based compensation">0.9</span> million and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20220101__20221231_zqecmkMXS192" title="Stock based compensation">0.4</span> million for the years ended December 31, 2023 and 2022, respectively, that were included in the following line items in our Consolidated Statements of Operations (in thousands):</span></p> <p id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z6cPKy3AHefj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zTgn2Tz8Jpbl" style="display: none">Schedule of Stock Based Compensation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20230101__20231231_zxg4nEkz8SSj" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20220101__20221231_zaYv2ZikIWQg" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__custom--CostOfRevenueMember_zsNqJdOXaCf8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Cost of revenue</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">120</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zivHxHFrnEud" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">159</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__custom--SellingExpenseMember_z4Hi1M8GBCD8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Selling</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">94</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6Yv0lb2WBfh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">535</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">317</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zmt2RwcaSAf2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total stock-based compensation expense</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">908</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">435</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A3_z3ItrN3X9CWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation expense in both years included approximately $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zHMgeOcSevz" title="Stock based compensation expenses"><span id="xdx_90C_eus-gaap--AllocatedShareBasedCompensationExpense_pn5n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z3LrlFYl92ll" title="Stock based compensation expenses">0.2</span></span> million related to restricted stock awards pursuant to a Director Compensation plan discussed below. The Company recognizes forfeitures of stock awards as they occur.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2023, the Company granted <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zy56HPmWROZb" title="Stock option granted">254,000</span> stock options, vesting <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_pid_dp_uPure_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znl3GnrI8L0k" title="Stock option vesting percentage">25</span>% per year over <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHBECGepT4da" title="Vesting period">four years</span>, with a <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z8VcqYtOaYTa" title="Expiration period::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl0956">ten-year</span></span> life. The Company determined the fair value of stock options granted during the year ended December 31, 2023 is based upon weighted average assumptions as provided below.</span></p> <p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zJwMgUDU0k88" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_ziutI4nvgz41" style="display: none">Schedule of Weighted Average Assumptions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20231231_zkJzEaGyJua1" style="width: 20%; text-align: right" title="Stock price"><span style="font-family: Times New Roman, Times, Serif">14.02</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Exercise price</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231_zYaFh4spe574" style="text-align: right" title="Exercise price"><span style="font-family: Times New Roman, Times, Serif">14.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231_zbrcPBpy3Di6" title="Dividend yield">0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20231231_zI2B0B8aJ4i" title="Expected volatility">72</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20231231_zdYeCVuIsHEc" title="Risk-free interest rate">3.39</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zcwORC4SOire" title="Expected life (in years)">6.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A4_zcPRtXfUow5a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The expected life is the number of years the Company estimates that the awards will be outstanding based on the simplified method that considers the vesting period and contractual period of the option. The Company has <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20231231_zUZJ7czQCTa5" title="Outstanding stock options">846,875</span> of outstanding stock options under the three plans at December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – Stock-Based Compensation (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuS0Tg3L2sqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock options awards for the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_z6JFbDy5kxcb" style="display: none">Schedule of Stock Options Awards</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Awards <br/>(in Shares)</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Weighted <br/>Average</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></p></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zR8gbA12mjGg" style="width: 16%; text-align: right" title="Stock option awards outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">618,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zcmVYzbps18j" style="width: 16%; text-align: right" title="Weighted average exercise price outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">11.26</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zzJjmArETzR9" style="text-align: right" title="Stock option awards, granted"><span style="font-family: Times New Roman, Times, Serif">198,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zlk3yjRoG6b2" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">5.04</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expired / cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_zcvEmKFBMUJ3" style="text-align: right" title="Stock option awards, expired / cancelled"><span style="font-family: Times New Roman, Times, Serif">(144,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zq7R0pr3KF99" style="text-align: right" title="Weighted average exercise price, expired / cancelled"><span style="font-family: Times New Roman, Times, Serif">11.72</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zikDIWEZmij5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock Option Awards, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0988">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zdyz70SrKLD2" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0990">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zmME6YZbOsOb" style="text-align: right" title="Stock option awards outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">673,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_z3pRtiC6cup6" style="text-align: right" title="Weighted average exercise price outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">5.70</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zo3sWyCIDYA7" style="text-align: right" title="Stock option awards, granted"><span style="font-family: Times New Roman, Times, Serif">254,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zmpUCCqgSWF5" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">14.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expired / cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zS4mTiToVao6" style="text-align: right" title="Stock option awards, expired / cancelled"><span style="font-family: Times New Roman, Times, Serif">(44,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z3yAUGX3CR6a" style="text-align: right" title="Weighted average exercise price, expired / cancelled"><span style="font-family: Times New Roman, Times, Serif">6.57</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zQoGEfZ9TQt" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock option awards, exercised"><span style="font-family: Times New Roman, Times, Serif">(35,625</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z5f6SJHNP4fe" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif">4.53</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zimrkVhD0hRc" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock option awards outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif">846,875</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zv9nNH0GrLJc" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif">8.20</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A1_za6ftv7D6Mbk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z77XExB9Prjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes information about the outstanding and exercisable options at December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zEcOVQfjWDe8" style="display: none">Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Exercisable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price Range</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zAFlkR7lL8Ue" title="Exercise Price Range">4.00</span>-<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zuujfaH8LMe2" title="Exercise Price Range">7.00</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zREyIOqk2r8h" style="width: 9%; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">463,375</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zs75y7e0iNXj" title="Number of options outstanding, weighted average remaining contractual term">7.9</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zmuJ8yhRk5Va" style="width: 9%; text-align: right" title="Number of options outstanding, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">4.55</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zfgWOJHMK2J8" style="width: 9%; text-align: right" title="Number of options outstanding, intrinsic value"><span style="font-family: Times New Roman, Times, Serif">76,655</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zITfsV0iaObk" style="width: 9%; text-align: right" title="Number of options exercisable"><span style="font-family: Times New Roman, Times, Serif">195,375</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zO1wJ6CTzHXb" style="width: 8%; text-align: right" title="Number of options exercisable, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">4.47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zBmip0rIicm2" style="width: 8%; text-align: right" title="Number of options exercisable, intrinsic value"><span style="font-family: Times New Roman, Times, Serif">37,064</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zB7NMXi5HYn5" title="Exercise Price Range">7.01</span>-<span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zORk3Fv5bWD2" title="Exercise Price Range">10.00</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z5Lbk84BRtwf" style="text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zCNbNGHif433" title="Number of options outstanding, weighted average remaining contractual term">4.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zKpm94apg1v7" style="text-align: right" title="Number of options outstanding, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">8.07</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zakwHGomQ2i5" style="text-align: right" title="Number of options outstanding, intrinsic value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zE8vTzABf17g" style="text-align: right" title="Number of options exercisable"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z5I6PipUUyLa" style="text-align: right" title="Number of options exercisable, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">8.07</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zcK9EdNoIyf5" style="text-align: right" title="Number of options exercisable, intrinsic value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zYEx3bTNA0Le" title="Exercise Price Range">10.01</span>-<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zVRlU9ywNY59" title="Exercise Price Range">13.00</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zdFs9QMNPZed" style="text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">130,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zs2mTrpyDGC1" title="Number of options outstanding, weighted average remaining contractual term">4.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z9BsF6gUOUKk" style="text-align: right" title="Number of options outstanding, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">11.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zP2hV0ObzuBa" style="text-align: right" title="Number of options outstanding, intrinsic value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zak4DkcZEkX3" style="text-align: right" title="Number of options exercisable"><span style="font-family: Times New Roman, Times, Serif">120,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zXbVL1Tp9WR8" style="text-align: right" title="Number of options exercisable, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">10.52</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zikj0Dhjgvni" style="text-align: right" title="Number of options exercisable, intrinsic value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_ztxckospTbTd" title="Exercise price range, lower limit">13.01</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zYPr82yhCe1i" title="Exercise price range, upper limit">16.00</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zY8h63aqZ9E" style="text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">233,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zh4BhYA5us7j" title="Number of options outstanding, weighted average remaining contractual term">9.2</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zyYAKGQYpTDf" style="text-align: right" title="Number of options outstanding, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">14.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zsumoV6tdKr3" style="text-align: right" title="Number of options outstanding, intrinsic value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zyofgOCDVgBh" style="text-align: right" title="Number of options exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zyvRMrP6AVI6" style="text-align: right" title="Number of options exercisable, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1082">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zHCTy6uDjDl3" style="text-align: right" title="Number of options exercisable, intrinsic value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1084">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8AE_zvcGrE75zpie" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2023, there was $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zeApNPPbU1ag" title="Unrecognized compensation costs">2.4 </span>million of unrecognized compensation costs related to stock options expected to be recognized over a weighted average period of <span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTXjJjswc0jb" title="Unrecognized compensation costs, recoginition period">2.6</span> years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Restricted Stock Awards</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the Director Compensation plan approved on October 11, 2021<i>, </i>each of the five independent directors is entitled to compensation for an annual equity retainer in the amount of $<span id="xdx_905_ecustom--SharebasedPaymentArrangementAnnualEquityRetainerAmount_iI_c20211011__srt--TitleOfIndividualAxis__custom--FiveDirectorsMember_zgYynahutjkb" title="Annual equity retainer amount">40,000</span> per director, to be automatically granted on the date of the Company’s annual meeting of shareholders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 12 – Stock-Based Compensation (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zRsPc6cihWYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes restricted stock awards for the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zJEzk49iKHr7" style="display: none">Schedule of Restricted Stock Awards</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average Grant</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares of</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Date Fair</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Unvested outstanding at January 1, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqi1k0F9oU6h" style="text-align: right" title="Unvested outstanding, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1094">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFV0mCwRg1Bk" style="text-align: right" title="Unvested outstanding, weighted average grant date fair value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1096">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuHkzzkcVftk" style="width: 16%; text-align: right" title="Granted, shares"><span style="font-family: Times New Roman, Times, Serif">32,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFOgZwHfbtpi" style="width: 16%; text-align: right" title="Granted, weighted average grant date fair value"><span style="font-family: Times New Roman, Times, Serif">5.02</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3pqXsteSNN5" style="text-align: right" title="Vested, shares"><span style="font-family: Times New Roman, Times, Serif">(32,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zsKwQlwnR5O7" style="text-align: right" title="Vested, weighted average"><span style="font-family: Times New Roman, Times, Serif">5.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited or cancelled</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1RXYjH2YXG1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zq9Wmvx559pa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited, weighted average grant date fair value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Unvested outstanding at December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjPIJ7Cji7L8" style="text-align: right" title="Shares of restricted stock, unvested outstanding"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zExavebxSRC1" style="text-align: right" title="Weighted average grant date fair value, unvested outstanding"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7APAxADcsq8" style="text-align: right" title="Shares of restricted stock, granted"><span style="font-family: Times New Roman, Times, Serif">41,320</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBdbUsZI8rpa" style="text-align: right" title="Weighted average grant date fair value, granted"><span style="font-family: Times New Roman, Times, Serif">6.65</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUVo9cWCxEci" style="text-align: right" title="Shares of restricted stock, vested"><span style="font-family: Times New Roman, Times, Serif">(24,187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMPEb43jw04i" style="text-align: right" title="Weighted average grant date fair value, vested"><span style="font-family: Times New Roman, Times, Serif">6.81</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Forfeited or cancelled</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKstezA1GgU2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares of restricted stock, forfeited or cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkZAhjkxo5If" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited or cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested outstanding at December 31, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKqWmHalUZ3" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares of restricted stock, unvested outstanding"><span style="font-family: Times New Roman, Times, Serif">17,133</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4ZImpPk2AO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, unvested outstanding"><span style="font-family: Times New Roman, Times, Serif">6.53</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p id="xdx_8A6_zvn6nEMk62aa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The fair value of the restricted stock awards is recorded as stock-based compensation expense over the <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zVRBHcGQE5I3" title="Vesting period::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1130">one-year</span></span> vesting period and totaled $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_pn4n6_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zXjDIkcluFil" title="Stock based compensation">0.17</span> million $<span id="xdx_90D_eus-gaap--AllocatedShareBasedCompensationExpense_pn4n6_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zPkwTHuIU3i" title="Stock based compensation">0.16</span> million for the years ending December 31, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Restricted Stock Units</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In prior years, the Company issued restricted stock units or RSUs. During the year ended December 31, 2022, <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zPoWDELyCPEi" title="Restricted stock units, vested">5,500</span> RSUs vested which had an intrinsic value of $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zkjmOVTJDC5d" title="Restricted stock units vested, intrinsic value">22,745</span>. <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_do_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zr80ZmPA5Rch" title="Restricted stock units, vested">No</span> restricted stock units vested during the year ended December 31, 2023 and there were <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_do_c20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zmF6EL90gdzi" title="Restricted stock units outstanding"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_do_c20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z2WT35sRGcXj" title="Restricted stock units outstanding">no</span></span> RSUs outstanding as of December 31, 2023 and 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 750000 120000 750000 442125 515000 284750 P10Y 26948 188930 900000 400000 <p id="xdx_897_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z6cPKy3AHefj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zTgn2Tz8Jpbl" style="display: none">Schedule of Stock Based Compensation</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20230101__20231231_zxg4nEkz8SSj" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2023</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_493_20220101__20221231_zaYv2ZikIWQg" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__custom--CostOfRevenueMember_zsNqJdOXaCf8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Cost of revenue</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">120</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">34</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zivHxHFrnEud" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Research and development</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">159</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">57</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__custom--SellingExpenseMember_z4Hi1M8GBCD8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Selling</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">94</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">27</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_403_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z6Yv0lb2WBfh" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">General and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">535</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">317</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_405_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_zmt2RwcaSAf2" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total stock-based compensation expense</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">908</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">435</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 120000 34000 159000 57000 94000 27000 535000 317000 908000 435000 200000 200000 254000 0.25 P4Y <p id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zJwMgUDU0k88" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_ziutI4nvgz41" style="display: none">Schedule of Weighted Average Assumptions</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%"><span style="font-family: Times New Roman, Times, Serif">Stock price</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--SharePrice_iI_pid_c20231231_zkJzEaGyJua1" style="width: 20%; text-align: right" title="Stock price"><span style="font-family: Times New Roman, Times, Serif">14.02</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Exercise price</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_pid_c20231231_zYaFh4spe574" style="text-align: right" title="Exercise price"><span style="font-family: Times New Roman, Times, Serif">14.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Dividend yield</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_c20230101__20231231_zbrcPBpy3Di6" title="Dividend yield">0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected volatility</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_c20230101__20231231_zI2B0B8aJ4i" title="Expected volatility">72</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Risk-free interest rate</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_c20230101__20231231_zdYeCVuIsHEc" title="Risk-free interest rate">3.39</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expected life (in years)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231_zcwORC4SOire" title="Expected life (in years)">6.00</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 14.02 14.02 0 0.72 0.0339 P6Y 846875 <p id="xdx_897_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuS0Tg3L2sqg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes stock options awards for the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_z6JFbDy5kxcb" style="display: none">Schedule of Stock Options Awards</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Awards <br/>(in Shares)</span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Weighted <br/>Average</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif">Exercise Price</span></p></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2021</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zR8gbA12mjGg" style="width: 16%; text-align: right" title="Stock option awards outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">618,500</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231_zcmVYzbps18j" style="width: 16%; text-align: right" title="Weighted average exercise price outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">11.26</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20221231_zzJjmArETzR9" style="text-align: right" title="Stock option awards, granted"><span style="font-family: Times New Roman, Times, Serif">198,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zlk3yjRoG6b2" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">5.04</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expired / cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20221231_zcvEmKFBMUJ3" style="text-align: right" title="Stock option awards, expired / cancelled"><span style="font-family: Times New Roman, Times, Serif">(144,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zq7R0pr3KF99" style="text-align: right" title="Weighted average exercise price, expired / cancelled"><span style="font-family: Times New Roman, Times, Serif">11.72</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220101__20221231_zikDIWEZmij5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock Option Awards, Exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0988">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231_zdyz70SrKLD2" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0990">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zmME6YZbOsOb" style="text-align: right" title="Stock option awards outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">673,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231_z3pRtiC6cup6" style="text-align: right" title="Weighted average exercise price outstanding, beginning balance"><span style="font-family: Times New Roman, Times, Serif">5.70</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20230101__20231231_zo3sWyCIDYA7" style="text-align: right" title="Stock option awards, granted"><span style="font-family: Times New Roman, Times, Serif">254,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_zmpUCCqgSWF5" style="text-align: right" title="Weighted average exercise price, granted"><span style="font-family: Times New Roman, Times, Serif">14.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Expired / cancelled</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20230101__20231231_zS4mTiToVao6" style="text-align: right" title="Stock option awards, expired / cancelled"><span style="font-family: Times New Roman, Times, Serif">(44,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z3yAUGX3CR6a" style="text-align: right" title="Weighted average exercise price, expired / cancelled"><span style="font-family: Times New Roman, Times, Serif">6.57</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Exercised</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20230101__20231231_zQoGEfZ9TQt" style="border-bottom: Black 1.5pt solid; text-align: right" title="Stock option awards, exercised"><span style="font-family: Times New Roman, Times, Serif">(35,625</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231_z5f6SJHNP4fe" style="padding-bottom: 1.5pt; text-align: right" title="Weighted average exercise price, exercised"><span style="font-family: Times New Roman, Times, Serif">4.53</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Outstanding at December 31, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zimrkVhD0hRc" style="border-bottom: Black 2.5pt double; text-align: right" title="Stock option awards outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif">846,875</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231_zv9nNH0GrLJc" style="padding-bottom: 2.5pt; text-align: right" title="Weighted average exercise price outstanding, ending balance"><span style="font-family: Times New Roman, Times, Serif">8.20</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 618500 11.26 198500 5.04 144000 11.72 673000 5.70 254000 14.02 44500 6.57 35625 4.53 846875 8.20 <p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_z77XExB9Prjb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes information about the outstanding and exercisable options at December 31, 2023:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BF_zEcOVQfjWDe8" style="display: none">Schedule of Outstanding and Exercisable Options Ranges of Exercise Prices</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Options Exercisable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Remaining</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Number</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercise</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Intrinsic</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price Range</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Outstanding</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Contractual</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Exercisable</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zAFlkR7lL8Ue" title="Exercise Price Range">4.00</span>-<span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zuujfaH8LMe2" title="Exercise Price Range">7.00</span></span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zREyIOqk2r8h" style="width: 9%; text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">463,375</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zs75y7e0iNXj" title="Number of options outstanding, weighted average remaining contractual term">7.9</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zmuJ8yhRk5Va" style="width: 9%; text-align: right" title="Number of options outstanding, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">4.55</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zfgWOJHMK2J8" style="width: 9%; text-align: right" title="Number of options outstanding, intrinsic value"><span style="font-family: Times New Roman, Times, Serif">76,655</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zITfsV0iaObk" style="width: 9%; text-align: right" title="Number of options exercisable"><span style="font-family: Times New Roman, Times, Serif">195,375</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zO1wJ6CTzHXb" style="width: 8%; text-align: right" title="Number of options exercisable, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">4.47</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zBmip0rIicm2" style="width: 8%; text-align: right" title="Number of options exercisable, intrinsic value"><span style="font-family: Times New Roman, Times, Serif">37,064</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_90B_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zB7NMXi5HYn5" title="Exercise Price Range">7.01</span>-<span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zORk3Fv5bWD2" title="Exercise Price Range">10.00</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z5Lbk84BRtwf" style="text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zCNbNGHif433" title="Number of options outstanding, weighted average remaining contractual term">4.3</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zKpm94apg1v7" style="text-align: right" title="Number of options outstanding, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">8.07</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zakwHGomQ2i5" style="text-align: right" title="Number of options outstanding, intrinsic value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1042">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zE8vTzABf17g" style="text-align: right" title="Number of options exercisable"><span style="font-family: Times New Roman, Times, Serif">20,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_z5I6PipUUyLa" style="text-align: right" title="Number of options exercisable, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">8.07</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zcK9EdNoIyf5" style="text-align: right" title="Number of options exercisable, intrinsic value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1048">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_903_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zYEx3bTNA0Le" title="Exercise Price Range">10.01</span>-<span id="xdx_902_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zVRlU9ywNY59" title="Exercise Price Range">13.00</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zdFs9QMNPZed" style="text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">130,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zs2mTrpyDGC1" title="Number of options outstanding, weighted average remaining contractual term">4.0</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z9BsF6gUOUKk" style="text-align: right" title="Number of options outstanding, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">11.51</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zP2hV0ObzuBa" style="text-align: right" title="Number of options outstanding, intrinsic value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1060">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zak4DkcZEkX3" style="text-align: right" title="Number of options exercisable"><span style="font-family: Times New Roman, Times, Serif">120,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zXbVL1Tp9WR8" style="text-align: right" title="Number of options exercisable, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">10.52</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zikj0Dhjgvni" style="text-align: right" title="Number of options exercisable, intrinsic value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">$ <span id="xdx_90C_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_ztxckospTbTd" title="Exercise price range, lower limit">13.01</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zYPr82yhCe1i" title="Exercise price range, upper limit">16.00</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zY8h63aqZ9E" style="text-align: right" title="Number of options outstanding"><span style="font-family: Times New Roman, Times, Serif">233,500</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zh4BhYA5us7j" title="Number of options outstanding, weighted average remaining contractual term">9.2</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zyYAKGQYpTDf" style="text-align: right" title="Number of options outstanding, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif">14.11</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zsumoV6tdKr3" style="text-align: right" title="Number of options outstanding, intrinsic value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1078">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zyofgOCDVgBh" style="text-align: right" title="Number of options exercisable"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1080">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zyvRMrP6AVI6" style="text-align: right" title="Number of options exercisable, weighted average exercise price"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1082">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20231231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeFourMember_zHCTy6uDjDl3" style="text-align: right" title="Number of options exercisable, intrinsic value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1084">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 4.00 7.00 463375000 P7Y10M24D 4.55 76655000 195375000 4.47 37064000 7.01 10.00 20000000 P4Y3M18D 8.07 20000000 8.07 10.01 13.00 130000000 P4Y 11.51 120000000 10.52 13.01 16.00 233500000 P9Y2M12D 14.11 2400000 P2Y7M6D 40000 <p id="xdx_89D_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_zRsPc6cihWYk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes restricted stock awards for the years ended December 31, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BD_zJEzk49iKHr7" style="display: none">Schedule of Restricted Stock Awards</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Weighted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Average Grant</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Shares of</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="text-align: center"><span style="font-family: Times New Roman, Times, Serif">Date Fair</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Restricted Stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Value</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Unvested outstanding at January 1, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zqi1k0F9oU6h" style="text-align: right" title="Unvested outstanding, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1094">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFV0mCwRg1Bk" style="text-align: right" title="Unvested outstanding, weighted average grant date fair value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1096">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuHkzzkcVftk" style="width: 16%; text-align: right" title="Granted, shares"><span style="font-family: Times New Roman, Times, Serif">32,000</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zFOgZwHfbtpi" style="width: 16%; text-align: right" title="Granted, weighted average grant date fair value"><span style="font-family: Times New Roman, Times, Serif">5.02</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z3pqXsteSNN5" style="text-align: right" title="Vested, shares"><span style="font-family: Times New Roman, Times, Serif">(32,000</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zsKwQlwnR5O7" style="text-align: right" title="Vested, weighted average"><span style="font-family: Times New Roman, Times, Serif">5.02</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Forfeited or cancelled</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1RXYjH2YXG1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited, shares"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1106">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20220101__20221231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zq9Wmvx559pa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited, weighted average grant date fair value"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1108">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Unvested outstanding at December 31, 2022</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zjPIJ7Cji7L8" style="text-align: right" title="Shares of restricted stock, unvested outstanding"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1110">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zExavebxSRC1" style="text-align: right" title="Weighted average grant date fair value, unvested outstanding"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1112">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Granted</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7APAxADcsq8" style="text-align: right" title="Shares of restricted stock, granted"><span style="font-family: Times New Roman, Times, Serif">41,320</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zBdbUsZI8rpa" style="text-align: right" title="Weighted average grant date fair value, granted"><span style="font-family: Times New Roman, Times, Serif">6.65</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Vested</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zUVo9cWCxEci" style="text-align: right" title="Shares of restricted stock, vested"><span style="font-family: Times New Roman, Times, Serif">(24,187</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zMPEb43jw04i" style="text-align: right" title="Weighted average grant date fair value, vested"><span style="font-family: Times New Roman, Times, Serif">6.81</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Forfeited or cancelled</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKstezA1GgU2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares of restricted stock, forfeited or cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1122">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zkZAhjkxo5If" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value, forfeited or cancelled"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1124">-</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Unvested outstanding at December 31, 2023</span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKqWmHalUZ3" style="border-bottom: Black 2.5pt double; text-align: right" title="Shares of restricted stock, unvested outstanding"><span style="font-family: Times New Roman, Times, Serif">17,133</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_c20230101__20231231__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4ZImpPk2AO1" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average grant date fair value, unvested outstanding"><span style="font-family: Times New Roman, Times, Serif">6.53</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 32000000 5.02 32000000 5.02 41320000 6.65 24187000 6.81 17133000 6.53 170000 160000 5500 22745 0 0 0 <p id="xdx_804_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zqW00ZARPuXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 13 – <span id="xdx_820_zxxIkDOSpUqj">Defined Contribution Plan</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains a 401(k) Plan for the benefit of all eligible employees. All employees as of the effective date of the 401(k) Plan became eligible. An employee is eligible to become a participant after three months of continuous service.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Participants may elect to contribute from their compensation any amount up to the maximum deferral allowed by the Internal Revenue Code. Employer contributions are optional.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective July 1, 2022, the Company implemented a matching contribution of <span id="xdx_903_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_dp_uPure_c20220701__20220701_z4bkBFPwhw49" title="Defined contribution plan percentage">50</span>% of an employee’s contributions up to <span id="xdx_904_eus-gaap--DefinedContributionPlanEmployerMatchingContributionPercent_dp_uPure_c20220701__20220701_zGs0Hdu2PlH9" title="Defined contribution plan percentage of employees contribution">6</span>% of their compensation. The Company recorded compensation expense of $<span id="xdx_90E_eus-gaap--DefinedContributionPlanCostRecognized_c20230101__20231231_znWvCnGwxrs" title="Defined contribution plan cost">243,000</span> and $<span id="xdx_90C_eus-gaap--DefinedContributionPlanCostRecognized_c20220101__20221231_z7uZXpgOp5I3" title="Defined contribution plan, compensation expense">90,000</span> during the years ended December 31, 2023 and 2022, respectively, for matching contributions to the 401(k) plan.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_do_c20230101__20231231_zNHOuYjfrDOl" title="Defined contribution plan cost employer discretionary contribution amount"><span id="xdx_90B_eus-gaap--DefinedContributionPlanEmployerDiscretionaryContributionAmount_do_c20220101__20221231_zTavbYAEwqx8" title="Defined contribution plan, employer discretionary contribution amount">No</span></span> discretionary employer contribution has been made for 2023 and 2022.</span></p> 0.50 0.06 243000 90000 0 0 <p id="xdx_808_eus-gaap--SegmentReportingDisclosureTextBlock_zXSVCKy1xEJ5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 14 – <span id="xdx_827_zJsPqc0MVMej">Segment Reporting</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates through <span id="xdx_903_eus-gaap--NumberOfOperatingSegments_pid_dc_uSegment_c20230101__20231231_zAJ1Gp0r0cMf" title="Number of operating segments">three</span> segments: CVD Equipment, Stainless Design Concepts (“SDC”) and CVD Materials. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport and similar equipment. SDC manufactures ultra-high purity gas control systems. The CVD Materials segment provides material coatings for aerospace, medical, electronic and other applications. The Company evaluates performance based on several factors, of which the primary financial measure is income (loss) before taxes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s corporate administration activities are reported in the “Corporate” column. These activities primarily include expenses related to certain corporate officers and support staff, expenses related to the Company’s Board of Directors, stock option expense for shares granted to corporate administration employees, certain consulting expenses, investor and shareholder relations activities, and all of the Company’s legal, auditing and professional fees, and interest expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Elimination entries included in the “Eliminations” column represent intersegment revenues and cost of revenues that are eliminated in consolidation. Intersegment sales for the year ended December 31, 2023 and 2022 by the SDC segment to the CVD Equipment segment were $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zzvuvQ2fxgmi" title="Revenue from contract with customer, including assessed tax">439,000</span> and $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20220101__20221231__srt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zXMWoqahlnXd" title="Revenue from contract with customer, including assessed tax">573,000</span>, respectively. <span style="background-color: white">Intersegment sales by the CVD Equipment segment to the SDC segment for the year ended December 31, 2023 were $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDEquipmentMember_zbgFdbo8HPng" title="Revenue">109,000</span>. There were <span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_do_c20220101__20221231__srt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDEquipmentMember_zblfy37zw8U7" title="Revenue">no</span> intersegment sales by the CVD Equipment segment to the SDC segment during the year ended December 31, 2022.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zu0VkM2cB6pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents certain information regarding the Company’s segments as of and for the years ended December 31, 2023 and December 31, 2022 (in thousands, including amount in notes): </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zWjWYjf67LPc" style="display: none">Schedule of Segments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2023</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDEquipmentMember_zFDnknpfnyC5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">CVD Equipment</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49B_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zLMdcNpMEqp6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">SDC</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember_zNrJja4xABAa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">CVD Materials</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zQ23M6ZlhV8i" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Corporate</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember_zRQdjo9ej9A3" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Eliminations</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230101__20231231_zRKm22zUnb92" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Consolidated</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif">Assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDEquipmentMember_zLymT5lit5Dc" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">31,401</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zoLA9qEyAJR7" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">3,468</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember_z8g3hq4YYcx" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">211</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zUZeHUVQf5Jf" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1180">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember_z2xmNJEC3gP5" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">(55</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--Assets_iI_pn3n3_c20231231_zZIwLVptd5Kk" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">35,025</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zJh8NtMi3qv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,139</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,184</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1189">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(548</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,109</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_zuu7m114ez9f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating (loss) <br/>income<span id="xdx_F47_zrGvaicsryHh">(1)</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,129</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,677</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(193</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,118</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(118</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,881</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zToG34aqcxR6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pretax (loss) income <span id="xdx_F4E_zdxRG8wO2OX9">(1)</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,070</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,677</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(141</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,542</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(118</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,194</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_406_eus-gaap--DepreciationAndAmortization_pn3n3_ziDv99yXQeU6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation and amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">620</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">123</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1210">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--SegmentExpenditureAdditionToLongLivedAssets_pn3n3_zOvUO3nckuEg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Purchases of property, <br/>plant &amp; equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">404</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">418</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2022</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20220101__20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDEquipmentMember_z1Rf8Ucm92l6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD Equipment </b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20220101__20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zakcT9ot4Ix4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">SDC</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20220101__20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember_z5AfFqF3aCx" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">CVD Materials</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20220101__20221231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zMsmWiaQ5Mgc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Corporate</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20220101__20221231__srt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember_ziVG4SAdAyN8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Eliminations</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20220101__20221231_zJ4dztNVXrEb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Consolidated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif">Assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDEquipmentMember_zCSUiLxMseBi" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">31,622</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--Assets_iI_pn3n3_c20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_ze6N0zbDaMP1" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">4,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember_zZ1TO6Ezh1d1" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">2,099</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--Assets_iI_pn3n3_c20221231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zgSAwrW9M7j9" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--Assets_iI_pn3n3_c20221231__srt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember_z7CESQViOUCg" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">42</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--Assets_iI_pn3n3_c20221231_zaYhyFTMgrD3" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">37,912</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zPYcTAgWuS56" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,674</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,541</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,171</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(573</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,813</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_zLXGA2y1LwX2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating (loss) income</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,430</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,546</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,050</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,989</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1244">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,823</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zG3JYW3poLu2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pretax (loss) income <span id="xdx_F4B_zla1YYbLB5Y1">(2)</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(156</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,849</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,076</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,989</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1251">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(220</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_406_eus-gaap--DepreciationAndAmortization_pn3n3_zx4ZXjxVjtXf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation and amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">652</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">166</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1257">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1258">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">867</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--SegmentExpenditureAdditionToLongLivedAssets_pn3n3_zc52lnrbA0ma" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Purchases of property, plant &amp; equipment <span id="xdx_F4A_ziAvTIvcpeeb">(3)</span></td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1266">-</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0C_z4SOBP2r5eTj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zTNpLuopQr44" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CVD Materials segment includes loss on sale of Tantaline of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNlZ21lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--GainLossOnSaleOfBusiness_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_z6qtkrSn93Rc" title="Loss on disposition of tantaline">0.2</span> million and an impairment charge related to MesoScribe fixed assets of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNlZ21lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zqYExVcbAbv1" title="Asset impairment charges">0.1</span> million.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F08_zqGohyfTcxji" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zOb4E6cgUXi6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes other income related to ERCs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNlZ21lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--OtherIncome_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--CVDEquipmentMember_zQYLDNpnEZ31" title="Other income">1,103</span>, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNlZ21lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--OtherIncome_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zmroeiOnKD58" title="Other income">303</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNlZ21lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--OtherIncome_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember_zPxcyR1AJEC2" title="Other income related to ERC">123</span> for the CVD, SDC and Materials segments, respectively.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F04_zm8DTnU6z7x" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zw127Rw4rhmf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Include $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNlZ21lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--LoanToFundAcquisitionOfMachineryEquipment_iI_pn5n6_c20221231_zmkv7UrBnFrh" title="Loan to fund acquisition of machinery equipment">0.4</span> million of purchased equipment financed with a loan</span></td></tr> </table> <p id="xdx_8A2_zvIgKJsh0HSl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 3 439000 573000 109000 0 <p id="xdx_893_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zu0VkM2cB6pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents certain information regarding the Company’s segments as of and for the years ended December 31, 2023 and December 31, 2022 (in thousands, including amount in notes): </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 9pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zWjWYjf67LPc" style="display: none">Schedule of Segments</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2023</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_496_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDEquipmentMember_zFDnknpfnyC5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">CVD Equipment</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49B_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zLMdcNpMEqp6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">SDC</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_498_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember_zNrJja4xABAa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">CVD Materials</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_497_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zQ23M6ZlhV8i" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Corporate</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20230101__20231231__srt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember_zRQdjo9ej9A3" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Eliminations</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49A_20230101__20231231_zRKm22zUnb92" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif">Consolidated</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif">Assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDEquipmentMember_zLymT5lit5Dc" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">31,401</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98A_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zoLA9qEyAJR7" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">3,468</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98C_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember_z8g3hq4YYcx" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">211</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98E_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zUZeHUVQf5Jf" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1180">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_985_eus-gaap--Assets_iI_pn3n3_c20231231__srt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember_z2xmNJEC3gP5" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">(55</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--Assets_iI_pn3n3_c20231231_zZIwLVptd5Kk" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">35,025</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_407_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zJh8NtMi3qv1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,334</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">7,139</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,184</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1189">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(548</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">24,109</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_zuu7m114ez9f" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating (loss) <br/>income<span id="xdx_F47_zrGvaicsryHh">(1)</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,129</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,677</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(193</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,118</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(118</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,881</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zToG34aqcxR6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pretax (loss) income <span id="xdx_F4E_zdxRG8wO2OX9">(1)</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,070</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,677</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(141</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(3,542</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(118</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(4,194</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_406_eus-gaap--DepreciationAndAmortization_pn3n3_ziDv99yXQeU6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation and amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">620</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">123</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1210">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1211">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">792</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--SegmentExpenditureAdditionToLongLivedAssets_pn3n3_zOvUO3nckuEg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Purchases of property, <br/>plant &amp; equipment</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">404</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">14</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1216">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1217">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1218">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">418</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline">2022</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20220101__20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDEquipmentMember_z1Rf8Ucm92l6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD Equipment </b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49C_20220101__20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zakcT9ot4Ix4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">SDC</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20220101__20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember_z5AfFqF3aCx" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">CVD Materials</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_490_20220101__20221231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zMsmWiaQ5Mgc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Corporate</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_491_20220101__20221231__srt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember_ziVG4SAdAyN8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Eliminations</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" id="xdx_49D_20220101__20221231_zJ4dztNVXrEb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Consolidated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif">Assets</span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_98D_eus-gaap--Assets_iI_pn3n3_c20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDEquipmentMember_zCSUiLxMseBi" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">31,622</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--Assets_iI_pn3n3_c20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_ze6N0zbDaMP1" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">4,149</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_983_eus-gaap--Assets_iI_pn3n3_c20221231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember_zZ1TO6Ezh1d1" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">2,099</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_988_eus-gaap--Assets_iI_pn3n3_c20221231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zgSAwrW9M7j9" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1227">-</span></span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_982_eus-gaap--Assets_iI_pn3n3_c20221231__srt--ConsolidationItemsAxis__us-gaap--IntersegmentEliminationMember_z7CESQViOUCg" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">42</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td id="xdx_981_eus-gaap--Assets_iI_pn3n3_c20221231_zaYhyFTMgrD3" style="width: 6%; text-align: right" title="Assets"><span style="font-family: Times New Roman, Times, Serif">37,912</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3n3_zPYcTAgWuS56" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="font-family: Times New Roman, Times, Serif">Revenue</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">16,674</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,541</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">3,171</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1236">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(573</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">25,813</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_40E_eus-gaap--OperatingIncomeLoss_pn3n3_zLXGA2y1LwX2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Operating (loss) income</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,430</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,546</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,050</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,989</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1244">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(1,823</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_402_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_pn3n3_zG3JYW3poLu2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Pretax (loss) income <span id="xdx_F4B_zla1YYbLB5Y1">(2)</span></span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(156</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,849</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,076</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(2,989</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1251">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">(220</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr id="xdx_406_eus-gaap--DepreciationAndAmortization_pn3n3_zx4ZXjxVjtXf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Depreciation and amortization</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">652</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">49</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">166</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1257">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1258">-</span></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">867</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr id="xdx_400_eus-gaap--SegmentExpenditureAdditionToLongLivedAssets_pn3n3_zc52lnrbA0ma" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Purchases of property, plant &amp; equipment <span id="xdx_F4A_ziAvTIvcpeeb">(3)</span></td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">653</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">3</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1264">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1266">-</span></td><td style="text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_F0C_z4SOBP2r5eTj" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1C_zTNpLuopQr44" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CVD Materials segment includes loss on sale of Tantaline of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNlZ21lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_902_eus-gaap--GainLossOnSaleOfBusiness_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_z6qtkrSn93Rc" title="Loss on disposition of tantaline">0.2</span> million and an impairment charge related to MesoScribe fixed assets of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNlZ21lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20231231__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zqYExVcbAbv1" title="Asset impairment charges">0.1</span> million.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F08_zqGohyfTcxji" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F1E_zOb4E6cgUXi6" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes other income related to ERCs of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNlZ21lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90E_eus-gaap--OtherIncome_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--CVDEquipmentMember_zQYLDNpnEZ31" title="Other income">1,103</span>, $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNlZ21lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_909_eus-gaap--OtherIncome_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--SDCMember_zmroeiOnKD58" title="Other income">303</span> and $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNlZ21lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90A_eus-gaap--OtherIncome_pn3n3_c20220101__20221231__us-gaap--StatementBusinessSegmentsAxis__custom--CVDMaterialsMember_zPxcyR1AJEC2" title="Other income related to ERC">123</span> for the CVD, SDC and Materials segments, respectively.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_F04_zm8DTnU6z7x" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_F18_zw127Rw4rhmf" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Include $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNjaGVkdWxlIG9mIFNlZ21lbnRzIChEZXRhaWxzKSAoUGFyZW50aGV0aWNhbCkA" id="xdx_90F_ecustom--LoanToFundAcquisitionOfMachineryEquipment_iI_pn5n6_c20221231_zmkv7UrBnFrh" title="Loan to fund acquisition of machinery equipment">0.4</span> million of purchased equipment financed with a loan</span></td></tr> </table> 31401000 3468000 211000 -55000 35025000 16334000 7139000 1184000 -548000 24109000 -2129000 1677000 -193000 -4118000 -118000 -4881000 -2070000 1677000 -141000 -3542000 -118000 -4194000 620000 49000 123000 792000 404000 14000 418000 31622000 4149000 2099000 42000 37912000 16674000 6541000 3171000 -573000 25813000 -1430000 1546000 1050000 -2989000 -1823000 -156000 1849000 1076000 -2989000 -220000 652000 49000 166000 867000 653000 3000 3000 200000 100000 1103000 303000 123000 400000 <p id="xdx_807_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zPaIDrX1eWfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 15 – <span id="xdx_828_zk62BI9g4jB4">CVD Materials – Tantaline and MesoScribe Subsidiaries</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>Tantaline Subsidiary</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On May 26, 2023, the Company sold its Tantaline subsidiary located in Nordborg, Denmark in exchange for a nominal amount at closing and an earn-out provision based on any net income that Tantaline may earn during the five-year period ending December 31, 2027. The Company recorded a loss of $<span id="xdx_905_eus-gaap--GainLossOnSaleOfBusiness_pn5n6_c20230526__20230526__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_zncXg0tcn4Ck" title="Loss on disposition of tantaline">0.2</span> million upon the sale. Any earn-out amounts will be recognized when and if any such amounts become probable of receipt.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The decision to sell Tantaline was based on the Company’s ongoing strategy to focus on the equipment business consisting of the CVD Equipment and SDC segments and reduce its focus on the non-core CVD Materials business.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Including the loss on disposition of $<span id="xdx_903_eus-gaap--GainLossOnSaleOfBusiness_pn5n6_c20230526__20230526__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_zFvNMdPpIpm7" title="Loss on disposition of tantaline">0.2</span> million, the revenues and net income of Tantaline were $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20230101__20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_zf8nfBgfRig" title="Revenues">0.5</span> million and $<span id="xdx_90B_eus-gaap--NetIncomeLoss_pn5n6_c20230101__20231231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_zzjKUxlJOkI1" title="Net income">0.1</span> million, respectively, for the year ended December 31, 2023. The total assets and total liabilities of the Tantaline subsidiary were $<span id="xdx_90B_eus-gaap--Assets_iI_pn5n6_c20221231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_zR6cNb1aXFWc" title="Assets">1.1</span> million and $<span id="xdx_903_eus-gaap--Liabilities_iI_pn5n6_c20221231__us-gaap--IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis__custom--TantalineASOfNordborgMember_zau1s2csEItg" title="Liabilities">0.4</span> million as of December 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><i>MesoScribe Subsidiary</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On August 8, 2023, the Company entered into a Purchase and License Agreement (the “Agreement”) with a third-party. Pursuant to the Agreement, the Company will sell certain proprietary assets relating to its plasma spray technology and material deposition system and grant a non-exclusive license to use certain of the Company’s related intellectual property as more fully described in the Agreement, for an aggregate purchase price of $<span id="xdx_900_ecustom--SaleOfProprietaryAssetsAndLicenseCertainProprietyInformationAggregatePurchasePrice_iI_pn5n6_c20230808__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zuZSJuhxCzy8" title="Aggregate purchase price">0.9</span> million. The purchase price is payable in several installments and contingent upon certain performance metrics and other milestones.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company will continue to fulfill remaining orders for MesoScribe products through the end of 2024 at which time it plans to cease the remaining operations of MesoScribe and dispose of any remaining equipment. During the year ended December 31, 2023, the Company recorded an impairment charge of $<span id="xdx_901_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_ztgKXdqeJMm4" title="Asset impairment charges">0.1</span> million for certain equipment of MesoScribe based on its decision to cease the operations of MesoScribe upon fulfillment of remaining orders. There were no impairment charges recorded in 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The Company received payments under the Agreement in the amount of $<span id="xdx_90A_ecustom--DepositsFromPurchaserOfMesoscribeAssets_iI_pn5n6_c20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zSwaALhWcABh" title="Deposits from purchaser of equipment">0.6</span> million which has been reflected as “deposits from purchaser” in the accompanying consolidated balance sheet as of December 31, 2023. The Company expects the transaction to be completed in 2024 with the shipment of the equipment to the purchaser.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The revenues and net income of MesoScribe were $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zpbDfqaRcsh9" title="Revenues">0.7</span> million and $<span id="xdx_903_eus-gaap--NetIncomeLoss_pp0p0_c20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zDw56Vu1Yc4h" title="Net income">33,000</span> for the year ended December 31, 2023, including the impairment charge of $<span id="xdx_908_eus-gaap--AssetImpairmentCharges_pn5n6_c20230101__20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zVk00LG4Zde9" title="Asset impairment charges">0.1</span> million.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">The total assets and total liabilities of the MesoScribe subsidiary were $<span id="xdx_909_eus-gaap--Assets_iI_pn5n6_c20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zkFOVNh6fJbd" title="Assets">0.2</span> million and $<span id="xdx_907_eus-gaap--Liabilities_iI_pn5n6_c20231231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zLLqETcW0Toa" title="Liabilities">0.7</span> million, respectively, as of December 31, 2023 and $<span id="xdx_908_eus-gaap--Assets_iI_pn5n6_c20221231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zNHHejK59711" title="Assets">0.9</span> million and $<span id="xdx_906_eus-gaap--Liabilities_iI_pn5n6_c20221231__srt--ConsolidatedEntitiesAxis__custom--MesoScribeTechnologiesIncMember_zVyGqGeZaRJc" title="Liabilities">0.1</span> million, respectively, as of December 31, 2022.</span></p> 200000 200000 500000 100000 1100000 400000 900000 100000 600000 700000 33000 100000 200000 700000 900000 100000 <p id="xdx_803_ecustom--RisksAndUncertaintiesTextBlock_zoOuK0vuNeT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 16 – <span id="xdx_82A_zVQ89lowusR1">Risks and Uncertainties</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently operates in a challenging economic environment as the global economy continues to confront the remaining impacts from the pandemic, geopolitical conflicts, inflationary pressures, and adverse supply chain disruptions. The specific impacts on the Company have included:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant geopolitical developments across Europe and Asia (including the war in Ukraine) have and may continue to restrict the Company’s ability to procure raw materials and components such as nickel and integrated circuits, as well as impact the Company’s ability to sell its products into China, Russia and other Eastern European and Asian regions.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supply chain disruptions have led to much longer lead times to acquire raw materials for production and has led to inflationary pressures in both materials and labor. These supply chain disruptions have impacted the Company’s ability to recognize revenue timelier as it delays the Company’s manufacturing processes.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While management has initiated actions to mitigate the potential negative impacts to its revenue and profitability, the Company is unable to predict the impact that the above uncertainties may have on its future results of operations and cash flows.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> CVD Materials segment includes loss on sale of Tantaline of $0.2 million and an impairment charge related to MesoScribe fixed assets of $0.1 million. Includes other income related to ERCs of $1,103, $303 and $123 for the CVD, SDC and Materials segments, respectively. Include $0.4 million of purchased equipment financed with a loan